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Abstract 
Genome-wide association study (GWAS) is an effective method for mapping genetic 
variants underlying common and complex diseases. 
This thesis describes the investigation of the disorders, frontotemporal dementia (FTD) 
and progressive supranuclear palsy (PSP). FTD affects the frontal/temporal lobes and 
presents behavioural changes (bvFTD), cognitive decline or language dysfunction 
(primary progressive aphasia [PPA]), whilst PSP affects predominantly the brain stem 
resulting in loss of balance, falls, and parkinsonian signatures. Beside recent 
advancements in the understanding of the clinical and neuropathological characteristics 
as well as the genetics associated with these diseases, their underlying pathogenic 
mechanisms are still unclear. 
The main aims of the work in this thesis were to perform a complete GWAS on clinical 
FTD and a follow up targeted study of new loci identified in the recent PSP-GWAS in a 
cohort of ~100 pathologically confirmed PSP cases. 
By completing these projects the main expected outcomes were to: 1 – Identify novel risk 
loci associated with FTD, and; 2 – Identify SNPs and haplotypes associated with 
increased risk of developing PSP and genetic variants possibly affecting expression 
and/or splicing of transcription elements relevant to PSP. 
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CHAPTER 1 – Introduction 
 
1.1 Overview 
1.1.1 Ageing societies 
Overall improved quality of life has led to unprecedented population growth over the past 
six decades in our societies accounting considerably for an increase of diseases of the 
older age. 
In high-income countries (HIC) as well as low/middle income countries (LMIC) ageing is 
the major global risk factor contributing to dementia [1], whose incidence and prevalence 
is expected to dramatically increase in the next decades [2].  
In the year 2010, 4.7% of the people over 60 years of age (~36 million people) were 
affected by dementia, worldwide [1]. 
An analysis of regional distribution of prevalence of dementia showed that 6.2% 
individuals were affected in Europe, 6.9% in North America, 8.5% in Latin America, 
~4% in Asia, ~6% in Australasia and ~3% in Africa [1, 2] and it was estimated that the 
incidence of dementia would almost double every 20 years reaching ~115 million in 2050 
[1] (Table 1-1).  
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Table 1-1. Prevalence and estimated incidence of dementia worldwide 
World region Prevalence of dementia (%) Estimated incidence  
!! (in individuals >60 years of age) 2010 2030 2050 
Africa ~3% 
~36M ~66M ~115M 
Asia ~4% 
Australasia ~6% 
Europe ~6% 
North America ~7% 
Central/South America ~8.5% 
Table 1-1. Data are adapted from [1, 2]. The prevalence of dementia is expressed in percentages and 
reflects the estimates of elderly over 60 years of age affected by dementia in the year 2010. The estimated 
incidence of dementia is expressed in millions (M). 
 
The costs associated with dementia represent a financial burden that impacts families of 
affected individuals, the health/medical, and social services. It was estimated that in 2010 
the overall costs of dementia worldwide reached $604 billion [3]. The distribution of 
these costs seemed to differ across HIC and LMIC: HIC (including Western Europe, 
North America and East/Pacific Asia) accounted for ~70% of total costs despite a lower 
prevalence of dementia compared to LMIC (~42% vs. 58%) [3]. It was suggested that 
such disparity was the result of differences in the average wages (~$30,000 in HIC vs. 
$903-12,000 in LMIC) and disparity in services or resources for dementia care [3]. In 
fact, one third to half of the affected individuals in HIC relies on formal care (residential 
or nursing homes), whilst in LMIC this service is essentially not offered and patients 
undergo informal care, i.e. caregivers are (unpaid) family members [3]. Also, different 
healthcare systems across different countries contribute to differences in direct 
medical/social costs as well as availability of medical/social assistance [3]. 
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Another important socio-economic aspect is that the financial burden of dementia is 
currently higher than that of other chronic conditions. For instance, a study performed in 
the UK revealed that yearly societal costs for dementia (£23 billion) exceeded those for 
cancer (£12 billion) or heart disease (£8 billion) [3].  
These statistics urge for a collective and global shift in the strategies to face dementia and 
advocate for intervention at the government level including the development of programs 
and policies targeting issues such as: 
1 – Early diagnosis and intervention; 
2 – Families/caregivers support and training, and; 
3 – Availability of cost effective services (e.g. medical and social care) [1]. 
 
In summary, these statistics, together with the fact that there is still an almost complete 
lack in both the understanding of the mechanisms that lead to disease and the availability 
of disease-modifying or curative therapies, call for more investment in infrastructure to 
support research and advocacy for the care of those affected by dementia [3, 4]. 
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1.1.2 Dementias 
Dementia is among the main causes of impairment of broad cognitive functions in 
individuals of older age leading to a wide range of deficits that impact memory, 
cognition, behaviour as well as motor skills and, eventually, the whole body as a system. 
These syndromes, alone or collectively, contribute to a progressive deterioration in the 
performance of normal daily activities and leave the affected individual in need of 
assistance [1]. 
Recently, the fifth edition of the diagnostic and statistical manual of mental disorders 
(DSM-5) was published providing the most updated guidelines for defining and 
diagnosing the broad spectrum of mental disorders [5]. 
In the DSM-5, Alzheimer’s and non-Alzheimer’s types of dementias fall within the 
extended category of neurocognitive disorders (NCDs) [5]. The main feature driving the 
diagnosis is impaired cognition that is defined as an acquired rather than inborn condition 
[5]. In the DSM-5, NCDs have been divided into two groups: Major and mild. 
Although the differences between the major and the mild form are rather subtle, a 
distinction may be ascribed to the presence of a “notable” (major NCDs) vs. “modest” 
(mild NCDs) cognitive decline compared to previous performances of the same 
individual and/or “interference” (major NCDs) vs. “no major interference” (mild NCDs) 
with normal everyday activities [5]. To diagnose the type of NCD as well as the “major” 
vs. the “mild” form, the specific abilities which are tested and assessed concern complex 
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attention, executive function, learning and memory, language and perceptual motor/social 
cognition [5]. 
The two distinct groups, Alzheimer’s type and non-Alzheimer’s type of dementia, are 
distinguished by their clinical presentation. The former is identified exclusively by 
Alzheimer’s disease (AD) because of its relatively unique early clinical features that 
include short-term memory loss, visuo-spatial deficits as well as cognitive decline and 
language impairment. The latter encompasses a long list of conditions characterised by 
differential symptomatology that in the vast majority of cases do not overlap with those 
specific to AD. Non Alzheimer’s type of dementia include, among others, vascular 
dementia (second in incidence and prevalence only to AD), dementia with Lewy bodies 
(DLB), Creutzfeld-Jakob (prion) disease, frontotemporal dementia (FTD) and other 
forms of neurodegenerative disorders that present a major motor component that may 
overlap with dementia symptoms such as the cases of  Parkinson’s disease (PD), 
progressive supranuclear palsy (PSP), corticobasal syndrome/degeneration (CBS/D) and 
amyotrophic lateral sclerosis (ALS). For each and every neurological disorder, the 
clinical picture is a reflection of the topographical areas of the brain that undergo 
degeneration. Subsequently, the neuropathology is still the gold standard for the definite 
diagnosis. 
In this thesis the neurodegenerative disorders under study are frontotemporal dementia 
(FTD) and progressive supranuclear palsy (PSP). Their main clinical, pathological and 
known genetic features are summarised in the upcoming sections. 
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1.2 Frontotemporal dementia (FTD) 
1.2.1 Relevance and statistics of the disease 
In 1892 the neuropsychiatrist Arnold Pick (1851-1924) reported the case of an individual 
with signs of progressive cognitive impairment, bouts of aggressiveness and aphasia 
whose brain pathology assessment revealed atrophy in the left temporal lobe [6, 7]. This 
is the first patient with FTD-like features in medical history. In the early 1900s Pick 
presented a further case with stereotyped behaviour [8] and semantic dementia-like 
symptoms [9]. These types of neurodegenerative disorders were named Pick’s disease 
(PiD). The study of the brain pathology revealed inclusions (Pick bodies) in neurons of 
the frontal lobes [10] that became the histopathological hallmark of PiD. Much later the 
microtubule associated protein tau (MAPT) and ubiquitin were shown to be the main 
component of these inclusions [11] [12]. PiD is currently considered a subgroup of FTD 
[13], as Pick bodies are found in 10-30% of sporadic FTD cases [14] and based on the 
historical case reports Arnold Pick is considered the father of FTD. 
Worldwide, FTD is the second most common form of young-onset dementia in the 
population under 65 years and contributes to ~10-20% of all dementias [15] and appears 
with average onset age of mid to late 50s [16]. FTD occurs in approximately 3-15 out of 
100,000 individuals that are in their mid to late 50s or early 60s [16]. The disease has 
insidious onset, it can present as familial (30-50% of cases) or sporadic (50-70% of 
cases) form [17, 18] and its incidence is almost equal among men and women [19]. 
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1.2.2 Diagnostic criteria and clinical features 
FTD is characterised by cognitive decline and behavioural dysfunction (bvFTD), which 
result in changes in personal and social conduct, and by language dysfunctions broadly 
called primary progressive aphasia (PPA). PPA is subdivided in semantic dementia (SD) 
(or semantic variant PPA), progressive nonfluent aphasia (PNFA) (or 
nonfluent/agrammatic variant PPA) and logopenic progressive aphasia (LPA) (or 
logopenic variant PPA) [20, 21]. Within this extended clinical picture, memory and 
visuo-spatial abnormalities remain initially intact. 
 
1.2.2.1 Behavioral variant FTD (bvFTD) 
Patients in this subtype may show disinhibition, emotional blunting, loss of insight, 
tendency to binge eating, loss of volition and inertia [21] and, in addition, deficits in 
executive functions, such as planning, reasoning and problem solving [21]. 
 
1.2.2.2 Semantic dementia (or semantic variant PPA) 
This syndrome is a disorder of conceptual knowledge characterised by a severe naming 
and word comprehension impairment, whilst speech output remains fluent [20]. SD is 
classified as right or left SD temporal variant based on the temporal lobe affected by 
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atrophy [22] and signs of behavioural changes can be seen although distinctive from 
those observed in pure bvFTD [23]. 
 
1.2.2.3 Progressive non fluent aphasia (or nonfluent/agrammatic variant PPA)  
This syndrome is a disorder of expressive language characterised by effortful non fluent 
speech, phonological and grammatical errors, and by difficulties in word retrieval as well 
as in reading and writing [20]. Behavioural changes are less common in PNFA but may 
emerge later while disease progresses [23]. 
 
1.2.2.4 Logopenic progressive aphasia (or logopenic variant PPA) 
The main features of this syndrome are represented by word retrieval (although milder 
than in SD) and repetition deficits [20]. Speech is slow and interrupted because of word-
finding problems, however the grammar is intact but accompanied by occasional 
phonological errors [24]. Caution has been suggested as this syndrome may be a subtle 
and atypical early presentation of AD [25].  
 
The Neary criteria [21] have been the most common diagnostic criteria for FTD since 
1998 (Table 1-2). 
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Table 1-2. Diagnostic criteria for FTD 
Table 1-2. Summary of main diagnostic criteria for FTD. Abbreviations: BvFTD=behavioural variant FTD; 
SD=semantic dementia; PNFA=progressive nonfluent aphasia. Table taken, or adapted, from [26]. 
 
More recently, two international consortia developed revised guidelines specifically for 
the diagnosis of the bvFTD subtype [27] and the language variants [20]. Guidelines for 
bvFTD are structured in five categories, each, summarizing symptoms that must be 
present to meet criteria for bvFTD (Table 1-3). 
 
 
Neary criteria Reference 
    
bvFTD 
[21] 
Insidious onset and gradual progression 
Early decline in social interpersonal conduct 
Early impairment in regulation of personal conduct 
Early emotional blunting 
Early loss of insight 
SD 
[21] 
Insidious onset and gradual progression 
Progressive, fluent, empty spontaneous speech 
Loss of word meaning (impaired naming and comprehension) 
Semantic paraphasias 
Impaired recognition of familiar faces (prospagnosia) 
Impaired recognition of objects 
Preserved perceptual matching and drawing reproduction 
Preserved single-word repetition 
Preserved ability to read aloud and write 
PNFA 
[21] Insidious onset and gradual progression 
Nonfluent spontaneous speech with at least one of the following: Agrammatism, phonemic 
paraphasias, anomia 
More details to be found in [21]   
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Table 1-3. Revised diagnostic criteria for the bvFTD 
bvFTD Reference 
    
Category I (Neurodegenerative disease)  
[27] 
Gradual deterioration of behaviour and/or cognition 
Category II (Possible bvFTD)  
[27] 
Disinhibition 
Apathy or inertia 
Loss of sympathy or empathy 
Stereotyped or ritualistic behavior 
Executive dysfunction 
Category III (Probable bvFTD) 
[27] 
Ascertained "Possible bvFTD" (category II) 
Significant functional decline 
Presence of frontal and/or anterior temporal atrophy (MRI) or 
hypometabolism (PET or SPECT) 
Category IV (bvFTD with specific FTLD pathology)  
[27] 
Ascertained "Possible bvFTD" (category II) or "Probable bvFTD" 
(category III) 
Presence of pathological hallmarks (e.g. FTLD-tau or FTLD-TDP) 
Presence of known pathogenic mutations  
Category V (Exclusion criteria for bvFTD)  
[27] 
Dysfunctions typical of other neurological disorders 
Behavioural changes resembling psychiatric disorders 
Biomarkers reflecting other neurological disorders 
More details to be found in [27]   
Table 1-3. Summary of the revised diagnostic criteria for the bvFTD subtype. Abbreviations: 
BvFTD=behavioural variant FTD; SD=semantic dementia;   PNFA=progressive nonfluent aphasia, MRI-Magnetic resonance imaging; 
PET=positron emission tomography; SPECT=single-photon emission computed tomography; FTLD=frontotemporal lobar 
degeneration; FTLD-TDP=frontotemporal lobar degeneration with ubiquitin/TDP-43 pathology; FTLD-tau=frontotemporal lobar 
degeneration with tau pathology. Table taken, or adapted, from [26]. 
 
Guidelines for the diagnosis of the main PPA syndromes (SD [or semantic variant PPA], 
PNFA [or nonfluent/agrammatic variant PPA]) are summarised in Table 1-4. 
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Table 1-4. Revised diagnostic criteria for PPA 
Language variant Reference 
    
Category I (SD or semantic variant PPA)  
[20] 
Impaired naming 
Impaired single word comprehension 
Impaired knowledge of low familiar objects 
Impairment in learning or writing 
Spared repetition and speech production 
Category II (SD or semantic variant PPA)   
[20] Ascertained clinical diagnosis (category I) 
Presence of anterior temporal lobe atrophy (MRI) or hypometabolism (PET or SPECT) 
Category III (SD or semantic variant PPA) 
[20] Ascertained clinical diagnosis (category I) 
Presence of pathological hallmarks (FTLD-TDP most common) or pathogenic mutation (MAPT 
or GRN mutations)  
Category I (PNFA or nofluent/agrammatic variant PPA)  
[20] 
Agrammatism or apraxia of speech  
Impaired comprehension 
Spared single-word comprehension 
Spared object recognition 
Category II (PNFA or nofluent/agrammatic variant PPA)  
[20] Ascertained clinical diagnosis (category I) 
Presence of left posterior fronto-insular atrophy (MRI) or hypometabolism (PET or SPECT) 
Category III (PNFA or nofluent/agrammatic variant PPA)  
[20] Ascertained clinical diagnosis (category I) 
Presence of pathological hallmarks (FTLD-TDP or FTLD-tau) or pathogenic mutation (GRN 
mutations)  
More details to be found in [20]   
Table 1-4. Summary of the revised diagnostic criteria for the PPA subtypes. Abbreviations: SD=semantic 
dementia; PNFA=progressive nonfluent aphasia; MRI-Magnetic resonance imaging; PET=positron emission tomography; 
SPECT=single-photon emission computed tomography; FTLD=frontotemporal lobar degeneration; FTLD-TDP=frontotemporal lobar 
degeneration with ubiquitin/TDP-43 pathology; FTLD-tau=frontotemporal lobar degeneration with tau pathology; 
MAPT=microtubule-associated protein tau; GRN=progranulin. Table taken, or adapted, from [26]. 
 
Both the revised diagnostic criteria for bvFTD [27] and for the language variants [20] 
represent an improvement of the Neary criteria [21] in that they increase the sensitivity of 
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the clinical diagnosis of each syndrome, they provide robust tools to diagnose the disease 
at insidious early stages, and they substantially contribute to uniform and harmonize the 
diagnosis of FTD across research centres worldwide.  
 
1.2.3 Neuropathology 
The brains of FTD patients show shrinkage in the frontal and temporal areas and present 
spongiform morphology due to neuronal loss that progressively increases during the 
course of the disease. Based on the topography of the lesions, frontotemporal dementia is 
also called FTLD (frontotemporal lobar degeneration).  
In bvFTD atrophy affects frontal lobes bilaterally, i.e. the medial frontal lobes and the 
anterior temporal lobes [22]. In PPA, the SD subtype shows asymmetric atrophy in the 
middle, inferior and medial anterior temporal lobe [20, 22], whilst the PNFA subtype 
presents mainly with left posterior frontal and insular regions atrophy [20]. The 
molecular pathology in FTLD is characterised by abnormal accumulation of protein 
aggregates [13] that cause inclusion bodies (i.e. neuronal cytoplasmic inclusions [NCI] 
and/or neuronal intranuclear inclusions [NII]) in neurons and/or glial cells, and by 
dystrophic neurites (DN) in the affected areas [28]. It has been suggested that protein 
misfolding, cleavage, phosphorylation and changes in protein solubility are key factors 
leading to protein aggregates [13]. FTLD pathology is differentially classified, based on 
the protein inclusions identified in the brains of patients. Currently, ≤40-50% of FTLD 
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cases show tau pathology (FTLD-tau), ≤40-50% ubiquitin/TDP-43 pathology (FTLD-
TDP), ≤10% FUS positive and tau/TDP-43 negative pathology (FTLD-FUS) and ≤1-2% 
ubiquitin/p62 pathology (FTLD-UPS) (Table 1-5) [28]. 
 
1.2.3.1 FTLD-tau 
Hyperphosphorylated tau inclusions accumulate in the cytoplasm of neurons and glial 
cells located, mainly, in the frontal/temporal cortex, hippocampus and subcortical nuclei 
and, more rarely, in the midbrain, brain stem, cerebellum and spinal cord [17, 29]. Tau 
hyperphosphorylation seems to be mediated by the activity of several kinases including 
the glycogen synthase kinases (GSKs) [13] (Table 1-5). FTLD-tau is associated with 
mutations in MAPT [28], nevertheless tau pathology can also occur in absence of MAPT 
variations [25]. 
 
1.2.3.2 FTLD-TDP 
Ubiquitin/TDP-43 positive inclusions accumulate in the cytoplasm (NCI) or nucleus 
(NII) of neurons and cause dystrophic neurites in brain cortex, subcortex and 
hippocampus [30]. TDP-43 pathology has recently been sub-classified in the subtypes A, 
B, C and D [31] (Table 1-5) as an updated classification system to replace previous 
conflicting nomenclature. FTLD-TDP is associated with genetic variability in GRN, 
C9orf72 and VCP (see the genes further below in section 1.2.4 Genetics) and each 
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subtype (A, B, C and D) is characterised by specific signatures (Table 1-5). Type A, 
which associates mainly with bvFTD and PNFA, presents with dystrophic neurites (DN) 
and oval neuronal cytoplasmic inclusions (NCI) in the neocortical layer and is mainly 
associated with mutations in GRN [31]; type B, primarily seen in bvFTD as well as FTD-
MND cases, shows NCI and rather few DN in all cortical layers and is associated with 
chromosome 9, i.e. with C9orf72 [31]; type C, described in bvFTD and SD cases, is 
defined by presence of elongated DN and few NCI in the upper cortical layers and no 
particular genetic association has been recognised thus far [31], and; type D, which 
associates with familial inclusion body myopathy with Paget’s disease of bone and 
frontotemporal dementia (IBMPFD), is characterised by short DN and lentiform neuronal 
intranuclear inclusions (NII) in all layers and is associated with VCP mutations [31]. 
 
1.2.3.3 FTLD-FUS 
FUS immunoreactive inclusions have been described in ~10% of FTD cases (FTLD-
FUS) that do not present TDP-43 or tau positive inclusions (Table 1-5) [22]. FUS 
pathology has been consistently reported in rare FTD subtypes such as atypical FTD 
(aFTD), neuronal intermediate filament inclusion disease (NIFID) and a subgroup of 
FTLD-U with early onset and caudate atrophy. The topographic distribution of FUS 
pathology includes cortical layers, the hippocampus, subcortical regions, brainstem and 
spinal cord (Table 1-5) [32] [33]. The molecular pathology may vary based on the 
affected brain region and/or on the syndrome (NIFID vs. aFTD). In the cortical layers a 
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common feature between NIFID and aFTD is represented by crescent-shaped NCI; 
globular or flame-like NCI, and rod-shaped (occasionally) and vermiform NII are more 
frequently found in NIFID, whereas bean- or annular-shaped NCI, and FUS-positive 
neurites (in white matter) mainly characterise aFTD [33]. In the hippocampus crescent-
shaped NCI, bean-like or globular NCI/NII as well as coiled body-like inclusions in white 
matter have been described in NIFID; conversely, only bean-shaped NII may be found in 
aFTD [33]. Globular NCI and skein-like NCI in motor neurons as well as (occasionally) 
bean-shaped NCI are found in the brainstem of NIFID cases, whereas dense globular NCI 
and skein-like NCI in motor neurons characterise aFTD [33]. Last, in the spinal cord 
differential FUS positive aggregates including filamentous skein- or dot-like inclusions 
define NIFID, whereas mainly skein-like NCI have been described in aFTD [33]. It has 
been suggested that a minority of cases presenting FUS pathology carry mutations in 
FUS [28] [33]. 
 
1.2.3.4 FTLD-UPS  
FTLD-UPS defines a very rare subgroup of FTD which is linked to chromosome 3 
(FTD3) [34] and is characterised by ubiquitin/p62 positive NCI either in the dentate 
gyrus or sparse in the frontal or other cortical areas [35] (Table 1-5). Based on the fact 
that these proteins are part of the ubiquitin proteasome system (UPS) this FTD subtype 
(≤1-2%) is named FTLD-UPS [36] [37]. FTLD-UPS has been associated with variability 
in CHMP2B [35]. 
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In summary, the nomenclatures used to classify FTLD pathology are based on the most 
frequently observed patterns of atrophy and types of protein inclusions and are being 
constantly updated in order to uniform the classification of FTLD. 
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Table 1-5. Classification of pathology and genetics associated with FTD 
Pathology and 
Genetics 
FTLD-tau 
(≤40-50%) 
FTLD-TDP 
(≤40-50%) 
FTLD-FUS 
(≤10%) 
FTLD-UPS 
(≤1-2%) 
Inclusion protein Tau Ubiquitin/TDP-43 FUS Ubiquitin/p62 
Cellular location Neurons and glial cellsa1,a2 Neurons
c Neurons and glial cellse Neurons
f 
Brain topography 
Frontal  cortexa1,a2 Frontal cortexc Cerebral cortexe Dentate gyrusf 
Temporal cortexa1,a2 Subcortexc Hippocampuse Frontal  cortex (rarely)f 
Hippocampusa1,a2 Hippocampusc Subcortical regionse Other cortical areas (rarely)f 
Subcortical nucleia1,a2  Branistem
h  
Midbrain (rarely)a1,a2  Spinal cord
h  
Brain stem 
(rarely)a1,a2    
Cerebellum 
(rarely)a1,a2    
Spinal cord 
(rarely)a1,a2    
Pathological 
features 
  
FUS inclusions 
(vermiform NII)e p62 inclusions (NCI)
f 
Hyperphosphorylated 
tau inclusionb 
Type A: DN or oval 
NCI 
in neocortical layer 2d 
Paired helical 
filamentsb 
Type B: Mostly NCI 
and few DN in all 
cortical layersd 
Neurofibrillary 
tanglesb 
Type C: Mostly 
elongated DN and few 
NCI  in upper cortical 
layersd 
 
Type D: Short DN and 
lentiform NII in all 
layersd 
  
Genetic features MAPT mutationsg 
 
FUS mutations (very 
rarely)g CHMP2B mutations
g  
Type A: GRN 
mutationsd 
Type B: C9orf72 
expansiond 
Type C: genetic 
component not known 
Type D: VCP 
mutationsd 
 
Table 1-5. Classification of pathology associated with FTD and their characteristics. Abbreviations: FTLD-
tau=frontotemporal lobar degeneration with tau pathology; FTLD-TDP=frontotemporal lobar degeneration with ubiquitin/TDP-43 
pathology; FTLD-FUS=frontotemporal lobar degeneration with FUS pathology; FTLD-UPS=frontotemporal lobar degeneration with 
ubiquitin/p62 pathology (which are elements of the Ubiquitin Proteasome System);TDP-43=transactive response DNA-binding 
protein 43 kDa; FUS=fused in Sarcoma; p62=ubiquitin proteasome system associated sequestosome p62; DN=dystrophic neurites; 
NCI=neuronal cytoplasmic inclusions; NII=neuronal intranuclear inclusions. References: a1-[17]; a2-[29]; b-[38]; c-[30]; d-[31]; e-
[32]; f- [35]; g- [28]; h- [33] . Table taken, or adapted, from [26]. 
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1.2.4 Genetics 
Genetics of FTD is heterogeneous. Approximately, 50% of familial cases show 
association with MAPT and progranulin (GRN) genes [17]. Recently, a proportion of FTD 
cases, mainly bvFTD (7-11% for sporadic cases and 12-25% for familial cases [39]), was 
associated with abnormal repeat expansion in either the promoter region or the first intron 
of chromosome 9 open reading frame 72 (C9orf72). These three genes are currently the 
main genetic factors associated with FTD. In addition, variations in valosin containing 
protein (VCP), charged multivesicular body protein 2B (CHMP2B), TDP-43, FUS, 
sequestosome 1 (SQSTM1) [40] and genetic variability in the transmembrane protein 106 
B (TMEM106B) [41] genes contribute, all together, to ≤5% of cases [17]. 
In the next paragraphs each gene will be described in their most relevant characteristics, 
with a particular attention for MAPT, GRN and C9orf72. 
 
1.2.4.1 MAPT 
MAPT is located on chromosome 17q21.1 and encodes the microtubule associated protein 
tau. There are 8 different isoforms of tau protein. Six of these are present in the CNS and 
are produced due to alternative splicing of exons 2, 3, and 10 [42, 43]. 
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The protein holds an amino-terminal projection domain and a carboxy-terminal 
microtubule binding domain (MT-binding domain). The latter consists of three or four 
repeats (3R- or 4R-tau) depending on alternative splicing of exon 10 [44] (Figure 1-1). 
From a functional perspective, tau binds and stabilizes the microtubules (MTs) 
supporting the maintenance of cell shape and the trafficking of molecules in the axon [45, 
46]. 
Tau seems also to have a role in neuronal polarity, signal transduction [29] and in 
mediating MTs interaction with other elements of the cytoskeleton as well as with 
components of the neural plasma membrane [46]. 
Not least, it has been suggested that tau regulates the spacing between MTs [29]. 
Currently, more than 70 variations in MAPT have been reported [44, 47] (Figure 1-1). Of 
these ~45 lead to deletions, missense and splice site mutations through: 
1 – Exonic point mutations [45]; 
2 – Intronic mutations that affect exon 10 splicing [45, 48], and; 
3 – Structural variations [49]. 
Exonic variants cause mainly missense mutations, most of which are located within the 
four MT-binding domains and contribute to a decrease the ability of tau in binding MTs 
and/or an increase in aggregation propensity [50].  
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Figure 1-1. MAPT gene 
 
Figure 1-1. The MAPT gene consits of 13 exons of which 3 (exons 2, 3 and 10) are alternatively spliced 
and 3 are rarely transcribed (exons 4a, 6 and 8). The 6 isoforms of MAPT are here represented showing the 
3 and 4 repeats (3R and 4R) that compose the MT-binding domain. The most important reported mutations 
are shown with amino-acid change and position. Figure taken from [51]. 
 
Several missense mutations (Ala152Thr, Pro332Ser, Gly366Arg and Pro364Ser) were 
recently isolated and shown to negatively affect the interaction between tau and the MTs 
[52-54]. Other missense mutations (Arg5Leu, Lys257Thr, Ile260Val, Pro301Leu, 
Pro301Ser, Gln336Arg, Val337Met, and Arg406Trp) promote tau’s self-aggregation 
[50], whilst a minority of missense mutations (Asn279Lys, Asn296His, Ser305Asn), 
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together with deletions (ΔK280, ΔN296) and intronic mutations (intron 9 g(-10)t and 
intron 10 +3, +11, +12, +13, +14, +16) affect exon 10 splicing and, therefore, the ratio 
between 3R/4R and between the different isoforms [47, 50]. 
Features such as mental retardation and learning disabilities in children were reported in 
presence of structural changes at the MAPT locus [55-57]. A more detailed and critical 
assessment of structural variability at the MAPT locus and its association with FTD is 
discussed in Chapter 4, section 4.2.2.4. 
The overall frequency of MAPT mutations in FTD is 2-11% [25]. The mean onset age in 
FTD cases caused by MAPT mutations is ~55 years and disease duration is on average 9 
years (5-20 years) [17]. MAPT variability is mainly associated with bvFTD whilst 
occasionally (and rather rarely) with SD (Pro301Leu) [58] or PNFA (Val363Ile and 
Gly304Ser) [59, 60]. 
 
1.2.4.2 GRN 
The progranulin gene (GRN) is located on chromosome 17q21.32 and codes for the 593 
amino-acid long protein PGRN, which is a precursor of granulins (GRNs) [61] (Figure 1-
2). PGRN is expressed in epithelial and hematopoietic tissues and within the cerebral 
cortex, cerebellum, and hippocampus in the central nervous system (CNS) [62]. From a 
functional perspective, it is involved in cell cycle progression, cell growth regulation, 
wound healing and inflammatory processes [63]. Interestingly, PGRN acts as an anti-
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inflammatory agent, whilst GRNs have pro-inflammatory effect [64]. Finally, PGRN is 
known to activate several kinase-dependant signalling cascades, the vascular endothelial 
growth factor (VEGF), and, not least, to play a role in brain development [65]. The first 
GRN mutations in FTD were reported in 2006 [66, 67]. Currently, more than 140 variants 
have been reported [47] (Figure 1-2). Approximately 65 of these lead, mainly, to non-
sense, frameshift, missense, and intronic mutations [47, 61, 65]. 
 
Figure 1-2. GRN gene 
 
Figure 1-2. The GRN gene consists of 12 coding exons and one non-coding exon (exon 0). PGRN protein 
is precursor of granulins. The most important reported mutations are shown with amino-acid change and 
position. Figure adapted from [51]. 
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Non-sense, frameshift, and intronic (IVS1 +5G>C) mutations cause haploinsufficiency (a 
decrease in the amount of translated protein) due to either mRNA non-sense mediated 
decay (NMD) or nuclear degradation of transcripts retaining the first intron of GRN [61]. 
Also some missense mutations contribute to a decreased secretion of PGRN [68]: 
Ala9Asp [69], Pro248Leu and Arg432Cys [70] have been reported causing a functional 
haploinsufficinecy due to cytoplasmic missorting [61, 70]. Other missense mutations can 
affect PGRN functionality (Cys105Arg, Ile124Thr, Gly168Ser, Pro248Leu, Arg432Cys, 
Trp541Cys, and Arg556Cys) [61, 68] or its structure and stability (Ile124Thr, 
Pro248Leu, Ser258Asn, Ala324Thr, and Arg432Cys) [61]. Structural variations such as 
large deletions (54-69kb comprising GRN) [61] or removal of exons 1-11 [71] can also 
lead to PGRN loss of function. Recent studies reported novel variants/mutations such as 
IVS9+1delG, identified and characterised in a patient with bvFTD and asymmetrical 
parkinsonism [72], Ala266Pro associated with reduced PGRN plasma levels [73] and 
Cys157LfsX97 in a patient diagnosed with PNFA [74].  
The overall frequency of GRN mutations in FTD is 5-11% [25]. The mean onset age is 
~60 years (35-89) and the average duration of disease is 8 years (3-22 years) [17]. 
Individuals carrying GRN mutations manifest mainly apathy and social withdrawal as 
behavioural symptoms, whilst cases with language impairment are by far less frequent 
but can also occur [17]. GRN mutations have been associated with asymmetrical frontal, 
temporal, and inferior parietal lobe atrophy [75] and, at the molecular level, mainly with 
tau-negative and TDP-43 positive inclusions (FTLD-TDP type A). 
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1.2.4.3 C9orf72 
The chromosome 9 open reading frame 72 gene (C9orf72) encodes the uncharacterised 
protein C9orf72. The two isoforms derived from alternative splicing of exons 1a and 1b 
(481 or 222 amino-acid long protein, respectively) are ubiquitously expressed in kidney, 
lung, liver, heart, testis and in various brain regions such as frontal cortex and 
cerebellum. In cells, C9orf72 protein locates to the cytoplasm and the nucleus [76, 77].  
Several studies reported a link to chromosome 9, locus 9p21.2, in amyotrophic lateral 
sclerosis (ALS) and FTD-ALS cases [78-82]. This locus comprises kinase activator MOB 
3B (MOB3B or MOBKL2B), interferon kappa (IFNK) and C9orf72. No coding variants 
were identified in these genes [78, 83] until a GGGGCC hexanucleotide repeat expansion 
in the promoter region of isoform 1a and in intron 1 of isoform 1b in C9orf72 was 
reported as the reason for the association with 9p21.2 [76, 77]. 
To date, the repeat expansion seems more frequent in familial cases, such as familial ALS 
(fALS), fFTD-ALS or fFTD, and less frequent in sporadic cases with the same diagnoses. 
Further, it seems that European and American (with European background) populations 
carry the expansion the most, especially, northern European such as Finnish and Swedish 
populations [39]. In FTD cases, the vast majority of carriers present with bvFTD (>60%), 
occasionally with PNFA and very rarely with SD.  
Frequencies of the repeat expansion across different studies (and populations) are 
summarized in Table 1-6. 
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Table 1-6. Summary of features associated with C9orf72 expansion 
Study 
cohort 
(ethnicity) 
Study size 
of FTLD 
cases (n) 
Frequency of 
expansion in 
FTLD cohort 
(%) 
Diagnosis of 
positive cases 
Status of 
positive cases 
(Sporadic/ 
Familial) 
Pathology 
of positive 
cases 
References 
(adapted from) 
Finnish 75 ~29 bvFTD (n=16) , PNFA (n=6) Familial (n=8) N.A [77] 
White (92), 
Asian (1) 93 ~18 N.A N.A FTLD-TDP 
[76] White (366), Asian (5), Black 
or African 
American (3) 
374 
~3 
clinical FTD 
Sporadic 
N.A 
~12 Familial 
Flanders-Belgian 305 
16 N.A Familial N.A 
[84] 
~4 N.A Sporadic N.A 
UK 398 ~8 
bvFTD(n=19), PNFA 
(n=3), SD/FTD 
(n=1), FTD-MND 
(n=9) 
Familial (n=20) , 
Sporadic (n=11) , 
Data N.A (n=1) 
FTLD-
TDP(n=4), 
FTLD-tau (n=1) 
[85] 
Dutch 353 ~12 bvFTD(n=34) , PPA (n=8) 
Familial (n=37) , 
Sporadic (n=5) 
FTLD-TDP 
(n=10) [86] 
Finnish 48 ~19 
N.A Sporadic N.A 
[87] 
UK 543 ~6 
Dutch 224 ~2 
French 150 ~9 
Finnish 27 ~48 
N.A Familial N.A 
UK 170 ~16 
German 29 ~14 
Dutch 116 ~26 
French 50 ~44 
Spanish 75 ~9 bvFTD Familial N.A [88] 
Australian 
(European 
descent) 
89 ~10 bvFTD  (n=6), FTD-ALS (n=3) Familial N.A 
[89] 
22 ~41 
bvFTD (n=4), 
AD (n=3), 
FTD-ALS (n=2) 
Familial (n=5), 
Sporadic (n=4) FTLD-TDP 
European and 
North Americans 
(European 
descent) 
520 ~5 
bvFTD (n=11), 
FTLD unspecified 
(n=8), 
FTLD-MND (n=8) 
Familial (n=22), 
Sporadic (n=5) N.A [90] 
Combined 
European and 
Flanders-Belgian 
cohorts 
1118 ~6 
bvFTD (n=22), 
PNFA (n=1), Others 
(n=48, Data N.A) 
Familial (n=33) , 
Sporadic (n=22), 
Others (n=16, 
Data N.A) 
FTLD-TDP 
(n=11) [39] 
Western 
European 
(meta-analysis) 
2668 ~10 N.A 
Familial (n=494), 
Sporadic (n=167), 
Others (n=2007, 
Data N.A) 
N.A [39] 
Table 1-6. Frequency, clinical and neuropathological characteristics of C9orf72 expansion carriers from 
different FTLD studies. Abbreviations: N.A= Data not available; C9orf72=chromosome 9 open reading frame 72; 
FTLD=frontotemporal lobar degeneration; bvFTD=behavioural variant FTD; SD=semantic dementia; PNFA=progressive nonfluent 
aphasia; SD/FTD = semantic dementia with frontal features; FTD/MND = Frontotemporal dementia with motor neuron disease; FTD-
ALS = frontotemporal dementia with amyotrophic lateral sclerosis; AD= Alzheimer's disease; FTLD-TDP=frontotemporal lobar 
degeneration with ubiquitin/TDP-43 pathology (that is subdivided in Types A, B, C, D);   FTLD-tau=frontotemporal lobar 
degeneration with tau pathology. 
! 60!
The pathology associated with C9orf72 falls within the FTLD-TDP group, specifically, 
types A and B [31, 84-86, 89, 91] with some unique features such as the ubiquitin/p62 
positive and TDP-43 negative inclusions in cerebellum and hippocampus [92]. The 
ubiquitin/p62 positive inclusions occur as NCI in cerebellum (molecular and granular 
layers) and in the hippocampus (pyramidal layer), and as NII in the cerebellum (just 
granular layer) and hippocampus (pyramidal layer) [86, 93, 94] [95]. Moreover, 
concomitant ubiquilin positive inclusions [96] or tau pathology have been described in 
some expansion carriers with typical expansion associated pathology [97, 98].  
Mean age at onset is ~55-57 years of age [76, 84-86] (Table 1-6) and, among the clinical 
features, a psychotic component has been constantly described across studies [85, 99]. 
The neuroimaging profile shows symmetrical atrophy in frontal and temporal neocortex, 
cerebellum and hippocampus (hippocampal sclerosis) [39, 92, 95]. The pathogenic 
mechanisms of C9orf72 expansion remain poorly understood. However, it has been 
hypothesized that the C9orf72 expansion may lead to haploinsufficiency by affecting 
transcription or splicing, or to RNA toxicity by sequestering non-identified RNA binding 
proteins, or to the aberrant translation and accumulation of poly-GA/GP/GR (glycine-
alanine/glycine-proline/glycine-arginine poly-dipeptides) by non ATG-initiated 
translation [100, 101]. Specifically, the two mechanisms involving RNA toxicity as well 
as the aberrant di-peptide repeat (DPR) deserve further consideration. The former (RNA 
toxicity) is supposedly a consequence of aberrant interaction between the expansion and 
RNA transcripts leading to the accumulation of intranuclear RNA foci in neurons [76, 
102-105]. The downstream effect of the formation of RNA foci has been suggested 
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affecting major RNA processing thus impacting vital cellular physiological processes 
such as the RNA metabolism [106]. The latter (DPR) has been proposed as a 
consequence of unconventional repeat-associated non-ATG (RAN) initiated translation of 
the G4C2 repeat. Based on immunohistochemical evidence, DPR accumulates in neurons 
of the neocortex, hippocampal pyramidal neurons and cerebellum [104]. DPR represents 
a unique and typical feature of the C9orf72 expansion carriers, specifically, as part of the 
NCI-TDP-43-negative inclusions in the cerebellum [104]. Nevertheless, although being 
undoubtedly a pathological hallmark associated with presence of C9orf72 expansion, the 
direct implication of DPR in neurodegeneration, specifically in terms of clinico-
pathological correlations, has been, to date, unclear and controversial [107]. 
In summary, the pathogenic role of the C9orf72 expansion in FTLD (as well as in ALS 
and the FTD-ALS spectrum) is currently not elucidated, mainly owing to a limited 
number of studies assessing correlation between clinical and pathological aspects of the 
disease, and will thus need to be further studied and characterised. 
A critical and updated assessment of the C9orf72 expansion is detailed in Chapter 5, 
section 5.2.3.3. 
 
1.2.4.4 VCP 
The valosin-containing protein gene (VCP) maps to chromosome 9p13.3 and encodes the 
806 amino-acid long protein VCP. VCP is expressed in most mammalian tissues [108] 
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and is involved in maintaining the balance between protein synthesis and degradation 
[109] as well as in various processes such as cell cycle regulation, post-mitotic Golgi 
reassembly, suppression of apoptosis, DNA-damage response and protein degradation 
[110-114]. 
Mutations in VCP cause autosomal dominantly inherited inclusion body myopathy (IBM) 
associated with Paget’s disease of the bone (PDB) and frontotemporal dementia (FTD) or 
IBMPFD [115, 116]. Currently, more than 15 mutations have been reported in VCP [47], 
being Arg155Cys the first pathogenic missense mutation reported in FTD [117]. Other 
missense mutations were identified in selective domains of the VCP protein: The amino-
terminal domain (Ile27Val, Arg93Cys, Arg95Cys/Gly, Pro137Leu, Gly157Arg and 
Arg159His/Cys), the L1 linker connecting the amino-terminal and D1 domains 
(Arg191Gln and Leu198Trp), the D1 domain (Ala232Glu, Thr262Ala, Asn387His) and 
the L2 linker (Ala439Ser) [115]. VCP variability has phenotypically also been associated 
with early signs of language impairment [118] and ALS [119]. To date functional studies 
have been partially equivocal, but it seems sensible to consider that VCP mutations 
negatively affect autophagic structures and processes [115]. 
IBMPFD patients present three main phenotypic signatures: Either disabling weakness 
(mean onset age 45), or osteolytic lesions with PDB or language and behavioural 
impairment (mean age of onset 54) [116]. IBMPFD pathology was originally reported 
being ubiquitin-positive and tau-, β-amyloid- and α-synuclein-negative (beside a few 
cases with law density staining for the latter proteins) [120]. In IBMPFD the ubiquitin 
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positive inclusions are abundantly intranuclear (NII), and may also be identified in DN 
and as NCI [120]. In addition, and relevantly, the ubiquitin-positive inclusions were 
reported to co-stain, thus co-localise, with TDP-43 predominantly as NII, feature which is 
consistent with FTLD-TDP Type D [25, 110] [120]. 
 
1.2.4.5 CHMP2B 
The charged multivesicular body protein 2B gene (CHMP2B) is located on chromosome 
3p11.2 and codes for the 213 amino-acid long protein CHMP2B that holds a coiled coil 
domain at the amino-terminus and a microtubule interacting transport (MIT)-interacting 
region (MIR) at the carboxy-terminus. CHMP2B is a subunit of the endosomal sorting 
complex required for transport III (ESCRT-III) involved in sorting and trafficking surface 
receptors or proteins into intraluminal vesicles (ILVs) for lysosomal degradation [35]. 
CHMP2B is expressed in frontal and temporal lobes, cerebellum and hippocampus [121].  
A familial FTD case was linked to chromosome 3 (FTD3) [122] and later two variants, 
CHMP2Bintron5 and CHMP2BΔ10, were reported co-segregating with disease in that family 
[121]. To date, 12 variants have been reported [47] in FTD, ALS and CBS cases [34, 121, 
123-127] [128]. Although the majority of the variants seem non-pathogenic three have 
been associated with disease or aberrant phenotype [121, 127, 129].  
With a mean onset age of 57 years, FTD3 patients present clinically with personality 
change, hyperorality, dyscalculia, a range of speech disturbances and dystonic postures 
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[35]. Brain atrophy affects, symmetrically, the frontal and temporal cortex and TDP-43 
negative and ubiquitin and/or p62 positive neuronal inclusions are identified in the 
dentate gyrus or sparse in the frontal cortical areas (FTLD-UPS) [35]. 
A critical and updated assessment of CHMP2B is detailed in Chapter 5, section 5.2.1.2. 
 
1.2.4.6 TDP-43 
The TAR DNA binding protein gene (TARDBP or TDP-43) is located on chromosome 
1p36.22 and encodes the 414 amino-acid long protein TDP-43 that holds two RNA 
recognition motifs and a carboxy-terminal glycine-rich region [130]. Wild-type (WT) 
TDP-43 is highly conserved and ubiquitously expressed in different tissues, including the 
central nervous system (CNS) [130]. TDP-43 localises to the nucleus of neurons and glial 
cells, and is involved in exon skipping of several genes and in the biogenesis of mRNA 
[130]. Over 40 variants have been reported in TDP-43 [47] of which >30 map to the 
glycine-rich region. Genetic screening of TDP-43 in FTD cases has been controversial. 
Initially, variants were not found in FTD [131] [132] and it was suggested that TDP-43 
pathology may be a consequence rather than a cause of FTLD [132]. Nevertheless, two 
studies reported a missense change (Lys263Glu) and concomitant TDP-43 pathology in a 
FTD/PSP/chorea patient [133], and a 3’-UTR (untranslated region) variant in TDP-43 
associated with increased TDP-43 mRNA levels in FTLD-TDP and bvFTD-ALS cases 
[134]. Also, the missense change Asn267Ser was identified in bvFTD and CBS cases 
! 65!
[135] [136] [137], and Ala382Thr was associated with a unique phenotype, comprising 
FTD, ALS and parkinsonian features [138]. 
Functional studies of 3 recurrent missense mutations Ala315Thr, Gly348Cys and 
Ala382Thr did not show differences with wild-type-TDP-43 in transfected cell lines, 
whilst a peculiar peri-nuclear localization and aggregation of TDP-43 in motor neurons 
were observed in living zebra-fish embryos [139]. In addition, investigation of amino- 
and carboxy-terminal TDP-43 fragments in mammalian cells and cultured neurons 
showed that, particularly, carboxy-terminal fragments can negatively affect neuronal 
differentiation and interfere with normal function of full length wild-type-TDP-43 
protein, contributing, possibly, to neurodegenerative processes [140]. Taken together, 
these results support the notion that TDP-43 abnormalities may associate with toxic gain- 
or loss-of-function. 
In summary, the association of TDP-43 genetic variability with FTD remains equivocal; 
in fact most of TDP-43 mutations seem mainly related to ALS cases [141]. Clearly, 
further screening is needed in order to shed light on TDP-43 genetic variability and its 
role in FTLD. 
 
1.2.4.7 FUS 
The fused in sarcoma gene (FUS) is located on chromosome 16p11.2 and encodes the 
526 amino-acid long protein FUS, which is part of the heterogeneous nuclear 
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ribonucleoprotein (hnRNP) complex and is involved in pre-mRNA splicing and in the 
export of fully processed mRNA to the cytoplasm. Mutations in FUS were reported in 
familial ALS (fALS), whilst no variants were found in sporadic ALS (sALS) cases [142, 
143]. These reports suggested FUS mutations as potential cause of fALS with a 
frequency of 4%, second only to superoxide dismutase-1 gene (SOD-1) mutations for 
fALS cases. To date over 40 variants have been reported for FUS gene [47], but their 
pathogenicity seems to some extent controversial. Findings support the notion that exon 
15 is highly polymorphic and variability in this gene mainly associated with fALS rather 
than sALS [144]. Further investigation of FUS in FTD led to discordant results: Despite 
the identification of variability in single cases such as a Arg521Cys mutation in one FTD 
case [144] and a missense mutation, Met254Val (predicted, in silico, to be pathogenic), in 
one FTLD patient [145], other studies mainly rejected the notion of association between 
FUS and FTD as in the case of the screening of exon 15 in a cohort of ~220 FTD cases 
[146], or a haplotype analysis (tagging the SNPs rs741810 and rs1052352) that failed to 
identify haplotypes associated with FTLD  in sporadic FTD [147]. In addition one of the 
insertion/deletion (indel) reported as pathogenic in the original reports [142, 143] was 
later also isolated in normal controls [145]. All these reports taken together may suggest 
that FUS is unlikely to be a susceptibility factor for FTLD and probably caution is needed 
in ascribing pathogenicity to FUS variants in neurodegenerative diseases. However, 
functional studies on mutations such as Arg521Gly, Arg521Cys and Arg521His showed 
aberrant retention of the mutated protein in the cytoplasm (Arg521Gly) [142] or 
increased cytoplasmic localization of the protein (Arg521Cys and Arg521His) [143]. 
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The penetrance and relevance of FUS variants in FTD is to date rather unclear. From a 
functional perspective, despite the identification of FUS pathology in a small minority of 
FTLD cases (FTLD-FUS pathology) and a correlation with aberrant cellular distribution 
of the FUS protein for some of the most relevant missense changes (Arg521Gly, 
Arg521Cys and Arg521His), the exact role of FUS in neurodegeneration will need to be 
further elucidated. 
 
1.2.4.8 TMEM106B 
TMEM106B gene is located on chromosome 7p21 and encodes the 274 amino-acid long 
protein TMEM106B, which has recently been described as a type 2 integral 
transmembrane protein characterised by an amino-terminal domain located within the 
cytoplasm and a carboxy-terminal domain that may also locate to the cytosol or protrude 
to the extracellular microenvironment [148]. Association between TMEM106B and FTLD 
was established through a genome-wide association study (GWAS) on 515 FTLD-TDP 
pathologically confirmed cases [41] and three top SNPs (rs1020004, rs6966915 and 
rs1990622) were reported being associated with increased expression levels of 
TMEM106B in brain [41]. Specifically, an increase of TMEM106B mRNA levels was 
shown in post-mortem human brain tissue in association with rs1990622, especially, in 
GRN mutation carriers [41, 149]. It has been suggested that increased expression of 
TMEM106B may modulate GRN plasma levels and, thus, contribute to pathogenic 
processes [150]. Several studies support the idea that variability in TMEM106B 
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predisposes to FTD, especially, in GRN mutation carriers [41, 151-153]. However its 
exact pathogenic role still remains widely unclear. The three most strongly associated 
SNPs (rs1020004, rs6966915 and rs1990622) and the missense mutation Thr185Ser 
(rs3173615) were extensively tested in different cohorts with the aim of identifying 
correlations between TMEM106B expression levels, GRN protein levels and disease 
onset age and progression [151, 152, 154]. The missense change T185S (rs3173615), 
predicted to be possibly damaging (PolyPhen-2, Chapter 2, section 2.3.3.1), was 
suggested to be possibly pathogenic in FTLD or FTLD-TDP cohorts in presence of GRN 
variability [152]. The SNP rs1990622 showed linkage disequilibrium (LD) with other 
SNPs within 10kb of the TMEM106B gene locus including complete LD with rs3173615. 
As well, in sporadic FTLD-TDP cases with GRN mutations, carriers of the homozygous 
allele T (rs1990622) showed association with thirteen years earlier onset and lower GRN 
plasma levels [151]. For SNP rs1020004 an association between genotype and disease 
course was identified in that the homozygous genotype A seemed to lead to shorter 
disease duration [41]. TMEM106B was shown to be involved in regulating lysosomal 
morphology and function in FTLD-TDP cases with GRN mutations [150] supporting a 
previous study suggesting a link between TMEM106B and GRN biology through late 
endosome and lysosome processes [148]. 
In summary, variability in TMEM106B is associated with FTLD-TDP and GRN mutation 
carriers as well as, to a certain extent, with features such as poor cognitive performance 
in ALS cases [153] and AD [155]. The main pathological signatures are Neuronal 
cytoplasmic inclusions and short dystrophic neurites in neocortex/cortical layers, 
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corresponding to FTLD-TDP Type A pathology [31]. It seems that TMEM106B might act 
as a disease modifier affecting age of onset and modulating PGRN protein levels [151]. 
The heterogeneous clinical, pathological and genetic features of FTD are summarised in 
Figure 1-3. 
 
Figure 1-3. Clinical, pathologic and genetic features associated with FTD 
 
Figure 1-3. The main clinical, pathological and genetic features associated with FTD are summarized. In 
each section the most common features are located at the top with bigger font size which is decreasing once 
features become less common or frequent. In the Genetics section TMEM106B is shown as a possible 
modifier of GRN. Abbreviations: FTD=frontotemporal dementia; bvFTD=behavioural variant FTD; PPA=primary progressive 
aphasia; SD=semantic dementia; PNFA=progressive nonfluent aphasia; LPA=logopenic progressive aphasia; FTLD-
TDP=frontotemporal lobar degeneration with ubiquitin/TDP-43 pathology; FTLD-tau=frontotemporal lobar degeneration with tau 
pathology; FTLD-FUS=frontotemporal lobar degeneration with FUS pathology; FTLD-UPS=frontotemporal lobar degeneration with 
ubiquitin/p62 pathology (which are elements of the Ubiquitin Proteasome System); MAPT=microtubule associated protein tau; GRN= 
progranulin; C9orf72=chromosome 9 open reading frame 72; VCP=valosin containing protein; TDP-43=TAR DNA binding protein 
43; CHMP2B=charged multivescicular body protein 2B; FUS=fused in sarcoma; TMEM106B=transmembrane protein 106 B. Figure 
adapted from [26]. 
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1.3 Progressive supranuclear palsy (PSP) 
1.3.1 Relevance and statistics of the disease 
Progressive supranuclear palsy (PSP) was first described in 1963-1964 by Steele, 
Richardson and Olszewski [156]. 
The disorder is characterised by early postural instability, supranuclear gaze palsy, and 
cognitive decline and can occur as early as 40 years of age, but the average onset age 
seems to be around 63 years of age [157]. The incidence of PSP has been estimated being 
5.3 or 6.4 per 100,000 [158, 159]. Depending on disease morbidity and severity the 
average disease duration is about 7 years [160]. Moreover, PSP shows a slight 
predominance in males (64%) [157]. 
PSP rather presents as a sporadic form (~85% of cases), whilst few familial forms with 
autosomal dominant inheritance have been described [161].  
  
1.3.2 Diagnostic criteria and clinical features 
The main clinical signatures of PSP are vertical gaze palsy, pseudobulbar palsy, axial 
rigidity and, in some cases, cognitive impairment [156]. Additional features such as 
sudden falls and supranuclear palsy are included in the clinical diagnostic criteria. 
Bradykinesia (slowed ability to start and continue movements, and impaired ability to 
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adjust the body's position), decreased fine motor skills and hypophonia (a weak voice due 
to incoordination of the vocal muscles) are among the early signs of PSP [157]. Gait 
(manner of walking) and visual problems are highly prominent symptoms in PSP 
representing features that help in diagnosing the disorder with higher specificity and 
sensitivity. In fact, gait difficulties that eventually result in lurching [156, 162], show a 
faster progression if compared to Parkinson’s disease (PD) representing a distinctive 
factor. Falls develop within the first year after disease onset and the symptoms range 
from unexplained falls to visual deficits (e.g. blurred vision), cognitive impairment (e.g. 
apathy or loss of executive functions or language dysfunction) and parkinsonian 
symptoms [157]. 
Given the overall picture of the disease summary the essential diagnostic criteria used to 
diagnose PSP are as follows: 
1 – Progressive akinetic-rigid syndrome appearing after age 40; 
2 – Progressive vertical supranuclear gaze palsy; 
3 – Slowing of vertical saccades, and; 
4 – Progressive and prominent postural instability with falls in the first year of illness 
[157] and at least 1 and 2 or 1 and 3 criteria need to be met for an individual to be 
diagnosed with PSP. 
Together with these pivotal and relevant symptoms additional features can support 
clinical diagnosis such as axial and appendicular rigidity, symmetry in symptomatology, 
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paucity of tremor and poor response to levodopa treatment [157]. It needs to be 
acknowledged that, although these clinical features are well described and may be easily 
recognisable by an expert physician, there is normally an average delay of 4 to 5 years 
between the onset of symptoms and diagnosis [157]. 
 
1.3.3 Neuropathology 
Atrophy patterns in PSP grossly affect the midbrain, particularly the tectum [160]. In 
addition, the substantia nigra shows loss of pigmentation, and the subthalamic nucleus as 
well as the superior cerebellar peduncle, pontine tegmentum and dentate nucleus may be 
atrophic [160].  
The molecular pathology of PSP is strictly correlated with tau pathology, hence PSP 
belongs to the group of disorders called tauopathies [163]. Topographically, tau 
pathology distributes in different brain areas such as the pallidum, the subthalamic 
nucleus, the red nucleus, the substantia nigra, the pontine tegmentum, the striatum, the 
oculomotor nucleus, the medulla and the cerebellar dentate nucleus [163, 164]. 
In PSP, tau pathology is defined by the accumulation of hyperphosphorylated tau protein 
inclusions that lead to the formation of neurofibrillary tangles (NFTs) in the cell body and 
neuropil threads in the dendrites of neurons [26]. NFTs and neuropil threads are 
composed of hyperphosphorylated 4R-tau isoforms, making PSP a predominantly 4R-
tauopathy, implying to a constitutive predominant transcription and translation of this 
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isoform that has been associated with the H1 MAPT haplotype (specifically the H1c 
clade) [166]. In addition, tau pathology also affects glial cells (astrocytes and 
oligodendrocytes) with features that are relatively unique to PSP [160, 165]. The 
argyrophilic tau-positive inclusions that have been described in astrocytes and 
oligodendrocytes [160] appear as irregular fibrous tufts in astrocytes (thus called tufted 
astrocytes) in the motor cortex and striatum; conversely they appear as perinuclear fibers, 
called coiled bodies, together with thread-like processes in oligodendrocytes in cerebellar 
white matter [160, 167].   
There are several variants that separate classical PSP from atypical PSP (aPSP) or PSP-
parkinsonism (PSP-P) due to differences in severity or regions of pathology or clinical 
features while the common link between them is tau pathology [163]. To date there are 
no definite diagnostic criteria to distinguish the atypical PSP from the classical PSP, 
however, it has been established that tau pathology is more severe in classical PSP rather 
than in atypical or PSP-P [163]. 
Another variant, known as PSP-pure akinesia with gaze freezing (PAGF) shows 
characteristics of gait disturbance, micrographia, hypophonia, and eventual gait freezing 
associated with neuronal loss and atrophy in the globus pallidus, substantia nigra and 
subthalamic nucleus [168, 169]. 
While other subgroups of PSP show different topography concerning the molecular 
pathology, tau pathology is more severe than classical PSP, manifested through 
asymmetric dystonia, apraxia and cortical sensory loss (PSP-CBS). The other subgroup is 
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characterised by apraxia of speech (PSP with progressive nonfluent aphasia [PSP-
PNFA]) [170, 171]. 
Due to the improved investigation methods, tau pathology has been identified also in the 
cortical areas with severe tau pathology in the mid-frontal and inferior parietal cortices in 
PSP-CBS and in the temporal cortex and superior frontal gyrus of patients with PSP-
PNFA when compared to classical PSP [171]. Nevertheless, it was recently shown that, 
although rarely, also accumulation of TDP-43 is detectable in PSP cases, specifically, 
within the limbic system [172]. 
 
1.3.4 Genetics 
Belonging to the group of tauopathies, it is not surprising that PSP has been consistently 
associated with common variation at the MAPT locus [173-175] [176]. This is reinforced 
by the robust genetic association with the MAPT H1 haplotype [173, 174, 177-179] that 
replicated in the recent GWAS with odds ratio greater than 5 [180]. 
While there is a strong genetic link between PSP and chromosome 17, specifically the 
locus encompassing the microtubule associated protein tau gene (MAPT), pathogenic 
coding mutations within the MAPT gene seem to be rare. To date, PSP has been 
associated with only four missense mutations, Arg5Leu, Asn279Lys, Leu284Arg, 
Gly303Val and the deletion of codon 296 [181-187]. Further, association was reported in 
MAPT with intronic variants such as intron 10+3 [188] and 10+16 [189], and with a silent 
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mutation Ser305 in exon 10 [190]. Despite the fact that association between MAPT H1 
haplotype and PSP has been previously described [173, 179], the mechanism leading to 
disease still needs elucidation as the H1 haplotype is relatively common among 
populations [160]. The H1 haplotype seems responsible for a 1.5-fold higher 4R-tau 
expression compared to the H2 haplotype, suggesting that, possibly, the lifelong higher 
expression of 4R-tau could be associated with the onset of PSP [160]. In view of this, 
SNPs rs1880753 and rs242557 were shown to associate with PSP by putatively 
influencing MAPT expression in –cis [177, 178]. A genetic link for PSP was also 
identified on chromosome 1q31.1 [186] as well as on chromosome 11p12 although, in the 
latter study, sample size was relatively small (288 cases vs. 344 controls) [191] and the 
association has not been replicated to date. Furthermore, a study argued for association 
between the polymorphism Val380Leu in parkin (park2) and PSP in that Val carriers 
might experience an increase of the risk of developing PSP compared to Leu carriers 
[192]. 
Elucidation of the possible functional basis of the H1 haplotype association with PSP has 
led to suggestions of allele-specific differences in transcription and alternative splicing of 
MAPT and its transcripts, respectively. In the first place, both PSP and CBD tau 
pathology is predominantly four-repeat tau (4R-tau), i.e. consisting of tau protein 
isoforms with four microtubule-binding domains as a result of alternative splicing of 
MAPT exon 10. Early work [193, 194] showed relative increases of 4R-tau mRNA and 
protein [195] in affected regions of the PSP brain and, owing to the surplus of these more 
fibrillogenic isoforms, they preferentially aggregate to form the characteristic 
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neurofibrillary inclusions. In vitro, and in brain, the H1 allele, compared to its counterpart 
H2 haplotype, is associated with increased splicing of exon 10 and decreased inclusion of 
exon 3 [196-199]. Furthermore, analysis of the underlying diversity of the H1 haplotype 
revealed H1c, a common variant of H1 that specifically drives the association with PSP, 
with a second common variant, H1b not associated and H2, negatively associated as a 
protective allele [179, 200]. One study showed both increased transcription and exon 10 
splicing of the H1c allele [201] with the A-allele of the SNP rs242557 in the MAPT 
promoter region, that segregates with H1c, associated with increased CSF tau levels 
[202]. Due to the extended region of linkage disequilibrium (LD) [203] that resulted due 
to a large chromosomal inversion of the region on chromosome 17q containing MAPT 
[204, 205], several other genes, including N-ethylmaleimide-sensitive factor (NSF) and 
corticotropin releasing hormone receptor 1 (CRHR1) are also defined by the H1/H2 
dichotomy and are thus likely associated with PSP [176]. 
H1/H2 allele-specific differences of MAPT gene expression have been demonstrated at 
the transcriptional level in vivo and in vitro [201, 206], though this has not been 
consistently replicated and recent work suggested that some expression array-based data 
have been hampered by errors due to SNPs within the gene-specific probes used to 
quantify expression levels [207]. In fact, Trabzuni et al failed to show differences in 
MAPT transcription but did show a clear allele-specific exclusion of the alternatively 
spliced exon 3 on the H1 haplotype [199]. They failed, however, to observe increased 
splicing of exon 10 on the H1 vs. H2 haplotype as reported in other studies [196, 198, 
201] and that was postulated to cause the predominant 4R-tau pathology in PSP. 
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The majority of studies on brain expression are affected by sampling issues likely to 
result in significant differences in neuronal and glial cell populations and different 
outcomes in expression levels. This can only be resolved by analysis of individual cell-
types isolated by methods such as laser-capture dissection. Recent work comparing gene 
expression sets from whole-brain sections versus individual neurons or glia showed 
significantly different outcomes, whereby predictions of Alzheimer’s disease progression 
based on neuronal gene expression are significantly more accurate than when based on 
glial or whole-tissue expression [208].  
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1.4 Genetic studies 
1.4.1 Basics of genetic variability 
Genetic variability (i.e. difference in genotype) is among the main driving factors at the 
basis of differences between individuals and populations. 
The majority of the variants are benign. However, some can be harmful either in a 
Mendelian fashion (gene/mutation/disease), e.g. in rare or familial forms of disease as in 
the case of Huntington’s disease [209] or cystic fibrosis [210]; or by contributing to 
increased risk of developing common/complex forms of disease through an interplay 
between genetic and environmental factors with variable effect size, e.g. as in the case of 
late onset Alzheimer’s disease (LOAD) [211]. 
Each disorder has a genetic component (with low, intermediate or full penetrance) and, in 
the majority of cases, the development of a disease is the result of downstream effects 
that accumulate with time and, ultimately, manifest in clinical symptoms. A better 
understanding of the variants in the genome and a better genotype-phenotype correlation 
are critical for understanding and discriminating the genetic factors that influence the 
conditions of health and disease. 
Today we are at a point in time where we can define and identify almost all types of 
variations that are present in the genome. 
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There are 2 categories of variants: The simple nucleotide variations (SNVs) and the 
structural variations (SVs) (Figure 1-4). SNVs, comprising single nucleotide 
polymorphisms (SNPs) and small insertion/deletions (small indels), affect single or few 
bases, whilst SVs, comprising copy number polymorphisms (CNPs) that include large 
indels (100bp – 1Kb) and copy number variations (CNVs) (>1Kb), affect larger genomic 
regions. Also inversions and translocations are types of SVs. 
 
Figure 1-4. Types of genetic variants 
 
Figure 1-4. Summary of the main types of variants in the genome involving (1) single (or few) base pairs 
(bp) or (2) larger areas of the genome. 
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In the majority of cases, SNVs (Figure 1-5) can cause direct changes to proteins (when 
located in coding regions) or can affect cis and/or trans gene expression or splicing 
(when located in intergenic or promoter regions or in introns). 
Changes within the coding regions can result in synonymous, missense, non-sense and 
frameshift mutations. Synonymous changes do not affect the amino-acid sequence of a 
protein, whilst missense mutations lead to amino-acid change. Non-sense mutations cause 
a premature truncation of the protein and frameshift mutations cause a shift in the reading 
frame giving rise to novel translated elements. Missense, non-sense and frameshift 
mutations can be harmful and exert a pathogenic effect through mechanisms such as loss 
or toxic gain of function. 
Conversely, changes in promoter regions can affect gene expression by negatively 
modulating the activity of transcription factors, blocking gene expression or causing 
aberrant gene expression. Changes in introns can affect splicing leading to non-functional 
or toxic forms of m-RNA and a decrease in protein production (i.e. haploinsufficiency). 
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Figure 1-5. Characteristics of simple nucleotide variations 
 
Figure 1-5. Schematic view of the main single nucleotide variations (SNVs) and their related effect. 
 
SVs (Figure 1-6) affect larger parts of the genome. These types of variants can cause the 
loss of portions of DNA (deletions) that, in turn, may lead to haploinsufficiency or 
aberrant regulation of gene-expression. On the other hand, duplications, which lead to 
multiple tandem copies of an allele, can cause aberrant phenotypes due to gene over-
expression. Duplications can also happen at the level of chromosomes causing over-
expression of the set of genes located on that chromosome. 
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Figure 1-6. Characteristics of structural variations 
 
Figure 1-6. Schematic view of the main structural variations (SVs) and their related effect. 
 
1.4.2 The study of genetic variability 
Clearly, the first milestone for a better understanding of the human genome was laid in 
the early 50s’ through the biochemical characterisation of the DNA structure [212] 
(Figure 1-7). This discovery provided the basic knowledge for further investigating and 
understanding how the genetic information is stored, replicated and how it is translated to 
the next functional level (proteins) [213]. In the late 70s the revolutionary method for 
sequencing – Sanger Sequencing – represented a paradigm shift in genetic research 
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because it allowed identification of the exact base sequence of a specific genetic region 
[214] (Figure 1-7). In the early 80s the development of the polymerase chain reaction 
method (PCR) (Figure 1-7) further revolutionized the field of molecular genetics by 
allowing amplification of fragments of interest (e.g. exons) to perform targeted screening 
of genetic regions (e.g. sequencing exons to identify coding variants).  
Along with the development of these techniques, ground-breaking advances were made 
in linking traits or diseases to the genome by the study of families (i.e. linkage analysis 
studies). In the early 80s, gene hunting through positional cloning became a popular 
approach for identifying specific loci co-segregating only in carriers of a trait/disease in 
families. This method allowed identification of the causative locus for Huntington's 
disease (HD), a genetically inherited disease affecting, cognition and psychology [209].  
As there was growing awareness in the scientific community that expanding the 
knowledge on the human genome was fundamental in order to further understand its 
characteristics as well as its role in health and disease, it was envisioned that sequencing 
the whole human genome would be the next ambitious endeavour to undertake. 
 
1.4.2.1 Human genome project (HGP) – 1990-2003 
The human genome project (HGP) was initiated in the late 80s 
(http://ornl.gov/sci/techresources/Human_Genome/home.shtml). This international 
endeavour was driven by the conviction that a deeper knowledge of the genome could, on 
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one hand, provide clues to better understanding human biology and on the other lead to 
revolutionary new ways to diagnose, treat, and prevent diseases. HGP accomplished the 
goal of sequencing the whole human genome providing paramount novel insight into the 
human genome by: 
1 – Revealing that the haploid human genome contains 3.2 billion base pairs; 
2 – Revealing that the total number of genes can be estimated being ~25,000; 
3 – Revealing that the genome is almost the same (99.9%) across individuals, and; 
4 – Mapping 3.7 million SNPs. 
These discoveries opened possibilities for entirely new approaches in biological research. 
In fact, instead of screening one or a few genes at a time it was possible to target the 
whole genome allowing studying more comprehensively genotype-phenotype 
correlations and the most fundamental causes of disease. 
 
1.4.2.2 Haplotype map (HapMap) project – 2002-2009 
The elucidation of the entire human genome through the HGP provided the basis for the 
haplotype map (HapMap) project (http://hapmap.ncbi.nlm.nih.gov/). With this 
international effort DNAs collected from populations of African, Asian, and European 
ancestry were sequenced to enable the identification of common haplotypes in different 
populations, worldwide. HapMap revealed that any two people have 99.5% identical 
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sequences and mapped up to ~10M SNPs with a minor allele frequency (MAF) ≥5%. 
Moreover, HapMap assessed their allelic and genotypic frequency and distribution 
among different populations. Considering that sets of nearby SNPs on the same 
chromosome are inherited in blocks (haplotypes) and that variability within the genome 
may affect disease risk, by mapping these haplotype blocks and their tag SNPs, HapMap 
set the basis for the investigation of common/complex diseases by means of genome-
wide association studies (GWAS). 
Both projects, HGP and HapMap, were fundamental for defining the sequence and the 
structure of the human genome and, at the same time, for identifying and mapping 
common polymorphisms. A remarkable advantage inherited from these two pioneering 
studies was the free availability of the generated data as these were merged and collected 
in publicly available databases such as dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/). In addition and finally, HGP and HapMap 
influenced an unimaginable boost of technology giving rise to the continuous 
improvement of the platforms and arrays available for genetic screening as well as 
bioinformatics and biostatistics tools to address the needs associated with data storage, 
analysis and interpretation. These advancements led to the development of massively 
parallel sequencing or next generation sequencing (NGS) that enables high coverage and 
high resolution sequencing of both the whole exome (whole exome sequencing [WES]), 
and the whole genome (whole genome sequencing [WGS]). 
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1.4.2.3 1000 Genomes project – 2008-2012  
Subsequent to the development of NGS, the 1000 Genomes project was designed to 
generate an extensive public catalogue of human genetic variation, including rare SNPs 
(MAF ≤1%), structural variants and their haplotype contexts. Overall, 2,500 unidentified 
people from about 25 populations around the world were sequenced using NGS 
technologies. This project was subdivided in three phases each revealing novel and 
complementary data. Most relevant information came from the first phase that revealed 
~15M SNPs and 1.33M indels (>50% of which were novel), and the third that revealed 
additional ~13K SNPs (70% of which were novel) and 96 indels. In total, the 1000 
Genomes project extended the knowledge of common variability up to ~17M variants 
including SNVs and SVs. The most important outcome of the 1000 Genomes project, 
besides advancing the pure knowledge of the genome variability and structure, is that the 
generated data are freely and publicly accessible to provide a robust dataset for the 
research community to impute genotypes and haplotypes as well as compare the allele 
frequencies and linkage disequilibrium (LD) patterns each group finds in their own 
studies. 
The HGP, HapMap and 1000 Genome projects have laid the basis of today’s deep 
analysis of the human genome and continuing development of platforms and 
bioinformatics tools available for the study of genetics of disease (Figure 1-7).   
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Figure 1-7. The study of the genome 
 
Figure 1-7. Schematic summary of the most important discoveries along with the development of 
technologies/experimental approaches for the study of the genome and for the study of genetics of disease. 
AA=amino-acid. 
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1.4.3 Genome-wide association studies (GWAS) 
Although recent (and continuing) improvements of the technologies available for the 
study of genetics of disease currently provide advanced tools and platforms to scan the 
exome and the whole genome, the focus of the following sections will be on reviewing 
the main concepts characterising genome-wide association studies (GWAS) as this 
investigative approach has been the one on which the project on progressive supranuclear 
palsy has been based (Chapter 3) and the one used to study the genetic underpinnings of 
frontotemporal dementia (Chapter 4) in this thesis.  
 
1.4.3.1 GWAS: Study design 
Based on the knowledge acquired through the HGP and the HapMap projects (sections 
1.4.2.1 and 1.4.2.2) along with the progressive development of powerful high throughput 
genotyping platforms supporting genetic studies of robust size, the design of SNP-based 
association studies became possible approximately around 2005. As such, the opportunity 
of high-density genome screening shifted the search for new genes from the traditional 
candidate gene approach (rare high-risk variants) to the association study approach 
(common low-risk variants). 
GWAS follow the broad hypothesis of “common disease – common variant(s)” and 
represent a large-scale example of classical cases vs. control studies to assess differences 
in the allelic frequencies of genotyped (and imputed) genetic markers between the two 
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study groups. Specifically, differences in the frequencies of the alleles are statistically 
evaluated for each SNP in order to detect discriminants that may associate 
with/contribute to disease. Conceptually, GWAS interrogate the genome in an unbiased 
manner by means of hundreds of thousands of evenly distributed SNPs and allow for the 
identification of loci that increase susceptibility for disease, i.e. genetic markers within 
genetic regions with small to moderate effect size. In addition, GWAS is ideal study 
approach to target common/complex diseases (diseases that are very common among 
population such as cardiovascular disease, diabetes or Alzheimer’s disease) that are the 
result of the interaction between single or multiple genetic factors and the environment, 
where both, variably, contribute to the disease. 
The workflow of a GWAS is relatively simple and consists of two phases: An exploratory 
and a replication phase. The exploratory phase (or phase I) is hypothesis free and through 
massive statistical analyses allows identifying one or more genetic loci that might be 
associated with the trait under study. Once loci are identified in the discovery phase those 
that are statistically significant, as well as those that are suggestive of association, need to 
be selected for replication (phase II) that is to be performed in a novel independent cohort 
of cases and controls for validation. When and if results of phase I are replicated in phase 
II it is sensible to infer that most probably the locus/loci that show association contain or 
are in linkage disequilibrium (LD) with the SNP(s) that is/are responsible for the 
association. 
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Generally and finally, after completion of phase II, the loci that are confirmed for 
association are further investigated through fine mapping, i.e. genotyping a smaller 
number of SNPs (~10K SNPs) within a smaller region (1-5Mbp) comprising the 
associated SNP, to identify other associated SNPs and/or, possibly, disease associated 
haplotypes, or through direct sequencing of all the neighbouring genes implicated by the 
associated SNP [215]. 
There is evidence that GWAS are a proven successful method for mapping novel 
common variants underlying common diseases. Since the beginning of the GWAS era 
over 1,500 GWASs for over 240 traits or diseases have been published 
(http://www.genome.gov/gwastudies/, accessed in November 2013). 
 
1.4.3.2 GWAS: Good practice for success 
GWAS is a long and complex experimental procedure and there is room for errors and 
confounding elements to contaminate the final outcome of the study. Errors can occur at 
different levels, including phenotyping, sample quality, genotyping errors/artefacts, 
conflicting genetic background within the study cohorts (population stratification) to 
name the most relevant. However, there are a number of good practices to implement in 
order to minimise their overall impact. As such, the requirements and the workflow for a 
successful GWAS can be summarized as follows: 
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1 – Choice of appropriate genotyping array in order to evenly cover the genome and best 
target the genetic background of the study population; 
2 – Detailed characterisation of the study cohorts through stringent clinical and/or 
pathological inclusion/exclusion criteria and a well-defined disease phenotype; 
3 – Accurate match of cases and controls and large sample and control size in order to 
increase the power of the study; 
4 – Use of stringent quality control (QC) steps prior to and after genotyping. Prior to 
genotyping excluding poor quality samples is fundamental to avoid genotyping 
errors/artefacts. After genotyping there are several quality measures to be implemented 
that target and filter both SNPs and samples to choose those to be included in the 
association analysis: 
4a – SNPs: SNPs with call rates ≥0.95 should be included. This measure 
can be more stringent (≥0.97-0.99) based, mainly, on study design. To 
eliminate possible confounding factors, all SNPs with no call, or which are 
outliers, or that deviate from the Hardy-Weinberg equilibrium law, or that 
have a MAF<0.01 need to be excluded. These inclusion/exclusion criteria 
need to be applied for both cases and control sample sets. 
4b – Samples: Cases and controls will need to be matched based on 
ancestry in order to exclude possible false positives simply due to 
differences in the genetic background of the two cohorts (population 
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stratification). Samples with missing data for >5% of SNPs, samples that 
might be related and samples with discordant gender (gender mismatch) 
need to be excluded because of their high probability of contaminating the 
results of the association analysis.    
After the preliminary QC steps the clean dataset (which means all informative cases, 
controls and SNPs have been identified and filtered) is used for the association analysis. 
The latter is performed by means of online free open-source whole genome association 
analysis toolsets such as Plink (http://pngu.mgh.harvard.edu/~purcell/plink/ ) and R 
(http://www.r-project.org/). 
In studies evaluating for dichotomous traits (i.e. cases vs. control) the association needs 
to be tested for its significance and the effect size. 
Significance can be assessed through a number of methods including the Chi-squared test 
with either one degree of freedom (df) (allelic) or two df (genotypic), the Fisher’s exact 
test, or logistic regression. The significance is expressed in p-values for which, currently, 
an association is considered genome-wide significant when the p-value is <5x10-08. Once 
the association analysis is performed, there is an additional step used to evaluate the 
impact on results of possible confounding factors. This is the assessment of the 
distribution of the data through the Quantile-Quantile plots (QQ plots) that allow 
appreciating inflation/deflation from the expected distribution (Figure 1-8). The genomic 
inflation factor (λ) defines the deviation from the expected distribution under the null 
model (null hypothesis). Inflation (λ>1) is generally a signal of possible population 
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stratification, or an issue of relatedness (sample duplicates), or a technical bias or due to 
DNA poor quality, whilst deflation (λ>1) is generally a sign of possible phenotype 
discordance. However, a value of λ~1.05 is considered acceptable in GWAS. 
 
Figure 1-8. Example of quantile-quantile plot 
 
Figure 1-8. Example of a QQ-plot. The red line identifies the expected distribution in concordance with the 
null hypothesis. The black line represents the observed distribution. The majority of the observed 
distribution (up to 99%) overlaps with the expected distribution. Only a minority of SNPs (≤1%) deviates 
from the expected distribution because of presumable association with the trait (disease). However, the 
deviation underlying true association is expected to be minimal as a major deviation (inflation: λ >1 or 
deflation λ <1) represents confounding issues (e.g. population stratification). 
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Effect size is measured in the vast majority of GWAS through odds ratio (OR). An OR 
greater than 1 generally suggests increased risk, whilst an odds ratio smaller than 1 
indicates protection. 
 
1.4.3.3 Key words and definitions 
Null hypothesis: The hypothesis that there is no association between genotype and 
phenotype (i.e. no association between any allelic frequency and disease). 
P-value: Probability of finding an association exclusively by chance. 
Type I error (α): Probability of identifying an association when there is actually none 
(false positive also called spurious association). 
Type II error (β): Probability of not identifying an association when there is actually one 
(false negative).  
Power: Probability of identifying an association when there is actually one (1-β). The 
power is function of:  
a – Sample size; 
b – Allele frequency; 
c – Effect size, and; 
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d – Haplotype structure. 
Effect size: Magnitude of risk conferred by a certain allele. 
Odds ratio (OR): The measure of association by comparing the odds of an event 
happening in the presence or absence of a specific variable (e.g. an allele). In the specific 
case of GWAS the OR is: 
!" = !"#$#%&#!!"!!""#"#! !!"#!!"#$#%&#!!"!!"#$%&'!#!/!!"#$#%&#!!!!!""#"#!!!!"#!!"#$%&$!!"!!!!"#$%&!!"#$%&$!!"!!""#"#! !!"#!!"#$#%&#!!"!!"#$%&'!#!/!!"#$%&$!!"!!""#"#!!!!"#!!"#$%&$!!"!!!!"#$%&!   
 
1.4.3.4 GWAS: How to interpret the load of data 
To date, one of the most important lessons of genome-wide association studies is that the 
SNPs with the smallest p-values are seldom the real reason of the association. 
In the majority of cases the SNPs with highest association, being tag-SNPs and acting as 
a surrogate for association, indirectly point to neighbouring SNPs in LD for the real cause 
of association at that locus. In addition, the SNPs showing association are rarely coding, 
whilst, more frequently, they are intronic or intergenic.  
When a GWAS is concluded (discovery + replication phases) caution is warranted in the 
interpretation of the outcome and following steps are generally recommended (Figure 1-
9): 
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1 – Identify all genes in proximity of the top hits and sequence them in the search of 
possible coding changes. This approach may lead to the identification of pathogenic 
coding variants and novel genes associated with the disease under study; 
2 – Select all identified known polymorphisms to build haplotypes within and around the 
associated locus/loci to possibly identify disease specific haplotypes and/or particular 
SNPs that are in linkage disequilibrium with the GWAS top hits to be further studied, 
and; 
3 – Evaluate effects of the associated SNPs (and of those in LD with the associated 
SNPs) on expression and/or splicing. 
For the latter analysis, all SNPs (intergenic, intronic or even synonymous variants) that 
show association or are in LD with associate SNPs are informative. In fact, when the 
associated loci do not affect proteins directly it is likely that they exert their effect by 
[215]: 
1 – Altering constitutively transcript levels; 
2 – Modulating transcript expression, and; 
3 – Affecting splicing. 
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Figure 1-9. Post-GWAS workflow 
 
Figure 1-9. Diagram highlighting the recommended workflow subsequent to completion of discovery and 
replication phases of a GWAS. These are the main (but not exclusive) immediate steps warranted for 
further interpreting the results of a GWAS. 
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1.5 Thesis aims and objectives 
Exploring the genetics of disease not only allows the identification of genes that may 
impact disease with differential penetrance (from high to low risk variants) but also may 
provide clues on expression/splicing patterns that may increase risk or confer protection 
and, not least, on cellular/biological processes possibly involved in disease pathogenesis. 
It is central to understand disease mechanisms, as these will allow the development of 
preventive as well as therapeutic measures. Within this picture, the genetic approach 
holds the fundamental role of determining whether and to what extent genetic variability 
influences pathogenesis and progression of the disease.  
To date, despite tremendous progress in the genetics of FTD and PSP, the role of 
common genetic factors contributing to FTD and PSP is still poorly understood. 
The aim of the two main projects presented in this thesis (Chapters 3 and 4) was to 
further characterise these two devastating complex neurological disorders through a 
follow up study of the recent PSP-GWAS project [180] and the first GWAS on clinical 
FTD to date. 
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1.5.1 PSP 
PSP is a tauopathy whose strong genetic link to the MAPT locus on chromosome 17 has 
been widely established across multiple studies including the recent GWAS [180]. 
Nevertheless, to date, the pathogenic mechanism underlying such association has not 
been fully elucidated, on one hand, because of absence of robust association with coding 
mutations in MAPT and, on the other, because studies of the MAPT haplotype only 
revealed an association with the H1c sub-haplotype without however unequivocally 
unravelling its pathogenic mode of action. In addition, the MAPT association alone does 
not explain the entire genetic component of PSP suggesting that other genetic loci 
together with hard-to-determine environmental risk factors must collectively contribute to 
disease. 
The recent GWAS [180] highlighted novel loci in association with PSP that point to 
specific and plausible biological processes being involved in the pathogenesis of PSP. 
The aim of the study of PSP presented in this thesis (Chapter 3) was to further 
characterise the newly identified loci by: 
1 – Sequencing the genes within the associated loci in the search of relevant coding 
variants; 
2 – Evaluating the presence and, in case, the frequency and distribution of putative 
disease associated haplotypes, and; 
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3 – Analysing possible cis effects on expression through expression quantitative trait loci 
(eQTL) analyses of the GWAS-associated SNPs and those in LD. 
 
1.5.2 FTD 
Frontotemporal dementia is clinically, pathologically and genetically relatively 
heterogeneous (Figure 1-3). Concerning the genetic component, the screening and 
characterisation of candidate genes has explained a number of cases (mainly familial) 
over the past fifteen years, but the vast majority still remain uncharacterised. In addition, 
and especially, the mechanisms leading to disease are by far not yet understood. The 
state-of-the-art in the field of FTD research advocates for a better and deeper 
understanding of genotype-phenotype correlation and, particularly, there is an urgent 
need for clues about the mechanisms and biological processes that contribute to disease 
onset and progression. The study presented in this thesis (Chapter 4) is the first GWAS 
on clinical FTD performed to date. 
The main aims of this project were to: 
1 – Identify novel genetic entities associated with increased risk of FTD, and; 
2 – Shed light on possible disease mechanisms to be further explored and transferred to 
the field of cell biology for functional assessments. 
! 101!
Especially the latter aim is of incommensurable importance as elucidating possible 
disease mechanisms will allow to better characterise and understand the molecular 
underpinnings of the disease and, probably even more importantly, establish biological 
pathways/processes as targets for the development of therapeutic measures, which, to 
date, are completely lacking in the field of FTD. 
In addition, the study of familial and sporadic FTLD cases is also presented in this thesis 
(Chapter 5). The main aim of the latter studies was to further characterise the known 
candidate genes and gain insight and/or expand on genotype-phenotype correlations 
through the genetic screening of the main known genes, such as MAPT, GRN, C9orf72, 
TDP-43, FUS and CHMP2B, associated with FTLD in population-specific families 
and/or cohorts. 
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CHAPTER 2 – Materials and methods 
 
2.1 Materials 
2.1.1 PSP cohort 
Eighty-four pathologically confirmed progressive supranuclear palsy (PSP) cases (Figure 
2-1) were analysed in the follow up study (Chapter 3) of the PSP-GWAS [180]. 
 
Figure 2-1. UK PSP cohort 
 
Figure 2-1. Code IDs of the 84 PSP cases analysed in the study. The diagnosis of PSP for each case was 
pathologically confirmed. DNA from each individual has been extracted from brain tissue.  
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All patients were white western Europeans and were collected over the past 10-15 years, 
primarily, by Dr Andrew Lees at the Queen Square Brain Bank and Sara Koe PSP 
Research Centre, Institute of Neurology (UCL). All the PSP cases met modified National 
Institute of Neurological Disorders and Stroke (NINDS) possible or probable criteria 
[216] and diagnosis was confirmed pathologically using standardized criteria [160, 217]. 
The brain pathology was evaluated by neuropathologist at the Queen Square Brain Bank, 
primarily by Drs Tamas Revesz and Janice Holton, at UCL. Samples were enrolled and 
collected under approved protocols followed by informed consent and every aspect of the 
study was approved by the Joint Medical Ethics Committee of the National Hospital of 
Neurology and Neurosurgery, London. 
 
2.1.2 FTD-GWAS: Cases cohort 
Forty-four international research groups from Europe, North America and Australia 
(Table 2-1) participated collectively in the study (Chapter 4). Sample collection and 
DNA extraction was performed at each individual collaborating site where appropriate 
informed consent was obtained. The DNA material was collected from the participating 
groups and stored at the three Institutions leading this project: The Department of 
Molecular Neuroscience at the University College of London (UCL), the Laboratory of 
Neurogenetics of the National Institute on Aging at the National Institutes of Health 
(NIH), and the Laboratory of Neurogenetics at the Texas Tech University Health 
Sciences Center (TTUHSC). 
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Table 2-1. FTD-GWAS: Collaborative groups 
Site PI Main Institutions Country 
Parastoo Momeni* Texas Tech University Health Sciences Center, Lubbock, Texas, USA USA/UK 
Caroline Graff Karolinska Institute, Department of NVS, Stockholm, Sweden SWEDEN 
Isabelle Leber* Unit of Research of Neurology and experimental Therapy, Paris, France FRANCE 
Jorgen Nielsen Section of Neurogenetics, University of Copenhagen, Denmark DENMARK 
Adrian Danek Department of Neurology, Ludwig-Maximilian University of Munich, Germany GERMANY 
Robert Perneczky Department of Psychiatry and Psychotherapy, Tech University Munich, Germany GERMANY 
Matthias 
Riemenschneider* 
Saarland University Hospital, Department for Psychiatry and Psychotherapy, Homburg/Saar, Germany GERMANY 
Johannes Schlachetzki Memory Clinic, University Hospital, Freiburg, Germany GERMANY 
Barbara Borroni Department of Medical Sciences, Neurological Clinic, University of Brescia, Italy ITALY 
Annibale Puca* Gruppo Multimedica, Milan, Italy ITALY 
Giacomina Rossi Neurological Institute Carlo Besta, Milan, Italy ITALY 
Daniela Galimberti* Department of Neurological Sciences, Dino Ferrari Institute, University of Milan, Italy ITALY 
 Innocenzo Rainero Department of Neuroscience, University of Torino, Italy ITALY 
Luisa Benussi NeuroBioGen Lab-Memory Clinic, Fatebenefratelli, Brescia, Italy ITALY 
Benedetta Nacmias Department of Neurological and Psychiatric Sciences, University of Florence, Italy ITALY 
Amalia Bruni Regional Center of Neurogenetic, Lamezia Terme, Italy ITALY 
Giancarlo Logroscino Department of Basic Medical Sciences, Neurosciences and Sense Organs,"Aldo Moro" University of Bari, Italy ITALY 
Jonathan Rohrer Institute of Neurology, UCL, London, UK UK 
Simon Mead Institute of Neurology, Prion Unit, UCL, London, UK UK 
James Rowe Cambridge University Department of Clinical Neurosciences, Cambridge, CB2 0SZ UK 
Stuart Pickering-
Brown* 
University of Manchester, Clinical Neuroscience, Manchester, UK UK 
Huw Morris Department of Neurology, Cardiff University School of Medicine, Cardiff, UK UK 
Ekaterina Roageva Center for research in Neurodegenerative diseases, Toronto, Canada CANADA 
Rosa Rademakers* Mayo Clinic Jacksonville, Florida, USA USA 
Vivianna Van Deerlin University of Pennsylvania Health System, Department of Pathology, Philadelphia, PA, USA USA 
Christine Van 
Broekhoven* 
Department of Molecular Genetics, University of Antwerp, Belgium BELGIUM 
Peter Heutink German Center of Neurodegenerative Diseases-Tübingen, Germany NETHERLANDS 
John van Swieten Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands NETHERLANDS 
Jordi Clarimon Genetics of Neurodegenerative Diseases Unit, IIB Hospital Sant Pau, Barcelona, Spain SPAIN 
Pau Pastor Center for Applied Medical Research, Division of Neurology, University of Navarra, Pamplona, Spain SPAIN 
Carlos Cruchaga Department of Psychiatry, HPAN, WU, St. Louis, USA USA 
Ian Mackenzie Department of Pathology, Vancouver General Hospital, Vancouver, BC, Canada CANADA 
Maria Landqvist Unit of Geriatric Psychiatry, Department of Clinical Sciences, Lund University, Sweden SWEDEN 
Agustin Ruiz ACE Foundation. Catalan Institute of Applied Neuroscience, Barcelona, Spain SPAIN 
Peter Schofield Neuroscience Research Australia, Sydney, Australia AUSTRALIA 
Table 2-1. List of the totality of the PIs of collaborative sites that directly sent DNA samples to the three 
institutions (UCL, NIH and TTUHSC) leading the project. * PI representing multiple centres. 
 
In total, 5,696 samples were collected considering both the discovery (n=3,657) and the 
replication phase (n=2,039). 
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I received and managed the samples at UCL (discovery + replication phases) and 
TTUHSC (replication phase). In addition, I performed all quality control (QC) steps prior 
to genotyping (section 2.1.2.1). I partially participated in the process of genotyping that 
was performed at the UCL core facility, UCL Genomics, located at the Institute of Child 
Health (ICH). The samples shipped to NIH were received by Cynthia Crews and Dena 
Hernandez and then underwent QC steps and genotyping that were performed by 
laboratory technicians at the Laboratory of Neurogenetics (NIH). 
 
2.1.2.1 Discovery phase 
Twenty-seven international research groups contributed samples (n=3,657) for the 
discovery phase (Table 2-2). 
Given the heterogeneity of the disease the inclusion/exclusion criteria for enrolment in 
the study were based on: 
1 – The most common and worldwide adopted clinical diagnostic criteria [21]; 
2 – The brain pathology (if available), and; 
3 – The genetic screening of the candidate genes (if available).  
This project started in late 2008. Being the Neary criteria [21] the gold standard for 
clinical diagnosis at the time, all samples collected during discovery phase were 
diagnosed based on those diagnostic criteria. 
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Table 2-2. FTD-GWAS: Discovery phase cases 
Participating Groups Sending Institution Samples sent 
  
Discovery phase 
Momeni (USA) Texas Tech University Health Sciences Center, Lubbock, Texas, USA 
TOTAL 3,657 
Graff (SWEDEN) Karolinska Institute, Department of NVS, Stockholm, Sweden 
French Consortium 
Unit of Research of Neurology and experimental Therapy, Paris, France 
Neurological Institute, University of Salpetriere Hospital, Paris, France 
Department of Neurology and Memory Center, Lille, France 
Nielsen (DENMARK) Section of Neurogenetics, University of Copenhagen, Denmark 
Danek (GERMANY) Department of Neurology, Ludwig-Maximilian University of Munich, Germany 
Perneczky (GERMANY) Department of Psychiatry and Psychotherapy, Tech University Munich, Germany 
Riemenschneider 
(GERMANY) Department of Neuropathology, Heinrich Heine University, Düsseldorf, Germany 
Schlachetzki (GERMANY) Memory Clinic, University Hospital, Freiburg, Germany 
Borroni (ITALY) Department of Medical Sciences, Neurological Clinic, University of Brescia, Italy 
Novelli - Puca (ITALY) Gruppo Multimedica, Milan, Italy 
Rossi (ITALY) Neurological Institute Carlo Besta, Milan, Italy 
Galimberti (ITALY) Department of Neurological Sciences, Dino Ferrari Institute, University of Milan, Italy 
Rainero (ITALY) Department of Neuroscience, University of Torino, Italy 
Benussi (ITALY) NeuroBioGen Lab-Memory Clinic, Fatebenefratelli, Brescia, Italy 
Nacmias (ITALY) Department of Neurological and Psychiatric Sciences, University of Florence, Italy 
Bruni (ITALY) Regional Center of Neurogenetic, Lamezia Terme, Italy 
Rohrer - Rossor (UK) Institute of Neurology, UCL and Division of Neuroscience and Psychological medicine, Imperial College, London, UK 
Mead (UK) Institute of Neurology, Prion Unit, UCL, London, UK 
Pickering-Brown (UK) University of Manchester, Clinical Neuroscience, Manchester, UK 
Morris (UK) Department of Neurology, Cardiff University School of Medicine, Cardiff, UK 
Roageva (CANADA) Center for research in Neurodegenerative diseases, Toronto, Canada 
Rademakers (USA) Mayo Clinic Jacksonville, Florida, USA 
Van deerlin (USA) University of Pennsylvania Health System, Department of Pathology, Philadelphia, PA, USA 
Van Broekhoven 
(BELGIUM) Department of Molecular Genetics, University of Antwerp, Belgium 
Heutink (NETHERLANDS) Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, Netherlands 
van Swieten 
(NETHERLANDS) Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands 
Pastor (SPAIN) Center for Applied Medical Research, Division of Neurology, University of Navarra, Pamplona, Spain 
Table 2-2. List of the research groups (identified by the PI’s name) that contributed samples for the 
discovery phase.  
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To address and cover the main syndromes associated with FTD, samples clinically 
diagnosed with behavioural variant FTD (bvFTD), semantic dementia (SD), progressive 
non-fluent aphasia (PNFA) [20, 21], and FTD with motor neuron disease (FTD-MND) 
[218] were included in the study. I paid particular attention in identifying cases diagnosed 
with logopenic aphasia (LPA), because the majority of these cases are associated with 
Alzheimer’s disease pathology [25], reason for which they were eventually excluded 
from the study. If the analysis of the brain pathology was available it was given priority, 
in terms of final diagnosis, over the clinical diagnosis. Samples with tau as well as 
FTLD-U/FTLD-TDP pathology where included in the study. Finally, samples known to 
carry mutations in the MAPT and GRN genes were excluded from the study. An ideal 
requirement was the characterisation of each sample for the MAPT haplotype, ApoE and 
MAPT/GRN sequencing in pre-genotyping phase. In addition, individuals with C9orf72 
expansions were not excluded from the discovery phase, because this locus was identified 
subsequently (almost 3 years) to sample collection. Of note, whole genome amplified 
samples were not included in the study to precautionary exclude possible errors in 
genotyping (Appendix 2-1). 
Eligible sporadic cases were all included in the study whilst, for familial cases, 
exclusively index patient/probands were included in the study.  
The samples, all of European-North American extraction and of confirmed European 
ancestry, were received either in tubes or 96 well plates each with a unique alpha-
numerical ID specific to the sample and the site. For each sample, a total amount of 2µg 
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of DNA extracted either from blood or brain at each collaborative site was collected. A 
description of the main clinical, pathological and genetic known features was integrated 
through a spread sheet summarizing a panel of information useful in further 
characterising the collected samples and identifying those eligible for inclusion in the 
study (Appendix 2-2).  
Each DNA sample was evaluated for integrity by means of gel electrophoresis on 1% 
agarose gel (section 2.2.2.2). Material purity and concentration were analysed by 
spectrophotometric (Nanodrop, Wilmington, DE, USA) quantification (section 2.2.1.3). 
Each sample was brought to a final concentration of 250ng as recommended by 
manufacturer (Illumina, San Diego, CA, USA) prior to being transferred onto chip for 
whole genome genotyping. 
 
2.1.2.2 Replication phase 
Twenty-eight research groups contributed samples (n=2,039) and matching 
neurologically normal controls (n=1,600) for the replication phase from Sweden, 
England, Italy and Spain (Table 2-3). Further cases and matching controls from North 
America (USA and Canada), France, Germany, England and Netherlands (section 
2.1.6.3) were collected at NIH.  
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Table 2-3. FTD-GWAS: Replication phase cases and controls 
Participating Groups Sending Institution Samples sent 
  
Replication phase 
  
Cases Controls 
Momeni (USA) Texas Tech University Health Sciences Center, Lubbock, Texas, USA 
TOTAL 
2,039 
TOTAL 
1,600 
Baborie (UK) Liverpool - Newcastle 
Graff (SWEDEN) Karolinska Institute, Department of NVS, Stockholm, Sweden 
French Consortium 
Unit of Research of Neurology and experimental Therapy, Paris, France 
Neurological Institute, University of Salpetriere Hospital, Paris, France 
Department of Neurology and Memory Center, Lille, France 
Perneczky (GERMANY) Department of Psychiatry and Psychotherapy, Tech University Munich, Germany 
Borroni (ITALY) Department of Medical Sciences, Neurological Clinic, University of Brescia, Italy 
Rossi (ITALY) Neurological Institute Carlo Besta, Milan, Italy 
Galimberti (ITALY) Department of Neurological Sciences, Dino Ferrari Institute, University of Milan, Italy 
Rainero (ITALY) Department of Neuroscience, University of Torino, Italy 
Benussi (ITALY) NeuroBioGen Lab-Memory Clinic, Fatebenefratelli, Brescia, Italy 
Nacmias (ITALY) Department of Neurological and Psychiatric Sciences, University of Florence, Italy 
Bruni (ITALY) Regional Center of Neurogenetic, Lamezia Terme, Italy 
Rohrer - Rossor (UK) Institute of Neurology, UCL and Division of Neuroscience and Psychological medicine, Imperial College, London, UK 
Mead (UK) Institute of Neurology, Prion Unit, UCL, London, UK 
Rowe (UK) Cambridge 
Pickering-Brown (UK) University of Manchester, Clinical Neuroscience, Manchester, UK 
Rademakers (USA) Mayo Clinic Jacksonville, Florida, USA 
Van deerlin (USA) University of Pennsylvania Health System, Department of Pathology, Philadelphia, PA, USA 
Van Broekhoven 
(BELGIUM) Department of Molecular Genetics, University of Antwerp, Belgium 
Heutink (NETHERLANDS) Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, Netherlands 
van Swieten 
(NETHERLANDS) Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands 
Clarimon (SPAIN) Genetics of Neurodegenerative Diseases Unit | IIB Hospital Sant Pau, Barcelona, Spain 
Pastor (SPAIN) Center for Applied Medical Research, Division of Neurology, University of Navarra, Pamplona, Spain 
Cruchaga (USA) Department of Psychiatry, HPAN, WU, St. Louis, USA 
Mackenzie (CANADA) Department of Pathology, Vancouver General Hospital, Vancouver, BC, Canada 
Landqvist (SWEDEN) Unit of Geriatric Psychiatry ,Department of Clinical Sciences, Lund University, Sweden 
Ruiz (SPAIN) ACE Foundation. Catalan Institute of Applied Neuroscience, Barcelona, Spain 
Schofield (AUSTRALIA) Neuroscience Research Australia ,Sydney ,Australia 
Table 2-3. List of the research groups that contributed samples for the replication phase. The third column 
is subdivided into two sub-columns which show the number of cases and neurologically normal controls 
that were received. 
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It needs to be acknowledged that during the course of the project the diagnostic criteria 
for FTD underwent revisions that resulted in two updated versions addressing specifically 
the behavioural variant [27] and the language variant syndromes [20]. The updated 
diagnostic criteria were adopted for a part of the samples collected during replication 
phase. However, inclusion/exclusion criteria for the replication phase were almost 
entirely the same as in the case of the discovery phase. The differences were only minor: 
1 – In addition to samples also matching neurologically normal controls from each site (if 
available) were collected to best match cases and controls in the association study; 
2 – Mutation carriers in the MAPT and GRN genes were excluded from the study, whilst 
cases harbouring the C9orf72 expansion were asked to be identified but were included 
(Appendix 2-3).  
The cases (and the controls) collected for the replication phase were a new set of samples, 
all of European-North American extraction and of confirmed European ancestry each 
with a unique alpha-numerical ID specific to the sample and the site. For each sample, a 
total amount of 2µg of DNA extracted either from blood or brain at each collaborative 
site was collected. The main clinical, pathological and genetic known characteristics were 
integrated through a spreadsheet that was slightly revised compared to that used in 
discovery phase (Appendix 2-3). 
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This step was entirely performed as in discovery phase with the difference that purity and 
concentration were assessed either by spectrophotometric (Nanodrop, Wilmington, DE, 
USA) or fluorometric (Qubit, Life Technologies, Grand Island, NY, USA) quantification. 
 
2.1.3 The Afrikaaner family 
The Afrikaaner family is a multigenerational kindred from South Africa with Dutch 
ancestry (Figure 2-2). 
Members of this family have been diagnosed with FTD and the mode of inheritance 
strongly seems autosomal dominant. Affected and unaffected family members were 
collected through a collaborative effort between the Institute for Ageing and Health at 
Newcastle University and The University of Stellenbosch by Drs. Rajesh Kalaria and 
Felix Potocnick who are the physicians following longitudinally this familial case of FTD 
since the past 10 years.  
The members of this family were consented prior to blood draw according to the ethics 
committee of the University of Stellenbosch. The DNA used for genetic screening 
(Chapter 5, section 5.1.1) was extracted from blood using the standard procedures and 
the brain pathology was evaluated at the University of Newcastle in three individuals 
(numbers 19, 20 and 22 in the pedigree; Figure 2-2) revealing typical tau pathology. 
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Figure 2-2. Afrikaaner family pedigree 
 
Figure 2-2. Multigenerational pedigree of the Afrikaner family. The individuals for whom there is 
availability of DNA for genetic screening (arrow), the affected members (bold squares or circles) and those 
individuals for whom data on the brain pathology are available (bold red squares or circles) are shown. 
 
2.1.4 The Finnish kindred 
The Finnish FTD kindred is a two generational family (Figure 2-3) of which 5 siblings of 
the second generation have been followed by a team of neurologists and pathologists at 
the University of Helsinki over the past 20-30 years.  
Two of the five siblings (1 and 2) were diagnosed with FTD at the Department of 
Neurology at the Helsinki Central University Hospital. Blood samples for DNA analysis 
were collected from the 2 index patients (1 and 2) and the 3 further siblings (3, 4 and 5) 
for genetic screening (Chapter 5, section 5.1.2) after all subjects gave informed consent 
for research. 
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Figure 2-3. Finnish family pedigree 
 
Figure 2-3. Pedigree of the Finnish FTD kindred. First generation: Parents of the five siblings who are 
depicted in the second generation. Individuals 1 and 2 of the second generation were diagnosed with FTD. 
Both are deceased. Patient 1 also developed gangliocytoma. This figure has been adapted from Ferrari et al, 
2013 [219]. 
 
2.1.5 The NINDS sample set 
Sporadic cases diagnosed with FTD (n=158) or CBS (n=70) were collected at the 
Cognitive Neuroscience Division of National Institute of Neurological Disorders and 
Stroke (NINDS) at the National Institutes of Health (NIH) starting in the early 2000s’.  
This cohort included patients with a diagnosis of behavioural variant FTD (bvFTD), 
progressive non-fluent aphasia (PNFA) [21], and CBS [220] and five of the FTD patients 
had concomitant motor neuron disease. These subjects were seen as part of an ongoing 
research study on FTD and CBS at the Cognitive Neuroscience Section of the NINDS of 
the NIH, Bethesda, MD. 
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The patients were either self-referred or referred by outside physicians, psychiatrists or 
neurologists. After arrival to NIH accompanied by a caregiver, they were diagnosed 
based on an initial clinical evaluation and examination performed by a team of 
neurologists and psychiatrists, led by Dr Wassermann, based on standard clinical criteria 
[21, 220]. The patients then spent ~7-10 days participating in extensive 
neuropsychological and neurologic testing and imaging studies. Their diagnoses were re-
evaluated by a neuropsychologist (Dr Jordan Grafman) based on the results of the testing 
performed at the NIH. All subjects were required to have an assigned research durable 
power of attorney prior to admission to the protocol and the assigned individuals gave 
written informed consent for the study. 
After the patients gave assent for the study, blood samples for a total of 228 index 
patients was collected. DNA was extracted for genetic screening (Chapter 5, extended 
section 5.2) either at NIH or, later, at TTUHSC. All aspects of the study and the consent 
procedures were approved by the NINDS, NIA and TTUHSC Institutional Review 
Boards. 
 
2.1.6 Normal controls 
Different types of neurologically normal controls or normal/healthy population samples 
were used based on the kind of study or on the purpose of the projects. 
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2.1.6.1 Familial cases 
For the two familial cases, the Afrikaaner family (section 2.1.3) and the Finnish kindred 
(section 2.1.4), unaffected family members of each family were used as normal controls. 
These individuals are identified in Figure 2-2 and Figure 2-3, respectively. 
 
2.1.6.2 Sporadic cases 
For the sporadic cases and, in general, to assess the presence and distribution of 
putatively pathogenic missense variants identified during the course of genetic screening 
of the dementia candidate genes (Table 5-1, in Chapter 5), DNA samples of 
neurologically normal controls/healthy individuals (n=672) were used, all obtained from 
the Coriell repository (http://www.ccr.coriell.org) (Table 2-4). 
 
Table 2-4. Normal controls from the Coriell repository 
Plate ID n Type of control Ancestry Web link 
     
NDPT096  94 Neurologically normal controls Caucasian http://ccr.coriell.org/Sections/Search/Panel_Detail.aspx?Ref=NDPT096&PgId=202 
NDPT098  92 Neurologically normal controls Caucasian Discontinued; Appendix 2-4 
NDPT099  92 Neurologically normal controls Caucasian http://ccr.coriell.org/Sections/Search/Panel_Detail.aspx?Ref=NDPT099&PgId=202 
NDPT031  94 Population/convenience control African American 
http://www.ccr.coriell.org/Sections/Search/Search.aspx?PgId=165&q=NDPT031 
HD200CAU 200 Human variation panel Caucasian http://www.ccr.coriell.org/Sections/Search/Panel_Detail.aspx?Ref=HD200CAU&PgId=202 
HD100MEX-2 100 Human variation panel Mexican http://www.ccr.coriell.org/Sections/Search/Panel_Detail.aspx?Ref=HD100MEX-2&PgId=202 
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2.1.6.3 Genome-wide association study 
Discovery phase 
The samples (cases) included in the discovery phase of FTD-GWAS were obtained from 
different European countries (France, England, Germany, Netherlands, Belgium, 
Denmark, Sweden and Italy) and from North America (USA and Canada). 
To match all the cases, genotyping data of normal controls generated in studies 
previously conducted at either the Laboratory of Neurogenetics of the National Institute 
on Aging at the National Institutes of Health or from the Department of Molecular 
Neuroscience at the University College London were used [221-223]. These control 
samples had been genotyped on a variety of chips such as Illumina 370K and 550K, and 
were matched as best as possible based on population ancestry and genotyping 
platform. Specifically, aggregate data for control samples were merged based on 
overlapping SNPs from the different chips. In total 7,444 control samples were selected 
after QC and filtering steps (section 2.3.5.1) for the association analysis of the discovery 
phase cohort. 
The controls originated from the USA, England, Italy, Germany, France, Sweden and the 
Netherlands. For each case, at least 2 controls were matched based on compatibility of 
genetic ancestry estimated by principal components analysis (PCA) (section 2.3.5.1). 
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Replication phase 
In replication phase the genotyping of controls was performed in concomitance with the 
genotyping of the cases. The cases that needed to be matched to neurologically normal 
controls were obtained from Europe (Spain, France, England, Netherlands, Belgium, 
Germany, Sweden and Italy), from North America (USA and Canada) and from Australia 
(with British ancestry). All samples were ultimately of European ancestry.  
The genotyping of controls was performed at the Laboratory of Neurogenetics of the 
National Institute on Aging at the NIH (90% of controls) and at the core facility at the 
Institute of Child Health at UCL (10% of controls). The total number of normal controls 
that had been collected exceeded the number of controls reported in Table 2-3. In fact, 
Table 2-3 reports only normal control samples that were collected at UCL, whilst more 
control cases were genotyped at NIH. All controls (n>7,000) used in the replication phase 
were genotyped using the NeuroX custom chip (section 2.2.2.8).  
Eventually, n=5,094 survived QC and were used for replication and joint analyses. The 
normal controls for the replication phase were from the following ancestry backgrounds: 
USA (European/American), England, Italy, France, Germany, Sweden, Spain, and the 
Netherlands. 
 
 
 
! 118!
2.2 Methods 
2.2.1 DNA extraction 
2.2.1.1 DNA from blood 
Genomic DNA is extracted from 4-5ml of blood using Promega Wizard DNA extraction 
kit (Promega, Madison, WI, USA), following manufacturer’s instructions. The dried 
DNA pellet is re-suspended in 250µl of DNA Rehydratation Solution (Promega) and kept 
2-5 days at 4°C prior to evaluating the concentration. 
 
2.2.1.2 DNA from Brain 
Total DNA is extracted from dissected samples (100–200mg) of human post-mortem 
brain tissue using the Qiagen DNeasy Blood and Tissue Kit (Qiagen, Manchester, UK) 
and was performed following manufacturer’s instructions (Qiagen). The dried DNA 
pellet is re-suspended in 100-200µl of DNA Rehydratation Solution (Qiagen) and kept 2-
5 days at 4°C prior to evaluating the concentration. 
 
2.2.1.3 DNA quantitation 
To evaluate the concentration of the DNA either a spectrophotometer or a fluorometer 
were used. 
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Nanodrop spectrophotometer 
The NanoDrop Spectrophotometer is equipped with the interactive software ND-1000 
V3.5.2 that needs to be installed on PC (NanoDrop Technologies Inc, Wilmington, 
Delaware, USA). The NanoDrop calculates concentration of a variety of molecular 
probes including DNA, RNA and proteins. As absorbance measurements will measure 
any molecules absorbing at a specific wavelength, DNA will absorb at 260 nm and 
contribute to the total absorbance. For quality control, the ratios of absorbance at 260/280 
nm and 260/230 nm are used to assess the purity of DNA. Ratios of 260/280=~1.8 and 
260/230=~2.0-2.2 denote pure DNA. The NanoDrop spectrophotometer is initiated with 
distilled water and then calibrated by using the solution/buffer in which the DNA that 
will be measured is re-suspended as a blank. Then, 2µl of DNA sample are loaded on the 
column of the NanoDrop that will read the absorbance and express the DNA 
concentration in ng/µl. Afterwards the DNA is diluted to the working concentration. 
 
Qubit fluorometer 
The Qubit fluorometer (Life Technologies, Paisley, UK) does not require a connection to 
PC and calculates concentration of a variety of molecular probes including DNA, RNA 
and proteins. To evaluate concentration of DNA the Quant-iTTM dsDNA BR assay (Life 
Technologies) is used and samples are prepared as suggested by manufacturer. The Qubit 
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fluorometer will display the concentration in ng/ml; therefore, calculations will need to 
be adjusted to ng/µl. Afterwards the DNA is diluted to the working concentration. 
 
2.2.2 Genetic screening 
2.2.2.1 Polymerase chain reaction (PCR) 
PCR is performed using Roche Faststart PCR Master (400 RXN/10 ML) (Roche Applied 
Science, Indianapolis, IN, USA), primers (designed with Primer 3 software; 
http://bioinfo.ut.ee/primer3-0.4.0/) at a dilution of 10pmol/µl and genomic DNA is added 
to the reaction at a final concentration of 15-20ng. The PCR amplification is performed 
using a program that uses 35 cycles at 95°C for 15” for denaturation, at 55-57°C for 15” 
to allow primers’ annealing and at 72°C for 30” for extension, followed by a final 7’ 
elongation at 72°C. 
 
2.2.2.2 Agarose gel electrophoresis 
Agarose gel electrophoresis is used to verify the quality and size of the PCR 
amplification product. Either 1%, 1.5% or 2% gel is prepared using Ultrapure agarose 
(Life Technologies, Grand Island, NY, USA) and Tris/Borate/EDTA (TBE) 1X buffer 
(diluted 1:10 from VWR, Radnor, PA, USA). To do so, either 1g, 1.5g or 2g of Ultrapure 
agarose are weighted and added to 100ml of TBE 1X, and heated in a microwave for 
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1’:30”. The GelRed nucleic acid gel stain (VWR) is added to visualize the DNA bands in 
the gel and the gel is left solidifying for 10-15’. Afterwards the gel is placed in a chamber 
and is covered with TBE 1X buffer. One µl of PCR product is mixed with 4µl of loading 
dye (EMD Millipore – Novagen, Madison, WI, USA). This mix is loaded into the wells 
of the solidified gel and the DNA ladder (100bp or 1Kbp) (EMD Millipore – Novagen) is 
loaded at the beginning of each row to have a mean of comparison for the size of the PCR 
product. After loading the samples and the DNA ladder the gel is exposed to 120-200mV 
of voltage for ~20-30’. The DNA fragments are then visualized using a UV trans-
illuminator. 
 
2.2.2.3 PCR product purification 
The PCR product is purified using either 96 well or 384 well PCR filter plates (Millipore, 
Billerica, MA, USA). Up to 70µl of distilled/purified water are added to the PCR product 
which is vacuum-filtered at -12 inch of Mercury (in.Hg). Subsequently, the PCR product 
is re-suspended in 80µl of distilled/purified water and shaken on the thermo-shaker 
(Eppendorf, Hauppauge, NY, USA) at 4°C at 300rpm for 10-15’. The purified PCR 
product is then used for the sequencing reaction. 
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2.2.2.4 Sequencing 
The sequencing reaction is prepared using BigDye Terminator v3.1, 5X Sequencing 
Buffer (Life Technologies), forward or reverse primers at 5pmol/µl and purified PCR 
product as recommended by manufacturer (Life Technologies). Standard program 
recommended by Life Technologies is used to run the sequencing reaction in the thermo-
cycler: A sequence of 45 cycles at 95°C for 10” for denaturation, at 50°C for 5” to allow 
primers’ annealing and at 60°C for 4’ for extension are performed. 
The sequencing reaction product is then purified through vacuum-filtering using 
Millipore filter plates (Millipore) and re-suspended in 30µl purified water. The filtered 
sequencing reaction product is transferred into 96 or 384 wells Optical Reaction Plates 
(Life Technologies) and loaded into the 3730 DNA analyzer (Life Technologies). The 
output data of the 3730 DNA analyzer is analysed and saved with the Sequencing 
Analysis Software (section 3.2). These files are then exported to the Sequencher 4.9 
software (section 3.2) for alignment with the reference sequence and for visual inspection 
and analysis.  
 
2.2.2.5 Repeat expansion 
The repeat-primed PCR is used to detect the presence of expansion in C9orf72. 
Briefly, 100ng of genomic DNA are mixed with FastStart Mix (Roche), dimethyl 
sulfoxide (DMSO) (VWR), Q Solution (Invitrogen), deazaGTP (Fisher Scientific, 
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Waltham, MA, USA), and the primers mix (Invitrogen). The primers include a 
fluorescently labelled forward primer: 6-FAM-AGTCGCTAGAGGCGAAAGC; a 
reverse primer annealing with the repeat: 
TACGCATCCCAGTTTGAGACGGGGGCCGGGGCCGGGGCCGGGG, and; an 
anchor primer: TACGCATCCCAGTTTGAGACG. To amplify this region a touch-down 
70-56°C PCR program is used. After the repeat-primed PCR is concluded 2µl of the PCR 
product are mixed with 0.5µl of Liz500 size standard (used as an internal size ladder, Life 
Technologies) and 7.5µl HiDi Formamide (Life Technologies). This reaction is loaded 
onto the 3730 DNA Analyzer for electrophoretic separation and fluorescence detection. 
Subsequently, the amplified fragment length polymorphism (AFLP) is analysed and 
visualised through the GeneMapper software (section 2.3.1). 
As a result of the analysis, the fluorescence intensities are shown in the vertical axis: The 
size marker is identified by orange vertical lines and the hexanucleotide repeats that 
extend beyond the 300 bp marker are marked in blue (Figure 2-4). 
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Figure 2-4. Repeat expansion analysis!
 
Figure 2-4. Example of software generated graph identifying the standard (orange vertical lines) and the 
amplified fragment length polymorphism (blue teeth saw pattern).  
 
2.2.2.6 Single SNP genotyping assays 
To genotype specific SNPs the TaqMan Genotyping Assay (Life Technologies), a pre-
made 5’-nuclease assay containing primers and two allele specific probes is used. Each 
probe contains a different fluorescent dye (most common fluorescein amidite [FAM; 
absorbance at 459nm; emission at 521 nm; colour: Green] and [VIC; absorbance at 
538nm; emission at 554; colour: Yellow]) for each of the two possible alleles and the 
primers are specifically designed to amplify the region of interest. 
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The reactions containing 10ng of DNA, the TaqMan Genotyping Assay (Life 
Technologies) and the Genotyping Master Mix (Life Technologies) are prepared as 
recommended by manufacturer (Life Technologies). 
The PCR is run on the 7900 HT light cycler (Life Technologies). The setting for the run 
as well as the post-PCR fluorescent read of the reactions that is performed in the 7900 
light cycler (Life Technologies) and the analysis to discriminate the genotypes are 
performed through the SDS software (section 2.3). 
This specific type of analysis is called “allelic discrimination” and allows evaluating the 
frequency and distribution of a certain genotype within a cohort of interest. One SNP at 
the time, per sample, can be screened and the results are visualized in the form of clusters 
in the following combinations: 2 types of homozygous calls (i.e. AA or BB) and one 
heterozygous call (i.e. AB) (Figure 2-5). 
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Figure 2-5. Allelic discrimination analysis 
!
Figure 2-5. Distribution of the allelic distribution analysis. The SNPs are called in either their homozygous 
or heterozygous combination and data can be exported to exactly match the genotype to the well/sample. 
 
2.2.2.7 Quantitative real-time PCR 
To assess specific copy number variations the TaqMan Copy Number Assays (Life 
Technologies) is used. This assay is run in concomitance with a TaqMan Copy Number 
Reference Assay (Life Technologies), the Genotyping Master Mix (Life Technologies) 
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and 10ng of DNA as per manufacturer instructions (Life Technologies). The copy 
number assay probe is fluorescently labelled with FAM, whilst the reference assay probe 
is labelled with VIC. The latter provides a standard for normal copy number to which the 
target probe is compared. The workflow is similar to that of the genotyping assay. The 
PCR is run on the 7900 HT light cycler (Life Technologies) and the settings for the run as 
well as the real-time reading are performed and monitored through the SDS software 
(section 2.3). 
This approach is called real time PCR because one can follow the process of 
amplification in real time due to the incorporation of fluorescently labelled probes in the 
exponentially growing PCR product. The amplification is simultaneously translated into 
an amplification curve where the threshold line is the level at which a reaction reaches a 
florescent intensity above background (Figure 2-6). The cycle at which the sample 
reaches this level is called cycle threshold (Ct), which is the value used during data 
analysis and quantitation. 
The SDS software allows saving and exporting the Ct values in a .txt format. These are 
imported into the Copy Caller software (section 2.3.2) where the results of the target 
probe are standardized to reference genes, such as RNase P. 
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Figure 2-6. Gene dosage analysis 
 
Figure 2-6. Example of a completed CNV/dosage experiment. The square in the top left shows the plate 
format; the square at the bottom left collects the analysed Ct values and the square on the right displays the 
final amplification curve and the cycle threshold (green horizontal line). 
 
2.2.2.8 Genome-wide genotyping 
Genotyping platform 
The Illumina Infinium is an ideal platform for different types of genetic studies including 
genome-wide association studies (GWAS). This platform allows to genotype from 300K 
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up to 1M genetic markers in the human genome and the genotyping is based on the 
BeadArray technology. The Beads are located into micro-wells, within the chip, at a 
distance of 5.7 microns from each other, and hold several 100,000 oligonucleotide probes 
(50-mer probes). After having performed quality control of the material (section 2.1.2.1) 
the workflow to perform the genome-wide genotyping is as follows: 
1 – Genomic DNA (gDNA), in the amount of ~250ng, is amplified through PCR-free 
whole genome amplification (day 1); 
2 – The amplified DNA is then fragmented and added onto the BeadChip in order to 
allow hybridization to the 50-mer probes (day 2), and; 
3 – The oligonucleotide sequence of these probes stops one base before the marker. After 
hybridization, a fluorescently labelled nucleotide is added through DNA Polymerase 
mediated enzymatic single-base extension and then the iScan imagining system detects 
the fluorescent staining discriminating, both, the colour (green or red for discriminating 
the allele) and the signal intensity (for discriminating the genotype) (day 3). 
Genotyping data are exported to Genome Studio (section 2.3.4) where, initially, call rates 
are assessed and the SNPs are manually clustered prior to performing data cleaning and 
association analysis (section 2.3.5). 
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Array chips 
During the discovery phase of the FTD-GWAS (Chapter 4) the samples were genotyped 
either with the Human 660W-Quad BeadChip (88% of the cases), or with the 
HumanOmniExpress BeadChip (12% of the cases). These chips include tag SNPs that 
derive from all three HapMap phases specific for the European population and that are 
optimised to capture large amount of common variation throughout the genome. 
The Human 660W-Quad BeadChip provides a relatively dense and uniform coverage of 
the genome including 550K SNPs and 110K CNV markers. There is the possibility of 
loading the amplified DNA of 4 samples per chip. 
The HumanOmniExpress-12 BeadChip holds more than 730K markers and up to 12 
DNA samples can be loaded on this chip. Of note, the normal controls used for analysis 
in the discovery phase had been previously genotyped on different Illumina array chips 
(300K and 550K). 
For the replication phase all cases and normal controls were genotyped using a custom 
designed chip called NeuroX. The NeuroX chip specifically targets SNPs and loci 
associated with different neurological disorders including AD, PD and ALS. The markers 
included on the NeuroX chip are obtained from published or available GWAS and/or 
whole exome sequencing data. In total there are ~267K SNPs of which 3,759 are 
specifically targeting FTD. The latter were selected among those SNPs that reached p-
values<1x10-04 during the discovery phase of the FTD-GWAS (Chapter 4). Of note, the 
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SNPs included onto the NeuroX chip are tag SNPs based on European ancestry (CEU) 
linkage disequilibrium (LD) patterns derived from the most recent CEU data from the 
1000 Genomes project [224]. For each marker, 5 LD-based proxies with r2>0.5 or 
technical replicates were included on the array per locus, tagging associations within +/- 
250Kb.  
 
2.2.3 Mutagenesis 
The QuikChange II Site-Directed mutagenesis kit (Startagene, CA, USA) was used to 
introduce point mutations in plasmid constructs (pcDNA3.1+; Invitrogen). For the study 
of the CHMP2B missense change Ser187Asn, a vector including the wild-type gene 
CHMP2B was obtained from mRNA extracted from lymphoblasts of a neurologically 
normal individual. The primers carrying the mutation are designed as per manufacturer’s 
instructions (Startagene). Forward Primer 5’-
CCATCAGCTGCTCGAAACTTACCATCTGCCTCTAC-3’ and Reverse Primer 5’–
GTAGAGGCAGATGGTAAGTTTCGAGCAGCTGATGG–3’. The base change G>A is 
bold and underlined in the forward primer (and in the reverse primer, C>T). PCR is 
performed following manufacturer’s instructions (Startagene) using the plasmid and the 
primers carrying the base change. Following, XL1-Blue Supercompetent cells (Agilent 
Technologies, Santa Clara CA, USA) are transformed with the digested PCR product 
(Dpn1 restriction enzyme) and incubated for 1 hour at 37°C. Afterwards transformed 
cells are plated on Luria Agar Base (LGA) (VWR) in Petri dishes and left at 37°C for 
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approximately 16 hours. Bacterial colonies are picked and transferred into Luria Broth 
(LB) medium (VWR) containing 1:1000 ampicillin (VWR). The plasmid DNA is 
extracted from the bacteria using of QIAprep spin Miniprep kit (Qiagen, Valencia, CA, 
USA) following manufacturer’s instructions. DNA concentration is measured with the 
NanoDrop (NanoDrop Technologies Inc). A portion of the DNA is sequenced to confirm 
the mutation and the rest is stored at -20°C for further experiments. 
The following experiments have been performed by Astrid Autier and Dr Hazel Urwin. I 
did not perform this work and have no access to the protocol. However, in brief, after 
having isolated the plasmids containing the point mutation these are used to transfect the 
SK-N-SH cell line (human neural epithelial cells obtained from bone marrow metastasis 
from the European Collection of Cell Cultures [ECACC, Salisbury, UK]) and fibroblast 
cell lines with Lipofectamine 2000 (Life Technologies) according to standard protocols. 
These cells are grown and the expression of mutated vs. wild-type CHMP2B is monitored 
through immunocytochemistry (immunofluorescence) to label CHMP2B markers to 
evaluate its location within the cytoplasm. The results of immunocytochemical 
experiments are visualised at the confocal microscope.  
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2.3 Analysis 
Different software packages for analysis have been used to either generate or analyse 
genetic data. 
 
2.3.1 3730 DNA Analyzer 
For the Sanger Sequencing analysis the Foundation Data Collection Version 3.0 software 
(Life Technologies) is used to manage instrument/runs setup, real-time data visualization, 
and collection of raw data. The latter is imported into the Sequencing Analysis Version 
5.2 software (Life Technologies) used to analyse, visualise, and save files generated from 
the 3730 DNA Analyzer. Specifically, the Sequencing Analysis software performs base-
call using the KB base-caller program. These files are then exported to the Sequencher 
4.9 software (Gene Codes Corporation, Ann Arbor, MI, USA) used to align all sequences 
to a reference sequence and analyse the data for the identification and annotation of 
single base pair changes and/or small indels. 
For the fragment or expansion analyses, the GeneMapper Version 4.0 software (Life 
Technologies) is used to assess DNA sizing and quality allele calls. Among other 
applications, this software is used for analysing and visualising amplified fragment length 
polymorphism (AFLP). 
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2.3.2 7900HT fast real-time PCR system 
For the SNP genotyping and the CNV assays the Sequence Detection System (SDS) 
software (Life Technologies) is used. SDS uses an advanced algorithm to calculate the 
intensities and the type of signal of each fluorescent marker from each well during the 
plate read to determine and assign a genotype call (allelic discrimination). Conversely, 
SDS creates and saves analysis templates on a per detector (fluorescent label) basis for 
the gene expression quantitation, providing the opportunity of visualizing the 
amplification plot and saving the threshold cycles (Ct) values (fractional cycle number at 
which the amount of amplified target reaches a fixed threshold) for the copy number and 
reference assay. The Ct values are exported to the CopyCaller v2.0 software (Life 
Technologies) that performs a comparative Ct (ΔΔCt) relative quantitation analysis of the 
real-time data. The comparative Ct (ΔΔCt) method calculates the difference between the 
threshold cycles of the target and reference assay sequences determining the number of 
copies of the target sequence in each test genomic DNA sample. The CopyCaller 
software displays the results of such computations in a bar graph format (Figure 2-7). 
 
 
 
 
! 135!
Figure 2-7. CNV analysis 
 
Figure 2-7. The output of the Copy Caller software allows visualising the copy numbers in a bar graph. 
The value can be exact (as in the figure) or normalised where the copy number is shown as an entire 
number (e.g. 2.2 is normalised to 2). The copy number is shown on the y axis and samples are displayed on 
the x axis. 
 
2.3.3 Other tools for analysis (free web resources) 
2.3.3.1 PolyPhen-2 
When identifying a single base pair transition that leads to a missense change there are a 
couple of preferable methods to assess pathogenicity. First, one should screen that 
specific variant in an elevated number of normal control individuals, and, second, one 
should possibly perform in vitro and in vivo functional studies. When the latter is not an 
immediate possibility, a preliminary assessment can be performed in silico, through the 
online free tool PolyPhen-2 (Polymorphism Phenotyping version 2) 
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(http://genetics.bwh.harvard.edu/pph2/). PolyPhen-2 predicts the possible effect of 
amino-acid substitutions on protein structure and function by performing functional 
annotation of SNPs, mapping coding SNPs to gene transcripts and by comparing protein 
sequence, structural attributes, and conservation profiles [225]. The analysis of these 
properties results in an estimate of effect: Benign (green/yellow area, 0.0 to 0.50), 
possibly damaging (0.50 to 0.80) and probably damaging with a score (0.80 to 1.0) and 
sensitivity/specificity estimates (Figure 2-8). 
 
Figure 2-8. Missense mutation effect: In silico analysis 
 
 
Figure 2-8. Example of the output of the analysis performed through the PolyPhen2 software. It predicts a 
score for the probability of the missense change of being benign (0.0-0.50), possibly damaging (0.50-0.80) 
or probably damaging (0.80-1.0) including an estimate of the specificity and sensitivity of the analysis. In 
the plot showing the results, the “HumDiv” annotation is the model for evaluating rare alleles or dense 
mapping of regions identified in GWAS, whilst the “HumVar” annotation is the model for Mendelian 
disease (assessing drastic vs. mild effect). 
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2.3.3.2 Haploview 
When performing genetic screening by sequencing or genotyping (either multiplexed or 
genome-wide), the availability of a number of markers that cover a large region within 
and around a gene (or locus) allows evaluating the presence and frequency of specific 
haplotypes segregating with a certain phenotype. To perform such kind of analysis the 
Haploview software is used (http://www.broadinstitute.org/scientific-
community/science/programs/medical-and-population-genetics/haploview/haploview). 
Haploview is an online free tool designed to create haplotype plots and evaluate 
haplotype frequencies (among other applications). The SNPs rs numbers, their 
chromosomal position as well as the allele frequencies need to be entered in the software 
that will calculate pairwise LD within a maximum of 500Kb surrounding each SNP of 
interest. Three coefficients provide an estimate of the strength of the association between 
two SNPs: 
1 – D’ is the LD coefficient that varies between 0–1 where the maximum value (1) 
implies that there is no definite evidence for recombination between two markers but 
does not entirely guarantees that there is absence of recombination between the two 
markers [226]; 
2 – r2 is the correlation coefficient that indicates the predictive power between two loci 
[226] indicating strong LD when r2=1, most probable LD when 0.8< r2<1 and 
decreasingly weaker LD when 0<r2<0.8, and; 
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3 – LOD (logarithm of the odds) score indicates whether linkage is suggested (LOD>2), 
established (LOD>3) or, weak or absent (LOD<2). The reason why LOD>3 indicates LD 
between two markers is due to the fact that in that specific case, the odds are a thousand 
(or more) to one that the two markers are linked/inherited together [226]. 
The haplotype plot visually shows the level of LD between SNPs under investigation 
(Figure 2-9). 
 
Figure 2-9. LD analysis 
 
Figure 2-9. In each box the r2 value between two SNPs is defined by numbers that range between 0 and 
0.99. Black boxes without a number indicate r2=1, i.e. complete LD. All three coefficients provide 
important information about the LD between two SNPs. For example, strong LD is identified between 
SNPs 8 and 9 with an r2=0.95, D’=1 and LOD>3.    
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2.3.3.3 National Center for Biotechnology information (NCBI) 
The ncbi website (http://www.ncbi.nlm.nih.gov) represents a remarkable source of data 
and information for genetic studies. The website services and tools have mainly been 
used to search through the literature (http://www.ncbi.nlm.nih.gov/pubmed/), to collect 
information on genes (http://www.ncbi.nlm.nih.gov/gene/), SNPs 
(http://www.ncbi.nlm.nih.gov/snp/), proteins (http://www.ncbi.nlm.nih.gov/protein/ and, 
eventually, diseases through the Online Mendelian Inheritance in Men (OMIM) 
encyclopedia (http://www.ncbi.nlm.nih.gov/omim/).  
 
2.3.4 Whole genome-wide data 
After generating whole genome genotyping data these are imported in the Genome Studio 
(GS) Data Analysis software (Illumina). This powerful informatics tool allows primary 
analysis of microarray-based data generated by the iScan System (or BeadXpress reader). 
The Genome Studio Genotyping (GT) Module (Illumina) is a specific supplementary 
software that enables a variety of features such as normalization of genotyping data, 
genotype calling, SNPs clustering, data intensity analysis, preliminary gender-mismatch 
check, loss of heterozygosity (LOH) calculation, and CNV analysis. Among other 
relevant features provided by GS and GT, most relevant are: 
1 – The calculation of LogR ratio and B Allele Frequency to estimate and visualise CNV; 
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2 – The availability of multiple CNV algorithms and copy number variation analysis 
tools (such as cnv partition), and; 
3 – The generation of a chromosomal browser heat map for examining and visualising 
SNPs distribution and CNV across the entire genome. 
Report data created through GS are then exported to third party software packages for 
further analysis: 
1 – Plink (http://pngu.mgh.harvard.edu/~purcell/plink/index.shtml) is a sophisticated 
whole genome association analysis bioinformatics toolset that provides all relevant 
applications to perform genotyping data cleaning and association analyses, and; 
2 – R software (http://www.r-project.org) provides different statistical and graphical 
techniques including linear and nonlinear modelling and classical statistical tests to 
perform association analysis on genome-wide data and efficiently visualise results. 
 
2.3.5 GWAS data analyses 
This part of the work has been performed by biostatistician Dr Michael Nalls at NIH. 
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2.3.5.1 Quality control (QC) and data filtering for the FTD-GWAS 
FTD-GWAS discovery phase data filtering 
The GWAS on frontotemporal dementia included a large number of samples with 
variable genetic background (although all of overall European ancestry) as they were 
collected across different countries in Europe and the USA. In addition, genotypes for 
cases and controls in the discovery phase were mainly generated using different 
genotyping arrays. Therefore population substructure and limited overlap between the 
different genotyping arrays represented a challenge at first. 
Low quality samples and poorly genotyped SNPs were excluded preliminarily based on 
the following criteria: Call rate (=percentage of successfully genotyped SNPs) <0.95, 
MAF<0.01, missing data >0.05, Hardy-Weinberg equilibrium (HWE) with p-
value>1x10-06 for cases and >1x10-04 for controls and gender mismatch (evaluated 
through chromosome X heterozygosity). Palindrome SNPs (i.e. AT or GC transitions) 
were excluded; SNPs were flipped to the forward strand position and re-mapped based on 
HapMap 2 and 23 releases. Then all cases and controls were merged with all HapMap 
samples to confirm European ancestry that was verified using multidimensional scaling 
(outliers, >6SD, from the European reference population mean for component vectors 1 
and 2 were excluded) and/or by Principal Component Analysis (PCA) as implemented in 
EIGENSTRAT [227] (cases and controls were matched based on similarity of the first 
two eigenvectors from PCA). Finally, the level of relatedness was evaluated by 
identifying and excluding 1st degree relatives through identity by descent (IBD) for any 
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two samples sharing >12.5% of the genome. To improve genome-wide coverage and 
statistical power surviving SNPs (~230K) were imputed to the 1000 Genomes August 
2010 release, excluding SNPs with MAF<0.01 or imputation quality (Rsq)<0.30. All 
samples were haplotyped using MACH1 
(http://www.sph.umich.edu/csg/abecasis/MACH/index.html) and these haplotype blocks 
were used for imputation through miniMac (http://genome.sph.umich.edu/wiki/Minimac). 
Each imputed region included 6,000 SNPs with ~500 SNPs overlapping with each 
neighbouring block. After regions were merged and the overlapping SNPs of lower 
quality were excluded 6M SNPs were used for association analysis. 
 
FTD-GWAS replication phase data filtering 
Standard QC was performed during replication phase as in the case of discovery phase. 
The NeuroX chip (section 2.2.2.8) includes candidate (standard) 
neurological/neurodegenerative disease SNPs and exonic content. The SNPs were called 
using a publicly available cluster file based on over 60,000 samples [228]. All the 
variants with GenTrain scores >0.70 from GS, indicative of high quality genotype 
clusters, were extracted first to calculate call rates. As in discovery phase, samples with 
call rates <95%, samples with conflicting gender (matching clinically reported vs. 
genetically determined sex) and samples exhibiting excess of heterozygosity were 
excluded. In addition, SNPs with MAF<5%, HWE p-values<1x10-05, and per SNP 
missingness rates>5% were excluded. Also, pairwise IBD filtering was used to remove 
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cryptically related samples and PCA was used to identify samples to be excluded due to 
genetic ancestry not consistent with European descent (based on comparisons with all 
HapMap reference populations). 
!
2.3.5.2 Association analysis 
Logistic regression was used based on genotyped and imputed SNP calls to assess the 
association between each SNP and any of the FTD subtypes first, adjusting for 
eigenvectors 1 and 2 from PCA as covariates to correct for population substructure. 
Second, a fixed effects meta-analysis was performed to combine results of each subtype 
and quantify heterogeneity across subtypes. Genomic inflation was minimal across 
subtypes and in the meta-analysis across subtypes (λ<1.05) supporting the notion that 
observed associations are overall trustworthy. 
 
2.3.6 Quantitative trait loci (QTL) analyses 
To evaluate cis-effects on quantitative traits such as expression and methylation patterns, 
QTL data were generated by the UK Brain Expression (UKBEC) and North American 
Brain Expression (NABEC) consortia (Appendix 2-5). Specifics about the generation of 
data and the analyses are included in the appropriate sections in Chapters 3 and 4. 
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2.4 Reagents and equipment 
2.4.1 Reagents 
The main reagents used to perform the experiments are summarised in the following 
paragraph. The provider name only is shown as their location has been previously 
reported (whole section 2.2). Promega Wizard DNA extraction kit (Promega), Cell Lysis 
Solution (Promega), Nuclei Lysis Solution (Promega), RNAse solution (Promega), 
Protein Precipitation Solution (Promega), isopropanol (VWR), ethanol (VWR), DNA 
Rehydratation Solution (Promega), Qiagen DNeasy Blood and Tissue Kit (Qiagen), 
proteinase K, Buffer AL (Qiagen), Buffer AW1 (Qiagen), Buffer AW2 (Qiagen), Buffer 
AE (Qiagen), Quant-iTTM dsDNA BR assay (Life Technologies), Quant-iT working 
solution (Life Technologies), DNA standards (Life Technologies), Roche Faststart PCR 
Master (400 RXN/10 ML) (Roche Applied Science), primers (Invitrogen), Ultrapure 
agarose (Life Technologies), TBE 1X buffer (VWR), GelRed nucleic acid gel stain 
(VWR), loading dye (EMD Millipore – Novagen), DNA ladder (EMD Millipore – 
Novagen), PCR filter plates (Millipore), BigDye Terminator v3.1 (Life Technologies), 
5X Sequencing Buffer (Life Technologies), dimethyl sulfoxide (DMSO) (VWR), Q 
Solution (Invitrogen), deazaGTP (Fisher Scientific), Liz500 size standard (Life 
Technologies), HiDi Formamide (Life Technologies), TaqMan Genotyping Assay (Life 
Technologies), Genotyping Master Mix (Life Technologies), TaqMan Copy Number 
Assays (Life Technologies), TaqMan Copy Number Reference Assay (Life 
Technologies), QuikChange II Site-Directed mutagenesis kit (Startagene, CA, USA), 
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plasmid constructs (pcDNA3.1+; Invitrogen), XL1-Blue Supercompetent cells (Agilent 
Technologies), Dpn1 restriction enzyme (New Englan Biolabs), Luria Agar Base (VWR), 
Luria Broth (VWR), Ampicillin (VWR), SK-N-SH cell line (European Collection of Cell 
Cultures [ECACC]), Lipofectamine 2000 (Life Technologies). 
All the reagents included in the Illumina Infinium assay used to perform the genome-
wide genotyping are summarised in the Infinium HD Super protocol guide, Chapter 2 
(http://supportres.illumina.com/documents/myillumina/05340b1f-c179-495d-b790-
fa91ecbb6ff2/inf_hd_super_assay_ug_11322427_revc.pdf). 
 
2.4.2 Equipment  
The following instruments have been used to perform as well as analyse PCR, sequencing 
reaction, genotyping (single SNP, multiplexed and high coverage), and gene dosage 
experiments. 
Veriti® 96-Well Thermal Cycler (Life Technologies): A thermal cycler for 96-well PCR 
plates used to perform high-throughput PCR and cycle sequencing applications.  
GeneAmp® PCR System 9700 (Life Technologies): A thermal cycler for two 384-well 
PCR plates used to perform high-throughput PCR and cycle sequencing applications. 
3730 DNA Analyzer (Life Technologies): A 48-capillary DNA Analyzer with medium-
to-high throughput genetic analysis used for traditional DNA sequencing and fragment 
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analysis. 
7900HT Fast Real-Time PCR (Life Technologies): A high-throughput real-time PCR 
system that detects and quantitates nucleic acid sequences. This instrument, that reads 
wavelength from 500-660 nm, is used to perform single SNP allelic discrimination 
(TaqMan SNP genotyping assay, section 2.2.2.6) and gene expression quantitation 
(TaqMan CNV assay, section 2.2.2.7). 
iScan Reader (Illumina): This instrument is a highly precise and sensitive scanner that 
supports an extensive range of array applications, including genetic analysis assays for 
genotyping. This system is used for scanning of high density genotyping assay (Illumina 
Infinium genotyping assay). 
 
 
 
 
 
 
 
 
! 147!
CHAPTER 3 – PSP-GWAS     
 
3.1 PSP-GWAS: The published study 
Recently, Drs. Höglinger, Schellenberg and colleagues led the first international genome-
wide association study (GWAS) of progressive supranuclear palsy (PSP) [180]. 
This study was undertaken to identify novel risk loci associated with PSP, beyond the 
known association with the MAPT locus and the H1 haplotype. It was a conventional 
two-stage case/control association study of a relatively large number of PSP cases 
provided and shared by Western European and American research groups (n>30). Stage 1 
included ~1,100 pathologically proven PSP samples, whilst in stage 2 ~1,000 new PSP 
samples (~89% clinical and ~11% autopsy confirmed) were analysed. 
The samples were genotyped on the Illumina Infinium platform using the 660W-Quad 
Infinium BeadChips for the cases and the HapMap550 Infinium BeadChip for the 
controls during stage 1. For stage 2 approximately 5,300 SNPs, that reached p-
values<1x10-3 during stage 1, were genotyped by means of the Infinium HD iSelect 
Custom BeadChip. Young individuals recruited at the Children’s Hospital of Philadelphia 
(CHOP) Health Care Network were utilised as controls for stages 1 and 2. Different sets 
of controls were used for stage 1 and 2. 
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3.1.1 Discovery phase analysis  
After data quality control, non-Caucasian samples and duplicates were dropped. Cases 
and controls were matched based on principal component analysis (PCA) and similarities 
of eigenvectors. The genomic inflation factor (λ=1.01) reflected good matching. After 
quality control filtering, 1,082 PSP cases and 3,317 controls were included in primary 
analysis. The genome-wide significance threshold was set at the p-value<1x10-7.5. The 
analysis revealed suggestive to significant association at 5 loci (Figure 3-1), including 
the expected MAPT locus (Table 3-1). More than 5,400 SNPs reached p-values<1x10-3.  
 
Figure 3-1. PSP-GWAS discovery phase: Manhattan plot 
 
Figure 3-1. Manhattan plot of –log10 (observed p-value) show suggestive to significant association on 
chromosomes 1, 3, 11, 12 and 17. Derived from files shared by Dr Schellenberg’s group. 
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Table 3-1. PSP-GWAS: Discovery phase associated loci 
 
Table 3-1. List of the genes mapping to the loci showing association after primary analysis. The known 
functions of each gene are shown in the third column (information was gathered from the NCBI website 
[http://www.ncbi.nlm.nih.gov/gene] and shared files by Dr Schellenberg’s group). Chr=chromosome; 
OR=odds ratio. 
 
Chr Gene SNP P-value; OR Function 
   Stage 1  
1 STX6 (syntaxin 6) 
rs12754041 
 
rs1411478 
1.91x10-11; 1.403 
 
7.33x10-12; 1.413 
A vesicle transporter protein. Modulator of P53 family. 
Member of the soluble N-ethylmaleimide-sensitive factor-
attachment protein receptor (SNARE) complex for transport 
from early endosomes to Golgi complex. Induced by P53 
and DNA damage. Knockdown leads to cell adhesion, cell 
cycle arrest and apoptosis 
1 
MR1 
(major 
histocompatibi
lity complex, 
class I-related) 
rs1411479 5.91x10-09; 1.36 
Has antigen presentation function. Involved in the 
development and expansion of a small population of T cells 
expressing an invariant T cell receptor alpha chain called 
mucosal-associated invariant T cells (MAIT) 
3 
MOBP 
(myelin-
associated 
oligodendrocy
tic basic 
protein) 
rs1768208 
 
rs1464047 
 
4.66x10-13; 1.481 
 
3.80x10-12; 0.7018 
Relatively abundant central nervous system (CNS)-specific 
myelin protein, which plays a role in stabilizing the myelin 
sheath in the CNS, has recently been implicated in the 
pathogenesis of multiple sclerosis (MS). Shares 
characteristics with myelin basic protein. Essential for 
normal arrangement of the radial component of CNS myelin. 
Target antigen in MS. Multiple splice variants. No 
myelination defects in MOBP-/- mice 
11 
CEP57 
(centrosomal 
protein 
57kDa) 
rs3017756 1.66x10-06; 1.277 
Links microtubules (MTs) to kinetochores and centrosome 
(centriole or centromatrix). Amino!terminus binds to γ!
tubulin. Carboxy!terminus binds to MTs (nucleates and 
bundles MTs in vitro) 
11 
MTMR2 
(myotubularin 
related protein 
2) 
rs530914 3.14x10-07; 0.77 
Small integral membrane protein of lysosome/late 
endosome. Member of broad family of phosphatases (eg 3!
phosphatase activity towards PtdIns3P and PtdIns(3,5) 
2polyphosphoinositides. Regulates intracellular trafficking 
and membrane homeostasis in Schwann cell myelination. 
Interacts with NFL (low molecular weight neurofilament 
subunit. Mutations in MTMR2 cause subtype of Charcot 
Mary Tooth (CMT) disease (CMT4B1; autosomal 
recessive). MTMR 13 mutations cause CMT4B2. MTMR2 
interacts with MTMR13. NFL assembly defects due to 
MTMR2 mutations could contribute to pathogenesis of 
CMT4B 
12 
NELL2 
(NEL-like 
protein 2) 
rs7299371 6.47x10-08; 1.373 
NELL2, a neuron!specific epidermal growth factor (EGF)!
like glycoprotein. Specifically expressed during the peak 
periods of both sensory and motor neuron differentiation. 
Alternative splicing results in two isoforms, one secretable, 
located in the ER/Golgi compartments, one non!secretable, 
cytoplasmic protein. Enriched in glutamatergic neurons. 
Involved in a major, glutamate!dependent, process of 
neuroendocrine regulation. May play an important role in the 
development of the CNS as well as maintenance of neural 
functions, by regulating the intracellular machinery 
involving Ca2+ signaling, synaptic transport and/or release 
of vesicles 
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3.1.2 Replication phase and joint analysis  
After genotyping ~5,300 SNPs chosen among those that reached p-values<1x10-3 in stage 
1, and performing standard quality controls, replication analysis was carried out for 4,099 
SNPs in 1,051 PSP cases and 3,560 controls, all of European ancestry. 
Of the 1,051 cases assessed in the replication phase 117 (~11%) were autopsy confirmed 
whilst the remaining were clinically diagnosed (~89%). 
After completion of the joint analysis of stages 1 and 2, besides the expected association 
with chromosome 17 and the MAPT locus, this study identified three novel loci 
associated with PSP (Figure 3-2):  
1 – Chr1q25.3 at the gene syntaxin 6 (STX6);  
2 – Chr2p11.2 at the eukaryotic translation initiation factor 2-alpha kinase 3 gene 
(EIF2AK3), and;  
3 – Chr3p22.1 at the myelin-associated oligodendrocyte basic protein gene (MOBP) 
[180]. 
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Figure 3-2. PSP-GWAS: Association analysis 
 
Figure 3-2. Summary of the results of the PSP-GWAS. P-values and OR for the associated loci are shown 
for respectively stage 1, stage 2 and the final meta (joint) analysis. The joint analysis shows the association 
at 1q25.3, 2p11.2, 3p22.1 and 17q21.31. OR was calculated based on the major allele. This Figure is taken 
form the published manuscript [180] 
 
3.1.3 Lessons learned from the PSP-GWAS 
The newly associated loci [180] point to specific pathways and processes that might be 
involved in the pathogenesis of PSP including:  
1 – Intracellular vesicular trafficking;  
2 – The endoplasmic reticulum (ER)-mediated cellular response to stress and abnormally 
unfolded proteins, and;  
3 – Central nervous system (CNS) myelination. 
More specifically, the associated SNP, rs1411478 (1q25.3; P(joint): 2.3x10-10), locates to 
the intronic region of STX6, between exons 4 and 5. STX6 encodes the protein, syntaxin 6 
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(STX6) that belongs to the SNARE (soluble N-ethylmaleimide-sensitive factor-
attachment protein receptor) proteins family and localizes to the trans-Golgi network 
(TGN) and endosomes, and is involved in intracellular endocytic and secretory 
trafficking processes [229, 230]. STX6 malfunction was recently associated with 
different human diseases such as cancer where STX6 seems to induce angiogenesis 
[231], cystic fibrosis (CF) [229] and Parkinson's and Alzheimer’s disease (PD and AD) 
where STX6 seems to impact neurite outgrowth through a nerve growth factor (NGF)-
dependent mechanism [232]. 
The associated SNP, rs7571971 (2p11.2; P(joint): 3.2x10-13), locates to the intronic region 
of EIF2AK3 between exons 2 and 3. EIF2AK3 encodes the eukaryotic translation 
initiation factor 2-alpha kinase 3 protein (EIF2AK3) that locates to the membrane of the 
endoplasmic reticulum (ER) and is involved in the ER stress response via the unfolded 
protein response (UPR) [233]. When unfolded proteins accumulate in the ER, EIF2AK3 
phosphorylates the eukaryotic translation-initiation factor 2 (EIF-2) leading to a 
downstream effect that results in a decrease of translation processes [234]. Moreover, 
mutations in this gene have been associated with Wolcott-Rallison syndrome (WRS), an 
autosomal recessive disease, characterised by neonatal diabetes, liver and pancreas 
dysfunctions accompanied, in some cases, by signs of mental retardation [235].  
The associated SNP, rs1768208 (3p22.1; P(joint): 1.0x10-16), locates to the intronic region 
of MOBP between exons 2 and 3. MOBP encodes the myelin-associated oligodendrocyte 
basic protein (MOBP) a member of the central nervous system (CNS) myelin-
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constituting proteins [236]. MOBP is abundantly expressed specifically in 
oligodendrocytes in the white matter of the CNS [237]. It was previously reported that 
MOBP is involved in stabilizing the myelin constituting the myelin sheath and that it may 
play a role in multiple sclerosis (MS) as an auto-antigen [238]. 
Recently, the three PSP-GWAS associated SNPs were genotyped in a Chinese cohort 
diagnosed with AD and association could not be identified other than for the risk alleles 
in EIF2AK3 and MOBP in ApoE-allele 4 carriers only [239]. Further, the GWAS 
associated SNP in STX6 did not show association with Parkinson’s disease (PD) in small 
series of diverse populations [240]. 
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3.2 PSP-GWAS: Follow up study 
3.2.1 The design  
Our group participated and contributed to the PSP-GWAS with a total of 141 
pathologically confirmed PSP cases collected at the Queen Square Brain Bank [180]. For 
this follow up study, we selected 84 of these 141 cases to further investigate the 
associated loci in order to possibly uncover the functional basis of the associations 
analysing coding variants (affecting protein structure and/or function) and non-coding 
variants (affecting gene expression and/or exon splicing) in our cohort. Specifically, we 
directly sequenced the coding and intronic flanking regions of the implicated genes with 
the following aims:  
1 – Identifying coding pathogenic polymorphisms;  
2 – Assessing genetic variability in the risk genes, the frequency of the variants, their 
allele frequencies and compare them to the normal population;  
3 – Assessing the presence of possible disease specific haplotypes encompassing the risk 
genes (and the GWAS associated SNPs) and;  
4 – Carrying out a regional genome-wide expression quantitative trait locus (eQTL) 
analysis in control brains to determine if any of the associated SNPs may influence allelic 
differences in gene expression. 
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3.2.2 Materials and Methods 
3.2.2.1 Patients  
We screened 84 pathologically confirmed PSP cases for which genome-wide data were 
available from the PSP-GWAS [180]. All our cases were of white western European 
ancestry. The patients diagnosis was assessed through the modified NINDS possible or 
probable criteria [216] and then confirmed pathologically by standardised criteria [160], 
[216], [217]. All patients gave informed consent and the samples were collected under 
protocols approved by the Joint Medical Ethics Committee of the National Hospital of 
Neurology and Neurosurgery, London. For this paragraph complementary information 
can be found in Chapter 2 section 2.1.1. 
 
3.2.2.2 Genetic analysis 
Genomic DNA was extracted from human post-mortem brain tissue using the Qiagen 
DNeasy Blood and Tissue Kit (Qiagen, UK). We sequenced all the coding exons and 
flanking intronic regions of the following genes: STX6 (exons 2-8), the major 
histocompatibility complex class I-related (MR1) (due to its close proximity to STX6 
[10.6 kb]; exons 2-7), EIF2AK3 (exons 2-17) and MOBP (exons 3-5). Primers for PCR 
amplification were designed using Primer3 (http://frodo.wi.mit.edu/primer3/). 
Sequencing reactions of purified PCR amplicons were carried out in a single direction or 
in both directions if variants needed to be confirmed. Sanger sequencing was performed 
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through the Big Dye Terminator kit (ABI, Foster City, CA, USA) as recommended by 
manufacturer, and run on a 3730 DNA Analyzer (ABI), followed by analysis with 
Sequencher 4.9 software (Gene Codes Corporation, Ann Arbor, MI, USA). The potential 
damaging effect of novel missense variants on protein structure and function was 
examined using PolyPhen-2 software [225]. Identified common coding and non-coding 
variants were used to build haplotypes spanning ~70kb at 1q25.3, ~42.6kb at 2p11.2, and 
~32kb at 3p22.1. LD was analysed using Haploview (www.broadinstitute.org/haploview) 
[241].  
 
3.2.2.3 Expression quantitative trait loci (eQTL) analysis 
This analysis was possible through the gene expression/genotyping data generated by the 
UK Brain Expression Consortium (UKBEC) [199], [207], [242], whose members’ names 
are acknowledged in Appendix 2-5. Frozen brains from 134 control individuals were 
collected by the Medical Research Council (MRC) Sudden Death Brain and Tissue Bank, 
Edinburgh, UK [243], and the Sun Health Research Institute (SHRI) [244]. All samples 
were consented and authorized for ethically approved scientific investigation. Mean age 
at death was 58 years and [male:female] ratio was [1:2.8]. The brain regions analysed 
included those commonly affected in PSP such as the substantia nigra, putamen, 
hippocampus and frontal cortex [245] [165]. Total RNA was isolated using the 
miRNeasy 96 kit (Qiagen) and its quality was evaluated through the 2100 Bioanalyzer 
and RNA 6000 Nano Kit (Agilent). Total RNA was processed with the Ambion WT 
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Expression Kit and Affymetrix GeneChip Whole Transcript Sense Target Labeling Assay 
and hybridized to the Affymetrix Exon 1.0 ST Arrays as recommended by manufacturer. 
Hybridized arrays were scanned on an Affymetrix GeneChip Scanner 3000 7G and 
visually inspected for hybridization artifacts. The Affymetrix probe sets were mapped to 
human genome build 19 (GRCh37). Analysis was restricted to 292K probe sets annotated 
to NCBI Reference Sequence build 36 through Netaffx annotation file Release 31 (HuEx-
1_0-st-v2 Probeset Annotations). Expression data was adjusted for brain bank, gender 
and batch effects in Partek’s Genomics Suite v6.6 (Partek Inc., USA). Samples were 
genotyped on the Illumina Infinium Omni1-Quad BeadChip and Immunochip [246] 
[221], scanned using an iScan (Illumina, USA). Genome Studio v.1.8.X (Illumina, USA) 
was used for generating SNP calls. After standard quality controls (exclusion of samples 
with non-European descent, call rate <95% and checks on gender, cryptic relatedness, 
autosomal heterozygosity rate, and HWE [p-value<0.0001]), imputation was performed 
using MaCH [247] and minimac (http://genome.sph.umich.edu/wiki/Minimac) using the 
European panel of the 1000 Genomes Project (March 2012: Integrated Phase I haplotype 
release version 3) leading to ~5.88 million SNPs and ~577K indels with good post-
imputation quality (Rsq>0.50) and MAF≥5%. QTL analysis was run for each expression 
profile (either exon- or gene-level) against either SNP or indel in MatrixEQTL [248]. 
Subsequent analyses were conducted in R (http://www.r-project.org). 
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3.2.3 Results 
After sequencing the exons and flanking intronic regions of STX6, MR1, EIF2AK3 and 
MOBP, we compared the minor allele frequencies (MAFs) of the known SNPs in our 
PSP cohort with data available from the 1000 Genomes 
(http://browser.1000genomes.org/index.html) and dbSNP 
(http://www.ncbi.nlm.nih.gov/SNP/). Furthermore, we used the sequencing results and 
the allele frequencies to build and possibly identify disease-associated haplotypes in 
linkage disequilibrium (LD) with the GWAS associated SNPs. The haplotype structures 
were assessed using Haploview [241]. In addition, of the 26 genetic variants of interest 
identified in this analysis (including the GWAS associated SNPs), 16 had a MAF of >5% 
and could be analysed within the available eQTL data set. Each genetic variant was 
assessed for evidence of regulation of any gene within 1 Mb with particular focus on the 
effects on STX6, MR1, EIF2AK3 and MOBP.   
 
3.2.3.1 STX6/MR1    
The sequencing of STX6 resulted in the isolation of three coding variants one of which 
was novel. The two known variants were synonymous changes, Glu13Glu (rs12125196) 
and Asn217Asn (rs3747957), whilst the novel variant was a missense mutation located to 
exon 8 of STX6, Cys236Gly (1/58, heterozygous change). In silico analysis through 
PolyPhen-2 software predicted this variant being probably damaging (score: 0.999; 
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sensitivity: 0.14; specificity: 0.99) [225] (Figure 3-3). The carrier of this mutation did not 
have a reported family history of PSP or other neurodegenerative disorders. 
 
Figure 3-3. STX6; missense change Cys236Gly. PolyPhen-2 analysis 
 
Figure 3-3. In silico analysis of the effect of the missense change Cys236Gly 
 
The sequencing of MR1 resulted in the identification of several variants, both, coding and 
non-coding. Four variants were intronic two of which very proximal to exon 3 
(rs75150495, 8 bp from the start of the exon) and exon 7 (rs3747956, 3 bp after the end 
of exon 7). The remaining 5 variants were coding. Three of them were missense 
mutations (rs41268456, Arg31His; rs2236410, His39Ala; rs149433107, Pro203Ser), 
whilst 2 were synonymous changes (rs3863720, Ser46Ser; rs35223984, Ans239Asn). Of 
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the missense mutations only Arg31His was predicted to be probably damaging after in 
silico analysis (score: 0.996; sensitivity: 0.55; specificity: 0.98) (Figure 3-4) [225].   
 
Figure 3-4. MR1; missense change Arg31His. PolyPhen-2 analysis 
 
Figure 3-4. In silico analysis of the effect of the missense change Arg31His 
 
The results of genetic screening of STX6 and MR1 are summarized in Table 3-2. Amino-
acid numbering for STX6 and MR1 proteins refers to GenBank Accession CAG46671.1 
and CAB77667.1, respectively. 
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Table 3-2. UK PSP study cohort: Genetic screening 
Gene Exon Intron rs number 
Amino- 
acid 
change 
Alleles/Frequency Minor allele MAF 
                  Our samples 
1000 
Genomes 
Caucasian/european 
(dbSNP) 
STX6 
2   rs12125196 Glu13Glu GG (58/60) GA (2/60) AA (0/60) A 0.017 0.011 0.017-0.025 
  4 *rs1411478 / GG (21/82) GA (44/82) AA (17/82) A 0.475 0.426 0.375-0.473-0.483 
7   rs3747957 Asn217Asn TT (14/62) TC (33/62) CC (15/62) T 0.492 0.427 0.473-0.483 
8   novel Cys236Gly TT (57/58) TG (1/58) GG (0/58) G 0.009 NA NA 
MR1 
  2 
rs2236412 / TT (64/70) TC (5/70) CC (1/70) C 0.050 0.050 NA 
rs75150495 / CC (63/70) CG (4/70) GG (3/70) G 0.070 NA NA 
3   
rs41268456 Arg31His GG (69/70) GA (1/70) AA (0/70) A 0.007 0.004 NA 
rs2236410 His39Ala AA (54/70) AG (16/70) GG (0/70) G 0.114 0.206 0.150 
rs3863720 Ser46Ser GG (69/70) GA (0/70) AA (1/70) A 0.014 0.017 0.042 
5   
rs149433107 Pro203Ser CC (78/79) CT (1/79) TT (0/79) T 0.006 0.001 NA 
rs35223984 Asn239Asn CC (74/78) CT (4/78) TT (0/78) T 0.026 0.014 0.033 
  7 
rs3747956 / GG (35/64) GA (23/64) AA (6/64) A 0.273 0.494 0.267-0.302 
rs75073791 / GG (62/64) GA (2/64) AA (0/64) A 0.016 0.011 0.050 
EIF2AK3 
2   rs867529 Ser136Cys CC (31/63) CG (28/63) GG (4/63) G 0.286 0.288 0.267-0.292 
  2 *rs7571971 / CC (36/80) CT (40/80) TT (4/80) T 0.300 0.287 0.267-0.317 
3   rs13045 Gln166Arg AA (6/59) AG (25/59) GG (28/59) A 0.313 0.347 0.300-0.343 
9   rs141901506 Asp502Asn GG (57/58) GA (1/58) AA (0/58) A 0.009 NA NA 
10   rs55791823 Asp566Val AA (59/61) AT (2/61) TT (0/61) T 0.016 0.001 0.002 
  10 rs6750998 / AA (39/59) AT (15/59) TT (5/59) T 0.212 0.196 0.242-0.258 
11   rs1805164 Gln597Gln AA (33/65) AG (26/65) GG (6/65) G 0.292 0.293 0.270-0.325-0.350 
13   rs1805165 Ala704Ser GG (3/43) GT (17/43) TT (23/43) G 0.267 0.287 0.267-0.274-0.280-0.292 
  13 rs4972221  / AA (30/64) AT (25/64) TT (9/64) T 0.336 0.347 0.300-0.317 
MOBP 
  2 *rs1768208 / CC (32/82) CT (43/82) TT (7/82) T 0.347 0.349 0.292-0.295-0.317 
3   novel Gln82Lys CC (63/64) CA (1/64) AA (0/64) A 0.008 NA NA 
  3 rs2233204  / CC (30/68) CT (27/68) TT (11/68) T 0.360 0.196 0.283-0.317-0.327 
  4 rs552724  / CC (54/69) CT (8/69) TT (6/69) T 0.145 0.210 0.183-0.195 
Table 3-2. Summary of common and novel variants identified at the loci associated with PSP [180]. All 
SNPs with their allele frequencies identified in our sample population are shown and compared with those 
obtained from the 1000 Genome and dbSNP datasets. Novel variants are shown in bold font. * PSP-GWAS 
associated SNPs. 
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In our sample population the minor allele frequency (MAF) of the variants identified in 
STX6 and MR1 did not differ substantially from the 1000 Genomes or dbSNP releases. 
The haplotype analysis did not reveal any evident LD pattern besides a complete LD 
(D’=1; r2=1; LOD=25.58) between the GWAS associated SNP rs1411478 and rs3747957 
(Asn217Asn in STX6) as seen in Figure 3-5.  
 
Figure 3-5. LD pattern at the Chr1q25.3 locus 
 
Figure 3-5. The relative location of STX6 and MR1 with chromosomal coordinates (Mb; Genome build 
hg19/GRCh37) is shown at the top. Arrows below gene symbols indicate direction of transcription. In each 
box the r2 value between two SNPs is shown with ranges that vary between 0 and 0.99. The black box with 
no number indicates r2=1, i.e. complete LD. Complete LD was evident only for SNPs rs3747957 and 
rs1411478 (* GWAS associated SNP).  
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Such trend, however, can be seen also in the normal population for both the 1000 
Genome release (Table 3-3A) and the HapMap 22 release (Table 3-3B), where it can be 
seen that LD between rs1411478 and rs3747957 is complete, with D’=1 and r2=1. 
 
Table 3-3. Pairwise LD in CEU population 
A 
1000G pilot SNP Proxy Distance RSquared DPrime Chr Coordinate_HG18 
 
rs1411478 rs12754041 4320 1 1 chr1 179224585 
 
rs1411478 rs3747957 8429 1 1 chr1 179220476 
 
rs3747957 rs12754041 4109 1 1 chr1 179224585 
 
rs3747957 rs1411478 8429 1 1 chr1 179228905 
B 
HapMap22 
release SNP Proxy Distance RSquared DPrime Chr Coordinate_HG18 
 
rs1411478 rs12754041 4320 1 1 chr1 179224585 
 
rs1411478 rs3747957 8429 1 1 chr1 179220476 
 
rs3747957 rs12754041 4109 1 1 chr1 179224585 
 
rs3747957 rs1411478 8429 1 1 chr1 179228905 
 
Table 3-3. Data extracted from the “Proxy Search” tool for the SNPs identified at the STX6 locus 
(http://www.broadinstitute.org/mpg/snap/ldsearch.php). Complete LD (D’=1; r2=1) can be seen for SNPs 
rs1411478 and rs3747957 in population with European ancestry from the 1000 Genome pilot study (A) and 
HapMap 22 (B) releases (as it was the case for our PSP population as per Figure 3-5). 
 
The eQTL analysis showed interesting results for rs1411478 as stratifying mRNA levels 
by genotype of this SNP provided evidence for association between the risk allele A and 
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decreased expression of STX6 (p=1.80x10-09; Affymetrix exon arrays, transcript ID 
2446567) in white matter but in no other brain region (Figure 3-6A and B).  
 
Figure 3-6. Rs1411478: Expression quantitative trait loci analysis 
 
Figure 3-6. eQTL signal associated with rs1411478. (A) Boxplot showing STX6 mRNA expression across 
four brain regions: White matter (WHMT), frontal cortex (FCTX), putamen (PUTM) and cerebellar cortex 
(CRBL). Whiskers extend from the box to 1.5 times the inter-quartile range. (B) STX6 mRNA expression 
stratified by the genotypes of the PSP risk SNP rs1411478 in WHMT, FCTX, PUTM and CRBL. The p-
values are shown on the x-axis. 
 
By investigating all SNPs (genotyped and imputed) within 1Mb of the transcription start 
and stop site for STX6 it was confirmed that rs1411478 was the only eQTL signal in this 
genomic region. Therefore it is difficult to assess whether the SNP rs3747957, which 
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corresponds to the silent change Asn217Asn, has any implication with the diseased 
status, considering that:  
1 – Strong LD with rs1411478 can be seen in both our PSP population (Figure 3-5) and 
in the normal population with European ancestry from both the 1000 Genomes and 
HapMap 22 releases (Table 3-3A and B), and;  
2 – the silent change does not affect the protein structure or function and our own QTL 
data don’t support the notion that the base change at rs3747957 may underlie effects on 
expression or splicing such as in the case for other silent mutations [190]. 
In addition, there was seemingly no cis effect on expression exerted by the intronic 
polymorphisms rs75150495 and rs3747956 located at 8bp from the start of the exon 3 
and at 3bp after the end of exon 7, respectively, in MR1. 
 
3.2.3.2 EIF2AK3 
The sequencing of EIF2AK3 resulted in the identification of several known coding and 
non-coding variants (Table 3-2). Two variants were intronic, one of which, rs6750998, 
locates just 6bp downstream of exon 13. Of the 6 coding variants 5 were missense 
changes (rs867529, Ser136Cys; rs13045, Gln166Arg; rs141901506, Asp502Asn; 
rs55791823, Asp566Val; rs1805165, Ala704Ser) and one was a synonymous change 
(rs1805164, Gln597Gln). After in silico analysis, all missense variants were predicted to 
be benign besides Asp566Val that was shown to be probably damaging (score: 0.993; 
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sensitivity: 0.7; specificity: 0.97) (Figure 3-7) [225]. Amino-acid numbering for 
EIF2AK3 refers to the NCBI Reference Sequence: NP_004827.4. 
 
Figure 3-7. EIF2AK3; missense change Asp566Val. PolyPhen-2 analysis 
 
Figure 3-7. In silico analysis of the effect of the missense change Asp566Val 
 
It is interesting to note that the MAF for rs55791823 (Asp566Val) was increased in our 
PSP cohort compared to the 1000 Genomes and dbSNP data for a Caucasian-European 
population (CEU) (0.016 vs. 0.001 and 0.002; Table 3-2), whereas MAFs for all the 
other EIF2AK3 SNPs did not differ substantially from the 1000 Genomes or dbSNP data. 
The haplotype block analysis identified LD associations (Figure 3-8). 
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Figure 3-8. LD pattern at the Chr2p11.2 locus 
 
Figure 3-8. The relative location of EIF2AK3 with chromosomal coordinates (Mb; Genome build 
hg19/GRCh37) is shown at the top. The arrow below the gene symbol indicates the direction of 
transcription. In each box the r2 value between two SNPs is shown with ranges that vary between 0 and 
0.99. Any value 0.8<r2<1 is suggestive of LD. * GWAS associated SNP  
 
From a careful analysis of the LD patterns in the PSP cohort the following can be 
derived:  
1 – The SNPs rs867529 (Ser136Cys) and rs13045 (Gln166Arg) are in almost complete 
LD with each other and, both, with the GWAS associated SNP rs7571971;  
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2 – rs867529 (Ser136Cys) and the GWAS associated SNP rs7571971 are both in almost 
complete LD with rs1805165 (Ala704Ser), and;  
3 – the SNP rs4972221 is in almost complete LD with rs13045 (Gln166Arg). All these 
observations were based on the notion that complete LD is defined by the following 
values: D’=1; r2=1; LOD>2. 
Of note, we compared the haplotype architecture and LD scores of our PSP cohort with 
those available for the control population with European ancestry obtained from the 
“Pairwise LD” analysis (http://www.broadinstitute.org/mpg/snap/ldsearchpw.php, from 
the HapMap 22 release), to possibly identify differences that might hint for a disease 
associated haplotype. 
However, the LD blocks observed in our study population did not differ from those of the 
control population as seen in Table 3-4. 
In addition, our QTL analysis did not reveal significant effects on cis expression or 
splicing for any of the SNPs at this locus. 
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Table 3-4. Comparison of pairwise LD in CEU population and UK PSP cohort 
Pairwise LD/HapMap 22 release Our study 
SNP Proxy Distance RSquared DPrime Chr Coordinate_HG18 RSquared DPrime LOD 
rs867529 rs7571971 17922 1 1 chr2 88676466 0.958 1 20.18 
rs867529 rs1805165 38382 1 1 chr2 88656006 0.942 1 14.33 
rs867529 rs13045 18150 0.848 1 chr2 88676238 0.844 1 16.62 
rs867529 rs1805164 34142 0.196 1 chr2 88660246 0.144 1 1.89 
rs867529 rs6750998 30331 0.116 1 chr2 88664057 0.125 1 3.07 
rs7571971 rs867529 17922 1 1 chr2 88694388 0.958 1 20.18 
rs7571971 rs1805165 20460 1 1 chr2 88656006 0.881 1 12.60 
rs7571971 rs13045 228 0.848 1 chr2 88676238 0.81 1 16.32 
rs7571971 rs1805164 16220 0.196 1 chr2 88660246 0.089 0.754 1.00 
rs7571971 rs6750998 12409 0.116 1 chr2 88664057 0.124 1 3.42 
rs13045 rs7571971 228 0.848 1 chr2 88676466 0.81 1 16.32 
rs13045 rs867529 18150 0.848 1 chr2 88694388 0.844 1 16.62 
rs13045 rs1805165 20232 0.848 1 chr2 88656006 0.768 0.932 9.93 
rs13045 rs1805164 15992 0.231 1 chr2 88660246 0.164 1 2.74 
rs13045 rs6750998 12181 0.137 1 chr2 88664057 0.149 1 3.72 
rs6750998 rs1805164 3811 0.172 1 chr2 88660246 0.119 1 1.75 
rs6750998 rs13045 12181 0.137 1 chr2 88676238 0.149 1 3.72 
rs6750998 rs1805165 8051 0.116 1 chr2 88656006 0.11 1 1.78 
rs6750998 rs7571971 12409 0.116 1 chr2 88676466 0.124 1 3.42 
rs6750998 rs867529 30331 0.116 1 chr2 88694388 0.125 1 3.07 
rs1805164 rs13045 15992 0.231 1 chr2 88676238 0.164 1 2.74 
rs1805164 rs1805165 4240 0.196 1 chr2 88656006 0.08 0.731 0.92 
rs1805164 rs7571971 16220 0.196 1 chr2 88676466 0.089 0.754 1.00 
rs1805164 rs867529 34142 0.196 1 chr2 88694388 0.144 1 1.89 
rs1805164 rs6750998 3811 0.172 1 chr2 88664057 0.119 1 1.75 
rs1805165 rs7571971 20460 1 1 chr2 88676466 0.881 1 12.60 
rs1805165 rs867529 38382 1 1 chr2 88694388 0.942 1 14.33 
rs1805165 rs13045 20232 0.848 1 chr2 88676238 0.768 0.932 9.93 
rs1805165 rs1805164 4240 0.196 1 chr2 88660246 0.08 0.731 0.92 
rs1805165 rs6750998 8051 0.116 1 chr2 88664057 0.11 1 1.78 
rs4972221 rs13045 24491 1 1 chr2 88676238 0.922 0.96 20.30 
rs4972221 rs1805165 4259 0.848 1 chr2 88656006 0.736 0.935 10.44 
rs4972221 rs7571971 24719 0.848 1 chr2 88676466 0.71 0.911 13.84 
rs4972221 rs867529 42641 0.848 1 chr2 88694388 0.777 0.955 15.11 
rs4972221 rs1805164 8499 0.231 1 chr2 88660246 0.19 1 3.52 
rs4972221 rs6750998 12310 0.137 1 chr2 88664057 0.145 1 3.84 
Table 3-4. D’ and r2 values in the normal population with European ancestry (HapMap 22 release) are 
compared with those of our PSP cohort. All the SNPs with D’=1 or >0.95 and 0.8<r2<1 are bolded and 
indicate the overlap between the two populations being compared. No substantial differences can be seen 
suggesting that there are no obvious divergent LD patterns between the PSP vs. the normal population. 
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3.2.3.3 MOBP 
The sequencing of MOBP resulted in the isolation of three variants: One novel missense 
mutation (Gln82Lys) and two known intronic variants (rs2233204 and rs552724). The 
missense mutation (1/64, heterozygous) resulted being a benign change after performing 
in silico analysis (Figure 3-9). The amino-acid numbering for MOBP is with reference to 
GenBank Accession BAA05660.1. 
 
Figure 3-9. MOBP; missense change Gln82Lys. PolyPhen-2 analysis 
 
Figure 3-9. In silico analysis of the effect of the missense change Gln82Lys 
 
MAFs in our cohort were overall comparable to those from the 1000 Genomes releases or 
Caucasian/European populations (Table 3-2).  
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No relevant data could be obtained from the haplotype analysis (Figure 3-10), leaving 
the association with this locus open for questions as it does not seem, at least in our study 
population, that there is genetic variability within MOBP that justifies the association 
neither from a coding nor an expressional perspective. For the latter case, in fact, there 
was no evidence of cis gene or exon level QTLs. 
 
Figure 3-10. LD pattern at the Chr3p22.1 locus 
 
Figure 3-10. LD pattern at 3p22.1. The relative location of MOBP with chromosomal coordinates (Mb; 
Genome build hg19/GRCh37) is shown at the top. The arrow below the gene symbol indicates the direction 
of transcription. In each box the r2 value between two SNPs is shown with ranges that vary between 0 and 
0.99. Any value 0.8<r2<1 is suggestive of LD. * GWAS associated SNP. 
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3.2.4 Discussion 
3.2.4.1 PSP and the MAPT locus 
MAPT has long held a distinctive contribution to progressive supranuclear palsy and its 
definition of primary tauopathy. PSP is, in fact, characterised by:  
1 – Hyperphosphorylated tau inclusions as its pathological hallmark, and;  
2 – Robust genetic association with the MAPT H1 haplotype on chromosome 17 [173], 
[179], [177], [178].  
The latter has been repeatedly reported across different studies and was further confirmed 
in the recent PSP-GWAS that showed extensive genome-wide significance at rs8070723 
(Pj=1.5x10-116) and rs242557 (Pj=4.2x10-70) (Figure 3-2) [180]. Some expression studies 
suggested the role of allele-specific differences in MAPT gene expression as the 
functional basis of this association [201] and as the reason for an increased production of 
tau isoforms with four microtubule-binding repeat domains (4R-tau), ultimately resulting 
in the 4R-tau dominant neuronal and glial inclusions in PSP brains [160]. To date, the 
majority of the variants identified in MAPT are point mutations mainly located within 
and/or around MAPT exon 10, which affect tau’s 4R/3R ratio [184], [182], [185], [186], 
[181], [183], [187], [188], [189], [190]. However, MAPT variability in this fashion seems 
too rare to justify the genetic link between PSP, MAPT and its extended haplotype. 
Several studies over the past 5-6 years have tried to untangle the functional basis of the 
MAPT haplotype and its association with PSP. The MAPT H1c sub-haplotype was shown 
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having strong association with PSP [201] [179] but, more recently, results rather seemed 
discordant as some studies reported a direct link between H1c and MAPT expression 
[201], [178],  [249] whilst other studies could not establish significant association, for 
example, between the H1c tagging SNP rs242557 and an increase in MAPT mRNA 
expression [198], [199]. It was therefore speculated that H1c might affect splicing rather 
than expression levels of MAPT [199], but this hypothesis still needs to be fully 
investigated. These data suggest that, to date, the exact mechanism by which the MAPT 
H1 haplotype exerts its pathogenic effect in PSP still remains, for the most part, unclear 
and that the MAPT H1 haplotype alone is most probably not sufficient to cause PSP. A 
yet unexplored possibility to consider might be epistasis. Some genes or genetic loci may, 
in fact, modulate and/or influence, in –trans, either MAPT expression/splicing or the 
expression of the extended MAPT haplotype. Conversely, MAPT, through the SNPs 
rs1880753 and rs242557, might influence, in –trans, other genes expression. All these 
mechanisms are possible but, clearly, whether they happen and, especially, whether they 
have pathogenic effect will need to be elucidated in the future.  
Taking all this into consideration, it is reasonable to infer that the biology of PSP likely 
goes beyond the genetic association with the MAPT H1 haplotype, suggesting that other 
hitherto unidentified environmental and genetic risk factors are most probably at play and 
contribute to disease pathogenesis. 
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3.2.4.2 New avenues 
The recent PSP-GWAS revealed that novel loci may be involved in the mechanisms 
leading to disease [180]. With a combination of direct sequencing, and haplotype and 
eQTL analyses we aimed at fine mapping and validating these loci to possibly better 
understand their contribution to the pathogenesis of PSP.  
For each of the new loci, their possible implication in PSP is discussed in separate 
paragraphs hereafter. 
 
STX6  
STX6 encodes the 255 amino-acid long protein STX6 that is expressed in different cell 
types including inflammatory/immune, endocrine, endothelial and neuronal cells. STX6 
is primarily involved in trafficking of proteins and lipids from the Golgi to the plasma 
membrane but also in other cellular processes such as endocytosis, exocytosis and 
recycling [230]. STX6 contains a functional SNARE (soluble N-ethylmaleimide-sensitive 
factor-attachment protein receptor) domain, which is located between amino-acids 163-
225. This domain is responsible for binding to homologue SNARE domains of other 
SNARE-proteins to direct the transfer of cargo from vesicles to target membranes. In 
addition, a tyrosine-based sorting motif (YGRL), located between amino-acids 140-143, 
mediates the retrograde transport of STX6 from the plasma membrane to the Golgi [230] 
and the carboxy-terminus, between amino-acids 235-255, presents a hydrophobic 
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transmembrane domain through which STX6 anchors to the Golgi, vesicles or plasma 
membranes [230]. STX6 is involved in different cellular mechanisms some of which are 
cell type specific. For example, STX6 mediates exocytosis of inflammatory granules and 
cytokines in inflammatory/immune cells or allows angiogenesis induced by vascular 
endothelial growth factor (VEGF) signalling in endothelial cells. More interestingly, 
STX6 has been suggested being involved in neurite outgrowth as a response to nerve 
growth factor (NGF) in neuronal cells [232], and impairment of such mechanism might 
link STX6 to neurological disorders as it was shown in PD and AD [230]. Clearly the 
recent results of the PSP-GWAS also suggest that STX6 might also be involved in the 
pathogenesis of PSP [180] supporting the notion of a possible functional link between 
STX6 and neurodegenerative diseases. 
In our genetic screening we did identify a novel missense mutation (Cys236Gly) in one 
individual. Its frequency in our cohort is clearly too low (1/58) to justify the genome-
wide association. The frequency and distribution of this mutation would need to be 
verified in bigger cohorts, i.e., ideally, in the totality of the samples included in the PSP-
GWAS (stage 1 + stage 2 = ~2,200 samples) to better assess its prevalence in the PSP 
population. This amino-acid change is located within the carboxy-terminal 
transmembrane domain of STX6, specifically, the portion of the protein that binds to the 
Golgi/vesicles membranes. Although to date there is no functional evidence at the 
cellular level, in silico analysis predicted this amino-acid change to be probably 
damaging (Figure 3-3). If this prediction is true and translates its putative damaging 
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effect to the protein, this mutation might impair the binding of STX6 to the membranes 
and possibly affect cytoplasmic vesicular trafficking [230].  
Moreover, we identified complete LD between the GWAS associated rs1411478 and 
rs3747957 (Asn217Asn in STX6), pattern that could however also be seen for the normal 
CEU population (Figure 3-5 and Tables 3-3A and B). Nevertheless, as a possible reason 
for association at this locus in our cohort, eQTL data revealed that the GWAS associated 
rs1411478 seems to influence cis expression of STX6 in white matter (p=1.80x10-09). 
Rs1411478 and rs3747957 are in complete LD, and rs3747957, within STX6, locates to 
exon 7. Interestingly, the encyclopaedia of DNA elements (ENCODE) tracks [250] for 
intron 7 indicate a conserved region in mammals that is featured by DNAseI 
hypersensitivity clusters, histone 3 acetylated at lysine 27 (H3K27Ac) and binding of 
multiple transcription factors from ChIP-seq data. Such epigenetic marks are indicative of 
gene enhancers [251] that could influence the distant promoter by the formation of 
chromatin loops and program tissue-specific expression during development [252]. As 
such, SNPs in LD with the GWAS SNP in this domain may exert an allele/brain region 
specific effect on STX6 expression in white matter. 
The link with white matter is of extreme interest as the involvement of white matter has 
been previously described in PSP. Tau lesions, for example, have been identified in white 
matter of pathologically confirmed PSP cases [253]. The 4R-tau isoform is overexpressed 
at the protein level in the subcortical regions and the brain stem of these cases of which 
>90% were H1 homozygous for the MAPT haplotype [253]. These two pieces of 
! 177!
information are particularly important as they suggest a possible link between tau 
pathology, the MAPT H1 haplotype and white matter degeneration. Considering our 
eQTL data, the cis–modulation of STX6 expression in white matter could be an additional 
factor involved in the pathogenesis of PSP. Another study suggested that the level and 
topography of degeneration of white matter tracts is likely to correlate with some of the 
PSP specific symptoms [254]. Specifically, abnormal diffusivity through diffusion tensor 
imaging was observed in:  
1 – Superior cerebellar peduncles;  
2 – Corpus callosum and;  
3 – Superior and inferior longitudinal fasciculus in patients diagnosed with PSP [254]. 
Degeneration of superior cerebellar peduncles correlated with disease severity and tau 
pathology, suggesting that imaging of this tract might serve as a biomarker to monitor 
PSP severity [254]. Further, degeneration of the superior and inferior longitudinal 
fasciculus correlated with saccadic impairment and motor functions respectively, whilst 
no correlations between degeneration of the corpus callosum and PSP specific 
symptomatology could be established [254]. More recently it was shown that:  
1 – White matter of PSP brains have enlarged vacuoles, especially in the alveus, the 
frontopontine fibers and the central tegmental tract and;  
2 – Glial inclusions can be found in basal ganglia, frontopontine fibers, cerebellum and 
superior frontal gyrus [255]. 
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These features, vacuolation and glial inclusions, were suggested being a consequence of 
adjacent grey cellular loss and downstream effects of tau pathology, respectively [255].   
All this taken together suggests that STX6 expression might correlate with tau pathology 
and white matter degeneration in PSP. Although our own eQTL data did not support any 
effect of rs3747957 (Asn217Asn in STX6) on cis expression or splicing and its complete 
LD with the GWAS associated SNP rs1411478 seems reflected also in the normal 
population, it is reasonable to invest in further investigations to assess whether the effect 
of rs1411478 on STX6 expression is replicated and confirmed in other PSP cohorts. Not 
least, the interplay between MAPT, STX6 and white matter degeneration is an intriguing 
possibility that deserves further studies to establish whether there is evidence of 
correlation and synergistic effects on disease-specific mechanisms eventually leading to 
PSP. 
 
MR1 
MR1 encodes the 341 amino-acid long transmembrane protein MR1, which belongs to 
the family of the major histocompatibility (MHC) class I molecules. MR1 is ubiquitously 
expressed and is implicated in immune response mechanisms such as the antigen 
presenting function [256]. 
We performed genetic screening on MR1 because of its close proximity to STX6 (10.6 
kb) in order to identify possible genetic variants that might further explain the genome-
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wide association at this locus. We did identify several known coding and non-coding 
variants. Among the coding variants, one missense change (Arg31His, rs41268456) was 
predicted, in silico, to be probably damaging (Figure 3-4). We identified this as a 
heterozygous change in 1/70 cases. Based on the results in our cohort, and in line with the 
1000 Genomes releases, this variant seems to be extremely rare. The amino-acid change, 
Arg to His, locates to the extracellular compartment of the MR1 protein and is part of the 
α1 ligand-binding domain that is highly conserved between different species [257]. It is 
not clear whether this amino-acid change may cause a severe biochemical change in the 
α1 subunit that could, in turn, impact the ability of MR1 to bind ligands in the 
extracellular environment.  
In summary, due to lack of LD between the GWAS SNP (rs1411478) and variability in 
MR1 as well as absence of significant gene-specific eQTL, it is less plausible that MR1 is 
responsible for the observed association at this locus. All the more, MR1 is a protein of 
the immune system for which there was no evidence of association in the PSP-GWAS 
[180], unlike in the case of other neurological disorders such as Parkinson’s disease (PD) 
[258] or multiple sclerosis (MS) [259]. It is therefore difficult to expect a possible role for 
MR1 in PSP. 
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EIF2AK3  
EIF2AK3 encodes the 1116 amino-acid long protein EIF2AK3 which is ubiquitously 
expressed in several cell types and tissues, including neurons and the brain 
(http://www.ebi.ac.uk/gxa/gene/ENSG00000135823). EIF2AK3 is a kinase protein 
located at the membrane level of the endoplasmic reticulum (ER). The first 514 amino-
acids of the protein locate to the lumen of the ER. These are followed by ~20 amino-
acids that identify the transmembrane domain. The cytoplasmic portion of the protein 
presents a structural polypeptide sequence of ~70 amino-acids followed by the ATP-
binding domain (amino-acids 599-607) and the kinase domains (amino-acids 593-1077) 
(http://www.uniprot.org/uniprot/Q9NZJ5). ER stress in eukaryotic cells is handled via the 
unfolded protein response (UPR), a relatively complicated mechanism that assures for:  
1 – Attenuation of translation in the cell;  
2 – Repair of unfolded proteins accumulated in the ER lumen, and;  
3 – Degradation of the unfolded proteins via the ER associated degradation (ERAD) 
mechanism [260], [234], [233]. 
EIF2AK3 is specifically involved in the first process. In steady conditions the lumenal 
portion of EIF2AK3 oligomerizes with the heat shock-binding protein (BiP). When 
unfolded proteins start accumulating in the lumen of the ER the BiP chaperone detaches 
from the amino-terminus of EIF2AK3 and binds to the unfolded proteins. This activates 
EIF2AK3 which dimerizes and phosphorylates itself and the α-subunit of the eukaryotic 
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translation-initiation factor 2 (EIF2) that, in turn, promotes the translation of the 
activating transcription factor 4 (ATF4). The downstream effect of such activation is a 
general decrease in cellular translation processes [260], [234], [233]. 
Our genetic screening of EIF2AK3 resulted in the isolation of several coding and non-
coding known variants. Asp566Val (rs5579182) was identified as a heterozygous change 
in 2/61 cases and was predicted being probably damaging (Figure 3-7). This amino-acid 
change resides in the cytoplasmic region of the protein, approximately 30 amino-acids 
before the ATP-binding and the kinase domains. The amino-acid Asp is conserved 
among mammals and the effect of the change from Asp to Val is not clear. Functional 
studies may elucidate whether such change could, for example, impact the tertiary 
structure (protein conformation). Comparing the MAF of this variant in our cohort with 
the 1000 Genomes releases and dbSNP data for a Caucasian-European population (CEU) 
its frequency seemed higher in our study population (0.016 vs. 0.001 and 0.002; Table 3-
2).  
It is interesting to note that Asp566Val (rs55791823) holds both features of being a 
probably damaging amino-acid change (Figure 3-7) and having a MAF that differs from 
the 1000 Genomes and dbSNP releases. Nevertheless, our cohort might be too small to 
consider these two co-occurring characteristics significant and/or strongly associated with 
disease. In addition, no significant LD pattern could be identified for this specific variant 
(rs55791823), therefore, its possible pathogenic impact remains hard to interpret in our 
cohort. The LD analysis identified a significant LD block of ~42 kb that included the 
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GWAS associated SNP rs7571971 and 4 SNPs, 3 of which were coding (rs1805165, 
rs13045 and rs867529) and 1 was intronic (rs4972221). The coding variants are all 
missense and are all in almost complete LD with the GWAS SNP (Figure 3-8). 
Nevertheless, all 3 are predicted to be benign and their MAFs reflect the expected values 
as of the 1000 Genomes releases and the Caucasian/European general populations. In 
addition, by comparing the haplotype structure of our PSP cohort with that of the normal 
CEU population obtained from the HapMap 22 release (and analysed through the online 
tool http://www.broadinstitute.org/mpg/snap/ldsearchpw.php) no outstanding differences 
could be identified. However, specific haplotype substructures at this locus had been 
previously reported [261, 262]. Data for our PSP population did reflect findings in [261, 
262] as shown in Table 3-5. 
 
Table 3-5. EIF2AK3 locus associated haplotypes 
Haplotype SNP/Amino-acid change Haplotype frequency per Study 
 rs867529/(Ser136Cys) rs7571971* rs13045/(Gln166Arg) rs1805165/(Ala704Ser) 
HapMap 
CEU [261] [262] 
Our 
study 
A C/(Ser) C G/(Arg) T/(Ser) 0.646 0.676 0.645 0.661 
B G/(Cys) T A/(Gln) G/(Ala) 0.294 0.311 0.288 0.287 
C C/(Ser) C G/(Arg) G/(Ala) / 0.013 0.001 0.011 
D C/(Ser) C A/(Gln) T/(Ser) 0.029/0.016 / 0.061 0.033 
Table 3-5. Comparison of the 4 different and most frequent haplotypes (A, B, C and D) associated with the 
EIF2AK3 locus. * PSP-GWAS associated SNP  
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Haplotype B has been suggested to be associated with an increased activation of 
EIF2AK3 and the UPR process in response to ER stress [261]. Haplotype B, that includes 
the minor and risk allele T of the PSP-GWAS associated SNP rs7571971, may be 
implicated in an increase in risk of developing PSP [262]. Interestingly, the frequency 
identified for the B haplotype in the Stutzbach study and ours, which are reporting data 
on PSP cases, are basically the same (0.288 vs. 0.287) regardless from the sample size 
(~1,000 samples in [262] and ~80 in our study). 
Furthermore, considering that our eQTL data did not suggest a possible role in expression 
or splicing for any of these SNPs it is difficult, at the current status, to assess what the 
reason of the association at this locus might be. Clearly, neither genetic screening, nor 
haplotype or eQTL analyses could explain the association with this locus suggesting that 
possibly trans-active elements might affect this locus and that the PSP-GWAS results 
rather point to a cellular process as possibly implicated in pathogenesis with yet unclear 
molecular underlying processes. 
In this view, from a functional perspective, it had been shown that efficient synaptic 
plasticity and memory are related with proper phosphorylation of the EIF-2 protein [235]. 
Functional EIF2AK3 is necessary for correct phosphorylation of the α-subunit of EIF-2 
which consequently suggests not only that EIF2AK3 may have a critical role in overall 
general cellular homeostasis by controlling protein translation processes but also that 
these mechanisms may play a role in neurological conditions [235]. It was shown that 
disrupted EIF2AK3 activity may be involved in the pathophysiology of schizophrenia 
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[235] and that impaired interaction between EIF2AK3, EIF-2 and ATF4 may contribute 
to conditions such as impaired cognitive functions and information processing [235]. 
Several neurological disorders, including AD and PD, have previously been linked to 
protein translation impairment [235] and EIF2AK3 may be one of the factors at play in 
this arena. In addition, activation of UPR was previously shown in presence of 
phosphorylated tau (p-tau) in AD and it was suggested that UPR coincides with early 
events of tau pathology [262, 263]. Stutzbach and colleagues however also specified that 
EIF2AK3 activation may precede tau accumulation rather than follow it [262]. This may 
indicate a link between the UPR and tau pathology leading to the assumption that UPR 
processes may be involved in a larger spectrum of tauopathies. In fact, not only this trend 
was observed in AD [263], but also, more recently, in FTLD-tau, whilst it seemed absent 
in FTLD-TDP or FTLD-FUS cases or in neurologically normal controls [264]. Another 
study suggested also a different mechanism by which UPR might be involved in the 
development of tauopathies in that activated EIF2AK3 may enhance phosphorylation 
processes with downstream effects on tau contributing, to a certain extent, to the 
formation of hyperphosphorylated tau and neurofibrillary tangles [264]. 
In summary, EIF2AK3 may be involved in PSP by, possibly, exerting a functional 
pathogenic role enhanced by an effect driven by the B haplotype [261, 262]. Such effect 
may happen in concert with MAPT and tau pathology. It remains to be established 
whether the UPR activates because of early tau aggregation (event that was recently 
dismissed as Tau does not locate to the ER [262]) and, consequently, the B haplotype at 
the EIF2AK3 locus increases risk for PSP for the carriers or downstream effects of 
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EIK2AK3 activation lead to hyper-phosphorylation of Tau [264]. Either possibility needs 
to be further investigated. 
 
MOBP  
MOBP encodes the 183 amino-acid long protein MOBP that locates to the cytoplasm of 
oligodendrocytes, which are brain cells involved in myelination processes [238]. It is the 
third most abundant protein in the CNS-myelin [238] and is expressed in humans in the 
form of two different isoforms resulting from alternative splicing of a single gene [237]. 
MOBP is expressed in white matter [237] and contains proline-rich tandem repeats which 
is common in proteins with structural functions [238]. It follows that MOBP is likely to 
be an important element stabilizing the multi-layered structure of the myelin sheath in the 
CNS [238]. It was suggested that MOBP may be involved in the pathogenesis of multiple 
sclerosis (MS) as a result of autoimmune reactivity against MOBP leading to 
destabilization and destruction of myelin [238]. 
Our genetic screening revealed a novel missense variant, Gln82Lys (1/63, heterozygous 
change) that resulted being a benign change after in silico analysis (Figure 3-9) and two 
common intronic variants. The missense variant locates to the proline-rich domain that 
spans between amino-acids 77-136. There was no evidence of LD for the two intronic 
variants with the GWAS associated SNP as well as no evidence of effect on either cis 
expression or splicing. Based on our data it is difficult to identify a genetic link between 
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locus and the disease in our cohort. Nevertheless, it was shown that tau pathology in PSP 
affects neurons, astrocytes and oligodendrocytes [253]. The latter provide the myelin 
sheath surrounding the axons of neurons. The association at this locus may be rather the 
result of interplay between MOBP and tau or a downstream effect triggered by tau 
pathology. Although this hypothesis is clearly intriguing and interesting, it needs to be 
further investigated before any assumption can be made. In addition, two MOBP 
isoforms are known. The two proteins are substantially different as one is 183 amino-
acids long (referred to as the “canonical”), whilst the other is 81 amino-acids long and is 
missing the carboxy terminal proline-rich repeat domain. A better understanding of the 
MOBP isoforms, their expression patterns and their functions, may help in locating this 
protein within the biological context, in health and disease. 
 
3.2.5 Conclusion 
It is worth noting that the PSP-GWAS [180] has, on one hand, confirmed the MAPT H1 
haplotype being strongly associated with PSP, and, on the other, given rise to novel 
possible perspectives on the pathogenesis of PSP.  
After having concluded our follow up study that aimed at further investigating the newly 
identified loci [180], our main findings can be summarized as follows:  
! 187!
1 – We identified complete LD between the GWAS associated SNP rs1411478 and 
rs3747957 (Asn217Asn) in STX6, and our data show correlation between STX6 risk allele 
and cis expression levels in white matter;  
2 – The EIF2AK3 locus showed a ~42kb that included the GWAS associated SNP 
rs7571971, the 3 coding SNPs rs1805165, rs13045 and rs867529, and the intronic SNP 
rs4972221. This LD block however did not seem disease specific as it almost equally 
reflects LD patterns that can be found in the normal population. In addition, no effects on 
expression/splicing could be identified for any of the SNPs at this locus, and;  
3 – There was no direct evidence from our genetic screening of MOPB or from our eQTL 
data for a reason that might underlie the GWAS association at this locus. In addition, 
although we identified a couple of novel missense changes (Cys236Gly in STX6 and 
Gln82Lys in MOBP) none seemed convincingly pathogenic, neither they were suggestive 
of underpinning association at their respective loci, given their extremely low frequency 
rate of occurrence. 
In addition, there are some limitations to this study that need to be acknowledged and 
kept in mind:  
1 – The limited sample size (n=84, although all cases were pathologically confirmed); 
2 – The use of neurologically normal control brains to assess expression that may not 
entirely represent conditions related to the diseased status (i.e. PSP);  
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3 – The presence of different cell populations (microglial cells, astrocytes, 
oligodendrocytes, etc.) in addition to neurons in the samples used to produce eQTL data 
(that might partially confound expression results) and;  
4 – The lack of availability of trans eQTL and splicing data. 
 
However, considering all of the above, our findings together with those of the PSP-
GWAS [180] may suggest a number of ambitious, but, at the same time, intriguing 
assumptions about possible disease related mechanisms. In fact, the notions that: 
1 – Tau pathology and white matter involvement are characteristics of PSP, and; 
2 – The newly identified genes/loci which relate to tau pathology and white matter, both 
offer a reasonable background to base upon the design of future genetic and functional 
studies in order to verify whether these processes are involved and, if so, to what extent 
in the pathogenesis of PSP.  
In conclusion, these speculations, which are highlighted and summarized in Figure 3-11, 
will clearly need to be further investigated in the near future, in order to be possibly 
confirmed and validated across studies. 
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Figure 3-11. Possible PSP-associated disease mechanisms: Speculations 
 
Figure 3-11. The novel loci highlighted in [180] may contribute collectively to the pathogenesis of PSP. 
Specifically: 
1 – Interplay between MAPT, the H1 haplotype, tau pathology, white matter degeneration and differential 
expression patterns of STX6 may influence each other and have a role in the pathogenesis of PSP; 
2 – Activated EIF2AK3 may either be a consequence of early tau pathology or induce phosphorylation of 
tau by activating the glycogen synthase kinase 3β (GSK-3β) which is involved in tau phosphorylation, 
implying that the EIF2AK3 may have a role in the process that leads to the formation of neurofibrillary 
tangles, and; 
3 – MOBP is mainly expressed in white matter and there is evidence of white matter involvement in PSP as 
well as tau pathology affecting white matter. It may be a possibility that the interaction between MAPT and 
MOBP through epistasis, or trans regulation of expression or splicing, or downstream effects of tau 
pathology may impact and impair the biology of MOBP and contribute to myelin disruption. 
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CHAPTER 4 – FTD-GWAS 
 
4.1 FTD-GWAS chronicle 
4.1.1 The rationale 
Over the past 15 years, the genetic study of frontotemporal dementia has brought to light 
a handful of mendelian genes/loci (MAPT, GRN and C9orf72) [26, 45, 66, 67, 76, 77] and 
one possible disease modifying factor (TMEM106B) [26, 41]. In addition, a limited 
number of other genes have been associated with the FTD spectrum although the 
occurrence of pathogenic mutations has been rare (VCP, SQSTM1 and UBQLN2), or 
equivocal (TDP-43, FUS and CHMP2B) [26, 265]. All the more, a clear disease 
mechanism has not yet been established and this is for the most part due to the fact that 
FTD is a complex disorder characterised by heterogeneous features in the clinical, 
pathological and genetic settings. In particular, the current genetics of FTD, besides 
explaining approximately 20% or less of cases, do not point to a clear and specific 
disease mechanism. Only variability in MAPT, by either directly affecting exons 9, 10, 
11, 12 and 13 or splicing of exon 10, has been proven to lead to an impairment of tau 
capabilities in binding the microtubules fact that, in turn, affects neuronal stability and 
partially also contributes to tau pathology [29, 50]. Taking all this together it follows that 
the molecular underpinnings of FTD are, to date, still not clear. 
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Advancements of the technologies available to researchers offer increasingly 
sophisticated tools to study diseases, especially, in the field of genetics. The quantum 
leap over the past 10-20 years has been unimaginable and unprecedented in this field, 
crossing over from targeted and limited (in size) Sanger sequencing to genome-wide 
association (GWA) or, the most recent, exome and whole genome sequencing. Such tools 
allow the investigation of the genome in a more comprehensive fashion and at a faster 
pace. Each of these methods facilitates the study different functional and structural 
characteristics of the genome: The GWA type of approach, for example, identifies 
genetic loci that are associated with disease [266] and are likely to indicate pathways 
and/or processes that play a substantial role in the pathogenesis of a certain diseased trait. 
With this background in mind, the rationale of the FTD-GWAS was to identify novel 
genes/loci associated with this neurodegenerative condition that could possibly also shed 
light on disease associated mechanisms. 
 
4.1.2 The development and its phases  
A detailed timeline of the FTD-GWAS is summarized in Figure 4-1. 
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Table 4-1. FTD-GWAS: Collaborative groups as of December 2008 
FTD-GWAS Investigators 
Martin Rossor/Jonathan Rohrer (UK) 
Stuart Pickering-Brown (UK) 
Huw Morris (UK) 
Rosa Rademakers (USA) 
Parastoo Momeni (USA) 
Bruce L Miller/Anna Karyadas (USA) 
Daniel Geschwind (USA) 
Vivianna Van deerlin (USA)!
Christine Van Broekhoven (BELGIUM) 
Caroline Graff (SWEDEN) 
Alexis Brice/Isabelle Leber (FRANCE) 
Jorgen Erik Nielsen (DENMARK) 
Johannes Schlachetzki (GERMANY) 
J van Swieten (NETHERLANDS) 
Barbara Borroni (ITALY) 
Annibale Puca/Valeria Novelli (ITALY) 
Giacomina Rossi (ITALY) 
Amalia C Bruni (ITALY) 
Pau Pastor (SPAIN) 
Table 4-1. List of the investigator(s) or contact people per country who agreed to participate in the FTD-
GWAS as of December 2008 after the announcement at the international FTD meeting in Rotterdam, 
Netherlands. 
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Table 4-2. FTD-GWAS: Sample receipt at UCL 
GROUP 1 = samples received at UCL before May 2010 Samples (n) 
Schlachetzki J (Germany)    
TOTAL 448 
Borroni B (Italy)     
Novelli V (Italy)     
Momeni P (USA)     
Rossi G (Italy)         
GROUP 2 = samples received at UCL in May 2010  Samples (n) 
Perneczky R (Germany)    
TOTAL 1,298 
Danek A/Bader B (Germany)    
Nielssen J (Denmark)     
Riemenschneider M (Germany)   
Galimberti D/Scarpini E (Italy)    
French Consortium    
Rainero I (Italy) 
    Binetti G (Italy)     
Nacmias B (Italy)     
Bruni AC (Italy)     
Graff C (Sweden)         
          TOTAL  1,746 
Table 4-2. List of the investigator(s) or contact people per country who had sent samples to UCL by May 
2010.  
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Table 4-3. FTD-GWAS: Summary of received and genotyped samples  
A 
Participating Groups Samples received Samples genotyped 
Momeni (USA) 
TOTAL 1,746 TOTAL 1,303 
Graff (SWEDEN) 
French Consortium 
Nielsen (DENMARK) 
Danek (GERMANY) 
Perneczky (GERMANY) 
Riemenschneider (GERMANY) 
Schlachetzki (GERMANY) 
Borroni (ITALY) 
Novelli - Puca (ITALY) 
Rossi (ITALY) 
Galimberti (ITALY) 
 Rainero (ITALY) 
Benussi (ITALY) 
Nacmias (ITALY) 
Bruni (ITALY) 
Table 4-3. (A) Summary of samples that have been collected at UCL during discovery phase. After 
material QC a total of ~450 samples were excluded. Genotyped samples were 1,303. 
B 
Participating Groups Samples received Samples genotyped 
Rohrer - Rossor (UK) 
TOTAL 1,911 TOTAL 1,655 
Mead (UK) 
Pickering-Brown (UK) 
Morris (UK) 
Roageva (CANADA) 
Rademakers (USA) 
Van deerlin (USA) 
Van Broekhoven (BELGIUM) 
Heutink (NETHERLANDS) 
van Swieten (NETHERLANDS) 
Pastor (SPAIN) 
Table 4-3. (B) Summary of samples that have been collected at NIH during discovery phase. After material 
QC a total of ~300 samples were excluded. Genotyped samples were 1,655. 
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Table 4-4. FTD-GWAS: Total of samples and controls received 
Participating Groups Samples sent 
  Discovery phase Replication phase 
    Cases Controls 
Momeni (USA) 
TOTAL 3,657 TOTAL 2,039 TOTAL 1,600 
Baborie (UK) 
Graff (SWEDEN) 
French Consortium 
Nielsen (DENMARK) 
Danek (GERMANY) 
Perneczky (GERMANY) 
Riemenschneider (GERMANY) 
Schlachetzki (GERMANY) 
Borroni (ITALY) 
Novelli - Puca (ITALY) 
Rossi (ITALY) 
Galimberti (ITALY) 
 Rainero (ITALY) 
Benussi (ITALY) 
Nacmias (ITALY) 
Bruni (ITALY) 
Rohrer - Rossor (UK) 
Mead (UK) 
Rowe (UK) 
Pickering-Brown (UK) 
Morris (UK) 
Roageva (CANADA) 
Rademakers (USA) 
Van deerlin (USA) 
Van Broekhoven (BELGIUM) 
Heutink (NETHERLANDS) 
van Swieten (NETHERLANDS) 
Clarimon (SPAIN) 
Pastor (SPAIN) 
Cruchaga (USA) 
Mackenzie (CANADA) 
Landqvist (SWEDEN) 
Ruiz (SPAIN) 
Schofield 
Table 4-4. Summary of the samples sent to the Institutions leading the FTD-GWAS project. The samples 
are subdivided by stage (discovery and replication phase) and by status (case vs. control).   
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4.2 FTD-GWAS: The project 
The materials and methods as well as the procedures adopted to accomplish the FTD-
GWAS project have been extensively reported and explained in Chapter 2, sections 
2.1.2, 2.1.6.3, 2.2.1.3, 2.2.2.8, 2.3.4 and 2.3.5. 
In the following sections, prior to the report of the results of the FTD-GWAS, the 
materials and methods used to perform methylation and expression quantitative trait loci 
(m/eQTL) analyses are described.     
 
4.2.1 Expression and methylation quantitative trait loci (QTL) 
The work to generate the expression and methylation data was performed by members of 
the UK Brain Expression Consortium (UKBEC) and North American Brain Expression 
Consortium (NABEC) whose names and affiliations are listed and acknowledged in 
Appendix 2-5. 
  
4.2.1.1 UK Brain Expression Consortium (UKBEC) 
Sample Collection 
One hundred and thirty four brain samples of control individuals were collected by the 
Medical Research Council (MRC) Sudden Death Brain and Tissue Bank, Edinburgh, UK 
! 199!
(n=100), and the Sun Health Research Institute (SHRI) Brain Donation Program, USA 
(n=34) [243, 244]. All samples were pathologically confirmed to be normal and were 
fully authorized for scientific investigation. Ten brain regions (cerebellar cortex (CRBL), 
frontal cortex (FCTX), hippocampus (HIPP), the inferior olivary nucleus (sub-dissected 
from the medulla, MEDU), occipital cortex (BA17, OCTX), putamen (at the level of the 
anterior commissure, PUTM), substantia nigra (SNIG), temporal cortex (TCTX), 
thalamus (at the level of the lateral geniculate nucleus, THAL) and intralobular white 
matter (WHMT) were sampled per individual for RNA analyses. 
 
RNA isolation and processing of samples using Affymetrix Exon 1.0 ST Arrays 
Total RNA was isolated using the miRNeasy 96 well kit (Qiagen, UK) and its quality was 
assessed through 2100 Bioanalyzer and RNA 6000 Nano Kit (Agilent, UK). Total RNA 
was then processed with the Ambion® WT Expression Kit and Affymetrix GeneChip 
Whole Transcript Sense Target Labeling Assay, and hybridized to the Affymetrix Exon 
1.0 ST Arrays as recommended by manufacturer. Hybridized arrays were scanned on an 
Affymetrix GeneChip® Scanner 3000 7G and visually inspected for hybridization 
artefacts. Arrays were processed using Robust Multi-array Average (quantile 
normalisation) algorithm [267] in Affymetrix Power Tools 1.14.3 software 
(http://www.affymetrix.com/partners_programs/programs/developer/tools/powertools.aff
x). After re-mapping the Affymetrix probe sets onto human genome build 19 (GRCh37), 
analysis was restricted to probe sets with gene annotation and containing at least 3 
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uniquely hybridized probes free from polymorphisms (MAF >1% in the European panel 
of the March 2012 release of 1000 Genomes) [242]. 
 
DNA extraction, genotyping and imputation 
Genomic DNA was extracted from human post-mortem brain tissue using Qiagen’s 
DNeasy Blood and Tissue Kit (Qiagen,UK) (100–200 mg). Samples from every 
individual were run on the Illumina Infinium Omni1-Quad BeadChip and the 
ImmunoChip [221, 222]. The BeadChips were scanned using an iScan (Illumina, USA) 
with an AutoLoader (Illumina, USA) and Genome Studio (Illumina) was used for 
generating SNP calls and analysing the data. Individuals with non-European ancestry 
were identified through PCA and, subsequently excluded from analysis.  Prior to 
imputation, standard QC was performed to exclude samples with call rate<95%, p-value 
of deviation from Hardy-Weinberg Equilibrium<0.0001 and CNV and indel markers. 
Then SNPs from both arrays were combined and imputed using MaCH [247] and 
minimac (http://genome.sph.umich.edu/wiki/Minimac) using the 1000 Genome release 
(March 2012). More than 5.5M SNPs and ~570K indels with good post-imputation 
quality (r2>0.50) and MAF of at least 5% were used in subsequent analyses. 
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4.2.1.2 North American Brain Expression Consortium (NABEC) 
Sample collection 
Cerebellar and frontal cortex samples originating from 399 neuropathologically 
confirmed controls were collected [222]. Briefly the samples originated from the 
University of Maryland Brain Bank, Baltimore (n=207), Sun Health Research Institute 
(n=52, non-overlapping with UKBEC), Baltimore Longitudinal Study of Aging (n=20), 
University of Miami (n=16), the Department of Neuropathology of John Hopkins 
University (n=9) and the Medical Research Council (MRC) Sudden Death Brain and 
Tissue Bank (n=95, subset of UKBEC). This study was approved by the appropriate 
institutional research ethics board. 
 
RNA isolation and processing of samples using Illumina Human HT12-v3 
Arrays 
Total RNA was extracted from (100–200 mg) human post-mortem brain tissue using a 
glass-Teflon homogenizer and 1mL TRIzol (Invitrogen, Carlsbad, CA) as recommended 
by manufacturers (100–200 mg). RNA was biotinylated and amplified using the 
Illumina® TotalPrep-96 RNA Amplification Kit and directly hybridized onto Human 
HT12 Expression BeadChips (Illumina Inc., USA). Expression data were analysed using 
the Gene Expression Module 3.2.7 within Illumina® BeadStudio. Raw intensity values 
for each probe were transformed using the cubic spline normalization method and then 
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log2 transformed for mRNA analysis. We re-mapped the annotation for probes according 
to ReMOAT [268] on the human genome build 19 and then restricted the analysis to 
genes that were uniquely hybridized and associated with gene descriptions. 
 
DNA isolation and processing of samples using Illumina Human 
Methylation27 arrays 
The CpG methylation in cerebellum and frontal cortex was determined in a subset of the 
NABEC dataset (n=292). Genomic DNA was phenol–chloroform extracted and 
quantified on the Nanodrop1000 spectrophotometer prior to bisulfite conversion. 
Bisulfite conversion of 1 µg of genomic DNA was performed using Zymo EZ-96 DNA 
Methylation Kit as recommended by manufacturer. CpG methylation status of at 27,578 
CpG dinucleotides at 14,495 genes was determined using Illumina Infinium 
HumanMethylation27 BeadChip, as per the manufacturer's protocol. Data were analyzed 
in BeadStudio software (Illumina Beadstudio v.3.0) with threshold call rate>95%. QC of 
sample handling included comparison of genders reported by the brain banks and 
determined by analyzing methylation levels of CpG sites on the X chromosome. Samples 
where genders did not match between brain bank and methylation data were excluded 
from our analyses. Individuals not overlapping with UKBEC were genotyped on Illumina 
Infinium HumanHap550 v3 (Illumina, USA). The SNPs that passed QC and were 
common to both UKBEC and non-UKBEC individuals were extracted for imputation. 
Approximately 5.3M SNPs were available after imputation and QC. 
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eQTL analyses 
SNP dosage was analysed through an additive genetic model using linear regression 
adjusting for covariates of gender, age at death, post mortem interval (PMI), brain bank, 
batch in which preparation or hybridization were performed (and for the first two PCA of 
population stratification in NABEC dataset). The analyses were conducted using 
MACH2QTLv1.11 (http://www.sph.umich.edu/csg/abecasis/MaCH/download/) for 
NABEC and MatrixEQTL [248] and R (http://www.R-project.org/) for UKBEC. 
Association was tested for all probe sets located within +/- 1Mb of each SNP. Gene 
expression and methylation data are available from Gene Expression Omnibus under the 
accession number GSE36192. 
 
4.2.2 Results 
In total (discovery + replication phases), 3,526 FTD samples that survived QC were 
analysed in this study. These were divided in 2,154 cases (discovery phase) and 1,372 
cases (replication phase) (Table 4-5). 
The QQ plots for all subtypes and the whole cohort are shown in Figure 4-2. 
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Figure 4-2. QQ-plots for all FTD-GWAS association analyses 
 
Figure 4-2. QQ plots for each subtype (A-D) and for the entire cohort (E). In each and every subtype there 
is almost no departure from the expected distribution. An inflation can be seen in the QQ plot of the entire 
cohort, however raw lambda value was 1.054, thus acceptable for GWAS standards.   
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4.2.2.1 Discovery phase 
Primary analysis for the discovery phase was performed on a total of n=2,154 cases 
(Table 4-5) and n=7,444 control samples (after quality control filtering). 
Based on the different subtypes that had been collected (and that contribute to the FTD 
spectrum), the primary association analyses were accordingly strategized leading to four 
separate analyses each targeting every single FTD subtype (bvFTD, SD, PNFA and FTD-
MND) individually (Table 4-6) followed by a final meta-analysis on the entire cohort.  
 
 
 
 
 
 
 
 
 
 
Ta
ble
 4-
6. 
FT
D-
GW
AS
: s
ub
typ
es 
Co
un
try
 
Su
bty
pe
s 
bv
FT
D 
SD
 
PN
FA
 
FT
D-
M
ND
 
FT
LD
-U
 
  
Di
sc
ov
er
y 
ph
as
e 
Re
pli
ca
tio
n 
ph
as
e 
To
tal
 
Di
sc
ov
er
y 
ph
as
e 
Re
pli
ca
tio
n 
ph
as
e 
To
tal
 
Di
sc
ov
er
y 
ph
as
e 
Re
pli
ca
tio
n 
ph
as
e 
To
tal
 
Di
sc
ov
er
y 
ph
as
e 
Re
pli
ca
tio
n 
ph
as
e 
To
tal
 
Di
sc
ov
er
y 
ph
as
e 
Re
pli
ca
tio
n 
ph
as
e 
To
tal
 
U
SA
 
31
5 
25
 
34
0 
14
7 
12
 
15
9 
81
 
15
 
96
 
36
 
21
 
57
 
0 
10
2 
10
2 
C
an
ad
a 
22
 
5 
27
 
1 
1 
2 
0 
5 
5 
1 
7 
8 
0 
11
 
11
 
U
K
" 
20
7 
15
2 
35
9 
75
 
53
 
12
8 
69
 
44
 
11
3 
50
 
16
 
66
 
0 
19
 
19
 
Sp
ai
n 
N
A
 
19
4 
19
4 
N
A
 
41
 
41
 
N
A
 
51
 
51
 
N
A
 
13
 
13
 
N
A
 
10
 
10
 
Fr
an
ce
 
13
5 
30
 
16
5 
3 
0 
3 
8 
3 
11
 
59
 
8 
67
 
0 
1 
1 
B
el
gi
um
* 
13
5 
27
* 
16
2 
13
 
1*
 
14
 
22
 
2*
 
24
 
21
 
2*
 
23
 
0 
10
* 
10
 
N
et
he
rla
nd
s 
15
9 
37
 
19
6 
47
 
31
 
78
 
24
 
6 
30
 
20
 
3 
23
 
0 
0 
0 
D
en
m
ar
k 
2 
N
A
 
2 
0 
N
A
 
0 
1 
N
A
 
1 
4 
N
A
 
4 
0 
N
A
 
0 
G
er
m
an
y 
20
9 
18
 
22
7 
45
 
8 
53
 
55
 
6 
61
 
11
 
1 
12
 
0 
0 
0 
Sw
ed
en
 
7 
53
 
60
 
2 
20
 
22
 
6 
10
 
16
 
3 
8 
11
 
0 
7 
7 
Ita
ly
 
44
3 
18
6 
62
9 
28
 
22
 
50
 
69
 
86
 
15
5 
24
 
16
 
40
 
0 
61
 
61
 
A
us
tra
lia
" 
N
A
 
56
 
56
 
N
A
 
26
 
26
 
N
A
 
19
 
19
 
N
A
 
20
 
20
 
N
A
 
0 
0 
M
eta
 
1,6
34
 
(1,
37
7°)
 
78
3 (
69
0°)
 
2,4
17
 
(2,
06
1°)
 
36
1 
(30
8°
) 
21
5 (
19
0°)
 
57
6 
(49
5°
) 
33
5 
(26
9°
) 
24
7 (
22
1°)
 
58
2 
(48
6°
) 
22
9 (
20
0°)
 
11
5 (
94
°) 
34
4 
(29
4°
) 
0 (
0) 
22
1 (
17
7°)
 
22
1 
(17
7°
) 
° =
 a
fte
r q
ua
lit
y 
co
nt
ro
l f
ilt
er
in
g;
 *
 =
 fr
om
 d
is
co
ve
ry
 p
ha
se
; "
 =
 sh
ar
in
g 
sa
m
e 
co
nt
ro
ls
 
 
 
 
 
 
 
 
 
 Ta
ble
 4-
6. 
Th
e 
nu
m
be
r o
f s
am
pl
es
 c
ol
le
ct
ed
 p
er
 su
bt
yp
e 
an
d 
pe
r c
ou
nt
ry
 a
re
 sh
ow
n.
 
207
! 208!
BvFTD subtype analysis 
During the discovery phase, the association analysis for the bvFTD subtype was 
performed on n=1,377 cases (Table 4-6) and n=2,754 controls (after quality control 
filtering). As a result of the statistical analyses two non-coding SNPs passed the genome-
wide significance threshold (p-value<5x10-08) in this subtype (Table 4-7). 
 
Table 4-7. Discovery phase: SNPs associated with the bvFTD subtype 
  Discovery phase 
Trait Marker Chr BP Candidate gene 
Effect 
allele 
Alternat
e allele 
Frequency of 
Effect allele 
Imputation 
quality OR SE P 
bvFTD 
rs302652 11 87894831 RAB38 T A 0.741 0.9296 1.369 0.057 2.02x10-08 
rs74977128 11 87936874 RAB38/CTSC T C 0.882 0.4182 0.551 0.107 3.06x10-08 
Table 4-7. SNPs exceeding genome-wide significance in discovery phase for the bvFTD subtype are listed 
along with their chromosomal position and nearby genes. The OR is calculated based on the effect allele 
whilst the risk allele can be derived. 
 
Both SNPs map to chromosome 11 at the locus 11q14: The first associated SNP, 
rs302652, had a p-value=2.02x10-08 and an OR=1.369, whilst the second, rs74977128, 
had a p-value=3.06 x10-08 and OR=0.551 (Table 4-7). 
It is noteworthy that rs302652 is located in intron 1 of the gene RAB38, member RAS 
oncogene family (RAB38), whilst rs74977128 maps to the intergenic region between 
RAB38 and cathepsin C (CTSC), however closer to the gene RAB38, being ~25 kb 
upstream from its open reading frame (ORF) (Figure 4-3). 
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Figure 4-3. BvFTD: Manhattan plot 
 
Figure 4-3. The Manhattan plot of −log10 p-values across genome for the bvFTD subtype and the locus 
bearing genome-wide significant associations are shown. The Manhattan plot depicts the associated region 
at 11q14. The red dots identify the SNPs that reached genome-wide significance; the orange dots identify 
the SNPs suggestive of association. 
 
SD, PNFA and FTD-MND subtypes analyses 
Similarly, association analysis was carried out on the other three FTD subtypes. After 
quality control filtering statistical analysis was performed on 308 SD cases (compared to 
616 controls), 269 PNFA cases (compared to 538 controls) and 200 FTD-MND cases 
(compared to 400 controls) (Table 4-6).  
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There were no SNPs that reached genome-wide significance for any of these three 
subtypes. This outcome can probably be ascribed to the fact that for each of the subtypes 
the sample size was relatively small and, therefore, most likely not sufficient to confer 
enough power to the association analysis. 
However, several SNPs showed suggestive associations (p-values between 10-06 and 10-
07) in each subtype (Figure 4-4), fact that suggests all such SNPs being a robust subset of 
markers of interest, which can be further investigated as they may hint subtype-specific 
associations and may be valuable candidates to be further investigated and followed up in 
fine mapping types of studies. 
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Figure 4-4. SD, PNFA and FTD-MND: Manhattan plots 
 
Figure 4-4. The Manhattan plots for each of the other subtypes are shown: SD (a), PNFA (b) and FTD-
MND (c). SNPs that achieved p-values<1x10-05 are depicted by the orange dots. SNPs with associated 10-
07≤p-values≤10-06 are suggestive of associations at loci to be further investigated as possibly relevant to 
each specific subtype. 
 
Whole cohort meta-analysis 
Next, the interest was to establish whether there was association with specific loci for the 
entire cohort. After performing association analysis for the totality of the samples 
included in the discovery phase (n=2,154 cases and n=7,444 controls after quality control 
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filtering), 29 SNPs resulted exceeding the threshold of genome-wide significance (p-
value<5x10-08) at the 6p21.3 locus, on chromosome 6 (Table 4-8). 
 
Table 4-8. Discovery phase: SNPs associated with the entire cohort 
SNP Chr Position (BP) 
Effect 
allele 
Alternate 
allele 
Frequency 
of effect 
allele 
Beta OR Standard error P-value 
Directionality 
across 
subtypes 
Heterogeneity p-
value 
(Cochrane's Q) 
rs9268877 6 32431147 A G 0.440 0.286 1.331 0.045 1.65E-10 ++++ 0.8184 
rs9268852 6 32429594 A G 0.439 0.280 1.323 0.044 1.68E-10 ++++ 0.8242 
rs9268863 6 32430289 A G 0.442 0.279 1.321 0.044 2.20E-10 ++++ 0.8295 
rs9268881 6 32431606 A T 0.560 -0.288 0.750 0.045 2.39E-10 ---- 0.8102 
rs9268888 6 32431867 T G 0.556 -0.302 0.740 0.048 2.99E-10 ---- 0.645 
rs9268912 6 32432509 A C 0.559 -0.300 0.741 0.048 3.88E-10 ---- 0.7369 
rs9268883 6 32431638 A T 0.553 -0.289 0.749 0.046 4.49E-10 ---- 0.7834 
rs9268893 6 32431927 T C 0.539 -0.290 0.748 0.048 1.42E-09 ---- 0.721 
rs9268856 6 32429719 A C 0.251 -0.285 0.752 0.050 1.30E-08 ---- 0.9437 
rs9268854 6 32429672 A G 0.752 0.288 1.334 0.051 1.47E-08 ++++ 0.943 
rs9268855 6 32429675 A G 0.248 -0.288 0.750 0.051 1.47E-08 ---- 0.943 
rs9268862 6 32430167 A C 0.750 0.284 1.328 0.050 1.48E-08 ++++ 0.9426 
rs9268845 6 32429204 T C 0.240 -0.295 0.744 0.052 1.48E-08 ---- 0.97 
rs9268857 6 32429739 A G 0.750 0.283 1.327 0.050 1.62E-08 ++++ 0.9431 
rs9268850 6 32429477 A G 0.248 -0.286 0.751 0.051 1.69E-08 ---- 0.9431 
rs9268840 6 32428804 T C 0.246 -0.284 0.753 0.051 2.06E-08 ---- 0.9504 
rs7747521 6 32431105 A G 0.761 0.303 1.353 0.054 2.26E-08 ++++ 0.9374 
rs4434496 6 32430508 T C 0.249 -0.289 0.749 0.052 2.31E-08 ---- 0.941 
rs4428528 6 32430362 C G 0.752 0.289 1.334 0.052 2.36E-08 ++++ 0.9406 
rs7766843 6 32430729 T C 0.245 -0.293 0.746 0.053 2.37E-08 ---- 0.9421 
rs6940440 6 32429087 A C 0.747 0.274 1.315 0.049 2.41E-08 ++++ 0.9543 
rs7766854 6 32430752 T C 0.245 -0.293 0.746 0.053 2.47E-08 ---- 0.9425 
rs7747010 6 32430800 A G 0.759 0.299 1.348 0.054 3.11E-08 ++++ 0.9409 
rs7747025 6 32430814 A G 0.759 0.299 1.348 0.054 3.11E-08 ++++ 0.9409 
rs4280993 6 32430604 A C 0.249 -0.289 0.749 0.052 3.20E-08 ---- 0.9399 
rs7746751 6 32430867 A G 0.249 -0.289 0.749 0.052 3.21E-08 ---- 0.9398 
rs7746922 6 32430975 A C 0.245 -0.292 0.747 0.053 3.82E-08 ---- 0.9374 
rs9268885 6 32431705 T C 0.245 -0.305 0.737 0.056 4.43E-08 ---- 0.9275 
rs1980493 6 32363215 T C 0.853 0.329 1.389 0.060 4.94E-08 ++++ 0.793 
Table 4-8. All the 29 SNPs exceeding the genome-wide significance threshold at 6p21.3 are shown. The 
OR is calculated based on the effect allele. 
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Among the associated SNPs three were chosen as reference SNPs having in mind the 
need to address the potential issue of basing the replication analyses on surrogate/proxy 
SNPs. The selected SNP rs1980493 (p-value=4.94x10-08, OR=1.389) locates in intron 5 
of the butyrophilin-like 2 (MHC class II associated) gene (BTNL2), whilst the other two 
selected SNPs rs9268877 (p-value=1.65x10-10, OR=1.331) and rs9268856 (p-
value=1·30x10-08, OR=0.752) are both located between the major histocompatibility 
complex class II, DR alpha and DR beta 5 genes (HLA-DRA; HLA-DRB5), specifically,  
~18.5–20 kb downstream from HLA-DRA (Table 4-9 and Figure 4-5). 
 
Table 4-9. Discovery phase: SNPs associated with the entire cohort (chosen for 
replication and joint analysis)  
  Discovery phase 
Trait Marker Chr BP Candidate gene Effect allele 
Alternate 
allele 
Frequency of 
Effect allele 
Imputation 
quality OR SE P 
All 
FTD* 
rs9268877 6 32431147 HLA-DRA/HLA-DRB5 A G 0.440 0.7783 1.331 0.045 1.65x10-10 
rs9268856 6 32429719 HLA-DRA/HLA-DRB5 A C 0.251 0.8563 0.752 0.050 1.30x10-08 
rs1980493 6 32363215 BTNL2 T C 0.853 0.9642 1.389 0.060 4.94x10-08 
Table 4-9. SNPs exceeding genome-wide significance in discovery phase for the entire cohort are listed 
along with their chromosomal position (BP) and nearby genes. The OR is calculated based on the effect 
allele whilst the risk allele can be derived. * denotes only minimal cross subtype heterogeneity, with 
heterogeneity p-values ranging from 0.793 – 0.944 based on Cochran's Q. 
 
Of note, the SNPs with smallest p-values (1x10-10≤ p-value <5x10-08) (Table 4-8) all 
encompassed the genetic region containing the BTNL2 and the HLA-DRA and HLA-
DRB5 genes (Figure 4-5). 
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Figure 4-5. Meta-analysis: Manhattan plot 
 
Figure 4-5. Manhattan plots of −log10 p-values across genome identifying the regions with genome-wide 
significant associations for the entire cohort. The Manhattan plot depicts the associated region at 6p21.3. 
The red dots identify the SNPs that reached genome-wide significance; the orange dots identify the SNPs 
suggestive of association. 
 
In summary, after completion of all the planned association analyses for the discovery 
phase two novel loci were evident.  
The first locus of interest was on chromosome 11, at 11q14, and was relevant for the 
bvFTD subtype only. The associated region included the RAB38/CTSC genes (Table 4-7 
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and Figure 4-3). The second relevant locus was on chromosome 6, at 6p21.3, and 
indicated a probable link between the FTD spectrum and the BTNL2 and HLA-DRA/HLA-
DRB5 genes (Table 4-9 and Figure 4-5).    
On the other hand, possibly due to sample size, no genome-wide significant association 
could be identified in the SD, PNFA and FTD-MND subtypes. 
Interestingly, there was no association at the expected or known loci such as those 
encompassing MAPT and PGRN genes on chromosome 17, or C9orf72 on chromosome 
9. The most likely reasons that explain the lack of association at these loci are: 
1 – The fact that all known chromosome 17 mutation carriers were excluded from 
analysis, and; 
2 – The frequency of C9orf72 expansion carriers within the whole discovery cohort was 
~8% as revealed by post hoc analysis (Table 4-10), therefore probably too low and 
insufficient for contributing to a genome-wide significant signal. 
Of note, the discovery phase dataset included samples collected from the USA and 
Europe and revealed a frequency of only 8% of expansion carriers (n=194/2412). First, 
this possibly suggests that the expansion may be more frequent in specific geographical 
areas (such as central/northern Europe, specifically, France, Belgium, Sweden and 
partially UK as reflected in the discovery cohort) and be more characteristic of a specific 
subtype, i.e. FTD-MND (=52/221, 23.5%), rather than the bvFTD subtype or the 
language variant syndromes (Table 4-10). A closer look at the Manhattan plots (Figures 
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4-3 – 4-5) shows complete absence of any signal at the C9orf72 locus in the bvFTD, SD 
and PNFA subtypes, as well as in the whole cohort, whilst a signal is only detectable in 
the FTD-MND subtype (Figure 4-4c), which, however, does not reach genome-wide 
significance, being the p-value=2.12x10-06 (Table 4-17). 
 
Table 4-10. Frequency of C9orf72 positive cases within the discovery cohort 
 Discovery phase 
 bvFDT SD PNFA FTD-MND Total 
C9orf 72+ 
n+/nS % n+/nS % n+/nS % n+/nS % n+/nS % 
121/1537 7.9 12/350 3.4 9/304 3.0 52/221 23.5 194/2412 8.0 
Table 4-10. Summary of the frequency of C9orf72 positive cases within the discovery cohort shown for 
each subtype separately and for the totality of samples. n+ = number of cases positive for the repeat 
expansion; nS = number of cases screened. 
 
It is also noteworthy that the association analyses performed during the discovery phase 
of the FTD-GWAS generated a robust number of SNPs with p-values between 1x10-07 
and 1x10-06. These SNPs are all suggestive of possible association and are all valuable 
candidates for follow up studies. It is in fact a possibility that specific loci that might act 
as disease modifiers are hidden within these data and, all the more, that they may 
highlight genetic differences between the different subtypes and point to specific genetic 
markers (and pathways) as factors underlying the development of one rather than the 
other phenotype. 
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4.2.2.2 Replication phase 
During the replication phase, n=1,372 cases were analysed (Table 4-5) along with 
n=5,094 controls. At this stage, the aim was to replicate the loci identified during the 
discovery phase that were associated with genome-wide significance with the bvFTD 
subtype and the entire cohort.  
Surrogate/proxy SNPs were used to assess replication for the bvFTD subtype, whilst the 
same associated SNPs identified during the discovery phase were evaluated for the entire 
cohort. 
 
Replication and joint analysis for the bvFTD subtype 
The surrogate/proxy SNPs rs302668 and rs16913634 were assessed at the 11q14 locus in 
n=690 bvFTD cases (Table 4-6). 
The immediate replication analyses revealed a moderately significant p-value in the case 
of SNP rs302668 (p-value=4.1x10-02, OR=1.139), whilst significance seemed weaker for 
rs16913634 (p-value=7.1x10-01, OR=1.037) (Table 4-11). 
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Table 4-11. Replication phase: SNPs associated with the bvFTD subtype 
  Replication phase 
 Trait Marker Chr BP Candidate gene Effect allele Alternate allele OR SE P 
bvFTD 
rs302668 (proxy) 11 87876911 RAB38 T C 1.139 0.064 0.041 
rs16913634 (proxy) 11 87934068 RAB38/CTSC G A 1.037 0.098 0.710 
Table 4-11. SNPs assessed to verify replication at the 11q14 locus. The markers along with their 
chromosomal positions (BP) and p-values are shown. The OR is calculated based on the effect allele whilst 
the risk allele can be derived. 
 
Following, the combination of datasets relative to the discovery and the replication 
phases showed joint p-values that were attenuated in the proximal SNPs rs302668 (p-
value=2.44x10-07, OR= 1.229) and rs16913634 (p-value=8.15x10-04, OR=0.801) (Table 
4-12) when compared with the p-values reached during discovery phase only.   
 
Table 4-12. Joint analysis: SNPs associated with the bvFTD subtype 
  Discovery and replication combined 
Trait  Marker Chr BP Candidate gene Effect allele Alternate allele OR SE P 
bvFTD 
rs302668 (proxy) 11 87876911 RAB38 T C 1.229 0.064 2.44x10-07 
rs16913634 (proxy)$ 11 87934068 RAB38/CTSC G A 0.801 0.049 8.15x10-04 
Table 4-12. SNPs assessed for the joint analysis at the 11q14 locus. The markers along with their 
chromosomal positions (BP) and p-values are shown. The OR is calculated based on the effect allele whilst 
the risk allele can be derived. $ denotes heterogeneity p-value < 0.01 in the meta-analysis of the discovery 
and replication phases combined. 
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These results most probably reflect a decrease in power due to proxy-based replication. 
However, given these circumstances, rs302668 closely approached genome-wide 
significance suggesting that this marker is, most probably, truly linked to the bvFTD 
phenotype and that variability at this locus may really contribute to disease, although, 
possibly, with small to moderate effect. 
 
Replication and joint analysis for the entire cohort 
The three SNPs rs9268877, rs9268856 and rs1980493 could be verified at the 6p21.3 
locus in the whole replication cohort for a total of n=1,372 cases (Table 4-5) and n=5,094 
controls after quality control filtering.  
The replication analysis revealed moderate significance for 2 of the 3 assessed SNPs, in 
that rs9268877 showed a p-value=1.04x10-01 with OR=1.080, whilst rs9268856 showed a 
p-value=1.4x10-02 with OR=0.878 and rs1980493 showed a p-value=2.0x10-02 with 
OR=1.172 (Table 4-13). 
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Table 4-13. Replication phase: SNPs associated with the entire cohort 
  Replication phase 
 Trait Marker Chr BP Candidate gene Effect allele Alternate allele OR SE P 
All FTD* 
rs9268877 6 32431147 HLA-DRA/HLA-DRB5 A G 1.080 0.047 0.104 
rs9268856 6 32429719 HLA-DRA/HLA-DRB5 A C 0.878 0.053 0.014 
rs1980493 6 32363215 BTNL2 T C 1.172 0.068 0.020 
Table 4-13. SNPs assessed to verify replication at the 6p21.3 locus. The markers along with their 
chromosomal positions (BP) and p-values are shown. The OR is calculated based on the effect allele whilst 
the risk allele can be derived. * denotes only minimal cross subtype heterogeneity, with heterogeneity p-
values ranging from 0.793 – 0.944 based on Cochran's Q. 
 
Combined analyses of discovery and replication phases confirmed the strong association 
seen in the discovery phase. In fact the p-values for each SNP passed the genome-wide 
threshold: rs9268877 (p-value=1.05x10-08, OR=1.204), rs9268856 (p-value=5.51x10-09, 
OR=0.809), and rs1980493 (p-value=1.57x10-08, OR=1.290) (Table 4-14). 
 
Table 4-14. Joint analysis: SNPs associated with the entire cohort 
  Discovery and replication combined 
 Trait Marker Chr BP Candidate gene Effect allele Alternate allele OR SE P 
All FTD* 
rs9268877$ 6 32431147 HLA-DRA/HLA-DRB5 A G 1.204 0.039 1.05x10-08 
rs9268856 6 32429719 HLA-DRA/HLA-DRB5 A C 0.809 0.029 5.51x10-09 
rs1980493 6 32363215 BTNL2 T C 1.290 0.058 1.57x10-08 
Table 4-14. SNPs assessed for the joint analysis at the 6p21.3 locus. The markers along with their 
chromosomal positions (BP) and p-values are shown. The OR is calculated based on the effect allele whilst 
the risk allele can be derived. $ denotes heterogeneity p-value <0.01 in the meta-analysis of the discovery 
and replication phases combined. * denotes only minimal cross subtype heterogeneity, with heterogeneity 
p-values ranging from 0.793 – 0.944 based on Cochran's Q. $ denotes heterogeneity p-value<0.01 in the 
meta-analysis of the discovery and replication phases combined. 
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The results for the replication and joint analyses in the entire cohort confirmed the 
association of the 6p21.3 locus with the FTD spectrum strongly arguing for a remarkable 
link between FTD and variability at the human HLA locus. 
 
4.2.2.3 Quantitative trait loci (QTL) analyses 
The GWAS hits identified in this study highlight two novel loci associated with the 
disease, namely the 11q14 locus, encompassing the genes  RAB38/CTSC for the bvFTD 
subtype, and the 6p21.3 locus, encompassing the genes BTNL2 and HLA-DRA/DRB5 for 
the entire FTD cohort. 
The next step was to evaluate whether any of the associated SNPs held a possible 
biological relevance, e.g. by influencing methylation and/or expression levels. These 
aspects could be investigated in brain tissues that were assayed to assess genome-wide cis 
methylation and expression patterns. 
 
Methylation quantitative trait loci (mQTL) 
The Methylation27 dataset (section 4.2.1) was used to assess effects on methylation 
exerted by any of the associated SNPs.  
SNPs identified in the discovery phase at the 6p21.3 locus showed significant 
associations with proximal CpG methylation probes after multiple test correction. 
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Of particular interest were two SNPs that were closely associated with changes in 
methylation levels related to the HLA-DRA gene in both frontal cortex and cerebellar 
tissue. 
The first SNP, rs1980493 (located in intron 5 of BTNL2, risk allele T), showed p-
value=3.34x10-08 in the cerebellum and p-value=2.17x10-08 in the frontal cortex, whilst 
the second SNP, rs9268856 (located downstream from HLA-DRA, risk allele C), revealed 
p-value=1.16x10-06 in the frontal cortex (Table 4-15). 
Data suggest that the risk alleles of both SNPs are associated with changes in the 
methylation levels related to HLA-DRA. 
Comparatively, there was no evidence of cis-mQTL at 11q14. 
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Expression quantitative trait loci (eQTL) 
To assess effects on expression exerted by the associated SNPs, several different datasets 
were scrutinized (section 4.2.1). 
There were no significant associations in the HT12 dataset after adjusting for multiple 
test correction, whilst in the ExonArray dataset there was only one cis-eQTL at the 
6p21.3 locus that passed Bonferroni correction of 0.05 (p=4.8x10-07) involving rs1980493 
(intron 5 of BTNL2, risk allele T) and exon 7 (Affymetrix ID 2903485) (Table 4-16a) of 
the solute carrier family 39 (zinc transporter), member 7 gene (SLC39A7) that encodes a 
protein involved in transport of zinc from both the extracellular environment and the 
intracellular storage (OMIM: #601416). 
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This eQTL appears to be tissue-specific (medulla) (Figure 4-6), and the risk allele is 
associated with increased expression of SLC39A7 (trans-membrane zinc transporter that 
transports zinc from Golgi and endoplasmic reticulum within the cytoplasm). A possible 
link between elevated expression of SLC39A7 and pathogenesis of neurodegenerative 
diseases needs to be further investigated. 
 
Figure 4-6. Regional distribution of SLC39A7 mRNA expression 
 
Figure 4-6. Box plots of mRNA expression levels for 10 brain regions are shown, based on microarray 
experiments and plotted on a log2 scale (y-axis). Abbreviations: Thalamus (THAL), medulla (MEDU), cerebellum 
(CRBL), substantia nigra (SNIG), temporal cortex (TCTX), hippocampus (HIPP), frontal cortex (FCTX), occipital cortex (OCTX), 
white matter (WHMT) and putamen (PUTM). Whiskers extend from the box to 1.5 times the inter-quartile range. 
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In addition, the Zeller et al dataset [269] revealed a remarkable cis-eQTL (p=5.05x10-32) 
at the 11q14 locus between SNP rs302652 (chr11: 87894881, risk allele T) (Table 4-16b) 
and decreased expression of RAB38 (Illumina ILMN_2134974 located in chr11: 
87846656-87846705) in monocytes suggesting a direct role in transcriptional processes in 
–cis for this SNP. 
In summary, both methylation and expression quantitative trait loci (m/eQTL) data did 
support the notion that risk at the associated loci may involve cis changes of methylation 
and expression levels pointing to the regulation of transcription as the likely mechanism 
by which variability at the associated loci exerts its effect. 
 
4.2.2.4 Copy number polymorphisms (CNPs) and FTD 
Background 
There is evidence in the literature of a link between some rare cases of FTD and the 
occurrence of copy number polymorphisms (CNPs) on chromosome 17, specifically, at 
the MAPT and GRN loci [49]. However, CNPs at these loci had also been described in a 
number of other phenotypes. For example, in 2006, several research groups reported 
aberrant rearrangements on chromosome 17 associated with mental retardation, 
developmental impairment, hypotonia and facial dysmorphism: This was named “the 
chromosome 17q21.31 microdeletion syndrome” with an estimated frequency of 1 in 
16,000 [55], [56], [57]. The microdeletion was suggested to span a region of 0.5 Mb on 
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chromosome 17, encompassing the 4 genes, MAPT, intramembrane protease 5 (IMP5), 
corticotropin releasing hormone receptor 1 (CRHR1) and saitohin (STH) [105]. 
Moreover, a de-novo duplication at the same locus, reciprocal to the 17q21.31 
microdeletion, was reported in an individual affected by psychomotor developmental 
delay, facial dysmorphism and microcephaly [102]. Finally, a microduplication on 
chromosome 17q21.31 was reported in a patient with behavioral problems as well as poor 
social interactions with features of the autism spectrum disorder [103]. 
In the FTD arena, two studies failed to identify association between CNPs at the MAPT 
and GRN loci and FTD phenotypes [270], [271]. However, two other studies reported a 
heterozygous 17.3 kb deletion responsible for the removal of exons 6 to 9 of MAPT in 
one FTD patient [272] and a 439 kb duplication in the region encompassing CRHR1, 
IMP5, MAPT and STH, in a patient diagnosed with bvFTD and amnestic syndrome [273]. 
Although CNVs at these loci seem to associate with a variety of phenotypes including 
developmental and mental impairments, autism spectrum, social/behavioural issues, and 
FTD, this implied to possible occurrence of CNVs among the FTD-GWAS discovery 
cohort. To investigate such possibility I visually inspected the chromosome 17 genotypes 
in the search for copy number polymorphisms (CNPs) within the extended discovery 
cohort assessing B Allele Frequency and LogR Ratio plots the chromosome browser tool 
from the Genome Studio software. 
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The analysis 
This preliminary analysis targeted exclusively chromosome 17 with the specific aim of 
evaluating presence of possible deletions and/or duplications at either the MAPT 
(chr17:43,960kb–44,120kb +/- 2Mb) or GRN (chr17: 42,422kb–42,431kb +/- 2Mb) loci. 
After having inspected a sample size of ~1,100 from the discovery phase cohort, which 
included FTD samples form the USA, France, Denmark, Germany, Sweden and Italy, the 
outcome could be interpreted based on three fundamental observations: 
1 – One group of samples showed LOH regions at the MAPT/GRN loci with sizes varying 
from a minimum of ~400 kb to a remarkable maximum of 22 Mb (Figure 4-7a-f); 
2 – One group of samples revealed duplications at other loci (not MAPT/GRN) (Figure 4-
8a-h), and; 
3 – One group of samples showed CNVs at other loci (not MAPT/GRN) (Figure 4-9a-h). 
 
LOH at the MAPT/GRN loci 
The smallest LOH region was ~400 kb (Figure 4-7a), and was encompassing MAPT. It 
still needs to be established whether this LOH causes a change in the gene dosage. In the 
case of the larger LOH regions of sizes of ~22 Mb (Figure 4-7b), 11.3 Mb (Figure 4-7c) 
and 9 Mb (Figure 4-7d), two points need to be mentioned: 
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1 – These LOH regions are extraordinarily large and encompass ~15-30 genes including 
both GRN and MAPT, and; 
2 – Although the LogR Ratio graph does not show an inflation, the LOH displayed in the 
B Allele Frequency graph is clearly evident. 
Provided further proof this may mean that either there is loss of one allele (that affects a 
remarkable number of genes collectively), or else, there is an extended and consecutive 
series of homozygous SNPs in this region that are unusual. It needs to be established 
whether either of these possibilities may influence the phenotype. 
Among the six cases presented in Figure 4-7, 3 were diagnosed with bvFTD (Figure 4-
7c, e and f), 2 with PNFA (Figure 4-7a and b) and one with SD (Figure 4-7d). 
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Figure 4-7. LOH analysis at the MAPT and GRN loci 
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Figure 4-7. Six different examples of LOH regions encompassing MAPT, or GRN or both, identified 
among ~1,100 samples from the discovery cohort. (a) Small LOH region of ~400 kb encompassing MAPT; 
this LOH pattern belongs to a patient diagnosed with PNFA. (b) Largest LOH region of ~22 Mb, 
encompassing ~30 genes including MAPT/GRN; this LOH pattern belongs to a patient diagnosed with 
PNFA. (c) Large LOH region of ~11.3 Mb, encompassing ~20 genes including MAPT/GRN; this LOH 
pattern belongs to a patient diagnosed with bvFTD. (d) Large LOH region of ~9 Mb, encompassing ~15 
genes including MAPT/GRN; this LOH pattern belongs to a patient diagnosed with SD. (e) Intermediate 
LOH region of ~2.4 Mb encompassing MAPT/GRN; this LOH pattern belongs to a patient diagnosed with 
bvFTD. (f) Intermediate LOH region of ~2 Mb encompassing GRN only; this LOH pattern belongs to a 
patient diagnosed with bvFTD. 
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Duplications on chromosome 17 
Duplications seemed evident in a number of cases. Keeping in mind that some may 
represent artefacts rather than indicate a true CNV and need therefore to be further 
investigated and confirmed, this analysis seemed interesting for three main reasons: 
1 – All putative duplications were detectable in various regions of chromosome 17 but 
not at the MAPT/GRN loci; 
2 – Six of the 8 of the presented cases (Figure 4-8a-h) were diagnosed with bvFTD, and; 
3 – Three putative duplications occurred in more than one sample and two out of three 
shared the same diagnosis (bvFTD). 
These CNV patterns need to be confirmed, first, in more/other patient cohorts; second, 
possibly, in familial cases where a clear pattern of inheritance is evident. Third, such 
CNVs need to be absent from the normal population to support the argument that 
duplications at these loci (Figure 4-8a-h) are associated with the diagnosis of FTD. 
Furthermore and very interestingly, there was one case (diagnosed with SD) that showed 
a duplication spanning almost the whole short arm of chromosome 17 (Figure 4-8a). 
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Figure 4-8. Duplications on chromosome 17 
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Figure 4-8. Eight different examples of duplications on chromosome 17 at loci different from MAPT/GRN 
identified among ~1,100 samples from the discovery cohort. (a) Duplication encompassing almost the 
complete short arm of chromosome 17 in one SD patient. (b) Duplication at q12 in one bvFTD patient. (c–
d) Duplication at q11.2 in two bvFTD patients. (e–f) Duplication at p11.2 in two bvFTD patients. (g–h) 
Duplication at q24.3 in one PNFA and one bvFTD patient. 
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CNVs at other loci (not MAPT/GRN) 
There were several cases that showed relatively large LOH regions spanning from ~2–
2.5Mb (Figure 4-9a and b), to 5.7–9.7Mb (Figure 4-9c, e, f and g), up to 13Mb (Figure 
4-9d and h) in different regions of chromosome 17 none of which were encompassing the 
MAPT/GRN loci. The majority of cases (6/8) were diagnosed with bvFTD (Figure 4-9a, 
c, d, f, g and h), SD (Figure 4-9e), and one case was PNFA (Figure 4-9b). The B Allele 
Frequency plots showed LOH, however the LogR Ratio plots did not clearly show an 
according inflation. This may mean that there is either a heterozygous deletion, with a 
hard to detect inflation, or that there are large portions of exclusive homozygous calls. 
The real nature of these CNVs needs to be further investigated through gene dosage 
experiments. If confirmed, haploinsufficiency of the genes in the LOH region may 
influence disease. 
In summary it is important to note that these are only preliminary results. In addition, 
there is room for some of the heterozygous deletions or duplications to be artefacts (e.g. 
Figure 4-8a or Figure 4-9d). At the same time, some CNVs seem real, as in the case of 
the duplications seen in Figure 4-8c, e–h. At this stage, the next crucial steps will be 
validating these preliminary results through gene dosage experiments followed by a 
scrupulous ascertainment of the genes involved at either deleted or duplicated regions. 
Only then it will be possible to correlate the actual CNVs to the genes functions and, 
eventually, to the phenotype. 
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Figure 4-9. Deletions on chromosome 17 
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Figure 4-9. Eight different examples of CNVs on chromosome 17 at loci different from MAPT/GRN 
identified among ~1,100 samples from the discovery cohort. (a–b) LOH encompassing two telomeric 
regions of the short arm of chromosome 17 in one bvFTD and one PNFA patient. (c–d) LOH 
encompassing part of both the short and the long arms of chromosome 17 in two bvFTD patients. (e–f) 
LOH encompassing two telomeric regions of the short arm of chromosome 17 in one SD and one bvFTD 
patient. (g–h) LOH encompassing two different regions of the long arm of chromosome 17 for two bvFTD 
patients. 
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4.2.2.5 Candidate loci 
This study provided the opportunity to explore possible genetic overlap among different 
neurological disorders. It is known that several neurodegenerative diseases share, to some 
extent, a number of features that can fall within the clinical, pathological or genetic 
categories. For example: 
1 – Features such as broad cognitive impairment, memory deficits, changes in the 
behavioural habits of an individual and language dysfunction can represent a subtle 
clinical overlap between AD and FTD [274]; 
2 – Features such as tau pathology or TDP-43 pathology represent a common factor 
characterising FTD, AD, CBS and PSP, or FTD and ALS, respectively [275-277], and; 
3 – Features such as the C9orf72 repeat expansion represent a genetic overlap for FTD 
and ALS or, more generally, for the FTD-MND spectrum [76, 77, 87]. 
To further explore possible genetic overlap among neurodegenerative diseases, a subset 
of candidate loci known to be associated either with FTD or other closely related 
conditions such as ALS [81], PSP/CBD [180] and AD [278] were investigated and 
compared for association (Table 4-17). 
Overlap between FTD and PSP/CBD 
Two SNPs (rs242557 and rs8070723) that were associated with the PSP/CBD phenotypes 
at the MAPT locus [180] reached p-values between 10-03 and 10-04 in the entire FTD 
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discovery cohort, whilst rs8070723 only in the bvFTD as well as in the PNFA subtypes, 
in the FTD-GWAS (Table 4-17). The risk associated with the effect allele was in the 
same direction as in the GWAS for progressive supranuclear palsy, but the noticeable 
difference in OR for rs8070723 (5.46 [180] vs. ~1.2-1.4 [FTD-GWAS]) (Table 4-17) 
may reflect a smaller proportion of subjects with tau pathology or association with the 
MAPT locus within the discovery cohort, most probably due to the exclusion of MAPT 
mutation carriers from the FTD-GWAS. 
Overlap between FTD and AD 
One SNP, rs2075650, defining the association between AD and the TOMM40/ApoE locus 
approached genome-wide significance in the entire dataset (p-value=8.81x10-07) and in 
the bvFTD subtype (p-value=1.37x10-06), but not in the SD, PNFA, and FTD-MND 
subtypes (Table 4-17). Several AD-GWAS reported association with the minor allele of 
this SNP with OR>2.5 [278], whilst in the FTD-GWAS the OR was ~1.3 for most 
subtypes and in the entire cohort (Table 4-17). This association may reflect subtle 
clinical overlap of clinically diagnosed FTD and AD cases [279], or may indicate that 
there is a link between this locus and FTD. Based on some studies that suggest that there 
may be an involvement for ApoE also in the FTD spectrum [280-283], this hypothesis 
will need to be further investigated to establish whether the association of this locus with 
FTD is actually phenotype specific and, if so, how it exerts its detrimental effect. 
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Overlap between FTD and ALS 
The marker for the C9orf72/MOB3B locus, rs3849942, (C9orf72/MOB3B locus) [81] 
achieved a p-value of 2.12x10-06 and an OR of 1.957 in the FTD-MND subtype consistent 
with post hoc analyses (~23% of expansion carriers among this subtype) (Tables 4-10 
and 4-18). In addition, rs3849942 reached p-values between 10-03 and 10-04 in bvFTD (p-
value=7.38x10-03, OR=1.155) and the entire discovery cohort (p-value=4.38x10-04, 
OR=1.166), whilst in the SD or PNFA subtypes p-values were not relevant (Table 4-17). 
Overall, association at this locus in the FTD-GWAS seemed rather surprising. 
Considering that the expansion carriers were included in the analysis because this genetic 
variant was not yet known at the time analysis on the discovery cohort was performed, 
and given the high frequency that had been reported in FTD-ALS cases across different 
studies [76, 87], one would have expected a robust signal at least in the bvFTD and FTD-
MND subtypes and, possibly, also in the meta-analysis. This was not the case if we 
exclude the FTD-MND subtype where a relatively high frequency among cases (~23%) 
and a sensible but not extraordinary large sample size (n=200) were not sufficient to lead 
to a signal with genome-wide significance. However, it is a possibility that if the FTD-
MND subtype would have included a larger number of samples, increasing therefore 
power of analysis, association at this locus might have reached genome-wide 
significance. At the same time there is another possibility that should not be dismissed a 
priori, i.e. the presence of C9orf72 expansion in neurologically normal controls [76, 77, 
86, 284, 285] that may have lowered the signal.  
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Overlap between FTD-GWAS and previous FTLD-TDP-GWAS 
The previous GWAS on FTLD-TDP [41] highlighted the TMEM106B locus as associated 
with the TDP-43 pathologically confirmed FTLD-TDP cases; such association was even 
stronger in the presence of concomitant GRN mutations [41]. Evaluating rs1990622 in the 
FTD-GWAS discovery cohort revealed that this SNP achieved p-values between 10-02 
and 10-03 in the entire dataset (p-value=7.88x10-02, OR=1.073) and in the bvFTD subtype 
(p-value=5.85x-03, OR=1.144) (Table 4-17). It has to be noted however that the original 
study [41] was performed with autopsy-confirmed FTLD-TDP cases and the current 
FTD-GWAS was with clinically defined cases. In addition, the previous study included a 
number of GRN mutation carriers [41], whilst in our study these are excluded. 
Considering these differences and the fact that recent studies suggested TMEM106B to be 
directly related to GRN metabolism [26], data for our FTD discovery cohort may suggest 
our results being a partial or limited replication of the original finding. 
 
4.2.2.6 Overlap with putative pleiotropic loci  
The results of the association, replication and joint analyses indicated two clear and novel 
susceptibility loci at 11q14 and 6p21.3 for FTD. At this point, one question that arose 
was whether association at these loci had previously been identified in other conditions 
and if there was any possible relation between those conditions and FTD. All 
comparisons discussed in this section are summarized in (Table 4-17). 
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Chromosome 11q14 
A suggestive association with the RAB38 locus had been reported for rs1386330 (p-
value=2·00x10-06) in multiple sclerosis (MS) [286]. Although the same locus points in 
this case to another neurological disorder it is hard to interpret this as a definite overlap 
between FTD and MS. In fact, rs1386330 was not statistically significant in the FTD 
discovery dataset, despite an OR>1 in almost all categories. The SNPs that reached 
statistical significance in the FTD-GWAS locate in intron 1 (rs302652) and upstream 
(rs74977128) of RAB38 whilst the SNP associated with MS (rs1386330) locates 
downstream of RAB38 gene. This could possibly indicate that the two different disorders 
associate with the same locus but are characterised by two different haplotype 
substructures, which are tagged by rs1386330 in the case of MS and 
rs302652/rs74977128 in the case of FTD. 
 
Chromosome 6p21.3 
Compared to the RAB38 locus, association with the HLA locus seemed to be more 
frequent and ubiquitous among other conditions. As such association with HLA was 
evident in a higher number of studies than in the case of RAB38 
(http://www.genome.gov/gwastudies/ accessed in the period June – September 2013). 
However, after careful assessment of the reported associated SNPs, only a handful of 
markers seemed potentially relevant.  
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First, SNP rs3806156 (p-value=7x10-19, OR=1.42), located in intron 1 of BTNL2, was 
found associated with vitiligo, an autoimmune condition that causes depigmentation in 
melanocytes [287]. Second, SNP rs9268853 (p-value=5x10-109, OR=2.4), intergenic 
between HLA-DRA and HLA-DRB5, was identified in a GWAS targeting rheumatoid 
arthritis [288]. Although these two forms of autoimmune disease were recently shown to 
be occasional co-morbidities in some FTLD cases [289], the two associated SNPs 
(rs3806156 and rs9268853) were not significant in the FTD discovery cohort.  
Third, rs3135388 (p-value=9x10-81, OR=1.99), located downstream of HLA-DRA, and 
rs3129871 (p-value=6x10-15, OR=1.72), located upstream of HLA-DRA, were associated 
with MS [259, 290]. These SNPs were not significant in the FTD-GWAS dataset, 
however, it is interesting to note that again MS showed association with a locus that also 
is closely related to FTD. It follows that by critically considering that for both loci, 
RAB38 and HLA, association was evident in two clinically distinct conditions (MS and 
FTD), the SNPs that did reflect the association were different. Especially, those that 
showed significance in one condition did not in the other and vice versa. This could mean 
that both loci are implicated in the pathogenic processes that lead to disease, but, at the 
same time, that the association is ultimately defined by different haplotype sub-structures 
that, eventually, exert their effect through diverse pathomechanisms. 
Fourth and finally, rs3129882 (p-value=2x10-10, OR=1.26), located in intron 1 of HLA-
DRA, was shown being associated with PD [291]. In our dataset, rs3129882 did not show 
significant association (p-values<0.05, OR>1) again suggesting that the same locus may 
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underpin two different neurodegenerative diseases such as PD and FTD but through 
different markers that, in turn, lead to different pathomechanisms. 
In summary, this section highlights that the extended loci that reached genome-wide 
significant association in the FTD discovery cohort had also been reported in a number of 
other conditions. Some of these fall under the category of neurodegenerative diseases 
(MS and PD) and others are autoimmune diseases (vitiligo and rheumatoid arthritis) that, 
interestingly, have also been shown to be occasional co-morbidities of FTD [289]. 
However, it is important to note that the markers driving the genetic association were 
different across the various conditions, for which it may be sensible to infer that 
variability for each marker ultimately contributes to the pathogenic effects leading to 
different diseased phenotypes through differential processes, pathways or mechanisms.   
 
4.2.3 Discussion 
Frontotemporal dementia is a complex disorder characterised by a broad range of clinical 
manifestations, differential pathological signatures and considerable genetic variability 
[17, 26, 166]. These features clearly imply to complex disease mechanisms. As such, 
many elements, including interplay between environmental and genetic risk factors, are 
likely to contribute to onset and progression.  
To date there have been few studies of environmental factors in FTD. These pointed 
mainly to head trauma and thyroid disease [292] as well as traumatic brain injury (TBI) 
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[293] as factors that may possibly influence or be related to an increased risk of 
developing FTD, whereas cerebrovascular disease seemed not to influence or sufficiently 
associate with FTD [293]. However, despite a handful of reports, environmental factors 
are still understudied and, as such, not too well defined in FTD. On the other hand, 
genetic investigation has led to the identification of a number of candidate genes [26, 45, 
67] [76], but ultimately only a number of mutations in these genes have proven to be 
pathogenic in FTD [47]. Currently, besides those cases carrying MAPT mutations that 
lead to tau pathology, there is still no clear and linear correlation between pathology, 
clinical syndromes and genetic variability. In addition, apart from a few highly penetrant 
pathological mutations in MAPT and GRN the other susceptibility genes seem to have 
lower penetrance and effect size, regardless of their frequency [26, 145, 294-296]. 
With this in mind, we performed the largest and most comprehensive genome-wide 
association study on frontotemporal dementia, to date, in the search for novel disease risk 
loci and modifiers associated with the disorder that could possibly also highlight 
pathways and mechanisms relevant to disease development and progression, as still not 
much is known about the underpinning molecular processes that influence the 
pathogenesis of FTD. After the completion of this project, we identified two novel loci 
associated with disease, specifically, the Chr11q14 locus, encompassing RAB38/CTSC 
for the bvFTD subtype, and the Chr6p21.3 locus, encompassing BTNL2 and HLA-
DRA/DRB5 for the entire cohort, suggesting that FTD pathogenesis likely involves 
lysosomal/phagosomal pathways (link to Chr11q14) and immune system processes (link 
to Chr6p21.3). 
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All the SNPs that met genome-wide significance (p-values<5x10-08) were non-coding. 
Although it is well known that the SNPs reflecting the association signal may not be the 
actual risk causing variants, it is relevant to note that either intronic or intergenic SNPs 
may underlie the reason of association especially by influencing expression or splicing 
events. In our study for example, expression and methylation quantitative trait loci data 
(e/mQTL) did support the notion that risk at these loci may be driven by cis changes of 
expression and methylation levels and, therefore, likely through regulation of 
transcription processes.  
Perhaps, however, the most important outcome of our study is that the association with 
these two loci provides, prospectively, novel and unprecedented insight into the 
pathobiology of FTD. 
 
4.2.3.1 The chromosome 11q14 locus 
The first gene of interest in this associated locus is RAB38, an oncogene that was reported 
being mutated in melanoma [297] and that encodes the transmembrane protein RAB38 
which is expressed in thyroid, elements of the immune system such as whole blood, 
lymph nodes and immune cells (dentritic cells, NK cells, T/B cells), and, most 
importantly, the brain (http://www.genecards.org/cgi-bin/carddisp.pl?gene=RAB38). 
From a functional perspective, RAB38 has been suggested to be involved in two main 
cellular processes: 
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1 – Mediation of protein trafficking to lysosomal-related organelles within the trans-
Golgi network (TGN) [298, 299], and; 
2 – Maturation of phagosomes that envelop pathogens [300]. 
It was speculated that impairment of these pathways may lead to cargo accumulation in 
the early endosomes with downstream effects on other pathways such as the recycling 
pathway (toward the plasma membrane) and/or the degradative pathway (affecting late 
endosome/multivesicular body [MVB]) [298].  
The second gene of interest in this locus is CTSC, a lysosomal cysteine-proteinase that 
participates in the activation of serine proteinases in immune/inflammatory cells that are 
involved in immune and inflammatory processes including phagocytosis of pathogens 
and local activation/deactivation of inflammatory factors (e.g. cytokines) (OMIM: 
#602365). 
The associated SNP at the RAB38/CTSC locus, rs302652, showed a remarkable eQTL in 
monocytes (p=5.05x10-32 [269]) for the Illumina probe ILMN_2134974 with the risk 
allele T being associated with decreased expression of RAB38. These data suggest that a 
decreased function of RAB38 might contribute to pathogenesis and may be the 
mechanism by which the association at this locus is mediated. Despite the fact that one 
should be cautious at interpreting expression data generated in a tissue which is different 
from the tissue of interest, in this case the data are extremely relevant since monocytes 
and microglial cells are both cells of the innate immune system and both derive from 
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myeloid progenitors [301]. It is interesting to note that both RAB38 and CTSC, based on 
their intracellular location and functions, correlate with lysosomal as well as phagosomal 
biology. An association with lysosomal processes in FTD was hinted by two studies on 
the GRN [302] and TMEM106B [150] genes. In fact, PGRN not only is ubiquitously 
expressed [62], but also it is involved in a variety of diverse biological processes [63-65]. 
Among these, PGRN is involved in regulating lysosome functions, and TMEM106B, 
which locates intracellularly to the late endosome/lysosome compartments, appears to 
regulate PGRN levels [150]. Considering that endolysosomal homeostasis is essential for 
the health of neurons, the link between the two proteins, RAB38 and CTSC, and FTD (in 
addition to the one of TMEM106B and PGRN) suggests that autophagosomal/lysosomal 
dysfunctions may play a critical role and be implicated in the onset and/or progression of 
the disease. 
 
4.2.3.2 The chromosome 6p21.3 locus 
The first genes of interest in this associated locus are HLA-DRA and HLA-DRB that, 
respectively, encode monomorphic and polymorphic class II HLA-DR transmembrane 
chains, which are expressed on the surface of antigen presenting immune cells. 
Microglial cells are scavenger cells that are involved in several processes in the brain 
such as modulation of immune responses (including phagocytosis) as well as cytokines 
and growth factor secretion [303]. The HLA-DR molecules are known to be expressed on 
the surface of microglia, and it has been suggested that increased expression of HLA-DR 
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molecules on microglia may reflect pathological activity, as previously reported, for 
example, in AD and PD [304]. From a functional perspective, the HLA-DRA/DRB 
molecules promote interaction between microglial cells and CD4+ T-cell receptors 
allowing for modulation and regulation of immune responses (OMIM#142860).  
The second gene of interest in this locus is BTNL2, which encodes a membrane protein 
that is ubiquitously expressed across different tissues, including the brain, and is involved 
in repressing T-cells proliferation [305]. 
Our own mQTL data and a couple of previous reports support the possibility of a link 
between this locus and effects on transcription [221, 291]. For example, our data reveal 
an association between the risk allele T of SNP rs1980493 (located in BTNL2), and 
increased methylation at HLA-DRA in cerebellum (p-value=3.34x10-08) and frontal cortex 
(p-value= 2.17x10-08), as well as a suggestive association (p-value=4.8x10-07) with 
increased cis expression of the gene SLC39A7. The latter gene encodes the protein 
SLC39A7, which is a cytoplasmic zinc transporter. The potential pathogenic effect of an 
increased expression of the SLC39A7 protein in neurodegenerative conditions is not 
known and needs to be fully elucidated before any speculation could be made. However, 
these transcription-related mechanisms highlight the likely functional reason for 
association at this locus. Besides the fact that the exact mode of action by which 
variability at this locus might exert its pathogenic effect needs to be further investigated, 
the valuable message here is that the association with HLA strongly supports a tie 
between FTD and the immune system. 
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Taking one step back, the immune system is known to be fundamental in modulating 
several processes in the central nervous system (CNS). For example, in normal 
conditions, microglial cells: 
1 – Play an important role during brain development by pruning neurons, and; 
2 – Maintain CNS homeostasis through removal of either debris and apoptotic cells or 
pathogens via phagocytosis [306, 307]. 
Considering that: 
1 – The class II HLA-DR molecules are expressed on the surface of microglial cells, and; 
2 – Microglia interact with CD4+ T cells, it follows that microglia themselves play a key 
role in regulating immune responses and homeostasis in brain. 
As such, these notions offer insight into a possible role for the HLA locus in FTD 
pointing to the fact that variability at this locus may lead to aberrant/detrimental immune 
responses in the brain and, ultimately, to neurodegeneration. 
 
4.2.3.3 The immune system and neurodegeneration 
Ageing causes changes in both the CNS and the immune system. There is evidence in the 
literature for a link between changes in immune responses (that happen during the 
process of aging) and an increased incidence of neurodegenerative diseases [306, 307]. 
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Specifically, the innate and the adaptive immune responses have been suggested to be 
involved in processes that lead to neurodegenerative diseases [306] including AD [308], 
PD [291, 309], ALS [310], MS [286, 311] and Huntington disease (HD) [312]. 
Our current study points to a possible role of the immune system in the pathogenesis of 
FTD adding this neurodegenerative disease to the above mentioned list. 
It is noteworthy that brain homeostasis is guaranteed by the harmonic interplay of 
microglial cells, regulatory T and B cells and efficient cross talk between neurons and 
microglia [306]. Ageing, stress as well as infection at site or peripheral inflammation 
have been reported as factors that can perturb brain homeostasis by possibly leading to an 
excessive or aberrant immune response in the brain that, in turn, may lead to 
neuroinflammation and neurodegeneration [306, 312]. Some reports have shown that 
increased vulnerability to infection in later age may associate with behavioural and 
cognitive deficits [313]. For example, peripheral infections have been associated with 
deterioration of cognition in AD patients [306]. 
However, to date, it is still not clear whether inflammation plays a primary or secondary 
role in neurodegenerative diseases. 
Microglia are activated in areas of pathology as shown in substantia nigra and areas 
where dopaminergic neurons die in PD [314] or within and around Aβ plaques in AD 
[312]. In addition, positron emission tomography (PET) imaging studies showed that 
such activation is visible in pre-manifest gene carriers; therefore, it is a possibility that 
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such an event (microglia activation) is not just secondary to large scale neuronal death 
[315], and so microglial chronic activation was suggested having a primary role in 
triggering neurodegenerative diseases and their progression [307]. 
Another important aspect is that inflammatory markers accumulate around the 
pathological lesions especially in the brain areas where synaptic or neuronal loss occur 
[312]. This was observed in a number of neurodegenerative diseases, including FTD 
[316]; it was shown that accumulation of inflammatory markers in areas of brain 
pathology is reflected, partially, by an increase of cytokine levels in the cerebrospinal 
fluid (CSF) [292] and/or in the plasma [312]. For example, elevated plasma levels of 
cytokines and chemokines such as Interferon γ (INF-γ) or tumour necrosis factor α (TNF-
α) were shown to correlate with cognitive decline in AD [317], and, furthermore, increase 
of TNF-α in CSF was also observed in FTD [318]. More recently, an elegant study, 
evaluating correlation between thyroid and non-thyroid autoimmune disorders and two 
groups of patients either diagnosed with SD or carrying GRN mutations, established a 
correlation between non-thyroid autoimmune diseases – including rheumatoid arthritis 
and vitiligo – and those two groups of patients, including elevated TNF-α plasma levels 
[289].   
All this taken together leads to the notion that the immune system may act as a disease 
modifier in neuropathogenesis and that systemic immune changes may affect disease 
onset and progression in neurodegeneration [312].  
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4.2.4 Summary and conclusion 
The associations identified in our study at Chr11q4 – encompassing RAB38 and CTSC – 
and at Chr6p21.3 – encompassing BTNL2, HLA-DRA and HLA-DRB5 – indicate genes 
involved in lysosomal/phagosomal as well as inflammatory processes to be likely 
involved in the pathogenesis of FTD.  
After completion of this study, there are, possibly, three important points to be 
highlighted: 
1 – The Chr11q4 locus has previously been associated with another neurodegenerative 
disorder, namely MS [286], a disease that is also associated with inflammation [319] 
[259, 290]. This possibly suggests shared pathogenic pathways in FTD and MS. 
However, the association with this locus for each disorder is driven by two different 
SNPs, probably implying to two distinctive disease-specific haplotypes; 
2 – Association with the Chr6p21.3 locus had been previously reported in MS and PD 
[291, 319] as well as in the autoimmune diseases vitiligo and rheumatoid arthritis [287, 
288]. Interestingly, the latter conditions were recently shown to correlate with either the 
diagnosis of SD or the presence of GRN mutations in concomitance with elevated TNF-α 
plasma levels [289]. It has been previously implied in the literature that deficiencies in 
the immune system trigger the development of neurodegenerative diseases [306]. The 
association with FTD that we report in this study provides further genetic evidence and 
support for this hypothesis, and; 
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3 – At this stage, considering that both RAB38 and CTSC are involved in lysosomal 
biology and, to a certain extent, in immune processes one might speculate that 
lysosomal/phagosomal pathways and immune system processes may individually as well 
as synergistically play a critical role in the development of FTD. 
 
Undoubtedly, the new loci presented in this work will need to be replicated in other FTD 
cohorts and further investigated in order to establish a link between the genetic 
association and biological processes underlying disease. 
These findings however hold promise for a better understanding of the pathogenesis of 
FTD and for the development of tools to be implemented for preventive and therapeutical 
measures. 
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CHAPTER 5 – Other FTD related projects 
 
During the course of this research, in addition to the two main projects, i.e. the follow up 
study on the PSP-GWAS [180] (Chapter 3) and the entire FTD-GWAS (Chapter 4), I 
have actively participated in a number of other research projects.  
These have mainly, but not exclusively, focused on the study of FTD. In fact, especially, 
at TTUHSC under my supervisor Dr Momeni, I have also been working on the screening 
of the known candidate genes for FTD (Table 5-1) in cases diagnosed with corticobasal 
syndrome/degeneration (CBS/CBD) [320]. In addition, I have been involved not only in 
the screening of the Alzheimer’s disease (AD) risk factors and candidate genes (Table 5-
1) in large AD cohorts [321], but also in an innovative and ongoing study aimed at 
untangling the gender differences in the incidence and prevalence of AD [322].  
In the following sections I will exclusively summarize the study of FTD families and the 
screening of the FTD candidate genes in our extended cohort of sporadic FTLD and 
CBS/D cases at TTUHSC, reason being that these research projects are of great interest 
in that they provide direct insight into the complexity of FTD and its genetic 
heterogeneity. 
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 Table 5-1. Candidate genes for genetic screening 
 
 
 
Gene Full name Chromosome Location BP Associated Disease Reference 
       
MAPT microtubule-associated protein tau 17 17q21.1 
43971702 - 
44105700 
FTD [45] 
CBS/D 
[180]; 
[179]; 
[323]; 
[324] 
PSP [180]; [179] 
AD [325]; [52]; [326] 
GRN granulin 17 17q21.32 42422491 - 42430474 
FTD [66]; [67] 
CBS/D 
[327]; 
[328]; 
[329]; 
[330] 
C9orf72 chromosome 9 open reading frame 72 9 9p21.2 
27546543 - 
27573864 FTD-ALS [76]; [77] 
TDP-43 TAR DNA binding protein 1 1p36.22 
11072462 - 
11085549 
ALS [331] 
FTD [136] 
FUS fused in sarcoma 16 16p11.2 31191431 - 31206192 ALS 
[142]; 
[143] 
CHMP2B charged multivesicular body protein 2B 3 3p11.2 
87276413 - 
87304698 FTD [121] 
ApoE apolipoprotein E 19 19q13.2 45409039 - 45412650 AD [332] 
APP amyloid beta (A4) precursor protein 21 21q21.3 
27252861 - 
27543446 AD [333] 
PSEN1 presenilin 1 14 14q24.3 73603143 - 73690399 AD [334] 
PSEN2 presenilin 2 1 1q31-q42 227057885 - 227083804 AD [335] 
CR1 complement component (3b/4b) receptor 1 1 1q32 
207669473 - 
207815110 AD [336] 
CLU clusterin 8 8p21-p12 27454434 - 27472328 AD 
[336]; 
[337] 
PICALM 
phosphatidylinositol 
binding clathrin 
assembly protein 
11 11q14 85668214 - 85780923 AD [337] 
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5.1 Familial cases 
5.1.1 A South African FTD familial case 
5.1.1.1 Introduction 
The Afrikaaner family is a South African kindred of Dutch ancestry whose members 
affected by FTD appear to inherit the disease in an autosomal dominant fashion. Affected 
and unaffected family members were collected by Drs. Rajesh Kalaria and Felix Potocnik 
through a collaborative effort between the Institute for Ageing and Health at the 
Newcastle University, UK and the University of Stellenbosch in South Africa. All 
members of the family participating in this longitudinal study were consented according 
to the ethics committee of the University of Newcastle prior to enrolment. 
 
5.1.1.2 Clinical and pathological features 
The Afrikaaner family is a multigenerational pedigree (Chapter 2, Figure 2-2) with 
early onset FTD as the affected individuals consistently develop the disease in their late 
40s or early 50s. The clinical phenotype is marked by executive dysfunction, social 
disinhibition and dementia, being alcohol dependency and violent behaviour the main 
early signs in most of the affected members. Pathological investigation was performed on 
post-mortem brain tissues of the consented affected individuals that went to autopsy and 
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revealed widespread tauopathy involving both the grey and white matter in three affected 
siblings (numbers 19, 20 and 22 in the pedigree). 
 
5.1.1.3 Genetic screening of the candidate genes 
The DNA material of the affected and unaffected members of this family was extracted 
from blood either at the University of Newcastle or at the National Institute on Ageing 
(NIA) using standard procedures (Chapter 2, section 2.2.1).  
The DNA has been screened for mutations in the candidate genes MAPT, GRN, CHMP2B 
(at the NIA by Dr Momeni) [125], and FUS and TDP-43 (at TTUHSC by me) [137]. In 
addition, I performed gene dosage experiments for MAPT at TTUHSC. 
There was no evidence of abnormal copy number variations (CNVs) in MAPT. In 
addition, sequencing experiments did not reveal any pathogenic variants in MAPT, GRN 
or TDP-43 [125, 137]. On the contrary, sequencing of the CHMP2B and FUS genes did 
lead to unexpected findings. 
  
CHMP2B 
The screening of CHMP2B revealed a truncation mutation, Arg186X due to the base 
change C>T in exon 6 of CHMP2B (Figure 5-1), in two unaffected siblings (individuals 
110 and 111 on the pedigree) (Figure 5-2). Interestingly, this mutation was not carried by 
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their affected father (number 22 on the pedigree) or by any other affected family member 
[125].  
 
Figure 5-1. CHMP2B: Chromatogram of Arg186X 
 
 
Figure 5-1. The chromatogram shows the base change C>T causing the non-sense change Arg186X in 
CHMP2B [125]. 
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Figure 5-2. FUS and CHMP2B mutations in the Afrikaaner pedigree 
 
Figure 5-2. Pedigree of the Afrikaner family identifying those individuals for which DNA samples are 
available for screening (arrows). Carriers of the FUS and CHMP2B mutations are highlighted in brown and 
yellow, respectively. 
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It is important to note that, since the Arg186X mutation was not carried by the affected 
father, it must have been inherited from the unaffected mother (number 109 in the 
pedigree, Figures 5-2) who died at the age of 68 years without any report of dementia or 
neurological dysfunctions. In addition, based on the available family history, the parents 
and 3 siblings of the unaffected mother were not reported having ever had signs of 
neurological impairment [125]. These findings are of interest when put into context. In 
fact, a previous study by Skibinski and colleagues [121] reported a G>C transition in the 
acceptor splice site of exon 6 of CHMP2B that co-segregated in 11 affected family 
members and that was projected to lead to two aberrant transcripts: CHMP2Bintron5 and 
CHMP2BΔ10 [121]. These three variants, intron5, Δ10 and Arg186X (circled in red in 
Figure 5-3), locate at the carboxy-terminus of the protein CHMP2B and cause the 
disruption of the microtubule interacting and transport (MIT)-interacting motif (MIM).  
Figure 5-3. Wild-type and mutated CHMP2B protein primary structure 
 
Figure 5-3. All the known mutations leading to a carboxy-terminal truncation phenotype are shown and 
compared to the wild-type protein sequence of CHMP2B (top). The carboxy-terminal protein sequence that 
is lost is underlined. These truncation mutations determine the loss of the MIT-interacting motif (MIM). 
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The MIM is a fundamental functional domain of the CHMP2B protein that recruits the 
vacuolar protein sorting 4 homolog A protein (VPS4), which is an ATPase and is 
involved in intracellular protein trafficking [338] (further discussed in section 5.2.1.2). 
Clearly, the loss of the MIM domain would be expected to impact the ability of CHMP2B 
in recruiting VPS4 and, in turn, the cytosolic protein/vesicular trafficking machinery 
[339]. In the attempt to interpret the relevance of the Arg186X mutation one needs to 
keep in mind that:  
1 – The two Afrikaaner family members who carry this truncation mutation are currently 
56 (individual 110) and 54 (individual 111) years old and, still, unaffected, and;  
2 – The mutation was inherited from the unaffected mother.  
Therefore, it is plausible, at this stage, to infer that Arg186X may be a non-pathogenic 
variant, and that the phenotype of this family may be independent from genetic variability 
in CHMP2B. In addition, since the mutations intron5, Δ10 and Arg186X are expected to 
similarly affect the CHMP2B protein because of their location, one might speculate that 
not all mutations leading to the disruption of the MIM domain are pathogenic or fully 
penetrant. A more comprehensive and critical assessment of the variability in CHMP2B 
and, especially, of the effects of the carboxy-terminal truncation mutations is elaborated 
in section 5.2.1.2. 
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  FUS 
Screening of the FUS gene in members of the Afrikaaner family also led to surprising 
results. At first, the novel Gln179Leu missense mutation (Figure 5-4) was identified in 
one affected individual (number 79 in the pedigree) (Figure 5-2) [137]. However, this 
variant was absent from other affected members of the family. In the attempt to better 
understand its origin and pattern of inheritance, we screened the DNA of the affected 
mother (number 20 on the pedigree) and the siblings (numbers 80, 81 and 82 on the 
pedigree) (Figure 5-2). The mother who died of FTD at the age of 74 years did not carry 
the variant, whilst two of the three siblings (numbers 81 and 82 on the pedigree) who are 
still asymptomatic did carry the variant. 
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Figure 5-4. FUS: Chromatogram of Gln179Leu 
 
 
Figure 5-4. The chromatogram shows the base change A>C in exon 6 of the FUS gene causing the 
missense mutation Gln179Leu [137]. 
 
The DNA from the unaffected father (number 78 on the pedigree), whose medical history 
shows no evidence of any neurodegenerative condition, was not available to test for 
segregation. Nevertheless, since the affected mother did not carry the Gln179Leu 
missense change, the unaffected father must be the obligate carrier. Therefore, although: 
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1 – PolyPhen-2 scores this missense change as possibly damaging (Figure 5-5) [225], 
and;  
2 – We did not isolate Gln179Leu in 659 neurologically normal controls; 
Due to its presence in unaffected family members (unaffected father [78] and unaffected 
siblings [81 and 82]) and its mode of inheritance, we assume that this is rather a rare non-
pathogenic variant [137].  
 
Figure 5-5. FUS; missense change Gln179Leu. PolyPhen-2 analysis 
 
Figure 5-5. Polyphen-2 predicted the variant Gln179Leu being possibly damaging. 
 
Taking these results together, the Afrikaaner family clearly resembles a complicated FTD 
familial case characterised by: 
1 – Early onset;  
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2 – Autosomal dominant mode of inheritance;  
3 – Tau pathology and absence of ubiquitin, TDP-43, FUS or p62 positive inclusions; 
4 – Absence of variants in MAPT, GRN and TDP-43, and;  
5 – Controversial variability and inheritance pattern for CHMP2B and FUS.  
 
5.1.1.4 Summary 
In conclusion, the screening of the known candidate genes did not reveal any pathogenic 
variant associated with the diseased condition, leaving the question open for the genetic 
component(s) underlying this familial case. To proceed with the investigation of this 
complex FTD kindred the next steps will entail a linkage analysis and exome sequencing. 
In the case of the first approach I have already generated genome-wide data (Chapter 4, 
section 4.1.2.3) and together with the extended team who is working on this project, we 
have identified the cases that will be used for the linkage study (Table 5-2). For the 
second endeavour a number of samples (either n=4/6 [2/3 affected vs. 2/3 unaffected] 
will be chosen to be screened by means of next generation sequencing tools. 
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Table 5-2. List of Afrikaaner family members for linkage analysis 
ID Status Notes Age in 2010 
Sample 1 A Dementia 64 
Sample 2 A Cognitive impairment 62 
Sample 3 A Cognitive impairment 55 
Sample 4 A Cognitive impairment 48 
Sample 5 U   37 
Sample 6 A Cognitive impairment 60 
Sample 7 U   56 
Sample 8 A Dementia 71 
Sample 9 U   54 
Sample 10 A Cognitive impairment 57 
Sample 11 U   50 
Sample 12 U   53 
Sample 13 U   49 
Sample 14 U   50 
Sample 15 A Dementia 62 
Table 5-2. List of the 15 samples of the Afrikaaner family to be included in the linkage analysis. 
A=affected; U=unaffected. 
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5.1.2 A Finnish FTD kindred 
5.1.2.1 Introduction 
During the discovery phase of the FTD-GWAS I genotyped nine DNA samples of a 
Finnish family (Chapter 4) that I received from Dr Myllykangas, a collaborator from the 
Department of Pathology, Haartman Institute University of Helsinki, Finland. Five 
members (1–5) are siblings, two of which (1 and 2) were diagnosed with FTD and are 
now deceased (Chapter 2, Figure 2-3). Hereafter the clinical, pathological and genetic 
characterisation of the affected individuals of this interesting FTD kindred is reported. 
  
5.1.2.2 Clinical assessment 
Dr Auli Verkkoniemi-Ahola performed the clinical analysis. Patient 1 was diagnosed at 
an early stage of the disease, whilst patient 2 was seen at a late stage of dementia when 
already hospitalized (with medical records available from 1979 to 2002). Of the 3 further 
siblings, one was suspected of being a possible FTD case (3) and two were unaffected (4 
and 5) (Chapter 2, Figure 2-3). Neuropsychological testing was performed for both 
index patients.  
The first signs seen in patient 1 were memory and orientation problems, and cerebellar 
symptoms such as ataxia, at age 55. Patient 1 showed a decline of cognitive functions 
(executive functions and attention) as well as visuospatial, memory and language 
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impairment. Patient 1 also had difficulties in writing, counting and learning, decreased 
initiative and lack of insight. In addition, hypomimia, reduced and slow speech, and 
bradykinesia of both upper and lower extremities were also evident. However, the 
minimental state examination (MMSE) was 28/30. Patient 1 died at 56 years of age due 
to pneumonia. Conversely, early signs in patient 2 were slowness of movements, 
reasoning and speech, and social avoidance at age 54. Patient 2 showed broad cognitive 
decline, disturbances in executive and language functions (aphasia), poor attention, and 
memory dysfunctions. Also extrapyramidal signs such as bradykinesia and reduced 
accessory movements were present. In the final phases of disease, the patient was 
hypomimic and unable to speak. The MMSE score was 14/30 at that stage. The patient 
died at 62 years of age due to bronchopneumonia. 
 
5.1.2.3 Brain imaging and pathology 
Both structural magnetic resonance imaging (MRI) and functional imaging using single-
photon emission computed tomography (SPECT) were performed for patient 1, whilst 
only computed tomography (CT) was available for patient 2. The MRI of patient 1 
showed general cerebral atrophy and a calcified tumour in the left cerebellar lobe, 
diagnosed as a dysplastic gangliocytoma (Figure 5-6), whilst SPECT showed 
hypoperfusion of both frontal lobes. 
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Figure 5-6. Finnish FTD family index patient: MRI 
 
 
 
 
 
 
Figure 5-6. The MRI from the index patient 1 shows a slightly thinned frontal cortex and dilated lateral 
ventricles. (i) cerebellar tumor (axial view). Axial (ii) and sagittal (iii) view of the tumour mass located in 
the left cerebellar hemisphere [219]. Thanks to Dr Myllykangas’ extended research group for this figure. 
 
The CT of patient 2 only revealed general central and cortical atrophy. 
Dr Myllykangas’ extended research group investigated the brain pathology. In patient 1 
the frontal cortex and the hippocampi appeared atrophic and the left lateral and third 
ventricles were enlarged. The thalamus and the brain stem were reduced in size, and the 
calcified cerebellar tumour (dysplastic gangliocytoma) obstructed the fourth ventricle. In 
patient 2 the atrophy was severe in the frontal lobes and in the striatum. It was less severe 
in the anterior and lateral parts of the temporal lobes, in the hippocampus and brain stem, 
whilst it was absent from the cerebellum and the spinal cord. Lastly, the substantia nigra 
was degenerated. 
       
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Concerning the molecular pathology, in patient 1 cytoplasmic pTDP-43-positive 
inclusions were seen in the dentate fascia, pyramidal neurons of the hippocampus and in 
all layers of the cortical areas, whilst p62-positive and TDP-43-negative cytoplasmic and 
intranuclear inclusions were found in the granular cells of the cerebellum. In patient 2 
there were cytoplasmic pTDP43-positive inclusions and abundant dystrophic neurites in 
the hippocampus and all layers of the cortical areas. The granular cells of the cerebellum 
had cytoplasmic and intranuclear p62-positive and TDP-43-negative inclusions, whilst 
the substantia nigra showed p62- and TDP-43-positive neuronal cytoplasmic inclusions.  
 
5.1.2.4 Genetic screening 
Analysis of the DNA was performed on the relevant family members, namely, the 2 
index patients (1 and 2) and the 3 further siblings (3, 4 and 5) (Chapter 2, Figure 2-3). 
All subjects gave informed consent for research.  
First, since these samples were included in the FTD-GWAS (Chapter 4) to generate 
genome-wide genotyping data, Dr Myllykangas and colleagues performed a linkage 
analysis with the goal of identifying disease specific locus/loci. Second, I performed the 
sequencing for four FTD candidate genes (MAPT, GRN, TDP-43 and C9orf72) in all 5 
siblings and I screened the phosphatase and tensin homolog gene (PTEN) a tumour 
suppressor associated with the development of hamartomas (including gangliocytomas 
that was observed in patient 1). 
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Linkage analysis 
Dr Myllykangas and her group performed linkage analysis of this kindred using the 
Merlin program (http://www.sph.umich.edu/csg/abecasis/Merlin/tour/linkage.html). I did 
not have access to the actual linkage data. However, I was informed about the outcome of 
the linkage analysis via personal (email) communication. The linkage analysis revealed 
several chromosomal areas with low LOD scores. Values of 0.6020 were seen in 
recessive model and 0.3010 in dominant model, the most interesting of which was found 
on chromosome 1 in proximity of the TDP-43 locus. The maximum LOD score in this 
peak (0.6020 in recessive and 0.3010 in dominant model) was found 9 Mb centromeric 
from TDP-43 locus. Also, a peak with max LOD score 0.931 was observed in the region 
encompassing the C9ORF72 gene in 9p21.2. 
 
Sequencing 
We decided to screen the candidate genes MAPT, GRN and, especially, TDP-43 and 
C9orf72 based on the linkage results (although the LOD scores were relatively low) and 
the type of pathology identified in the two index patients. 
The candidate genes MAPT (exons 1, 9, 10, 11, 12 and 13 and intronic flanking regions), 
GRN and TDP-43 (all exons and intronic flanking regions) were sequenced following 
standard methods (Chapter 2, section 2.2.2.4) and the repeat expansion in C9orf72 was 
assessed by repeat-primed polymerase chain reaction (RP-PCR) [77] in all 5 siblings. 
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As a result of the sequencing experiments, there was no evidence of pathogenic variants 
in the candidate genes MAPT, GRN and TDP-43. However, patients 1 and 2, and sibling 
3 did show a number of repeats that was above the presumed pathogenic range in 
C9orf72 (≥40 repeats) (Figure 5-7). 
 
Figure 5-7. Finnish FTD family: C9orf72 expansion analysis 
 
Figure 5-7. Results of C9orf72 repeat expansion screening through primed PCR method for all five 
siblings of the second generation. 
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Finnish chromosome 9 haplotype 
After having identified the presence of the expansion and verified its distribution among 
the family members, I evaluated if the expansion carriers also held the previously 
reported chromosome 9p risk haplotype [78, 340]. I could derive the genotypes of the risk 
haplotype directly from the FTD-GWAS data. The expansion carriers did bear at least 
one of the risk alleles of all 42 SNPs, whilst this was not the case in the non-expansion 
carriers (Table 5-3). These data support the notion that the risk haplotype block and the 
expansion are likely to be inherited together in the Finnish population [78, 340]. 
 
Table 5-3. Finnish C9orf72-risk haplotype analysis 
SNPs Risk allele Patient 
 
  2 3 5 4 1 
rs3849942 A AG AG GG GG AG 
rs1330921 T TT TT TT TT TT 
rs10121765 C AC CC CC CC AC 
rs1110264 A AG AG GG GG AG 
rs1110155 A AA AA AC AC AA 
rs2150336 C TC TC TC TC TC 
rs2225389 C AC AC AA AA AC 
rs1161680 G AG AG AA AA AG 
rs2120718 G AG GG AG AG AG 
rs2589054 G GG AG AG AG GG 
rs10812596 A AA AA AA AA AA 
rs1058326 C CC TC TT TT CC 
rs944404 T TT TT TT TT TT 
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Table 5-3. The 42 SNPs constituting the Finnish ALS risk haplotype and the distribution of their genotypes 
among the Finnish FTD kindred are shown. All the expansion carriers (1, 2 and 3) hold at least one risk 
allele when compared to the non-carriers (highlighted in light brown). When considering only the 21 of 24 
SNPs (highlighted in yellow) of the shorter haplotype [78, 340] (due to chip design), at least one of the risk 
alleles was present in all the expansion carriers whilst this was not the case in the non-expansion carriers. 
 
 
Table 5-3 (continued) 
   
SNPs Risk allele Patient 
  2 3 5 4 1 
rs765709 A AA AA AA AA AA 
rs1316679 G GG GG GG GG GG 
rs4406503 G GG GG GG GG GG 
rs10511817 C CC CC CC CC CC 
rs725804 A AA AC CC CC AA 
rs10511816 T TG TG TG TG TG 
rs1444533 A AA AG AG AG AA 
rs1822723 C CC CC TC TC CC 
rs4879515 T TT TC CC CC TT 
rs895023 T TT TT TT TT TT 
rs868856 T TC TC CC CC TC 
rs7046653 A AG AG GG GG AG 
rs2440622 A AA AA AA AA AA 
rs1977661 C CC CC CC CC CC 
rs903603 C CC TC TC TC CC 
rs10812610 C CC AC AC AC CC 
rs2814707 A AG AG GG GG AG 
rs12349820 T TT TT TC TC TT 
rs10122902 G AG GG GG GG AG 
rs10757665 T TT TT TC TC TT 
rs1565948 G AG GG AG AG AG 
rs774359 C TC TC TT TT TC 
rs2282241 G TG TG TG TG TG 
rs1948522 C TC CC CC CC TC 
rs1982915 G GG AG AA AA GG 
rs2453556 G GG AG AA AA GG 
rs702231 A AC AA AA AA AC 
rs696826 G AG GG GG GG AG 
rs2477518 T TC TT TT TT TC 
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Screening of PTEN 
As previously mentioned (section 5.1.2.3), patient 1 also had a dysplastic gangliocytoma 
that was evident from the neuroimaging data (Figure 5-6).  
The latter condition had been associated in the past with mutations in the phosphatase and 
tensin homolog gene (PTEN) [341, 342]. In the attempt to verify whether patient 1 did 
carry pathogenic variants in PTEN and, therefore, whether mutations in this gene may 
explain the presence of the tumour, we decided to screen this gene. The sequencing of 
PTEN in patient 1 only was first outsourced to the University of Ghent to assess the 
presence of coding variants through Multiplex ligation-dependent probe amplification 
(MLPA), because at the time there was no possibility to perform this experiment at any of 
the laboratories collaborating in this project. The MLPA screening did not result in the 
identification of any mutation in the coding regions of PTEN. Subsequently, further 
review of the literature revealed that not only single base pairs transitions leading to 
missense or non-sense changes [343], but also heterozygous deletions in the PTEN gene 
had been associated with the development of hamartomas [344, 345]. We had the 
opportunity to use the genotyping data derived from the whole genome-wide screening 
(FTD-GWAS) for a variety of types of analysis. As such, I thought of visually inspecting 
the PTEN locus using the Chromosome Browser tool in the Genome Studio software in 
all 5 siblings in the search for possible loss of heterozygosity (LOH) regions 
encompassing PTEN. Surprisingly there seemed to be a pattern suggestive of a possible 
LOH region spanning ~200Kbp, exclusively in the patient with gangliocytoma (B Allele 
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Frequency plot in Figure 5-8). An obvious inflation of the LogR Ratio plot was not 
detectable (Figure 5-8), but this also still does not entirely excludes the possibility of a 
true LOH. Taking these observations together, they imply that the putative LOH region 
could be due either to an extraordinarily long series of homozygous calls in the whole 
region (chromosome10: 89,586K–89,780K) or to a possible case of uniparental disomy 
(UPD) that results in a copy-neutral LOH (cnLOH) in Genome Studio (Figure 5-8). 
 
 Figure 5-8. Finnish FTD family: LOH analysis 
 
 
 
 
 
 
 
 
 
 
Figure 5-8. Suggestive LOH region (space delimited by the two orange vertical lines and indicated by the 
red arrow) encompassing the PTEN gene in patient 1.  
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This region included 27 SNPs that encompassed the whole PTEN gene (Table 5-4).  
 
Table 5-4. PTEN locus: Genotyping data 
Name Chr Position (bp) Patient MAF MA Location 
      3 5 4 1 2       
rs1871055 10 89571955 BB BB BB AB BB       
rs6586103 10 89573982 AB AA AA BB AA       
rs11202576 10 89574264 AA AA AA AB AA       
rs1871057 10 89574656 BB BB BB BB BB       
rs17702687 10 89575957 AB (T/C) AB (T/C) AB (T/C) AA (T/T) AB (T/C) 0.349 T 5' from PTEN 
rs10887755 10 89578868 AA AA AA AA AA       
rs12775504 10 89585632 AA AA AA AA AA       
rs7078010 10 89586538 AB (T/G) AB (T/G) AB (T/G) AA (T/T) AB (T/G) 0.356 T 5' from PTEN 
rs10509412 10 89589334 AB AA AA BB AA       
rs7076964 10 89589556 AB (A/G) AB (A/G) AB (A/G) BB (G/G) AB (A/G) 0.481 A 5' from PTEN 
rs10887758 10 89593295 AB (T/C) AB (T/C) AB (T/C) BB (C/C) AB (T/C) 0.23 C 5' from PTEN 
rs1022427 10 89596169 BB BB BB BB BB       
rs1234212 10 89598872 AB (T/C) AB (T/C) AB (T/C) AA (T/T) AB (T/C) 0.407 T 5' from PTEN 
rs1234221 10 89606459 AA AA AA AA AA       
rs1234220 10 89635453 AA AA AA AA AA       
rs11202596 10 89637134 BB BB BB BB BB       
rs2299939 10 89647130 AB (A/C) AB (A/C) AB (A/C) BB (C/C) AB (A/C) 0.147 A PTEN intron 2 
rs2248293 10 89697245 AB (T/C) AB (T/C) AB (T/C) BB (C/C) AB (T/C) 0.434 C PTEN intron 5 
rs11202607 10 89717394 BB BB BB BB BB       
rs478839 10 89721850 AB (A/G) AB (A/G) AB (A/G) AA (A/A) AB (A/G) 0.342 G 3' after PTEN 
rs10509532 10 89727534 AB (T/C) AB (T/C) AB (T/C) AA (T/T) AB (T/C) 0.179 T 3' after PTEN 
rs809367 10 89731786 BB BB BB BB BB       
rs644205 10 89735794 BB BB BB BB BB       
rs10887768 10 89745581 AB (T/C) AB (T/C) AB (T/C) BB (C/C) AB (T/C) 0.289 C 3' after PTEN 
rs10509533 10 89747929 BB BB BB BB BB       
rs10887774 10 89756023 AB (A/G) AB (A/G) AB (A/G) AA (A/A) AB (A/G) 0.309 A 3' after PTEN 
rs10788575 10 89758564 AB (A/G) AB (A/G) AB (A/G) AA (A/A) AB (A/G) 0.197 A 3' after PTEN 
rs2785070 10 89764558 AB BB BB AA BB       
rs2244092 10 89767768 AB BB BB AA BB       
rs2673825 10 89768475 BB (G/G) AB (A/G) AB (A/G) BB (G/G) AB (A/G) 0.344 T 3' after PTEN 
rs1360950 10 89770130 BB (G/G) AB (A/G) AB (A/G) BB (G/G) AB (A/G) 0.271 A 3' after PTEN 
Table 5-4. The genotypes of 27 SNPs that in the 660K Quad chip array cover the region between 
chromosomal positions 89,586K–89,780K encompassing the PTEN gene are shown. Patient 1 (red arrow 
and genotypes in bold) is the only case where the calls of the region encompassing PTEN are homozygous 
(between SNPs rs17702687 and rs1360950).  
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Considering that the known SNPs screened for PTEN through the MLPA method 
revealed only homozygous alleles (personal communication from Dr Myllykangas) in 
patient 1 this was supportive of the inference that there was a possible LOH, as suggested 
by the analysis through Genome Studio. To verify whether there was a deletion of one of 
the two alleles of PTEN gene which may have resulted in PTEN haploinsufficiency and, 
possibly, played a role in the development of the gangliocytoma in patient 1, I 
investigated the presence of CNV at this locus in patient 1 and the other 4 siblings 
through a TaqMan CNV assay (Chapter 2, section 2.2.2.7). As previous reports had 
shown that deletions occurring at the PTEN locus may affect either exon 1 only, or exons 
1-5 or the whole gene [344, 345], I chose an assay that was targeting exon 1 in order to 
capture either of the possibilities. 
The experiment was performed for the 5 siblings at two different concentrations and in 
quadruplicate each time (Figure 5-9a and b) and confirmed later using a second DNA 
extraction from sibling 1, 2 and 3 again at two different concentrations and in 
quadruplicate each time (Figure 5-9c and d). Each set of experiments revealed normal 
copy numbers (n=2) for each of the sibling. A priori, patient 1 could have been expected 
to carry a deletion (copy number=1) but the CNV experiment did not confirm this 
assumption. Such results pointed out that the LOH pattern seen in Figure 5-8 could most 
probably reflect either an extraordinarily extended region of exclusive homozygous calls 
or, although very unlikely, a cnLOH. 
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Figure 5-9. Finnish FTD family: CNV analysis 
 
Figure 5-9. CNV assay targeting exon 1 of PTEN. (a) The bars depict results of the 5 siblings for whom 
DNA was used at a concentration of 50 ng/ul. Each bar represents 4 replicates. (b) The bars depict results 
of the 5 siblings for whom DNA was used at a concentration of 25 ng/ul. Each bar represents 4 replicates. 
(c) The bars depict results of 3 (1, 2 and 3) siblings for whom new DNA extractions were performed. DNA 
was used at a concentration of 50 ng/ul. Each bar represents 4 replicates. (d) The bars depict results of 3 (1, 
2 and 3) siblings for whom new DNA extractions were performed. DNA was used at a concentration of 25 
ng/ul. Each bar represents 4 replicates. Normal copy numbers (2) are predicted for all siblings. The bars in 
this figure are not normalized. 
 
In order to verify homozygosity of PTEN gene in this family through a method other than 
chip or CNV TaqMan assay I sequenced exon 1, which was the target of the CNV assay 
and exon 5, which is known from the literature to be highly polymorphic. According to 
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dbSNP at least 8 SNPs (rs149772796, rs145695240, rs57374291, rs145124907, 
rs139767111, rs370795352, rs144545031 and rs9651492) are harboured in exon 5. 
Detecting homozygous alleles in patient 1 and, conversely, heterozygous calls in the 
other family members for the known SNPs could confirm at least the pattern seen in 
Figure 5-8. However, sequencing did reveal homozygous calls for all the known SNPs in 
all the siblings. At present, provided that the CNV assay showed 2 allele copies in this 
genetic region in all siblings, including patient 1, the reason underlying the LOH is still 
unresolved. 
 
5.1.2.5 Summary 
Genetics of the Finnish kindred 
This study was performed to identify the genetic underpinnings of a Finnish FTD 
kindred. After I included all family members on the 660K GWAS chip and generated 
genome-wide genotyping data, Dr Myllykangas performed a linkage analysis that pointed 
to the TDP-43 and C9orf72 loci as possibly associated in this family. Subsequently, the 
genetic screening was focused on the 5 siblings (Chapter 2, Figure 2-3) by screening for 
the candidate genes MAPT, PGRN, TDP-43 and C9orf72. No variants were detected in 
the coding regions of the first 3 genes, whilst three of the siblings (1, 2 and 3) carried the 
C9orf72 expansion (Figure 5-7). Of note, the third sibling (3) recently became 
symptomatic. All three siblings (1, 2 and 3) also carried the 42-SNP 9p21 risk haplotype 
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associated with ALS in the Finnish population which was absent from the two non-
expansion carriers (siblings 4 and 5) (Table 5-3), supporting previous reports specific to 
the Finnish population [78, 340] and pointing to this locus as associated with the diseased 
phenotype in this family.  
To put these data into context, it is relevant to consider the clinical and pathological 
features of the index patients.  
The early clinical signs in patient 1 involved memory and orientation problems on one 
hand and ataxia (movement problems) on the other. In addition, although with less 
emphasis, cognition and speech were impaired, and there was evidence of bradykinesia. 
The early clinical signs of patients 2 involved psychiatric problems (social avoidance) 
and movement impairment. As well cognition and language impairments were present 
accompanied by memory dysfunction and bradykinesia. In both cases the diagnosis was 
FTD but evidently the broad features were heterogeneous encompassing typical signs of 
AD (memory and visuospatial), FTD (cognition, executive function and language), and 
included features that are seen in FTD but less frequently (psychiatric and 
extrapyramidal/parkinsonian signs). These features on one hand reflect the topographic 
atrophy patterns observed in the brains of the patients and on the other, to a great extent, 
the pathological signatures that have been described in expansion carriers [85] [91, 92, 
346]. Although, to date, the most frequent diagnoses associated with the expansion fall in 
the categories of bvFTD and FTD-MND [86, 94, 347], heterogeneity of the clinical 
features in presence of C9orf72 expansions is evident [348]. The current work thus 
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confirms and shows that clinical signs associated with the expansion in C9orf72 can 
encompass features resembling AD, bvFTD, PPA and parkinsonism all together. 
However, it is difficult, at this stage, to correlate the expansion alone to these many co-
morbidities or broad clinical manifestations. Clearly, additional studies are needed to 
further elucidate this aspect. The molecular pathology associated with the index patients 
revealed FTLD-TDP pathology type B (patient 1) or A/B (patient 2) and included the 
typical signature of the expansion carriers, i.e., the cytoplasmic and intranuclear p62-
positive and TDP-43-negative inclusions in the granular cells of the cerebellum. These 
features collectively mirror previous reports describing the most common forms of 
pathology associated with C9orf72 expansions [31, 84, 85, 89, 91]. 
 
PTEN and gangliocytoma 
On the other hand, patient 1 had a dysplastic gangliocytoma (Lhermitte-Duclos disease), 
which is a rare benign brain tumour/hamartoma of cerebellar granular cells [341] that 
became an interesting, per se, study within the main (genetic) study of the Finnish FTD 
family. It had been hypothesized that the phenomenon of aberrant migration and 
hypertrophy of granule cells is at the basis of the development of these benign lesions 
[341]. Adult-onset dysplastic gangliocytomas can occur in individuals with Cowden 
syndrome, a condition that is associated with mutations in the PTEN gene [341, 342]. 
Although patient 1 did not explicitly show signs of Cowden syndrome we decided to 
screen PTEN to assess possible genetic variability in this gene and its association with 
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this condition. In normal conditions PTEN is a tumour suppressor that controls cell cycle, 
cell migration and apoptosis. When the gene presents either coding mutations, mutations 
in the promoter region or partial/complete gene deletion, PTEN malfunction enhances 
cell survival, cell growth and decreases apoptosis [349]. From a functional perspective it 
was shown that PTEN mutations lead to activation of Akt/mTOR pathway during the 
formation of dysplastic gangliocytoma [341, 342]. Interestingly, such activation was also 
seen in neurodegenerative diseases, including ALS, especially, in those cases associated 
with SOD1 mutations [349-353]. The biology of PTEN seems complex; knock-
down/inhibition of the protein leads to a robust sprouting of adult sensory neurons [354], 
which may seem a mechanism that supports neuronal survival. However, based on the 
nature of PTEN protein, it cannot be dismissed that such positive effect may be only 
initial due to the fact that the normal function of PTEN as a tumour suppressor is 
impaired leading, ultimately, to tumourigenesis. In fact, a reduction of PTEN protein 
levels has been shown to associate with or induce tumourigenesis across studies [342, 
354-356]. Targeted analysis, including sequencing and copy number variation (CNV) 
assessment, of PTEN did not support the presence of missense/non-sense mutations or 
heterozygous deletion in patient 1. However, genome-wide data showed a possible LOH 
encompassing PTEN in patient 1 but in none of the other siblings (Figure 5-8). A 
recurring segmental LOH pattern could be seen throughout chromosome 10 (where 
PTEN resides), but it was not encompassing a large continuous region of the chromosome 
virtually excluding the UPD as a possibility (Figure 5-10). At this stage, having ruled out 
a heterozygous deletion through the CNV experiments (copy number=2), it is difficult to 
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interpret the LOH patterns as presented in the B Allele Frequency plot (Figure 5-10). It is 
possible that such heterogeneous LOH pattern in patient 1 just represents regions in 
which the calls are unusually homozygous or it is an artefact due to a chip defect. 
However, the possibility of homozygous calls may be further investigated through whole 
genome sequencing, which would clarify whether the whole region encompassing the 
PTEN gene (and the other LOH regions; Figure 5-10) is/are truly homozygous.  
 
Figure 5-10. Finnish FTD family index patient: CNV analysis of whole chr10 
 
Figure 5-10. The chromosome browser view of the Genome Studio software is shown. The LOH patterns 
visible throughout chromosome 10 unlikely represent UPD. Putative LOH regions are highlighted by green 
bars on the B Allele Frequency and LogR Ratio plots. The red vertical line localises PTEN gene. 
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5.2 Sporadic cases 
This section summarizes work that targeted the extended FTLD and CBS/CBD cohorts 
received and stored at TTUHSC by Dr Momeni. 
In brief, the DNA material that was screened in these projects was extracted from blood 
samples of a total of 228 index patients with the broad diagnoses of FTLD (n=158) or 
CBS/CBD (n=40/30). These cases were originally collected at the Cognitive 
Neuroscience Division of National Institute of Neurological Disorders and Stroke 
(NINDS) at the National Institutes of Health (NIH) in collaboration with Drs. Grafman, 
Wassermann, Pietrini, Kapogiannis and Huey [137] and later sent to and stored at 
TTUHSC. This cohort included patients with diagnoses of behavioural variant FTD 
(bvFTD), FTD-MND, progressive nonfluent aphasia (PNFA) [21], and CBS/CBD [220]. 
The procedure to enrol and diagnose the patients was standardized at NIH by Dr 
Grafman. The patients were either self-referred or referred by outside physicians or 
psychiatrists or neurologists. At NIH each patient underwent extensive neurologicical, 
neuropsychological and imaging examination, and the diagnosis was based on standard 
clinical criteria [21, 220]. All subjects gave written informed consent for the study and 
the NINDS Institutional Review Boards, as well as those at TTUHSC, approved all 
aspects of the studies (Chapter 2, section 2.1.5). These samples were screened during the 
past 5–8 years for the main candidate genes (Table 5-1). 
 
! 292!
 5.2.1 FTD and CHMP2B  
5.2.1.1 Genetic screening and functional study 
During the aforementioned extended screening, I identified a novel heterozygous 
g.26218G>A variant in exon 6 of CHMP2B (Figure 5-11), predicted to cause the amino-
acid change Ser187Asn in the carboxy-terminal region of the CHMP2B protein [123].  
 
Figure 5-11. CHMP2B: Chromatogram of Ser187Asn 
 
Figure 5-11. The chromatogram shows the base change G>A causing the missense mutation Ser187Asn in 
CHMP2B [123]. 
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This variant was identified in one patient of English/Swedish heritage diagnosed with 
bvFTD characterised by executive dysfunction and personality change (Figure 5-12) 
[123].  
 
Figure 5-12. Index patient pedigree 
 
Figure 5-12. The pedigree of the FTD proband is shown. The paternal grandfather and two of his siblings 
were diagnosed with dementia. Family members screened along with the proband are countersigned by an 
asterisk [123]. 
 
The complete results of the genetic screening performed on the proband are shown in 
Table 5-5. These include characterisation for the ApoE genotype, the MAPT haplotype 
(H1 vs. H2), and a summary of the findings in the other candidate genes MAPT and GRN. 
Although a number of variants were identified in MAPT and GRN, none resulted being 
pathogenic. 
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Table 5-5. Candidate genes screening 
   
ApoE Sequencing MAPT Haplotype 
 MAPT   
E3/e3 Exon 1, A>G (+8) from 5' exon 1, homozygous G (rs17650901)  H2/H2 
 Intron 8, G>A (-26) from 5' of exon 9, homozygous A (rs62063850)    
 Exon 9, A>G, p.A227A (silent), homozygous G (rs1052553)   
 Exon 9, T>C, p.N255N (silent), homozygous C (rs17652121)   
 Intron 11,  G>A (+34) from 3' of exon 11, homozygous A *   
     
 GRN   
 Intron 3,  G>A (+21) from 3' of exon 3 (rs9897526)   
 Intron 4, del/ins GTCA (-47-50) from 5' exon 5, heterozygous deletion (rs34424835)   
 Intron 5,  G>A (+24) from 3' exon 5 (rs850713)   
 Intron 12, C>T (+78) from 3' exon 12 (rs5848)    
     
 CHMP2B   
 Exon 3,  T>C, p.T104T (silent), homozygous C (rs11540913)   
 Exon 6, G>A, p.S187N *   
 
Table 5-5. Sequencing analysis resulted in the identification of single nucleotide polymorphysms (SNPs) in 
MAPT, GRN and CHMP2B. Most of the SNPs are known. Novel (non-previously reported) SNPs are 
indicated by an asterisk. 
 
To evaluate the possible pathogenicity of the newly identified missense change, 
Ser187Asn, I screened neurologically normal controls of white Caucasian and African 
American ancestry. The g.26218G>A variant leading to Ser187Asn was not found neither 
in 273 (NDPT 098, NDPT 099, and NDPT 096: Coriell Cell Repositories, Camden, NJ, 
USA), nor it was present in additional 400 Caucasian neurologically normal controls that 
had previously been screened for CHMP2B exon 6 [125]. However, the novel CHMP2B 
change was harboured by 6 of 94 (6.4%) normal controls of African American heritage 
(Coriell Cell Repositories: NDPT 031). Unfortunately, it was not possible to determine 
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the mode of inheritance of this variant, since the father of the proband is deceased and 
blood samples from the mother could not be collected. However, samples from an uncle 
and 3 cousins of the proband were available and were screened (Figure 5-12). None of 
them carried the variant.  
In silico analysis of the effect of the Ser187Asn missense change on the protein structure 
and function was evaluated using the PolyPhen-2 software [225] and it was predicted to 
be benign (Figure 5-13). 
 
Figure 5-13. CHMP2B; missense change Ser187Asn. PolyPhen-2 analysis 
 
Figure 5-13. Polyphen-2 predicted the g.26218G>A variant (Ser187Asn) being benign. 
 
To further explore the pathogenicity of Ser187Asn I performed a functional study in the 
laboratory of Dr Collinge under supervision of Dr Adrian Isaacs at the Prion Unit, at the 
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Institute of Neurology at UCL. Mrs. Astrid Authier and I generated a plasmid construct 
containing the mutated base g.26218G>A within CHMP2B exon 6 by means of a 
mutagenesis assay (Chapter 2, section 2.2.3). To confirm the presence of the base 
change G>A in the plasmid I sequenced it for CHMP2B exon 6 (Figure 5-14).  
 
Figure 5-14. CHMP2B: Chromatogram of Ser187Asn (plasmid) 
 
 
Figure 5-14. The plasmid holding the homozygous G>A base change which causes Ser187Asn. 
 
To progress in the functional study SK-N-SH cell line (human neural epithelial cells 
obtained from bone marrow metastasis from the European Collection of Cell Cultures 
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[ECACC]) and fibroblast cell lines were used for transfection of mutated CHMP2B (this 
part of the work was performed by Mrs. Astrid Authier and Dr Hazel Urwin). The 
expression of CHMP2B carrying the missense mutation Ser187Asn was compared to the 
expression of wild-type CHMP2B. Analysis by confocal microscopy microscopy by Dr 
Urwin did not reveal differences in the cytoplasmic localization and distribution of 
CHMP2Bwild-type and CHMP2BS187N suggesting and confirming the most probable non-
pathogenicity of this missense change confirming the prediction of PolyPhen-2. This 
outcome was replicated in a further confirmation experiment (Dr H. Urwin, personal 
communication). 
 
5.2.1.2 Comment on variability in CHMP2B 
Mutations in CHMP2B seem to cause extremely rare cases of FTD [51].  
Although there is evidence of genetic variability in CHMP2B in the literature [47] and the 
original finding of a link to chromosome 3 as well as the segregation in the Danish family 
seem convincing stories [121, 122], there is also evidence and support for the notion that 
the role of CHMP2B in FTD is still, to date, equivocal.  
Based on reports of the past eight years mutations in CHMP2B can be divided into two 
groups:  
1 – The carboxy-terminal truncation, and;  
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2 – The missense mutations (Table 5-6). 
 
Table 5-6. Mutations in CHMP2B 
 
 Truncation mutations Base change Disease Reference 
 CHMP2B
intron5 g.26189G>C FTD [121] 
 CHMP2B
∆10 g.26189G>C FTD [121] 
 p.Gln165X g.25950C>T FTD [127] 
 p.Arg186X g.26214C>T FTD [125] 
        
 Missense mutations       
 p.Ile29Val  g.13227A>G FTD3 ALS [126, 128] 
 p.Asn143Ser g.25885A>G CBD [127] 
 p.Asp148Tyr g.25899G>T FTD [121] 
 p.Ser187Asn g.26218G>A FTD [123] 
 p.Gln206His g.26276A>C ALS [128] 
 
Table 5-6. Summary of most important truncation and missense mutations in CHMP2B. 
 
In order to better understand the effects of these mutations on the structure and function 
of the protein CHMP2B and their possible involvement in neurodegeneration, the role of 
wild-type CHMP2B needs to defined, first. The endosomal sorting complex required for 
transport (ESCRTs) I, II and III is a multimeric protein complex in charge for sorting 
proteins into the intraluminal vesicles (ILVs), which constitute multivesicular bodies 
(MVBs). These are a subset of late endosomes that eventually fuse with lysosomes for 
cargo proteins degradation. CHMP2B is part of the ESCRT-III complex, which is the 
portion directly involved in sorting the cargo proteins into ILVs [357, 358]. CHMP2B 
presents a coiled coil domain between amino-acids 25-55 at the amino-terminus (Figure 
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5-15A) and a microtubule interacting and transport (MIT) – interacting motif (MIM), 
between the carboxy-terminal amino-acids 201-211 (Figure 5-15B). 
 
Figure 5-15. CHMP2B protein domains 
 
Figure 5-15. (A) The coiled coil domain is located close to the amino-terminus of CHMP2B. (B) The 
microtubule-interacting and transport (MIT)-interacting motif (MIM) is located at the carboxy-terminus of 
CHMP2B. 
 
Within the ESCRT-III complex, the three proteins CHMP2B, CHMP2A and Vps24 
(vacuolar protein sorting 24), together, bind the MIT domain of the hexameric protein 
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Vps4 [359, 360]. The interaction between these components leads to two main functional 
consequences:  
1 – The active dissociation of ESCRTs from the endosomal membrane, and;  
2 – The formation and release of ILVs [361, 362].  
In this scenario, the carboxy-terminal truncation mutations are predicted to cause loss in 
CHMP2B of the domain that binds Vsp4. 
 
Carboxy-terminal truncation mutations 
Functional analysis of the intron 5 and Gln165X mutations (Table 5-6) showed that they 
lead to aberrant cytoplasmic phenotype if compared to cells transfected with wild-type 
CHMP2B [35, 121, 127]. However, interestingly, functional analysis of the Δ10 mutation 
did not reveal clear effects on neurodegeneration [363] suggesting that, possibly, not all 
reported CHMP2B mutations are pathogenic, including some of the carboxy-terminal 
truncating mutations [364]. In support of this observation, the isolation of the Arg186X 
truncation mutation in two asymptomatic members of an FTD family (section 5.1.1.3) 
also raises questions about the pathogenicity or penetrance of the carboxy-terminal 
truncating mutations in CHMP2B [125]. Of course those individuals from the Afrikaaner 
kindred who carry the truncation mutation will need to be longitudinally followed to 
verify whether they will eventually develop FTD. However, at the current stage, 
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Arg186X may either be a non-pathogenic change, or a pathogenic variant with variable 
penetrance or a pathogenic mutation associated with differential age of onset. 
 
Missense mutations 
Some missense mutations, such as Asp148Tyr and Asn143Ser, that were previously 
reported were neither associated with pathogenicity nor aberrant endosomal phenotype 
[121, 127, 364]. The variant leading to Ile29Val was identified in normal controls, 
weakening its pathogenic implication [34, 126] and Gln206His, which is located in the 
MIM domain (Figure 5-15B), was shown to lead to a cytoplasmic phenotype 
characterised by enlarged vacuoles [365]. Interestingly, Gln206His was isolated in both 
FTD [128] and ALS cases [365].  
The novel missense mutation that I identified, Ser187Asn, was not found in a total of 673 
Caucasian neurologically normal controls [123, 125]; however it was identified in a 
French control cohort [124]. In addition, it reached a frequency of 6.4% in African 
American controls suggesting it being a common polymorphism in the normal 
population. Although for the latter we could not verify the pattern of inheritance, its 
presence in the normal population, as well as the in silico prediction of non-pathogenicity 
through PolyPhen 2 software and the confirmation through a functional study (data not 
shown, section 5.2.1.1), all together, suggest that this variant is most probably not 
pathogenic. All these data do not entirely support a pathogenic role for CHMP2B 
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missense mutations in FTD. Possibly, due to its location within the MIM, Gln206His may 
be the only missense change with a detrimental effect. 
 
Functional studies and animal models 
Most of the functional work performed to date indicates that impaired trafficking of 
multivesicular bodies (MVBs) to lysosomes can cause cytoplasmic accumulation of 
vesicles [366, 367]. In this view, it was shown that:  
1 – Depletion of ESCRT subunits can lead to abnormal morphology of the MVBs fact 
that in turn affects late endosomal trafficking and causes protein or vesicles accumulation 
[368], and;  
2 – Intron 5 was implicated in the misregulation of Toll-like receptor (TLR) leading to 
abnormal sorting in the endocytic pathway [364].  
More recently, a study proposed the possibility of using RNA interference to knockdown 
the expression of mutated CHMP2B [369]. The authors argued that this approach could 
clear abnormally enlarged endosomes from the cytoplasm of fibroblasts derived from 
patients carrying the intron 5 and Δ10 mutations [369]. Although a partial decrease of 
abnormally enlarged endosomes was observed, the long term effects of CHMP2B 
depletion could not be assessed; therefore it would probably be sensible to verify this 
approach and replicate these findings in animal models as well as clinical trials to prove 
their chances of success in humans. Finally, an animal model developed to study the in 
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vivo effects of intron 5 reported a reduced survival of intron 5+ transgenic mice, in 
addition to lesions such as presence of p62 positive pathology and axonal degeneration 
[129]. These results are clearly of interest but, to support pathogenicity of carboxy-
terminal truncation mutations in CHMP2B, it would be illuminating if Δ10, Gln165X and 
Arg186X would replicate these findings and lead to the same phenotype. 
 
5.2.1.3 Summary 
In conclusion, some studies support the idea that variability in CHMP2B may lead to 
impairment of the ESCRT machinery. This may disrupt endosomal trafficking causing, 
potentially, a number of functional consequences:  
1 – Lack of trophic support for the cell;  
2 – Aberrant cellular signalling and;  
3 – Impairment of autophagy [35].  
Interestingly, especially the third mechanism seems supportive of the results of the FTD-
GWAS (Chapter 4) implying to impaired lysosomal biology in FTD. However, the 
CHMP2B locus did not reach suggestive association confirming that variability in 
CHMP2B is extremely rare and definitely not sufficient to give rise to genome-wide 
significant signals. All this taken together supports the notion that CHMP2B is a very rare 
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cause of FTD and indicates, all the more, that the pathogenicity of the wide range of the 
mutations identified in CHMP2B to date requires further supportive evidence. 
 
5.2.2 FTLD and CBS/CBD: Variability in TDP-43 and FUS 
5.2.2.1 Introduction 
In 2009, the fused in sarcoma gene (FUS) was suggested to be involved in the 
pathogenesis of familial amyotrophic lateral sclerosis (fALS) [142, 143]. FUS encodes a 
protein that regulates DNA repair and transcription processes such as RNA splicing. 
Similarly, the TAR-DNA Binding Protein 43 (TDP-43) acts as a transcription factor and 
is also involved in RNA alternative splicing processes [370]. Thus, both FUS and TDP-
43 play a critical role in the RNA metabolism. In addition, TDP-43 pathology occurs in 
~50% of FTD cases (FTLD-TDP pathology) [31] and represents a remarkable overlap 
between the FTLD and ALS spectrum in that it co-localises with ubiquitin positive 
deposits in the brains of both FTD and ALS patients [371, 372]. Genetic variability in 
FUS and TDP-43 was mainly associated with ALS [142, 143, 331, 373], whilst their 
mutation rate in FTD has been extremely rare and, all the more, yet under-investigated 
[135, 145].  
With study, we intended to further screen them in FTLD as well as in CBS/CBD cases in 
order to better assess their implication in these disorders. 
! 305!
 5.2.2.2 Genetic screening 
All exons of the FUS (n=15) and TDP-43 (n=6) genes and their flanking intronic regions 
were sequenced in 158 FTLD and 70 CBS/D cases. 
The variants identified in FUS were further screened in a total of 569 neurologically 
normal controls of Caucasian, African American and Mexican ancestry that were 
obtained from the Coriell Institute (http://www.ccr.coriell.org; Table 5-8). 
 
FUS 
Sequencing analysis of FUS resulted in the identification of a limited number of variants 
within the patient cohort: One missense change, 2 indels, 2 silent changes, and one 
intronic variant in the 3’UTR (Table 5-7).  
 
 
 
 
 
 
! 306!
Table 5-7. Candidate genes screening 
 
Patient ID Dx Mutation Exon Previously reported Controls 
FUS 
182 FTD Pro106Leu CCC>CTC 4 No No 
85 FTD Gly174-Gly175 del GG (g. 4180-4185 delGAGGTG) 5 
FALS [142] 
NC [145] No 
135 CBS Gly175-Gly176 insGG (g. 4185-4186insGAGGTG) 5 ALS [142] Yes (1/659) 
593-1 FTD Pro125 CCC>CCG 5  No 
568-1 FTD Arg522 AGG>AGA 15  Yes (1/659) 
87 CBS 3’UTR exon 15 STOP +41 3’UTR  Yes (9/659) 109 CBS 3’UTR exon 15 STOP +41 3’UTR  
TDP-43 
125 CBS Asn267Ser 6 ALS [374] FTLD [135] Not tested 
 
Table 5-7.  Genetic variants in the FUS and TDP-43 genes identified among the FTD and CBS patients. 
DX=diagnosis. 
 
The novel variant Pro106Leu in exon 4 of FUS (Table 5-7) was identified in an FTD 
patient characterised by personality/behavioural changes, executive dysfunction as well 
as a decrease in language production and apathy. Co-segregation with disease could not 
be verified in this case due to lack of DNA samples from informative members of the 
family of the proband. Although this variant was not identified in 569 neurologically 
normal controls it is difficult to fully assess its pathogenicity in absence of functional 
data. Nevertheless, in silico analysis suggested this missense change being most likely 
benign (Figure 5-16). 
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Figure 5-16. FUS; missense change Pro106Leu. PolyPhen-2 analysis 
 
Figure 5-16.  Polyphen-2 predicted the missense change Pro106Leu in FUS being benign. 
 
Further, we identified the heterozygous 6 base pair deletion Gly174-Gly175 del GG (g. 
4180-4185 delGAGGTG) in exon 5 of FUS in an FTD patient whose main symptoms 
resembled PNFA. Although the same deletion had previously been described in an fALS 
case [142] it was also, more recently, isolated in 2/638 controls aged 70 and 37 years, 
hence questioning the pathogenicity of this variant [145]. In addition, we isolated the 
heterozygous insertion Gly175-Gly176 insGG (g. 4185-4186insGAGGTG) in exon 5 of 
FUS in a patient with the diagnosis of CBS. This variant had also been previously 
reported in fALS [142] but we identified it in 1/659 of our normal controls population. 
The latter is the first report of this variant in a normal control suggesting that its 
pathogenic role may be questionable. In light of these results, the indel polymorphisms 
originally identified in familial ALS and thought to be pathogenic [142, 143] may, at this 
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point, be considered non-pathogenic and excluded from involvement in the pathogenesis 
of FTD, CBS and, retrospectively, ALS. In addition, we identified a synonymous variant, 
Pro125Pro, in a FTD patient and in none of our controls whereas we found another 
synonymous variant, Arg522Arg, in both one FTD patient and one control (Table 5-7). 
Of note, one variant that we isolated in the 3’UTR region of FUS (41 base pairs after stop 
codon) of two CBS patients was also present in nine controls (Table 5-7). To better 
interpret the potential pathogenicity of the FUS variants that were found in the cases, 
particular attention was given to the analysis of FUS exons 4, 5, 6, and 15 in 659 
neurologically normal controls. A detailed list of the variants identified in the normal 
controls with their respective DNA ID from Coriell is summarized in Table 5-8. 
 
Table 5-8. FUS screening in neurologically normal controls 
Coriell series ID Sample ID Mutation  Exon  Frequency 
Coriell NDP031 ND08239 C>G (exon 4  -23) 4 1/659 
Caucasian control plate 
101-200 
NA18010-061702 
NA18074-061802 
Y66YTAT>TAC 4 2/659 
Coriell NDP099 ND09433 B07 GGC>GGT G76G 4 1/659 
Coriell NDP031 ND13554 TAC>TAT Tyr91 
rs73530286 
4 1/659 
Caucasian control NA17229-121201 Ser135Asn AGC>AAC 
rs61732970 
4 1/659 
Caucasian control NA17295- 010902 Gly175-Gly176 insGG (g. 
4185-4186insGAGGTG) 
5 1/659 
Coriell NDP099 ND01689 C03 
ND02820 E04 
C>T intron 5 +22 Intron 5 2/659 
Coriell NDP098 ND06756 T>C intron (start ex6 -21) 
rs74015090 
Intron 5 34/659 
Coriell NDP99 ND10775 T>C intron (start ex6 -21) 
rs74015090 
Intron 5 
Coriell NDP96 ND11603 
ND11575 
T>C intron (start ex6 -21) 
rs74015090 
Intron 5 
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Table 5-8 (continued)    
Coriell series ID Sample ID Mutation  Exon  Frequency 
Coriell NDP031 ND04013 
ND09688 
ND11333 
ND14116 
ND14118 
ND03137 
ND05016 
ND09724 
ND05233 
ND09725 
ND09828 
ND11656 
ND04478 
ND05278 
ND04479 
ND09728 
ND09947 
ND11906 
ND02365 
ND04011 
ND12395 
ND08253 
homozygous C 
ND09824 
homozygous C 
ND12149 
homozygous C 
ND11905 
homozygous C 
T>C intron (start ex6 -21) 
rs74015090 
Intron 5 34/659 
Coriell Mexican 
American controls 
NA17452 MX00014 
120301 
NA17712 MX0099 
061002 
NA17678 MX0073 
061002 
NA17709 MX0096 
062402 homozygous 
C 
T>C intron (start ex6 -21) 
rs74015090 
Intron 5 
Caucasian control NA18069-062402 T>C intron (start ex6 -21) 
rs74015090 
Intron 5 
Coriell NDP031 ND09824 
ND09724 
ND05233 
ND09828 
ND05278 
ND11906 
ND02365 
ND12395 
ND12149 
homozygous T 
C>T intron ex6 -5 
rs73530287 
Intron 5 11/659 
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Table 5-8 (continued)    
Coriell series ID Sample ID Mutation  Exon  Frequency 
Coriell Mexican 
American controls 
NA17709 MX0096 
062402 
C>T intron ex6 -5 
rs73530287 
Intron 5 11/659 
Caucasian control NA18069-062402 C>T intron ex6 -5 
rs73530287 
Intron 5 
Coriell NDP098 ND05808 GGC.GGC.GGC.GGC.G
GT to GGC.GGT 
Gly228_Gly230del 
6 1/659 
Coriell NDP031 ND14118 
ND11656 
ND04479 
ND04011 
GAC>GAT D212D Exon 6 4/659 
Caucasian control NA17225-040902 GGT>GGC Gly222 
rs61732969 
Exon 6 1/659 
Coriell NDP031 ND00662 
ND09723 
ND09401 
ND09726 
ND09658 
(GGC)5/6/7 Gly224 
rs72550890  11 Gly 
Exon 6 6/659 
Caucasian control NA17225-040902 (GGC)5/6/7 Gly224 
rs72550890  9 Gly 
Exon 6 
Coriell NDP031 ND08253 
ND09728 
GGC>GGT G225G Exon 6 1/659 
Coriell NDP099 ND03969 GGC>GAC G227D Exon 6 1/659 
Coriell Mexican 
American controls 
NA17465 MX00025 
060602 
GGT>GGC G229G  1/659 
Coriell NDP098 ND05808 GGC.GGC.GGC.GGC.G
GT to GGC.GGT 
Gly228_Gly230del 
Exon 6 1/659 
Coriell NDP031 ND11333 
ND09947 
CGC>CGT R234R  2/659 
Coriell Mexican 
American controls 
NA17465 MX00025 
060602 
GGA ins R244 Exon 6 1/659 
Caucasian control NA17278-090601 AGG>AGA Arg522Arg Exon 15 1/659 
Coriell NDP099 ND01689 
ND02820 
G>A exon 15 STOP +41 
3'UTR rs80301724 
3’UTR 9/659 
Coriell NDP096 ND13769 G>A exon 15 STOP +41 
3'UTR rs80301724 
3’UTR 
Coriell Mexican 
American controls 
NA17676 MX0071 
061002 
G>A exon 15 STOP +41 
3'UTR rs80301724 
3’UTR 
Caucasian control NA17238-010202 
NA17242-040402 
NA17255-002 
040202 
NA18013-061102 
NA18059-062602 
G>A exon 15 STOP +41 
3'UTR rs80301724 
3’UTR 
Table 5-8. The complete list of variants found in the exons 4, 5, 6, and 15 of FUS gene among 569 Coriell 
normal control DNA samples is summarized. 
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The screening in the normal population resulted in an outstanding outcome in that it did 
lead to the isolation of a considerable number of variants that were exclusive of our 
control cohort. 
These included the missense variants, Ser135Asn (predicted to be benign, Figure 5-17A) 
(rs61732970) and Gly227Asp (surprisingly predicted to be probably damaging, Figure 5-
17B), the indels GGC.GGC.GGC.GGC.GGT to GGC.GGT Gly228_Gly230del [375], 
(GGC) 5/6/7 Gly224 (rs72550890) 11 or 9 Gly, and the GGA ins Arg244. 
Results of this kind are unprecedented. 
 
Figure 5-17. FUS; missense changes Ser135Asn and Gly227Asp. PolyPhen-2 
analysis 
A 
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B 
 
Figure 5-17.  PolyPhen-2 predicted the missense change Ser135Asn in FUS being benign (A), whilst 
Gly227Asp (B) was predicted to be probably damaging. Considering that both missense changes were 
identified in neurologically normal controls, provided further proof, the prediction for Ser135Asn is 
expected, the one for Gly227Asp is surprising. 
 
TDP-43 
The screening of TDP-43 resulted in the isolation of the Asn267Ser mutation in only one 
CBS patient (Table 5-7). 
This mutation had been previously reported in an ALS [331, 374] and in a FTD patient 
without motor neuron disease [135]. However, PolyPhen-2 predicted this missense 
change to be fully benign (Figure 5-18). Functional studies will need to further support 
this prediction. 
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Figure 5-18. TDP-43; missense change Asn267Ser. PolyPhen-2 analysis 
 
Figure 5-18.  Polyphen-2 predicted the missense change Asn267Ser in TDP-43 being benign. 
 
5.2.2.3 Comment on variability in FUS and TDP-43 
FUS 
Our results clearly show a high rate of variability in the FUS gene, which makes it 
challenging to discriminate the pathogenic from the non-pathogenic variants unless there 
is unequivocal proof of co-segregation with disease in familial cases and/or there is 
support of pathogenicity through convincing functional data. Indels in FUS have been 
reported to cause fALS [142, 143], but it is difficult to argue through what mechanism 
the same variants would exert pathogenic effect in cases and protective effect in 
neurologically normal controls unless there are modifying factors yet to be determined 
that drive the effect of these CNVs. Thus, these variants may not be fully penetrant or 
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have small effect size. As a matter of fact, none of the variants we identified in FUS 
could be unequivocally labelled as pathogenic. However, the relevance of these findings 
lies most probably in the fact that they highlight the polymorphic nature of FUS driven 
by greater variability than what was previously thought and encompasses heterogeneous 
phenotypes including ALS (as originally shown), FTD, CBS as well as the normal 
population. 
 
TDP-43 
To date, pathogenic variants in TDP-43 have been more common in ALS and FTD with 
motor neuron disease than in bvFTD or in the language variants, although TDP-43 
protein has been found in the majority of FTLD-U positive brains [131-133, 135, 331, 
376-378]. In this study, the screening of a robust cohort of FTLD and CBS/CBD patients 
resulted in the identification of only one variant in a CBS patient; the missense change 
Asn267Ser in exon 6 of TDP-43 that had previously been reported in one ALS and one 
FTD patient [135, 374]. It needs to be said that among the FTD cases, few had 
overlapping symptoms with ALS. The current is the first report of this variant in a case 
diagnosed with CBS. The frequency rate of this variant, however, has been proven to be, 
overall, relatively low: 1/666 in ALS (0.15%) [374], 1/252 (0.4%) in FTD  [136], 
whereas it was slightly higher in our CBS/CBD cohort (1/70, 1.4%) [137] but most 
probably because of the smaller sample size. Thus, the Asn267Ser missense change 
appears to be relatively rare and, although it has not been isolated in the normal 
! 315!
population [136], there is still no clear proof of pathogenicity because of lack of 
functional studies. All the more, although this is far from being conclusive, PolyPhen-2 
predicted it being fully benign suggesting that, currently, the pathogenicity of Asn267Ser 
needs to be further verified. 
 
5.2.2.4 Summary 
In conclusion, this study supports the idea that genetic variability in FUS and TDP-43 is 
associated with a broad range of phenotypes including neurologically normal controls (in 
the case of FUS) with a frequency that is unprecedented for candidate genes. In addition 
and, especially, given that these results for the most part contradict previous findings 
about the pathogenicity of FUS and, possibly, TDP-43 variants, examination of more 
patients with the diagnoses of the extended FTLD spectrum as well as functional studies 
may be warranted to elucidate the real effects of these variants. 
 
5.2.3 FTD and C9orf72 
5.2.3.1 Introduction 
There is evidence that ~15% of FTLD patients develop symptoms that are typical of 
motor neuron disease (MND) [379] and, conversely up to 50% of cases diagnosed with 
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ALS show signs typical of FTD [371]. In addition, TDP-43 inclusions represent a 
common and overlapping pathological hallmark in both FTLD and ALS cases [371, 380].  
Several linkage and association studies of ALS, FTD and FTD-ALS cases revealed 
association with a locus on chromosome 9p [78, 79, 81, 82, 381]. Later, a hexanucleotide 
GGGGCC repeat expansion was identified in the first intron of C9ORF72 in FTD-ALS 
families [76, 77] suggesting this expansion as the most probable reason underlying that 
association and as a genetic contributing factor to the FTLD-ALS spectrum.  
In the current study the goal was to evaluate the presence, frequency and distribution of 
the GGGGCC hexanucleotide expansion in 53 of our FTLD patients and 174 
neurologically normal controls from the Coriell Institute (plates NDPT 098 and 099). 
These samples are a subset of the 158 FTLD patients mentioned in section 5.2 and were 
included in the FTD-GWAS (Chapter 4).  
These 53 FTLD cases were all recently (2012) re-evaluated by Dr Huey based on the 
most recent and revised diagnostic criteria [20, 21, 27, 382]. The clinical features resulted 
to encompass a wide range of the FTLD syndromes: 27 cases were probable bvFTD, 11 
were possible bvFTD, 6 were PPA-PNFA, 2 were PPA-semantic, and 4 FTD-ALS. In 
addition, 2 eventually resulted being AD and 1 multiple system atrophy (MSA). 
The updated diagnoses together with the C9orf72 repeat sizes and a brief family history 
of each of the 53 patients used in this targeted genetic screening are summarized in Table 
5-9. 
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Table 5-9. C9orf72 expansion screening and samples characteristics 
Patient ID Diagnosis Repeat # Family history of neurological disorders 
158 Probable bvFTD > 50 Father: AD; Brother: MS 
198 Probable bvFTD > 45 Brother: TIA; Brother: Alcoholism; Daughter: Migraines; Paternal aunt: Dementia 
211 FTD-ALS > 50 
Mother: ALS; Brother: Alcoholism; Father: 
Dementia; Brother/Son: Depression; Daughter: 
Migraines, depression 
223 FTD-ALS > 50 Mother: Dementia; Father: Dementia; Sister: FTD; Brother: Alcoholism; Son: Depression 
81 Probable bvFTD 1 Father: Died of dementia at 77 
83 AD 7 Paternal grandfather: Dementia 
85 FTD-PPA 7 Father: Vascular dementia died at 68 
88 FTD-PPA 14 Sister: PD 
89 Probable bvFTD 8 Mother: LOAD; Paternal grandmother: Dementia died at 89 
90 Probable bvFTD 4 Father: CVA; Nephew: OCD 
95 SD 4 Maternal aunt: Dementia 
96 Probable bvFTD ~ 25 Father: AD onset 58; Maternal uncle: Schizophrenia 
97 FTD-PPA 3 Son: Schizophrenia 
98 Possible FTLD 15 Sister: CVA 
99 Probable bvFTD 10 
Father: PD died at 85; Mother: Dementia, brain 
tumour; 3 aunts: Dementia; Maternal grandmother: 
Dementia 
101 Probable bvFTD 3 Son: Schizophrenia, drug abuse; Daughter: Schizophrenia; Sister and Brother: Drug abuse 
103 SD 5 Maternal grandmother: CVA; Maternal aunt: CVA 
107 Probable bvFTD 1 Paternal uncle: Unknown mental illness 
111 Possible FTLD 2 
Sister: Korsakoff syndrome;  Mother: OCD, 
depression; Sister: Alcoholism; Twin brother: 
Alcoholism 
114 FTD-PPA 2 Father: AD, PD died at 63; 2 brothers: Schizophrenia 
115 Probable bvFTD 6 Father: Dementia onset at 72; paternal grandmother: PD and memory problem died in her 70"s 
118 Probable bvFTD 6 Father: AD; Mother: AD, depression both died in their early 90's 
123 Probable bvFTD 8 Brother: Learning disabilities, alcoholism;  Sister: Eating disorder, depression 
124 Probable bvFTD 7 Father: PD; aunt: AD died at 79 
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Table 5-9 (continued)  
Patient ID Diagnosis Repeat # Family history of neurological disorders 
127 MSA 1 Mother: AD; Brother: CVA; Brother: Brain cancer 
128 Probable bvFTD 3 Father: OCD; Mother: Mental disorder, NOS 
134 FTD-MND 1 Not available 
136 Probable bvFTD 2 Mother: Dementia at 87; maternal uncle: Dementia 
139 FTD-PPA 10 Mother: Depression, alcoholism 
143 Probable bvFTD 17 Daughter: OCD, depression 
144 Probable bvFTD 5 Not available 
163 FTD-MND 9 Paternal uncle: Dementia, alcoholism 
176 FTD-PPA 2 Mother: Depression; Daughter: ADD 
177 AD 3 Mother: LOAD; Father: Alcoholism; Son: Alcoholism 
183 Possible FTLD 2 
Father: PTSD and depression; mother: DLB, mutism; 
mat grandfather: PD and stroke; maternal uncle: DLB; 
2 paternal aunts: MND 
194 Probable bvFTD 3 Sister: Dementia; Father: Stroke; Mother: Depression; Son: Depression/anxiety 
195 Probable bvFTD 6 Mother: Action tremor; Paternal grandmother: dementia; maternal great grandmother: Dementia 
199 Possible FTLD 2 Father: Dementia; Daughter: Seizures; Maternal grandmother: Dementia 
200 Probable bvFTD 6 Daughter: ADD, anxiety; Son: Substance abuse 
201 Possible FTLD 4 
Father: Dementia in his 60's, stroke; Sister: Dementia; 
Brother: Stroke; Brother: Epilepsy, stroke; Son: 
Epilepsy, mental illness; grandfather dementia in his 
60's 
203 Probable bvFTD 3 
Paternal grandmother: Late onset dementia at 91; 
Mother: MS; maternal grandmother Parkinson’s onset 
at 78; maternal great aunt and uncle: LOAD 
205 Possible FTLD 10 
2 Sisters: Anxiety; Sister: PSP; Daughter: Eating 
disorder; Daughter: Anxiety, depression; Daughter: 
Schizophrenia; Son/2 Daughters: Depression 
207 Possible FTLD 7 
Siblings: Tremor, anxiety, alcoholism, substance 
abuse; mother died at 83 had dementia and anxiety; 
father died at 79 had Parkinson’s and anxiety. 
209 Probable bvFTD 7 Father: Stroke; Brother: Born whole in skull; Daughter: Seizure disorder 
210 Possible FTLD 7 Maternal grandfather: Dementia 
212 Probable bvFTD 5 Not available 
215 Possible FTLD 2 Mother: AD; Father: Dementia; Brother: Depression; Son: Arthrogyrosis 
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Table 5-9 (continued)  
Patient ID Diagnosis Repeat # Family history of neurological disorders 
216 Possible FTLD 9 Sister: Mild stroke, depression 
217 Probable bvFTD 2 Father died at age 82 no dementia but paternal grandfather died of dementia at 81 
218 Probable bvFTD ~ 25 Mother: Dementia; Son: ALS; Maternal aunt: AD 
219 Probable bvFTD 2 
Daughter: Anxiety, depression, neurocardiogenic 
syndrome; Brothers: Depression; Sister: Anxiety, 
depression, ADHD; Father: Dementia; Mother: Stroke 
221 Probable bvFTD 10 Father: Vascular dementia at 78 
222 Possible FTLD 2 Father: AD, PD, heart disease; Brother: Alcohol abuse 
 
Table 5-9. Sample IDs with corresponding diagnosis, number of hexanucleotide expansion and a brief 
family history of neurological disorders for each patient. All diagnoses are updated based on [20, 27]. 
Abbreviations: AD=Alzheimer’s disease; MS=Multiple sclerosis; TIA=transient ischemic attack; ALS=Amyotrophic lateral 
sclerosis; PD=Parkinson’s disease; LOAD=late onset Alzheimer’s disease; CVA=cerebrovascular accident; OCD=obsessive 
compulsive disorder; NOS=not otherwise specified; ADD=attention deficit disorder; PTSD=post-traumatic stress disorder; 
DLB=dementia with Lewy bodies; MND=motor neuron disease; PSP=progressive supranuclear palsy; ADHD=attention deficit 
hyperactivity disorder. 
 
5.2.3.2 Genetic screening 
Candidate genes 
The DNA samples of these 53 patients (Table 5-9) were characterised for MAPT, PGRN, 
FUS, TDP43 and CHMP2B, PSEN1, PSEN2 and APP (Table 5-1). However, as the main 
goal here was to evaluate the presence of the hexanucleotide expansions in the C9ORF72 
gene, we performed the RP-PCR experiments as described in [77] considering the 
putative pathogenic repeat range as ≥40, although more recent studies have indicated that 
such threshold is no longer entirely accurate and predictive of a “pathogenic” expansion 
[90, 219, 383]. The results of the screening of C9orf72 are summarized in Figure 5-19. 
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Figure 5-19. Sporadic FTLD: C9orf72 expansion analysis 
Figure_4-9a-d_Thesis_APRIL2014 
Figure 5-19. The range of >30 repeats is considered as the threshold suggestive of presence of expansion 
even though a direct and precise relatedness between this method and the actual repeat size has not been 
established and/or implemented yet being the RP-PCR method, as such, simply predictive of probable 
repeat expansion. Counts of approximately >45 or >50 repeats are depicted for, respectively, samples 
FTD158 (A), FTD198 (B), FTD211 (C), FTD223 (D) and for Coriell neurologically normal control 
ND07551 (E). 
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Four of the 53 patients (FTD158, FTD198, FTD211 and FTD223) and one out of 174 
neurologically normal controls (Coriell plate NDPT099; ID: ND07551; 
http://ccr.coriell.org/Sections/Search/Sample_Detail.aspx?Ref=ND07551&PgId=166) 
revealed presence of repeats in the putative pathogenic range (≥40) (Figure 5-19).  
FTD158 was diagnosed with bvFTD and language signs, whilst both FTD198 and 211 
were diagnosed with FTD-ALS. Finally, FTD223 was primarily diagnosed with bvFTD 
accompanied by signs of memory impairment.  
It is of interest and noteworthy to mention that, among the carriers of the hexanucleotide 
expansion, one patient (FTD158) also carried a novel GRN mutation Tyr294Cys (Figure 
5-20A) and a second patient (FTD223) carried a novel mutation in PSEN2 Ile146Val 
(Figure 5-20B). None of these mutations have been previously reported and their 
identification represents an important piece of information as they indicate that different 
mutations that are all potentially pathogenic can co-occur in FTD. Conversely, this also 
suggests that, possibly, the penetrance of any or all of these variants may not be complete 
and that each may rather act as modifiers. However, prior to speculating on the 
pathogenicity of these variants it needs to be mentioned that the GRN missense change 
was absent from the normal population [327, 384], whilst the PSEN2 missense change 
was not identified in the normal population (n=174; Coriell plates NDPT 098 and NDPT 
099). 
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Figure 5-20. GRN: Chromatogram of Tyr294Cys; PSEN2: Chromatogram of 
Ile146Val 
 
Figure 5-20. Electropherograms of the two novel missense mutations found in GRN (A) and in PSEN2 (B) 
in two of the hexanucleotide repeat carriers, respectively individuals FTD158 (A) and FTD223 (B). Both 
missense mutations are novel.  
 
In the absence of functional data, we examined, in silico, the prediction on their effect on 
the protein structure and function through the PolyPhen-2 software [225]: The GRN 
variant was predicted to be probably damaging, whilst the PSEN2 variant was predicted 
to be benign (Figure 5-21A and B). 
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Figure 5-21. GRN: Missense change Tyr294Cys; PSEN2: Missense change 
Ile146Val. PolyPhen-2 analysis 
A GRN Tyr294Cys 
 
B PSEN2 Ile146Val 
 
Figure 5-21. PolyPhen 2 effect prediction shows that the GRN missense change Tyr294Cys is probably 
pathogenic, whilst the PSEN2 missense change Ile146Val is predicted being likely benign. 
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Finnish chromosome 9 haplotype 
I genotyped the above mentioned 53 DNA samples (Table 5-9) as part of the FTD-
GWAS (Chapter 4), therefore the genotypes of the 42 SNPs which identify the 
chromosome 9p ALS-associated Finnish haplotype [78] could be derived from the 
GWAS and could be used to determine whether the carriers of the expansion also 
harboured the same ancestral haplotype [340].  
Our genotyping data revealed that the complete risk haplotype was not present in any of 
our patients. However, considering the SNP rs3849942 (suggested as surrogate marker 
for the risk haplotype [77]), we were able to verify that all the 4 patients with expansions 
(FTD158, FTD198, FTD211 and FTD223) did carry the risk allele A for this SNP (Table 
5-10). Nevertheless, also 20 of the remaining 49 patients without expansion did carry the 
A-risk allele for rs3849942. Of note, in our patients series there were two individuals 
diagnosed with FTD-MND (FTD134 and FTD163): Patient FTD134 did not carry neither 
the expansion nor the risk allele A (rs3849942), whilst FTD163 did not harbour the 
expansion but the risk allele (Table 5-10). These data suggest that the complete 
chromosome 9p risk haplotype, including the expansion, is possibly a specific 
characteristic of the Finnish population, whereas recombination events in mixed 
populations (although of mainly European ancestry as in the case of the US) rearranged 
the SNPs series on that haplotype. 
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Table 5-10. Finnish C9orf72-risk haplotype analysis 
SNPs Risk allele Patient 
    158 198 211 223 134 163 
rs3849942 A AG AG AA AA GG AA 
rs1330921 T TT TT TT TT TT TC 
rs10121765 C AC AA AA AC AC CC 
rs1110264 A GG GG GG AG GG GG 
rs1110155 A AA AA AA AC AA AA 
rs2150336 C TT TT TT TC TT TT 
rs2225389 C AA AA AA AA AA AA 
rs1161680 G AA AA AA AG AA AG 
rs2120718 G AA AA AA GG GG GG 
rs2589054 G GG GG GG AA AA AA 
rs10812596 A AA AA AA AG AA AG 
rs1058326 C CC CC CC TC TT TC 
rs944404 T TT TT TT TC TT TC 
rs765709 A AA AA AA AA AA AC 
rs1316679 G GG GG GG GG GG AG 
rs4406503 G GG GG GG GG GG AG 
rs10511817 C CC CC CC CC CC AC 
rs725804 A AA AA AA CC AC AC 
rs10511816 T TG GG TG TG TG TT 
rs1444533 A AA GG AA AA AA AA 
rs1822723 C TC CC CC CC TC CC 
rs4879515 T TT CC TT TT CC TT 
rs895023 T TT TT TT TT TT TT 
rs868856 T TC TC TT TT CC TT 
rs7046653 A AG AG AA AA GG AA 
rs2440622 A AA AA AA AA AA AA 
rs1977661 C AC CC CC CC CC CC 
rs903603 C TC TC CC CC TT CC 
rs10812610 C AC AC CC CC AA CC 
rs2814707 A AG AG AA AA GG AA 
rs12349820 T TT TT TT TT CC TT 
rs10122902 G GG GG GG GG GG GG 
rs10757665 T TT TT TT TT CC TT 
rs1565948 G GG GG GG GG AA GG 
rs774359 C TC TC CC CC TT CC 
rs2282241 G TG TG GG GG GG GG 
rs1948522 C CC CC CC CC CC CC 
rs1982915 G GG GG GG GG AA GG 
rs2453556 G GG AG GG GG AA GG 
rs702231 A AA AC AA AA AA CC 
rs696826 G GG GG GG GG GG AA 
rs2477518 T TT TT TT CC TT CC 
 
Table 5-10. The 42 SNPs building the Finnish ALS risk haplotype and the distribution of genotypes among 
the expansion carriers and two further FTD-MND cases (134 and 163) of our cohort are shown. None of 
the expansion carriers (158, 198, 211, 223 in bold) held the complete series of the risk alleles (highlighted 
in orange). When considering only the 21 of 24 SNPs (due to chip design; highlighted in yellow) of the 
shorter haplotype [340], only 158, 198 and 223 held at least one of the risk alleles. None of the two FTD-
MND cases (134 and 163) did fully carry the risk allele in neither the 42 nor the 21 SNPs series. 
 
! 326!
5.2.3.3 Comment on C9orf72 in this study cohort 
It is noteworthy to consider that the FTLD cases analysed in this study were recruited 
within the United States (US) and that they were not explicitly selected on the basis of 
family history, pathogenic mutations, or presence of MND features. As such, these 
samples likely represent the average US FTLD population characterised by substantial 
diversity in the ethnic and genetic background.  
In the current study, the expansion was identified in 4/53 (7.5%) cases, replicating, 
despite a rather small sample size, the original findings [76, 77]. Furthermore, our results 
also provided insight on a number of other aspects that can be summarised as follows:  
1 – There was not a linear correlation between the presence of expansion and the 
previously reported chromosome 9p risk haplotype [78, 340];  
2 – There was co-occurrence of the repeat expansion and missense changes in other 
dementia candidate genes in 2/4 cases;  
3 – The expansion was isolated also in neurologically normal controls, and;  
4 – One case presented heterogeneous clinical and pathological signatures indicative of 
co-existence of various co-morbidities.  
The first point cannot be considered entirely surprising, especially, when compared to the 
study on the Finnish FTD kindred (section 5.1.2), suggesting that the haplotype block on 
chromosome 9p [78] is possibly population specific (Finnish/Northern European 
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populations), whereas it is not necessarily associated with the hexanucleotide expansion 
or shared among populations worldwide. For example, the chromosome 9p risk haplotype 
block was also absent in a large Italian ALS cohort [385]. 
The second point is, in fact, of interest as it highlights co-existence of several potential 
pathogenic mutations. In this study, GRN (Tyr294Cys) and PSEN2 (Ile146Val) missense 
changes co-occurred with the expansion. Tyr294Cys was predicted to be pathogenic by 
PolyPhen-2 and the carrier had an earlier age of onset compared to the other three 
expansion carriers (53 vs. ~60 years of age). On the other hand, PolyPhen-2 revealed that 
Ile146Val may be benign. Although the Ile146Val PSEN2 missense change was not 
identified in 174 neurologically normal controls functional studies are still warranted to 
fully confirm its pathogenicity. As much as this rather reflects a rare scenario, other 
mutations were reported in concomitance of the C9orf72 expansion as in the cases of 
MAPT [98, 386], GRN [285, 386], and TDP-43 [385, 387, 388] to name the most 
relevant. This not necessarily only underlies heterogeneous clinical and pathological 
features but also suggests that in some cases the contribution to the diseased phenotype of 
either of the aforementioned genes may not be fully penetrant.  
The third point emphasises the need for more careful assessment of the penetrance of the 
C9orf72 expansion. Clearly, the identification of the repeat expansion in the normal 
population is a rare phenomenon (<1%); however, it has been observed across various 
studies [77, 86, 87, 285, 383]. The repeat expansion occurs with higher frequencies in the 
cases than in the controls. This is indicative of its most probable contribution to the 
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development of disease; however, at the same time, it is suggestive of probable variable 
penetrance [294, 389]. All the more, although this is not likely the case with C9orf72, as 
previously shown with the FUS gene (section 5.2.2), it is possible that variants initially 
reported as pathogenic [142, 143] are subsequently found also in normal controls which 
brings their relevance/pathogenicity into question. 
The fourth point suggests the need for a critical evaluation of the wide variety of 
phenotypic and pathological signatures that have been found associated with the 
expansion. Previous reports showed that the expansion is mainly detected in FTD-MND 
cases [76, 77, 84, 390] and that expansion carriers are likely to present memory and 
psychiatric symptoms [85, 391, 392]. One of our expansion carriers presented with 
paranoia as the predominant symptom. Two other expansion carriers showed 
significantly impaired memory functions and several had AD-like features [94, 393-397]. 
Of note, FTD211, the one patient whose autopsy report was available, showed amyloid 
plaques and tangles in addition to TDP-43 pathology, despite being only 65 years old at 
the time of death. This replicated earlier observations by Murray et al who described an 
expansion case with concomitant TDP-43 and AD pathology [92]. 
 
5.2.3.4 Summary 
In conclusion, the findings of this study suggest that the hexanucleotide expansion is 
most frequently associated with the FTD-ALS spectrum, but also occasionally with a 
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broader and more heterogeneous group of phenotypes possibly including some clinical 
and pathologically confirmed AD [92, 394], Parkinsons’ disease [398], CBS/CBD, PSP 
[85, 399] cases and neurologically normal controls.  
The findings of this current study need to be interpreted with caution and more 
importantly, replicated in larger numbers of samples. 
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5.3 Final remarks 
 
The study of two familial cases and extended screening of a robust number of sporadic 
cases diagnosed with FTLD and CBS/CBD contributed to the generation of valuable 
knowledge of the genetics of these diseases, especially in relation to the candidate genes: 
1 – The Afrikaaner family (section 5.1.1) confirmed the complexity of the disease in that 
an apparent dominant mode of inheritance associated with tau pathology did not reveal 
any genetic aberrations in the coding regions of MAPT or in its dosage. This has been 
observed before [25], suggesting that the involvement of tau in neurodegeneration, 
including FTD, may be due to genetic variability within the MAPT gene or its associated 
extended haplotype, or it may be driven by genetic defect(s) to be found in other genetic 
factors that contribute or lead to tau pathology independently from MAPT abnormalities. 
Mutations in MAPT exon 10 or affecting exon 10 splicing are known to directly affect the 
function and/or the ratio of isoforms with three or four of the microtubule binding repeat 
domains, leading to tau pathology [29]. Nevertheless, there is evidence of tauopathies, 
such as PSP or CBS/CBD, in which the link to chromosome 17 and MAPT seems to be 
driven by haplotype effects rather than by pathogenic single nucleotide coding variants 
[179, 199]. The variations in FUS and CHMP2B that we identified in this family are of 
interest as they raise question about the pathogenicity and/or penetrance of these genes. 
The FUS missense change was predicted to be probably damaging by PolyPhen-2 and, 
normally, truncation mutations (as in the case of CHMP2B) are considered pathogenic 
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based on the potential inactivation of the protein. However, variants in both genes were 
identified in unaffected members of the family, and were apparently inherited from the 
unaffected parents who were married into the family (Figure 5-2); 
2 – The Finnish kindred (section 5.1.2) highlighted specific characteristics of FTD: First, 
a certain heterogeneity of the clinical features at presentation and during the progression 
of the disease in C9orf72 expansion carriers; Second, an almost complete LD between the 
expansion in C9orf72 and the extended Finnish-risk haplotype [78] indicating this 
association being clearly population specific, and; Third, the pathological signatures 
associated with the expansion are highly replicated across different studies; 
3 – The CHMP2B missense change (section 5.2.1) was non-pathogenic (PolyPhen-2 
prediction, confirmed by functional study), suggesting that CHMP2B is highly 
polymorphic, with the majority of the variants being non-pathogenic (section 5.2.1.2). Of 
note, based on our screening of CHMP2B in both a familial and a sporadic case, we 
concluded that none of the CHMP2B variants that we identified were pathogenic and/or 
associated with disease; 
4 – The screening of FUS revealed that this gene is highly polymorphic (section 5.2.2). 
We provide evidence that variants previously reported as pathogenic and causing familial 
ALS [142, 143] are also common in the normal population (Table 5-7 and 5-8). In 
addition, we identified a novel missense change, predicted to be pathogenic (Figure 5-
17B), in one neurologically normal control. These findings put into question the 
pathogenicity or penetrance of variants in FUS; 
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5 – The screening of TDP-43 confirmed that variability in this gene is rare in FTLD 
(section 5.2.2). We, in fact, identified just one missense change, which was previously 
reported in ALS [331, 374] and FTLD [136], in a CBS case of our cohort. Although this 
suggests that TDP-43 mutations could also cause CBS, PolyPhen-2 predicts this variant is 
benign. Nevertheless, as this variant is absent in 400 neurologically normal controls 
[136], functional studies on its effect are needed to better elucidate its pathogenicity, and; 
6 – The investigation of C9orf72 (section 5.2.3) revealed a highly heterogeneous picture 
including almost complete absence of the chromosome 9p risk haplotype in populations 
other than Finnish, co-occurrence of the expansion with mutations in other candidate 
genes and presence of diverse pathological co-morbidities (i.e. TDP-43 inclusions and 
amyloid plaques) in expansion carriers. 
 
Of note, PolyPhen-2 is valuable for the prediction of potential pathogenicity of missense 
changes. Nevertheless, it is necessary to carry out functional studies to conclusively 
assess the effects of a missense change. Therefore, apart from the CHMP2B missense 
mutation Ser187Asn that PolyPhen-2 predicted to be benign, and confirmed by functional 
study, any other prediction that has been evaluated and reported in this chapter should be 
interpreted with caution in the absence of in vitro and/or in vivo functional studies. 
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In summary, this work has provided insight into the disease by confirming its complexity 
and heterogeneity in the different clinical, pathological and genetic aspects. In addition, 
these findings suggest that possibly some variants are not pathogenic as previously 
thought or have variable penetrance and emphasise the need to direct our attention to the 
study of splicing and expression modulation as well as to the identification of modifying 
factors that might contribute to disease onset and development with variable effect size. 
The latter represent critical aims to be pursued in the FTLD research environment for the 
future. 
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CHAPTER 6 – Discussion and conclusions 
 
6.1 Synopsis 
The work presented in this thesis primarily explored the genetic underpinnings of 
progressive supranuclear palsy (PSP) and frontotemporal dementia (FTD) and 
contributed to their characterisation through the assessment of newly identified PSP loci 
and identification of novel disease associated loci in FTD that point to new possible 
disease pathways and mechanisms, opening new horizons for the study of these disorders. 
The genetic analysis of PSP was designed and performed as a follow-up study based on 
the results of a recent PSP-GWAS [180], whereas the study of FTD (FTD-GWAS) was a 
pioneering endeavour aimed at identifying novel loci contributing to increased risk of 
developing the disease with small to moderate effect size. 
In addition, this work provides an extensive study of the main candidate genes in familial 
FTD as well as sporadic FTLD and CBS/CBD cases. The presented results confirmed, on 
one hand, the extremely heterogeneous nature of this neurodegenerative disorder and, on 
the other, highlighted that the known candidate genes need to be cautiously assessed as 
they seem to contribute to disease with variable degrees of penetrance. 
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6.1.1 PSP 
The study of a cohort of 84 pathologically confirmed PSP cases (Chapter 3) allowed to 
investigate the newly identified loci [180] in a well-defined and informative cohort. The 
study focused specifically on the loci surrounding the SNPs that showed highest 
association in the PSP-GWAS [180]. The characterisation of these loci was performed by 
sequencing of the genes STX6/MR1, EIF2AK3 and MOBP, analysing the haplotype 
architecture including and surrounding the associated SNPs (within +/- 15-35kb) and by 
evaluating possible effects on expression exerted by the associated SNPs and by any of 
those SNPs in LD with the GWAS associated SNPs. 
The load of information that was generated has some limitations that need to be 
acknowledged, in that, the sample size was relatively small (n=84) contributing to a 
certain decrease in the power of the study, and the expression data could only be assessed 
for cis but not for trans effects within a +/- 1Mb surrounding each SNP. Nevertheless, 
relevant information could be derived from this study. 
The data indicated that it is unlikely that coding variants underlie association at any of the 
novel loci associated with PSP because the frequency of coding variability was too low to 
justify association in this manner within our study cohort. This is likely to be as well the 
case of the large cohort that was used to generate the GWAS data [180]. It is possible that 
highly pathogenic mutations in the genes within the PSP-associated loci may hold 
relevance in disease pathogenesis just in single or familial cases, but they do not seem to 
be a common cause of disease. Moreover, the minor allele frequencies of the SNPs in our 
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study cohort did not differ from that of the normal population (assessed through 
comparison with data from the 1000 Genomes project or dbSNP on the Caucasian 
population). This was also reflected in our haplotype analysis, in that the LD patterns 
observed at each locus in the PSP population were almost entirely reflecting those 
reported in the normal population. However, based on pairwise LD analysis of the SNPs 
at the EIF2AK3 locus, there are 4 haplotypes (A, B, C, D) (Table 3-5), of which 
haplotype B has been associated with stress response mediated by the UPR [261]. Data 
for our cohort reflect that of a recent manuscript [262] that evaluated >1,000 
pathologically confirmed PSP cases (i.e. part of those that were included in the PSP-
GWAS [180]). Such outcome is important for, at least, two reasons: First, despite the 
difference in the cohort sizes (84 vs. >1,000), the frequency of the haplotype B at the 
EIF2AK3 locus was comparable in both studies (ours and [262]) meaning that, although 
small, our study population is valuable and fairly representative of the PSP population at 
larger scale; Second, and probably more importantly, the haplotype data point to a 
cellular mechanism, such as that of the unfolded protein response (UPR) (Chapter 3, 
section 3.2.4.2), being worthy of further investigation in genetic and functional studies in 
PSP for validation and for establishing its contribution to the pathogenesis of the disease. 
Another important aspect of our study of the PSP cohort derives from the expression 
data, in that the minor allele (A) of the GWAS-associated SNP at the STX6 locus 
(rs1411478) significantly associated in cis with expression levels (decreased expression) 
of STX6 in white matter. White matter has been reported as among those brain areas that 
are affected in PSP. This finding ties the genetic association at the STX6 locus to the 
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disease, pointing to a possible disease mechanism involving intracellular STX6-mediated 
vesicle trafficking in white matter. This hypothesis clearly needs to be further 
investigated and validated in functional studies to verify whether decreased levels of 
STX6 in white matter contribute to PSP pathogenesis. 
The last point that deserves mention involves the fact that PSP is a tauopathy. It is 
intriguing to consider two facts: First, aberrant tau biology has been linked to the UPR-
related markers in PSP and other tauopathies [263] and, second, tau pathology affects 
white matter in PSP. It follows that the interplay between MAPT H1 haplotype, tau 
pathology, the newly identified loci (specifically those encompassing STX6 and 
EIF2AK3) and related cellular pathways represents an intriguing topic to be further 
investigated in the near future. Special attention needs to be paid to the possible interplay 
between tau and the UPR: Specifically, it will need to be elucidated whether tau 
pathology triggers EIF2AK3 activation or activated EIF2AK3 triggers tau pathology by 
causing tau hyperphosphorylation. 
In summary, our study of PSP-GWAS loci is clearly not conclusive but indicates at least 
two possible and plausible disease mechanisms to be investigated in detail in the near 
future to better understand and characterise the molecular underpinnings that lead to the 
development of PSP.  
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6.1.2 FTD 
6.1.2.1 FTD-GWAS 
The study of FTD benefited from the collection and, subsequently, availability of an 
extremely large sample size gathered through an international consortium that was 
basically created through this thesis project. Two potential problems that needed to be 
addressed were the phenotypic characterisation and intrinsic population stratification due 
to samples originating from multiple countries in Europe, North America and Australia. 
However, the inclusion/exclusion criteria, as well as the bioinformatics and biostatistics 
measures used to filter samples have been extremely stringent in order to select the best 
possible samples for final inclusion in analysis. 
Although this was not the first GWAS on FTD, given a previous study of pathologically 
confirmed FTLD-TDP (n=515) [41], our study included a large number of clinical FTLD 
cases (n>5,000 samples) comprising the subtypes bvFTD, SD, PNFA and FTD-MND 
(Chapter 4), making this an extraordinarily unique study of this genre. 
Interestingly, none of the known FTD candidate loci reached genome-wide significance 
and this was, in fact, expected on one hand because all known MAPT and GRN mutation 
carriers were excluded from the study, eliminating or decreasing substantially the 
possible source of signal at 17q21 and, on the other hand, because, most possibly, all 
candidate genes and their risk alleles (including MAPT and GRN) were too rare within the 
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cohorts. This could also mean that those known candidate genes are rare causes of 
disease. 
The study resulted in the identification of novel loci associated with disease: The two loci 
that reached genome-wide significance belonged to the bvFTD subtype (Chr11q14) and 
the whole cohort (Chr6p21.3), including all subtypes (bvFTD, SD, PNFA and FTD-
MND). Not only were the associations significant after statistical corrections, but also 
quantitative trait loci for the associated SNPs revealed effects on expression and/or 
methylation (Chapter 4, section 4.2.2.3). Although these loci will need to be further 
investigated they hint at possible disease mechanisms involved in FTD. 
First, data point to lysosomes and phagosomes as two cellular compartments to be, from 
now on, considered as possibly involved in the pathogenesis of FTD and to be further 
investigated in both computational and functional studies; second, data suggest an 
involvement of the immune system in the development of disease. 
Our study confirms previous hypotheses and provides new insights: 
1 – Lysosomes have been suggested to play a role in FTD in association with GRN and 
TMEM106B variability. Our data not only support this hypothesis but clearly enhance 
and expand such notion including new genes within this picture, and; 
2 – The immune system has been associated with several forms of neurodegenerative 
diseases and ours is the first report that indicates its likely involvement also in FTD. 
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In summary, these results are promising in two ways: On one hand, they highlight two 
mechanisms to be further investigated in the next years in order to understand their 
relation to FTD and, on the other, in turn, they provide unprecedented and critical 
information on possible disease mechanisms(s) to be studied and targeted for the 
development of therapeutic measures. At the same time, if disease mechanism(s) are 
elucidated not only treatment but also preventive options for FTD are likely to be 
established. 
 
6.1.2.2 Candidate genes screening 
The study of familial and sporadic FTD cases helped in further characterising the main 
FTD candidate genes and associating genetic variability with phenotype. Each study 
provided novel insight into the genetics of the disease (summarised in Chapter 5, section 
5.3). Probably the main and most surprising outcome of this study is that it contradicts 
previous reports of pathogenicity of some variants. This may be due to variable 
penetrance and underlines the need to revisit previous genetic studies of TDP-43, 
CHMP2B and FUS, especially. 
It is fundamental to continue characterising the known candidate genes in more cohorts 
not only to expand on genotype-phenotype correlation, but also to better characterise the 
incidence, prevalence and geographical distribution of the disease due to variability in 
these genes. 
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6.2 Future directions 
Neurodegenerative diseases are insidious at onset and, generally, diagnosed when the 
patient is already years into disease. 
This fact highlights probably the most critical issue associated with neurological 
disorders, i.e. the lack of biomarkers for detecting the disease at an early stage. In 
addition to that, preventive (upstream) and therapeutic (downstream) measures are still 
completely lacking in this field. Insights from the clinical, neuropsychological, 
neuroimaging and neuropathological perspectives, together with the increasing 
knowledge of the genetic underpinnings of disease, have undoubtedly led to ground-
breaking advancements in the characterisation of neurodegenerative diseases. However, 
such knowledge has not been sufficient to date to address any of the aforementioned 
pressing issues. 
It needs to be stated that, in the attempt of dissecting the aetiology of these diseases, one 
crucial point to keep in mind is that they are complex and multifactorial, i.e. the result of 
cumulative processes to which many factors contribute. The pathogenesis of complex 
disorders is, in fact, determined by the interplay between several elements including a 
gamut of genetic factors with different degrees of penetrance influenced by epigenetic 
and environmental factors. This not only suggests that it is recommended to critically 
combine and interpret the enormous and ever growing data, but also that it is warranted to 
expand the investigations to new fields in order to combine different fields of expertise 
and generate more innovative body of knowledge. 
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Thus, the investigation of neurodegenerative disorders will considerably benefit from the 
implementation of a multi-faceted approach based on the: 
1 – Assessment of clinical (a) and neuropathological (b) features associated with disease 
to describe: 
a – The clinical syndromes, the physical/neuropsychological features and the 
associated neuroimaging profile; 
b – The atrophy patterns and associated functional loss, and the molecular 
pathology; 
2 – Assessment of the genetics associated with disease through GWAS (c), WES (d) and 
WGS (e) approach to identify: 
c – Loci (specific genetic regions) associated with disease, i.e. genes as well as 
non-coding regions to be further investigated; 
d – Coding variants associated with disease, i.e. rare coding variants affecting the 
proteasome; 
e – Coding and non-coding single nucleotide and structural variations hidden in 
the genome, i.e. rare coding/non-coding SNVs as well as SVs affecting the 
transcriptome and the proteome;  
3 – Assessment of transcriptome and proteome including the investigation of effects 
exerted by modifying factors such as regulatory elements and environmental factors, 
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and/or modifying mechanisms such as epigenetics and epistasis to evaluate effects on 
expression patterns, splicing processes and determine their impact on pathways that may 
underlie/lead to disease;  
4 – Implementation of bioinformatics and biostatistics tools to improve and facilitate 
large scale computational analyses including functional genomics and pathway analyses 
to further examine and integrate data generated by the aforementioned different fields of 
expertise and identify potential disease-associated pathways/mechanisms, and; 
5 – Design of pertinent functional studies aimed at validating and characterising, in vitro 
and in vivo, the computational findings, i.e. the pathogenic pathways and mechanisms 
leading to neuronal death and neurodegeneration. 
 
This approach and these integrative steps will be fundamental in order to shed light on 
the disease-associated molecular underpinnings to be targeted for the development of 
measures to ensure effective early diagnostic/preventive and treatment options. 
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Appendices 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Appendix 2-1. Comparison of genotypes: Genome amplified vs. genomic DNA 
General call rates barely reached 85% for the genome amplified samples. Cross-check of 
a sample of ~ 1000 SNPs – of which 424 overlapping between OMNI and 660K revealed 
average accuracy of calls of ~89-90% and miscalls of ~10-11% of which ~8-9% no calls 
and ~2% wrong calls. 
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[Header] [Header]
GSGT Version 1.9.4 GSGT Version 1.9.4
Processing Date 7/18/2012 13:34 Processing Date 7/18/2012 14:53
Content HumanOmniExpress-12v1_H.bpm Content
Human660W-
Quad_v1_A.bp
m
Num SNPs 1060 Num SNPs 701
Total SNPs 730525 Total SNPs 657366
Num Samples 12 Num Samples 11
Total Samples 12 Total Samples 175
[Data] [Data]
Problem
Sample ID SNP Name Allele1 Allele2 Sample ID SNP Name Allele1 Allele2
FTD001 rs1000000 C C Riem-001 rs1000000 C C
FTD001 rs10000023 T T Riem-001 rs10000023 T T
FTD001 rs10000030 A G Riem-001 rs10000030 A G
FTD001 rs10000041 T T Riem-001 rs10000041 T T
FTD001 rs1000007 A A Riem-001 rs1000007 A A
FTD001 rs10000081 T T Riem-001 rs10000081 T T
FTD001 rs10000092 T C Riem-001 rs10000092 T C
FTD001 rs1000016 A A Riem-001 rs1000016 A A
FTD001 rs10000160 G G Riem-001 rs10000160 G G
FTD001 rs10000169 T C Riem-001 rs10000169 T C
FTD001 rs10000185 T C Riem-001 rs10000185 T C
FTD001 rs1000022 T C Riem-001 rs1000022 T C
FTD001 rs10000226 T C Riem-001 rs10000226 T C
FTD001 rs10000255 T C Riem-001 rs10000255 C C WRONG CALL
FTD001 rs10000266 T C Riem-001 rs10000266 T C
FTD001 rs10000272 T C Riem-001 rs10000272 T C
FTD001 rs10000282 C C Riem-001 rs10000282 C C
FTD001 rs10000300 T G Riem-001 rs10000300 T G
FTD001 rs1000031 C C Riem-001 rs1000031 C C
FTD001 rs1000032 C C Riem-001 rs1000032 C C
FTD001 rs10000388 T C Riem-001 rs10000388 T C
FTD001 rs1000040 A A Riem-001 rs1000040 A A
FTD001 rs1000041 G G Riem-001 rs1000041 G G
FTD001 rs10000432 T C Riem-001 rs10000432 T C
FTD001 rs10000435 T C Riem-001 rs10000435 T C
FTD001 rs10000438 T C Riem-001 rs10000438 T C
FTD001 rs10000456 T T Riem-001 rs10000456 T T
Genome amplified samples Genomic DNA samples
369
368
FTD001 rs10000471 T C Riem-001 rs10000471 T C
FTD001 rs10000487 A A Riem-001 rs10000487 A A
FTD001 rs1000050 T C Riem-001 rs1000050 T C
FTD001 rs10000538 T C Riem-001 rs10000538 T C
FTD001 rs10000543 - - Riem-001 rs10000543 C C NO CALL
FTD001 rs1000055 C C Riem-001 rs1000055 C C
FTD001 rs10000595 C C Riem-001 rs10000595 C C
FTD001 rs1000061 A G Riem-001 rs1000061 A G
FTD001 rs1000068 A G Riem-001 rs1000068 A G
FTD001 rs10000708 G G Riem-001 rs10000708 G G
FTD001 rs1000071 G G Riem-001 rs1000071 G G
FTD001 rs10000719 - - Riem-001 rs10000719 T T NO CALL
FTD001 rs1000073 T T Riem-001 rs1000073 T T
FTD001 rs10000762 C C Riem-001 rs10000762 C C
FTD001 rs1000079 T C Riem-001 rs1000079 T C
FTD001 rs1000083 C C Riem-001 rs1000083 C C
FTD001 rs10000918 A A Riem-001 rs10000918 A A
FTD001 rs1000094 T T Riem-001 rs1000094 T T
FTD001 rs10000959 T T Riem-001 rs10000959 T T
FTD001 rs10000976 T C Riem-001 rs10000976 T C
FTD001 rs1000104 A C Riem-001 rs1000104 A C
FTD001 rs10001148 A G Riem-001 rs10001148 A G
FTD001 rs1000115 T C Riem-001 rs1000115 T C
FTD001 rs10001154 T C Riem-001 rs10001154 T C
FTD001 rs10001188 G G Riem-001 rs10001188 G G
FTD001 rs10001198 - - Riem-001 rs10001198 G G NO CALL
FTD001 rs1000121 - - Riem-001 rs1000121 T T NO CALL
FTD001 rs10001214 T C Riem-001 rs10001214 T C
FTD001 rs10001236 - - Riem-001 rs10001236 G G NO CALL
FTD001 rs10001280 G G Riem-001 rs10001280 G G
FTD001 rs10001348 A A Riem-001 rs10001348 A A
FTD001 rs1000137 T C Riem-001 rs1000137 T C
FTD001 rs10001385 T T Riem-001 rs10001385 T T
FTD001 rs1000140 T C Riem-001 rs1000140 T C
FTD001 rs1000141 A G Riem-001 rs1000141 A G
FTD001 rs10001415 T T Riem-001 rs10001415 T T
FTD001 rs10001462 G G Riem-001 rs10001462 G G
FTD001 rs10001478 G G Riem-001 rs10001478 G G
FTD001 rs10001480 C C Riem-001 rs10001480 C C
FTD001 rs10001483 A A Riem-001 rs10001483 A A
FTD001 rs10001495 A G Riem-001 rs10001495 A G
370
369
FTD001 rs1000152 T T Riem-001 rs1000152 T T
FTD001 rs10001565 C C Riem-001 rs10001565 C C
FTD001 rs10001577 T C Riem-001 rs10001577 T C
FTD001 rs10001580 A A Riem-001 rs10001580 A A
FTD001 rs100016 A G Riem-001 rs100016 A G
FTD001 rs10001608 T C Riem-001 rs10001608 T C
FTD001 rs10001613 A A Riem-001 rs10001613 A A
FTD001 rs10001638 T T Riem-001 rs10001638 T T
FTD001 rs10001657 A A Riem-001 rs10001657 A A
FTD001 rs10001661 A G Riem-001 rs10001661 A G
FTD001 rs10001689 - - Riem-001 rs10001689 T G NO CALL
FTD001 rs10001694 - - Riem-001 rs10001694 A A NO CALL
FTD001 rs10001729 G G Riem-001 rs10001729 G G
FTD001 rs1000174 G G Riem-001 rs1000174 G G
FTD001 rs10001776 A G Riem-001 rs10001776 A G
FTD001 rs10001818 C C Riem-001 rs10001818 C C
FTD001 rs10001834 - - Riem-001 rs10001834 T G NO CALL
FTD001 rs10001851 C C Riem-001 rs10001851 C C
FTD001 rs10001877 C C Riem-001 rs10001877 C C
FTD001 rs1000198 T G Riem-001 rs1000198 T G
FTD001 rs10001989 G G Riem-001 rs10001989 G G
FTD001 rs10002028 T T Riem-001 rs10002028 T T
FTD001 rs10002068 G G Riem-001 rs10002068 G G
FTD001 rs10002121 A G Riem-001 rs10002121 A G
FTD001 rs10002142 A C Riem-001 rs10002142 A C
FTD001 rs10002171 C C Riem-001 rs10002171 C C
FTD001 rs10002189 C C Riem-001 rs10002189 C C
FTD001 rs1000219 T G Riem-001 rs1000219 T G
FTD001 rs1000221 G G Riem-001 rs1000221 G G
FTD001 rs10002224 C C Riem-001 rs10002224 C C
FTD001 rs10002254 A G Riem-001 rs10002254 A G
FTD001 rs1000226 T C Riem-001 rs1000226 T C
FTD001 rs10002325 A A Riem-001 rs10002325 A A
FTD001 rs1000236 A G Riem-001 rs1000236 A G
FTD001 rs10002388 A A Riem-001 rs10002388 A A
FTD001 rs10002393 T T Riem-001 rs10002393 T T
FTD001 rs10002472 A A Riem-001 rs10002472 A A
FTD001 rs1000251 G G Riem-001 rs1000251 G G
FTD001 rs1000255 T T Riem-001 rs1000255 T T
FTD001 rs1000256 T T Riem-001 rs1000256 T T
FTD001 rs10002573 T T Riem-001 rs10002573 T T 371
370
FTD001 rs10002598 C C Riem-001 rs10002598 C C
FTD001 rs1000264 A G Riem-001 rs1000264 A G
FTD001 rs10002688 A G Riem-001 rs10002688 A G
FTD001 rs10002695 C C Riem-001 rs10002695 C C
FTD001 rs1000270 - - Riem-001 rs1000270 A C NO CALL
FTD001 rs10002703 G G Riem-001 rs10002703 G G
FTD001 rs1000272 C C Riem-001 rs1000272 C C
FTD001 rs10002743 A A Riem-001 rs10002743 A A
FTD001 rs10002760 T C Riem-001 rs10002760 T C
FTD001 rs1000280 A G Riem-001 rs1000280 A G
FTD001 rs10002811 - - Riem-001 rs10002811 T T NO CALL
FTD001 rs10002842 C C Riem-001 rs10002842 C C
FTD001 rs1000286 C C Riem-001 rs1000286 C C
FTD001 rs1000290 A A Riem-001 rs1000290 A A
FTD001 rs10002917 T C Riem-001 rs10002917 T C
FTD001 rs10002965 C C Riem-001 rs10002965 C C
FTD001 rs10002981 A A Riem-001 rs10002981 A A
FTD001 rs1000299 G G Riem-001 rs1000299 G G
FTD001 rs10003025 T C Riem-001 rs10003025 T C
FTD001 rs10003040 T C Riem-001 rs10003040 C C WRONG CALL
FTD001 rs1000308 G G Riem-001 rs1000308 G G
FTD001 rs10003106 G G Riem-001 rs10003106 G G
FTD001 rs1000313 G G Riem-001 rs1000313 G G
FTD001 rs10003143 A C Riem-001 rs10003143 A C
FTD001 rs10003194 A A Riem-001 rs10003194 A A
FTD001 rs1000320 T T Riem-001 rs1000320 T T
FTD001 rs10003214 C C Riem-001 rs10003214 C C
FTD001 rs10003271 G G Riem-001 rs10003271 G G
FTD001 rs10003327 A A Riem-001 rs10003327 A A
FTD001 rs10003330 A A Riem-001 rs10003330 A A
FTD001 rs10003349 A A Riem-001 rs10003349 A A
FTD001 rs10003420 A A Riem-001 rs10003420 A A
FTD001 rs10003467 T C Riem-001 rs10003467 T C
FTD001 rs10003471 C C Riem-001 rs10003471 C C
FTD001 rs10003496 A A Riem-001 rs10003496 A A
FTD001 rs10003497 A G Riem-001 rs10003497 A G
FTD001 rs10003585 T T Riem-001 rs10003585 T T
FTD001 rs10003606 G G Riem-001 rs10003606 G G
FTD001 rs10003638 A A Riem-001 rs10003638 A A
FTD001 rs10003688 - - Riem-001 rs10003688 A A NO CALL
FTD001 rs10003689 - - Riem-001 rs10003689 T T NO CALL
372
371
FTD001 rs1000374 G G Riem-001 rs1000374 G G
FTD001 rs10003746 T C Riem-001 rs10003746 T C
FTD001 rs10003762 A A Riem-001 rs10003762 A A
FTD001 rs10003777 A G Riem-001 rs10003777 G G WRONG CALL
FTD001 rs1000380 T T Riem-001 rs1000380 T T
FTD001 rs10003861 C C Riem-001 rs10003861 C C
FTD001 rs10003864 T T Riem-001 rs10003864 T T
FTD001 rs10003889 A A Riem-001 rs10003889 A A
FTD001 rs10003904 A A Riem-001 rs10003904 A A
FTD001 rs1000394 G G Riem-001 rs1000394 G G
FTD001 rs10003973 C C Riem-001 rs10003973 C C
FTD001 rs10003999 C C Riem-001 rs10003999 C C
FTD001 rs10004010 A A Riem-001 rs10004010 A A
FTD001 rs10004030 A A Riem-001 rs10004030 A A
FTD001 rs10004038 A A Riem-001 rs10004038 A A
FTD001 rs10004063 T T Riem-001 rs10004063 T T
FTD001 rs1000408 C C Riem-001 rs1000408 C C
FTD001 rs1000411 T T Riem-001 rs1000411 T T
FTD001 rs10004128 T C Riem-001 rs10004128 T C
FTD001 rs10004130 G G Riem-001 rs10004130 G G
FTD001 rs1000416 C C Riem-001 rs1000416 C C
FTD001 rs10004181 T C Riem-001 rs10004181 T C
FTD001 rs1000421 T T Riem-001 rs1000421 T T
FTD001 rs10004266 T C Riem-001 rs10004266 T C
FTD001 rs1000427 G G Riem-001 rs1000427 G G
FTD001 rs10004274 A A Riem-001 rs10004274 A A
FTD001 rs10004285 - - Riem-001 rs10004285 G G NO CALL
FTD001 rs1000433 G G Riem-001 rs1000433 G G
FTD001 rs10004397 A C Riem-001 rs10004397 A C
FTD001 rs10004437 A A Riem-001 rs10004437 A A
FTD001 rs10004440 G G Riem-001 rs10004440 G G
FTD001 rs10004459 G G Riem-001 rs10004459 G G
FTD001 rs10004475 T T Riem-001 rs10004475 T T
FTD001 rs1000449 A G Riem-001 rs1000449 A G
FTD001 rs10004500 C C Riem-001 rs10004500 C C
FTD001 rs10004503 C C Riem-001 rs10004503 C C
FTD001 rs10004516 G G Riem-001 rs10004516 G G
FTD001 rs10004523 A C Riem-001 rs10004523 C C WRONG CALL
FTD001 rs10004557 C C Riem-001 rs10004557 C C
FTD001 rs10004565 T T Riem-001 rs10004565 T T
FTD001 rs1000459 C C Riem-001 rs1000459 C C
373
372
FTD001 rs10004643 A A Riem-001 rs10004643 A A
FTD001 rs1000465 C C Riem-001 rs1000465 C C
FTD001 rs1000466 T T Riem-001 rs1000466 T T
FTD001 rs10004753 T G Riem-001 rs10004753 T G
FTD001 rs10004765 C C Riem-001 rs10004765 C C
FTD001 rs10004776 - - Riem-001 rs10004776 T T NO CALL
FTD001 rs10004779 T G Riem-001 rs10004779 T G
FTD001 rs10004837 A G Riem-001 rs10004837 A G
FTD001 rs10004910 A G Riem-001 rs10004910 A G
FTD001 rs10004929 C C Riem-001 rs10004929 C C
FTD001 rs10004976 - - Riem-001 rs10004976 A A NO CALL
FTD001 rs10004988 C C Riem-001 rs10004988 C C
FTD001 rs1000499 G G Riem-001 rs1000499 G G
FTD001 rs1000505 A A Riem-001 rs1000505 A A
FTD001 rs10005058 A A Riem-001 rs10005058 A A
FTD001 rs1000507 C C Riem-001 rs1000507 C C
FTD001 rs10005074 T C Riem-001 rs10005074 T C
FTD001 rs1000510 - - Riem-001 rs1000510 A C NO CALL
FTD001 rs10005140 G G Riem-001 rs10005140 G G
FTD001 rs10005156 C C Riem-001 rs10005156 C C
FTD001 rs1000516 A G Riem-001 rs1000516 A G
FTD001 rs10005160 G G Riem-001 rs10005160 G G
FTD001 rs10005175 - - Riem-001 rs10005175 A A NO CALL
FTD001 rs1000521 A A Riem-001 rs1000521 A A
FTD001 rs10005242 G G Riem-001 rs10005242 G G
FTD001 rs10005281 A A Riem-001 rs10005281 A A
FTD001 rs1000530 - - Riem-001 rs1000530 C C NO CALL
FTD001 rs1000531 C C Riem-001 rs1000531 C C
FTD001 rs10005317 C C Riem-001 rs10005317 C C
FTD001 rs1000533 T C Riem-001 rs1000533 T C
FTD001 rs10005380 G G Riem-001 rs10005380 G G
FTD001 rs1000543 C C Riem-001 rs1000543 C C
FTD001 rs10005483 A G Riem-001 rs10005483 A G
FTD001 rs10005500 C C Riem-001 rs10005500 C C
FTD001 rs1000551 A G Riem-001 rs1000551 A G
FTD001 rs10005531 - - Riem-001 rs10005531 T G NO CALL
FTD001 rs10005550 A G Riem-001 rs10005550 G G WRONG CALL
FTD001 rs10005569 C C Riem-001 rs10005569 C C
FTD001 rs1000559 C C Riem-001 rs1000559 C C
FTD001 rs10005640 A A Riem-001 rs10005640 A A
FTD001 rs10005702 T T Riem-001 rs10005702 T T 374
373
FTD001 rs10005718 - - Riem-001 rs10005718 T T NO CALL
FTD001 rs1000574 - - Riem-001 rs1000574 C C NO CALL
FTD001 rs1000578 C C Riem-001 rs1000578 C C
FTD001 rs10005789 A G Riem-001 rs10005789 A G
FTD001 rs1000579 A A Riem-001 rs1000579 A A
FTD001 rs10005809 T T Riem-001 rs10005809 T T
FTD001 rs10005811 A A Riem-001 rs10005811 A A
FTD001 rs1000585 A G Riem-001 rs1000585 A G
FTD001 rs1000588 A A Riem-001 rs1000588 A A
FTD001 rs10005886 T T Riem-001 rs10005886 T T
FTD001 rs10005912 T T Riem-001 rs10005912 T T
FTD001 rs10005935 - - Riem-001 rs10005935 T G NO CALL
FTD001 rs10005962 C C Riem-001 rs10005962 C C
FTD001 rs10006044 - - Riem-001 rs10006044 A G NO CALL
FTD001 rs10006144 C C Riem-001 rs10006144 C C
FTD001 rs10006195 C C Riem-001 rs10006195 C C
FTD001 rs10006196 T C Riem-001 rs10006196 T C
FTD001 rs1000620 T C Riem-001 rs1000620 T C
FTD001 rs10006225 - - Riem-001 rs10006225 G G NO CALL
FTD001 rs10006242 A G Riem-001 rs10006242 A G
FTD001 rs10006245 A A Riem-001 rs10006245 A A
FTD001 rs10006257 C C Riem-001 rs10006257 C C
FTD001 rs10006308 - - Riem-001 rs10006308 A A NO CALL
FTD001 rs10006314 T T Riem-001 rs10006314 T T
FTD001 rs10006329 T T Riem-001 rs10006329 T T
FTD001 rs10006363 G G Riem-001 rs10006363 G G
FTD001 rs10006395 C C Riem-001 rs10006395 C C
FTD001 rs10006423 T T Riem-001 rs10006423 T T
FTD001 rs10006439 C C Riem-001 rs10006439 C C
FTD001 rs10006443 G G Riem-001 rs10006443 G G
FTD001 rs10006458 T T Riem-001 rs10006458 T T
FTD001 rs1000658 T T Riem-001 rs1000658 T T
FTD001 rs10006622 C C Riem-001 rs10006622 C C
FTD001 rs1000664 - - Riem-001 rs1000664 G G NO CALL
FTD001 rs10006644 G G Riem-001 rs10006644 G G
FTD001 rs1000672 - - Riem-001 rs1000672 G G NO CALL
FTD001 rs10006741 T C Riem-001 rs10006741 T C
FTD001 rs10006747 A G Riem-001 rs10006747 A G
FTD001 rs1000676 G G Riem-001 rs1000676 G G
FTD001 rs10006766 A A Riem-001 rs10006766 A A
FTD001 rs10006864 T T Riem-001 rs10006864 T T
375
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FTD001 rs10006892 A A Riem-001 rs10006892 A A
FTD001 rs1000691 G G Riem-001 rs1000691 G G
FTD001 rs10006955 T C Riem-001 rs10006955 T C
FTD001 rs10006997 T T Riem-001 rs10006997 T T
FTD001 rs1000703 A G Riem-001 rs1000703 A G
FTD001 rs10007066 G G Riem-001 rs10007066 G G
FTD001 rs10007083 A A Riem-001 rs10007083 A A
FTD001 rs10007197 C C Riem-001 rs10007197 C C
FTD001 rs10007205 T C Riem-001 rs10007205 T C
FTD001 rs10007245 T C Riem-001 rs10007245 T C
FTD001 rs1000726 A A Riem-001 rs1000726 A A
FTD001 rs1000727 C C Riem-001 rs1000727 C C
FTD001 rs1000730 - - Riem-001 rs1000730 G G NO CALL
FTD001 rs10007367 T T Riem-001 rs10007367 T T
FTD001 rs1000737 T C Riem-001 rs1000737 T C
FTD001 rs1000738 G G Riem-001 rs1000738 G G
FTD001 rs10007396 A A Riem-001 rs10007396 A A
FTD001 rs10007440 C C Riem-001 rs10007440 C C
FTD001 rs10007472 T T Riem-001 rs10007472 T T
FTD001 rs1000752 A A Riem-001 rs1000752 A A
FTD001 rs10007543 A A Riem-001 rs10007543 A A
FTD001 rs10007576 T C Riem-001 rs10007576 T C
FTD001 rs10007590 A A Riem-001 rs10007590 A A
FTD001 rs10007601 A G Riem-001 rs10007601 G G WRONG CALL
FTD001 rs10007635 T T Riem-001 rs10007635 T T
FTD001 rs10007704 C C Riem-001 rs10007704 C C
FTD001 rs10007707 A G Riem-001 rs10007707 A G
FTD001 rs1000772 C C Riem-001 rs1000772 C C
FTD001 rs10007743 A A Riem-001 rs10007743 A A
FTD001 rs1000775 - - Riem-001 rs1000775 A A NO CALL
FTD001 rs1000778 G G Riem-001 rs1000778 G G
FTD001 rs10007784 T T Riem-001 rs10007784 T T
FTD001 rs10007790 G G Riem-001 rs10007790 G G
FTD001 rs10007810 A G Riem-001 rs10007810 A G
FTD001 rs10007812 G G Riem-001 rs10007812 G G
FTD001 rs10007887 C C Riem-001 rs10007887 C C
FTD001 rs10007934 - - Riem-001 rs10007934 G G NO CALL
FTD001 rs10007938 A G Riem-001 rs10007938 A G
FTD001 rs1000797 C C Riem-001 rs1000797 C C
FTD001 rs10007998 C C Riem-001 rs10007998 C C
FTD001 rs10008006 A A Riem-001 rs10008006 A A
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FTD001 rs1000810 A A Riem-001 rs1000810 A A
FTD001 rs10008174 T G Riem-001 rs10008174 T G
FTD001 rs1000821 T C Riem-001 rs1000821 T C
FTD001 rs10008238 C C Riem-001 rs10008238 C C
FTD001 rs10008278 T C Riem-001 rs10008278 T C
FTD001 rs10008281 - - Riem-001 rs10008281 A C NO CALL
FTD001 rs10008418 - - Riem-001 rs10008418 A G NO CALL
FTD001 rs10008442 G G Riem-001 rs10008442 G G
FTD001 rs10008462 G G Riem-001 rs10008462 G G
FTD001 rs10008492 C C Riem-001 rs10008492 C C
FTD001 rs1000850 G G Riem-001 rs1000850 G G
FTD001 rs1000858 C C Riem-001 rs1000858 C C
FTD001 rs10008587 T T Riem-001 rs10008587 T T
FTD001 rs10008621 C C Riem-001 rs10008621 C C
FTD001 rs10008623 A A Riem-001 rs10008623 A A
FTD001 rs10008636 T T Riem-001 rs10008636 T T
FTD001 rs10008679 T C Riem-001 rs10008679 T C
FTD001 rs10008710 T C Riem-001 rs10008710 - - NO CALL
FTD001 rs10008744 A A Riem-001 rs10008744 A A
FTD001 rs10008779 A C Riem-001 rs10008779 A C
FTD001 rs10008808 A G Riem-001 rs10008808 A G
FTD001 rs10008834 T T Riem-001 rs10008834 T T
FTD001 rs10008858 T C Riem-001 rs10008858 T C
FTD001 rs10008892 C C Riem-001 rs10008892 C C
FTD001 rs10008894 A G Riem-001 rs10008894 A G
FTD001 rs10008923 A G Riem-001 rs10008923 A G
FTD001 rs10008952 G G Riem-001 rs10008952 G G
FTD001 rs10008978 C C Riem-001 rs10008978 C C
FTD001 rs10008981 C C Riem-001 rs10008981 C C
FTD001 rs10009030 C C Riem-001 rs10009030 C C
FTD001 rs10009033 G G Riem-001 rs10009033 G G
FTD001 rs10009093 G G Riem-001 rs10009093 G G
FTD001 rs1000911 G G Riem-001 rs1000911 G G
FTD001 rs10009111 A G Riem-001 rs10009111 A G
FTD001 rs10009152 T T Riem-001 rs10009152 T T
FTD001 rs10009186 C C Riem-001 rs10009186 C C
FTD001 rs1000919 A G Riem-001 rs1000919 G G WRONG CALL
FTD001 rs10009221 A G Riem-001 rs10009221 A G
FTD001 rs10009228 A G Riem-001 rs10009228 A G
FTD001 rs10009253 T C Riem-001 rs10009253 T C
FTD001 rs10009269 C C Riem-001 rs10009269 C C
377
376
FTD001 rs1000927 A A Riem-001 rs1000927 A A
FTD001 rs10009272 T C Riem-001 rs10009272 T C
FTD001 rs1000933 T C Riem-001 rs1000933 T C
FTD001 rs10009342 T T Riem-001 rs10009342 T T
FTD001 rs10009368 T C Riem-001 rs10009368 T C
FTD001 rs1000939 G G Riem-001 rs1000939 G G
FTD001 rs10009448 A A Riem-001 rs10009448 A A
FTD001 rs10009456 T G Riem-001 rs10009456 T G
FTD001 rs10009464 C C Riem-001 rs10009464 C C
FTD001 rs1000950 A C Riem-001 rs1000950 A C
FTD001 rs10009522 T C Riem-001 rs10009522 T C
FTD001 rs10009533 G G Riem-001 rs10009533 G G
FTD001 rs10009566 T T Riem-001 rs10009566 T T
FTD001 rs10009607 T T Riem-001 rs10009607 T T
FTD001 rs1000962 - - Riem-001 rs1000962 A A NO CALL
FTD001 rs10009693 C C Riem-001 rs10009693 C C
FTD001 rs10009701 A G Riem-001 rs10009701 A G
FTD001 rs10009750 T T Riem-001 rs10009750 T T
FTD001 rs10009807 G G Riem-001 rs10009807 G G
FTD001 rs10009816 C C Riem-001 rs10009816 C C
FTD001 rs10009834 T T Riem-001 rs10009834 T T
FTD001 rs10009892 C C Riem-001 rs10009892 C C
FTD001 rs10009898 T C Riem-001 rs10009898 T C
FTD001 rs10009967 A G Riem-001 rs10009967 A G
FTD001 rs10009998 G G Riem-001 rs10009998 T G WRONG CALL
FTD001 rs10010069 T C Riem-001 rs10010069 T C
FTD001 rs10010106 A G Riem-001 rs10010106 A G
FTD001 rs10010115 T T Riem-001 rs10010115 T T
FTD001 rs10010188 - - Riem-001 rs10010188 C C NO CALL
FTD001 rs10010217 T C Riem-001 rs10010217 T C
FTD001 rs10010236 G G Riem-001 rs10010236 G G
FTD001 rs10010240 G G Riem-001 rs10010240 G G
FTD001 rs10010241 - - Riem-001 rs10010241 T T NO CALL
FTD001 rs10010285 T T Riem-001 rs10010285 T T
FTD001 rs1001034 C C Riem-001 rs1001034 C C
FTD001 rs10010346 T T Riem-001 rs10010346 T T
FTD001 rs10010358 - - Riem-001 rs10010358 A C NO CALL
FTD001 rs10010385 T T Riem-001 rs10010385 T T
FTD001 rs10010445 A G Riem-001 rs10010445 A G
FTD001 rs10010466 T T Riem-001 rs10010466 T T
FTD001 rs10010472 A G Riem-001 rs10010472 A G 378
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FTD001 rs1001049 A C Riem-001 rs1001049 A C
FTD001 rs10010505 G G Riem-001 rs10010505 G G
FTD001 rs10010565 C C Riem-001 rs10010565 C C
FTD001 rs10010623 G G Riem-001 rs10010623 G G
FTD001 rs10010638 C C Riem-001 rs10010638 C C
FTD001 rs1001073 G G Riem-001 rs1001073 G G
FTD001 rs10010758 T T Riem-001 rs10010758 T T
FTD001 rs1001098 T C Riem-001 rs1001098 T C
FTD001 rs1001099 T T Riem-001 rs1001099 T T
FTD001 rs10010994 A C Riem-001 rs10010994 A C
FTD001 rs10011007 A A Riem-001 rs10011007 A A
FTD001 rs1001110 T C Riem-001 rs1001110 C C WRONG CALL
FTD001 rs10011107 A A Riem-001 rs10011107 A A
FTD001 rs1001111 T T Riem-001 rs1001111 T T
FTD001 rs10011134 T C Riem-001 rs10011134 T C
FTD001 rs10011142 T C Riem-001 rs10011142 T C
FTD001 rs10011174 G G Riem-001 rs10011174 G G
FTD001 rs1001118 T C Riem-001 rs1001118 T C
FTD001 rs10011190 - - Riem-001 rs10011190 G G NO CALL
FTD001 rs1001120 C C Riem-001 rs1001120 C C
FTD001 rs10011202 A A Riem-001 rs10011202 A A
FTD001 rs1001131 A A Riem-001 rs1001131 A A
FTD001 rs10011351 A A Riem-001 rs10011351 A A
FTD001 rs10011402 T G Riem-001 rs10011402 T G
FTD001 rs1001145 A G Riem-001 rs1001145 A G
FTD001 rs10011452 C C Riem-001 rs10011452 C C
FTD001 rs1001148 T C Riem-001 rs1001148 T C
FTD001 rs1001149 T C Riem-001 rs1001149 T C
FTD002 rs1000000 C C Riem-002 rs1000000 C C
FTD002 rs10000023 T T Riem-002 rs10000023 T T
FTD002 rs10000030 - - Riem-002 rs10000030 A A NO CALL
FTD002 rs10000041 T T Riem-002 rs10000041 T T
FTD002 rs1000007 A A Riem-002 rs1000007 A A
FTD002 rs10000081 T T Riem-002 rs10000081 T T
FTD002 rs10000092 T T Riem-002 rs10000092 T T
FTD002 rs1000016 A A Riem-002 rs1000016 A A
FTD002 rs10000160 G G Riem-002 rs10000160 G G
FTD002 rs10000169 C C Riem-002 rs10000169 C C
FTD002 rs10000185 T C Riem-002 rs10000185 T C
FTD002 rs1000022 T C Riem-002 rs1000022 T C
379
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 Appendix 2-2. Discovery phase: Phenotype data collection 
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 Appendix 2-3. Replication phase: Phenotype data collection 
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 Appendix 2-4. NDPT098 Coriell plate 
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46 Males/46 Females
Ref Well Number blank well for user control
ND08998 A01
ND10875 A02
ND06787 A03
ND11515 A04
ND08394 A05
ND03937 A06
ND09880 A07
ND02206 A08
ND05808 A09
ND10728 A10
ND05414 A11
ND02747 A12
ND07950 B01
ND05771 B02
ND10393 B03
ND09830 B04
ND05008 B05
ND08492 B06
ND06434 B07
ND05684 B08
ND05682 B09
ND05899 B10
ND09791 B11
ND07536 B12
ND01680 C01
ND10977 C02
ND06350 C03
ND06432 C04
ND10275 C05
ND10864 C06
ND10769 C07
ND10827 C08
ND08240 C09
ND10496 C10
ND05653 C11
ND10297 C12
ND05900 D02
ND10541 D03
ND06362 D04
ND06234 D05
ND01789 D06
ND09589 D07
ND08978 D08
ND10876 D09
ND10743 D1
NDPT098: Neurologically Normal Caucasian Control Plate
Age Range at Time of Collection: 56-91
Control Individuals
(Replaces NDPT022)
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ND07112 D10
ND05295 D11
ND03927 D12
ND04237 E01
ND09957 E02
ND09939 E03
ND07615 E04
ND07427 E05
ND09579 E06
ND05868 E07
ND07423 E08
ND10897 E09
ND06235 E10
ND10529 E11
BLANK E12
ND03363 F01
ND12254 F02
ND07980 F03
ND10906 F04
ND10896 F05
ND06010 F06
ND06232 F07
ND07300 F08
ND05981 F09
ND06228 F10
ND07535 F11
BLANK F12
ND07105 G01
ND08927 G02
ND07048 G03
ND06351 G04
ND08955 G05
ND06026 G06
ND07428 G07
ND08079 G08
ND10469 G09
ND06855 G10
ND09671 G11
BLANK G12
ND05501 H01
ND06756 H02
ND05997 H03
ND09777 H04
ND08059 H05
ND10189 H06
ND10655 H07
ND05809 H08
ND09789 H09
ND10668 H10
ND10577 H11
BLANK H12
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 Appendix 2-5. NABEC and UKBEC 
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NABEC and UKBEC members:  
Group First Name Middle Surname Affiliation 1 Affiliation 2 
NABEC Andrew B Singleton Laboratory of Neurogenetics, National Institute on 
Aging, National Institutes of Health, Bethesda, MD, USA  
NABEC Mark R Cookson Laboratory of Neurogenetics, National Institute on 
Aging, National Institutes of Health, Bethesda, MD, USA  
NABEC J. Raphael  Gibbs Laboratory of Neurogenetics, National Institute on 
Aging, National Institutes of Health, Bethesda, MD, USA Reta Lila Weston Institute and 
Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 
3BG, UK 
NABEC Dena G Hernandez Laboratory of Neurogenetics, National Institute on 
Aging, National Institutes of Health, Bethesda, MD, USA Reta Lila Weston Institute and 
Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 
3BG, UK 
NABEC Allissa  Dillman Laboratory of Neurogenetics, National Institute on 
Aging, National Institutes of Health, Bethesda, MD, USA Department of Neuroscience, 
Karolinska Institutet, 171 77 Stockholm, Sweden 
NABEC Michael A Nalls Laboratory of Neurogenetics, National Institute on 
Aging, National Institutes of Health, Bethesda, MD, USA  
NABEC Alan B Zonderman Research Resources Branch, National Institute on Aging, 
National Institutes of Health, Bethesda, MD, USA  
NABEC Sampath  Arepalli Laboratory of Neurogenetics, National Institute 
on Aging, National Institutes of Health, Bethesda, MD, USA  
NABEC Luigi  Ferrucci Clinical Research Branch, National Institute on Aging, 
Baltimore, MD, USA  
NABEC Robert  Johnson NICHD Brain and Tissue Bank for Developmental 
Disorders, University of Maryland Medical School, Baltimore, Maryland 21201, USA  
NABEC Dan L Longo Lymphocyte Cell Biology Unit, Laboratory of Immunology, 
National Institute on Aging, National Institutes of Health, Baltimore, MD, USA  
NABEC Richard  O'Brien Brain Resource Center, Johns Hopkins University, Baltimore, 
MD, USA  
NABEC Bryan  Traynor Laboratory of Neurogenetics, National Institute on Aging, 
National Institutes of Health, Bethesda, MD, USA  
387
387
NABEC Juan  Troncoso Brain Resource Center, Johns Hopkins University, 
Baltimore, MD, USA  
NABEC Marcel  van der Brug Laboratory of Neurogenetics, National Institute on 
Aging, National Institutes of Health, Bethesda, MD, USA ITGR Biomarker Discovery Group, 
Genentech, South San Francisco, CA, USA 
NABEC Ronald H Zielke NICHD Brain and Tissue Bank for Developmental Disorders, 
University of Maryland Medical School, Baltimore, Maryland 21201, USA  
UKBEC John  Hardy Reta Lila Weston Institute and Department of Molecular 
Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK  
UKBEC Michael E Weale Department of Medical and Molecular Genetics, King s 
College London, 8th Floor, Tower Wing, Guy s Hospital, London SE1 9RT, UK  
UKBEC Mina  Ryten Reta Lila Weston Institute and Department of Molecular 
Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK  
UKBEC Adaikalavan  Ramasamy Department of Medical and Molecular Genetics, 
King s College London, 8th Floor, Tower Wing, Guy s Hospital, London SE1 9RT, UK Reta Lila 
Weston Institute and Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, 
London WC1N 3BG, UK 
UKBEC Daniah  Trabzuni Reta Lila Weston Institute and Department of Molecular 
Neuroscience, UCL Institute of Neurology, Queen Square, London WC1N 3BG, UK Department of 
Genetics, King Faisal Specialist Hospital and Research Centre, PO Box 3354, Riyadh 11211, Saudi 
Arabia 
UKBEC Colin  Smith Department of Neuropathology, MRC Sudden Death Brain Bank 
Project, University of Edinburgh, Wilkie Building, Teviot Place, Edinburgh EH8 9AG  
UKBEC Robert  Walker Department of Neuropathology, MRC Sudden Death Brain Bank 
Project, University of Edinburgh, Wilkie Building, Teviot Place, Edinburgh EH8 9AG  
388
388
 Appendix 4-1. FTD-GWAS: Initial questionnaire 
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General questions for the collaborators for the WGA about their samples. We will need to check 
if the quality of their information is enough detailed.  
Also prepare an excel file for specific questions. 
 
1. Information about the patient: do they know where exactly the patient comes from (to see 
if the patients could be distantly related)? What is their geography? 
2. Information about experiments performed on the samples: 
- MAPT: sequenced for exons 1, 9, 10, 11, (12), 13? 
 Gene dosage? 
- PGRN: sequenced for exons 1,-, 12? 
 Gene dosage? 
- CHMP2B: sequenced for exons 1,-, 6 (John suggests that from what is known from 
the literature it is not worth it anymore to check on exons 1, 2, 3, 4). 
- Haplotype genotyping 
3. Information on the diagnosis for sporadic cases: 
- Behavioral variant 
- Semantic dementia 
- Progressive non-fluent aphasia 
- FTD/MND/ALS 
- FTD not further described 
4. Information on the pathology for sporadic cases: 
- Tangle? (cases not sent to UPENN) 
- TDP43? (cases not sent to UPENN) 
- Ubiquitin-positive inclusions? (cases not sent to UPENN) 
5. Information on the familial cases; do they show; 
- MAPT mutations? 
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- PGRN mutations 
- CHMP2B mutations? 
- Other familial cases? 
 
After having received the information by phone we will send out an excel file to cover all the 
details.  
We will send bar coded 96 wells plates to the collaborative groups with 4 blanks (so that we 
know what the direction of the plate is).  
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Minutes/slide 
 
 
Slide1 
 
Names and contacts of the people leading the WGA-FTD project are shown to acknowledge the 
attendants 
 
Slide2 
 
The 1) list of the collaborative groups taking part of the project so far and 2) the number of samples that 
are going to be collected for initial screening are displayed for everyone to have an idea about who is 
involved. John acknowledges the attendants that there is a verbal confirmation for funding of the study 
and genotyping of  ≥ 3000 samples. Also he says that there is availability of a large amount of control data 
for samples coming from UK, USA and ITALY and there is less data available from other European 
countries like BELGIUM, GERMANY, NETHERLANDS, DENMARK, SWEDEN and SPAIN. 
 
Slide3 
 
Summarizes the main issues to be discussed: 
 
a.       Sample quality and sample shipping 
b.       Diagnostic criteria and extra clinical information 
c.       The genotyping and analysis of samples with mutations 
d.     The genotyping and analysis of more than one sample from the same pedigree. 
e. Data availability  
  
Slide4 
 
Point a. is discussed: John says that if we are going to do chipping only 2ug of DNA are going to be 
enough. The amount of DNA should be increased up to at least 5ug if also sequencing is going to be 
performed. Andy says that first he will need to prepare the IRB for permission to collect the samples, 
process that would take, more or less, 3-4 months. 
John says that the time frame to collect samples should be between now and January 2010. 
The mailing contact of Cynthia Crews is shown. 
 
PM&RF 
As of the meeting we think it is clear that we will need 2ug DNA for Genotyping or 5ug if we decide to 
perform sequencing. We should decide if we want to do sequencing for the samples involved in the study 
before the genotyping (fill the gaps for those samples that have not been screened yet) and if yes what 
genes (TAU, PGRN, FUS, TAU haplotype and ApoE genotype?). 
In that case people should then prepare 2 aliquotes: 1) with 2ug for genotyping  to  be  sent  to  Andy’s lab 
and 2) with 3ug for sequencing to be shipped to our lab in Texas. So we can do the sequencing before and 
after genotyping.  
 
 
Slide5 
 
Point b. is discussed: John summarizes that we should consider the Neary criteria for diagnosis 
considering enrollable patients those with Behavioural variant, language variant (semantic dementia, 
393
393
progressive non fluent aphasia), and maybe FTD-MND. John says that also imaging (MRI, SPEC [single-
photon emission computed tomography], FDG-PET) is considered as a good diagnostic tool. 
Diagnosis: we had some controversial views on how to manage this issue, in fact some attendants were 
keen on reviewing the cases with a novel agreed upon set of criteria some were not. Neary criteria plus 
imaging (if available) should be followed/used to identify clinical characteristics of the samples/patients. 
Rohrer said that trying to collect all these information is time consuming (time is money) and that some 
groups might have more information than others and there would be discrepancies in the type and amount 
of available clinical data. Vivianna says that MRI/PET SCAN would raise the quality of the clinical 
information. Mackenzie was wondering how much an accurate diagnosis would influence the study since 
FTD will mainly be BV and PNFA. Neil said that in any way it would be good if every group would add 
most possible clinical data for their samples and Andy agreed that it would be good to know a priori the 
characteristics of the samples to refine genotyping and statistical analysis.  
As a conclusion for this section it was agreed to keep CBS/CBD samples out of the study. Also, autopsy 
cases are accepted for enrollment. It was suggested to have a meeting between physicians to further 
discuss and define clinical criteria. Right now we would go by Neary criteria (should we include FTD-
MND?). For clinical data it would be good, if possible, to include neuropsychology, imaging and 
pathology. But, in the end, as a minimum, for enrollment, the Neary criteria should be met. 
 
Slide6 
 
Point c. and d. are discussed:  
c. John emphasizes that the first important question regards whether to include or not those samples with 
mutations. Further what mutations do we need to care about? TAU, PGRN, CHMP2B, VCP, TDP-43, 
FUS? John said that it would be helpful that every group would share the sequencing analysis results for 
the samples they want to share for the project. Vivianna says that probably not all the groups will have 
sequencing data available for all the samples they want to share and that it would be good to have an idea 
of what has been sequenced per group. 
Rosa said that in case we care about the sequencing data we should only worry about TAU and PGRN. 
Based on Van Broeckhoven suggestions, only samples with no variants in TAU and PGRN should be 
genotyped. 
At the end of the discussion it was proposed to have at least sequencing data available for TAU and 
PGRN. 
 
PM&RF 
We think that it would be important to include mutation carriers in the study and divide the samples for 
genotyping into 2 groups: 1) mutation carriers and 2) non mutation carriers. It would be an internal 
control and a tool to compare the results at the end of genotyping.  
 
If John agrees Raf can start screening of the samples which have not been sequenced for TAU, PGRN, 
FUS, TAU haplotype and ApoE genotype as soon as the samples are available. If John wants to do so, 
Parastoo will submit the IRB protocol soon. 
We think that before starting genotyping we should have a clear sequencing characterization. It is 
understandable that doing the sequencing is time consuming and that some labs might even not be able to 
perform those experiments. The DNA can be shipped to us in Texas for sequencing purposes. Raf can do 
all the necessary sequencing: our lab is well equipped, we have PCR machines and 3730XL and every 
other equipment necessary for sequencing. Our sequencing protocol is highly standardized and efficient. 
So genotyping will be performed at NIH, while sequencing could all be performed at Texas Tech. We 
have developed protocols for gene dosage for TAU and PGRN that we could perform if necessary (we do 
it for all of our samples).              
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d. Big question to be answered here is whether we want to include or not family members of the proband. 
John says NO, we should not, unless we want to produce linkage data and also Amalia Bruni said that 
linkage could be useful. A final decision on that is pending. 
 
Slide7-8 
 
Data analysis and data availability. The last two slides have been presented but not deeply discussed. For 
now the analysis will regard association, maybe long haplotype analysis (for founders), sequencing after 
loci will be (hopefully) identified and experiments for deletions and gene duplications. It will also be 
interesting to consider the results of the van Deerlin study (TDP-43 WGA)/MND and PSP(Schellenberg 
WGA)/AD misdiagnosis studies (?). 
Data could be made available through dbGAP that, Andy said,will need 6-9 months to be prepared. In this 
case everyone of the groups could be able to check for their updated data online at anytime. Important is 
to communicate when results are close to be delivered and discuss results by conference calls and 
eventually meetings prior to data analysis.  
  
GENERAL COMMENTS. 
  
Rosa said that we could delay the start date of the project in our request for money to have time to do the 
IRB and collect the samples. 
 
John said that he wants to create a Google doc to communicate and share information/files between 
groups. 
 
Van Broeckhoven said:  
1. Is money there or not yet?  
2. Speed up the process to get genotyping data as soon as possible.  
3. Focus on FTD and try to be sure to exclude AD  
4. Include samples showing no variants and no multiple samples from the same family 
5. Yes to most complete clinical data (MRI, SPEC, FDG-PET) if available 
6. What about money for follow up?  
 
Mackenzie gave his point of view for diagnosis and clinical information. He said that there should be a 
minimum of clinical information for the samples. He suggested having a meeting for physicians to 
identify the best minimum criteria to categorize the samples clinically and he suggested that neuro-
imaging and basic initial criteria should be used before beginning the study. 
 
The group of Italians who were present (A. Bruni, G. Rossi and G. Binetti) asked to develop general and 
universal inclusion/exclusion criteria for samples enrollment and for a copy of the Grant application so 
that they can do their IRB. Specifically A. Bruni said that she has problems in doing sequencing because 
she does not have an actual lab. So I told her for TAU and PGRN we can do sequencing for her in Texas 
(and  she  said  that  it  is  fine  but  she  wants  to  be  sure  legally  that  we  won’t  use  data  obtained  from  her  
samples to write our own papers [!!!!!]). She also said that it is not clear to her how to consider sporadic 
or  familial  cases  for  the  study….  Finally  she  said  that  she  has  well  characterized  clinical  data  
(neuropsychology, neuroimaging, etc) and that she thinks it would be good to write a legal agreement on 
how to manage data on the dbGAP (!!).  
 
TIME TABLE. 
 
1) Now to 3-4 months IRB approval at NIH and at Texas Tech University. 
2) Start collecting the samples at the two facilities. 
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  WGA 
Whole genome association studies (WGAs) represent a proven successful method for genotyping and for 
mapping novel common variants underlying common diseases. The requirements for successful GWAs 
can be summarized as follows: large cohort sizes, well-characterized phenotypes and, robust association 
and follow-up platforms. 
The Principal Investigator of the proposed study, Dr. John Hardy, organized an open meeting at the 
Rotterdam FTD meeting in September 2008 to promote the participation in the project of all centers that 
have been and are leaders in the investigation of Frontotemporal Dementia (FTD). 
 
FTD 
Frontotemporal Dementia (FTD) belongs to a wide spectrum of neurological disorders and is the focus of 
this study: FTD is the second or third most common cause of dementia in the developed world (depending 
on disease definitions). It is clinically, pathologically and genetically heterogeneous and presents with a 
frequency that increases with age. The clinical diagnosis of FTD relies on the presence of a progressive 
dementia together with variable initial features that can include behavioral changes, semantic problems or 
aphasia. FTD has been defined, clinicopathologically, by the presence of either TDP-43 or tau/tangle 
inclusions (1). Mutations in the 3 known genes (MAPT, PGRN and CHMP2B) explain many, but not all 
of the autosomal dominant cases and truncating mutations in PGRN (which is incompletely penetrant) 
explains a high proportion, though not all, of the familial cases. The clinical phenotype, as in most 
neurologic disorders, is variable due to the location and density of the lesions in the brain.   Four clinical 
subgroups of the syndrome have been characterized: 
1. Behavioural variant (50% of cases with evenly split tau and TDP-43 pathology);  
2. Semantic Dementia variant (20% of cases with usually TDP-43 pathology);  
3. Progressive nonfluent aphasia (20% of cases with largely tau pathology) and  
4. Cases with MND complications (10% of cases all with TDP-43 pathology). 
As of today, even if there has been tremendous progress in FTD genetics the role of genetic factors for 
common forms of FTD is still poorly understood. 
 
AIM 
The proposed study is the largest and most comprehensive GWA study for FTD to date.  
The major aim is to discover common genetic variants that influence disease risk, progression and 
variation.   
 
STUDY DESIGN 
Samples collection 
A large series of well characterized patients is expected to be collected (~3500 cases). This study will be 
based on a series of ongoing detailed clinical studies from nearly all the centers who have published on 
FTD in the last 5 years. 
Samples will be collected either in tubes (sent by the owner) or in 96 wells plates sent by the group 
organizing the study to be filled by the owner of samples and sent back by courier. Samples will be sent 
to and managed by Cynthia Crews, Building 35 Room 1A 1000 35 Lincoln Drive Bethesda MD20892 at 
NIH and by John Hardy and Raffaele Ferrari at UCL. 
Samples will be stored with a specific ID and a description of their main clinical, pathological and genetic 
known characteristics will be integrated. 
The samples are all of European-North American extraction. Whole genome amplified samples will not 
be used for the WGA. 
The amount of DNA requested will be varying between 2-5 µg. DNA will be used for genotyping in the 
initial phase of the study. In a second phase DNA will be used to perform sequencing, gene dosage and 
replicates. Unused DNA will be returned to the source. 
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Inclusion/exclusion criteria 
Clinically: samples will be collected based on the Neary Criteria. Clinical features as behavioral variant, 
language variant (semantic dementia, progressive non fluent aphasia) and FTD-MND will be considered 
as relevant for sample enrollment.  
Genetically: samples carrying mutations in MAPT and PGRN will be initially excluded from the study. 
Sporadic cases of FTD will be included in the study and, for familial cases, just one sample (index 
patient) will be included in the study. Samples should be characterized for MAPT haplotype, ApoE and 
MAPT/PGRN sequencing in pre-genotyping phase. 
Genetic screening: genotyping 
Illumina 610-660 Quad chips will be used for genotyping. Dr.  Hardy’s  group  has extensive experience in 
generating and handling the data from this robust and reliable platform. Control data are already available 
for this platform: the WTCCC data will be used for UK; own data on >2000 US controls (now publicly 
available at dbGAP) will be used for the US; own data generated on ~600 samples on the inCHIANTI 
study will be used for Italy; 50 control samples are available for Spain and more are going to be generated 
as part of our NIH intramurally funded whole genome study in ischaemic stroke.  Additionally, Swedish 
and German Illumina control data from other centers are available as well as the CEPH-Human Genome 
Diversity Panel. 
Analysis 
Polymorphisms with real effects will not necessarily have the lowest p values in the study, but may be 
hidden amongst many other polymorphisms that have similar or greater levels of association. The issue of 
false positives will be best addressed with replication and by increasing numbers of samples.  
Data cleaning: after gender and call quality checks, Eigenstrat will be used to assess whether cases and 
controls are matched. Cases or controls which are outliers won’t  be  used.  SNPs which have a minor allele 
frequency of <5% will be discarded. 
Primary analysis will be looking for additive associations using PLINK. The top 1,000 SNPs in the 
UPenn FTD, the MND and the PSP/CBD databases and those which replicate in any of the 3 other 
studies* (at p<0.01 for this stage alone) will be initially assessed. 
At this stage, also the SNPs which show putative association for their affects on gene expression, 
(particularly of the MAPT and TDP43 genes) as well as for cis effects on their own expression in the 
expression databases will be assessed. 
Because much of the control data is historical and because samples are of different ethnicities, association 
analysis will be arduous process and will probably show many apparent strong positives (due to chip 
differences). Several have shown up in previous analyses and thus easily identifiable; undoubtedly, there 
will be new ones which will need to be checked visually and bioinformatically. Unreliable associations 
will be discarded.  
Additional analyses: in datasets as rich as whole genome sets, there are also additional ways in which we 
may find risk genes for FTD.  1. homozygosity mapping since, even if in ostensibly outbred populations, 
a significant amount of autozygosity occurs (2): this approach could point to causative loci (3), 2. 
identification of insertions and deletions (an ataxia locus was recently found by this approach [4]) and 3. 
identification of long common haplotypes in affected individuals (5). There is a history of useful common 
founders in FTD syndromes: for example the occurrence of many families with a tau mutation and a 
common Welsh founder (6) and a common Belgian founder for many of the FTD kindreds with 
(inpenetrant) PGRN mutations (7). Data obtained by this study will be parsed to search for such common 
haplotypes. 
Database entry and management 
A central database (dbGAP) will be established. The db will contain age at onset, sex and centre codes 
together with the whole genome data set. Data collection and uploading will take approximately 6-9 
months. 
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EXPECTED OUTCOMES 
One of the major difficulties underlying complex disease is the presumed and likely heterogeneous nature 
of the disorder. One of the strengths of this consortium is the previous work by the applicants in their  
patient series to permit further analysis on subsets of the samples.   
We expect to identify novel loci relevant to disease onset and progression and, possibly, we will be 
able to begin understanding the genetic basis of the different subtypes of the disease. 
Finally, we expect this study to be also useful in enlightening on the mechanisms of cell death in 
Alzheimer’s   disease   (AD),   motor   neuron   disease   (MND)   and   progressive   supranuclear   palsy   (PSP)  
because FTD shares pathologic features with these diseases. 
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*  
The small majority of cases of FTD (TDP-43 pathology) has two replication series:  
 
(a) the WGA at UPenn on ~600 pathologically defined FTD cases which is also being run on an 
Illumina platform  (PI: Dr. Vivianna van Deerlin) 
(b) the collaborative WGA on motor neuron disease which we are part of: we have run ~3000 
MND samples from the US, Ireland, Italy and Finland on the Illumina platform (analysis is 
ongoing) and a collaborative group is being put together to perform a meta-analysis on ~7,000 
MND samples including ours by the (US) ALS Association which is due to be complete ~July 
2009.   
 
The large minority of cases of FTD has MAPT pathology has an immediately relevant replication series: 
 
(c) the collaborative whole genome analysis of progressive supranuclear palsy (1,200 samples) 
and corticobasal degeneration (140 samples) which is being run at UPenn (PI: Dr. Gerry 
Schellenberg).   
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FTD-GWAS – Montreal October 12, 2011 
 
Minutes 
 
 
Meeting started at 11:00AM EST-US time. Attendees were as follows: 
 
Attendees Centers 
Stuart Pickering-Brown University of Manchester, Clinical Neuroscience, Manchester, UK 
Rosa Rademakers  Mayo Clinic Jacksonville, Florida, USA 
Julie van der Zee, Ilse Gijselinck, Marc 
Cruts Department of Molecular Genetics, University of Antwerp, BELGIUM 
John van Swieten Department of Neurology, Erasmus Medical Center, Rotterdam, NETHERLANDS 
Pau Pastor, Oswaldo Lorenzo  Center for Applied Medical Research, Division of Neurology, University of Navarra, Pamplona, SPAIN 
Parastoo Momeni, Raffaele Ferrari Texas Tech University Health Sciences Center, Lubbock, Texas, USA 
Huei-hsin Chiang  Karolinska Institute, Department of NVS, Stokholm, SWEDEN 
Alexandra Dürr  French Consortium, FRANCE 
Riemenschneider Matthias Universität des Saarlandes, Klinikum für Psychiatrie & Psychotherapie, Homburg/Saar, GERMANY 
Andy Singleton, Mike Nalls, Bryan 
Traynor  Laboratory of Neurogenetics, NIA, NIH, Bethesda, MA, USA 
Carlos Cruchaga Dept. of Psychiatry, Washington University School of Medicine, St Louis, MO, USA 
John Hardy, Rita Guerreiro, Jose Bras Department of Molecular Neuroscience, Institute of Neurology, UCL, Queen's Square, London, UK 
 
John Hardy introduced the FTD-GWAS project mentioning, at first, the initial funding issues. In 2007 
the project was submitted to the Wellcome Trust UK, but, even if appreciated by the reviewing 
committee, it was not funded at the time. Afterwards, the project was presented at NINDS and was funded 
by Intramural funding through intercession of Story Landis and Andy Singleton. This allowed providing 
Illumina 660K chips to perform genotyping. Samples collection and genotyping was then split between 
the two facilities, University College of London (UCL) and National Institute of Health (NIH). Samples 
collection and genotyping happened between January 2010 and May 2011. John Hardy acknowledged 
Jonathan Rohrer for his help in defining clinical criteria for samples’ enrollment. John Hardy also 
mentioned that in July 2011 genotyping data were sent back to every individual group for them to start 
looking into their own cohorts and that, recently, 1. Raf Ferrari has checked for genotyping quality as 
well as for duplications/deletions in chromosome 17 (especially at the MAPT/PGRN loci) and 2. Mike 
Nalls has performed preliminary checks and analysis on the whole cohort. John Hardy finally mentioned 
that he would think of performing the analysis as a whole group, the FTD-Consortium, and that the FTD-
GWAS meeting in Montreal would be crucial for strategizing and planning the next steps of the project. 
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Then John Hardy introduced the first talk held by Raf Ferrari at ~ 11:30AM. 
 
INSERT  RAF’S  SLIDES  HERE 
 
During and after Raf’s  talk  some discussion points came up. John van Swieten asked what happened to 
1 plate that was sent from Amsterdam and that seemingly was not genotyped and Rosa Rademakers 
asked what happened to Ian Mackenzie’s  samples  as  they  were  not  shown  in  the slides. John Hardy’s  
answer was that we will need to double check internally. Another point that was briefly discussed was 
concerning the criteria for performing primary analysis: Julie van der Zee asked if we are going to 
include mutation carriers at all and Rosa Rademakers asked  how  will  Pick’s  – Tau – FUS pathology be 
considered in terms of analysis. John Hardy said that we are probably going to exclude mutation carriers 
even   though  we   don’t   know   about   all   samples   as  many   haven’t   been   screened   and,   yes, samples with 
pathology as above (corresponding to a clinical diagnosis falling between bvFTD, SD, PNFA and FTD-
MND) will be included. Mike Nalls said that all samples with diagnosis other than bvFTD, SD, PNFA 
and FTD-MND will need to be taken out from the study. John Hardy said that samples with the 
diagnosis of (or path confirmed) AD, PSP, CBS-CBD and, of course, normal controls will be fished out 
and excluded before actual primary analysis. Andy Singleton added, concerning replication phase, that it 
will depend on hits identified after primary analysis: 1. if hits will be found we will replicate those hits 
and  a  cohort  of  ≥  1,000 samples would suffice or 2. if  we  don’t  get  hits  we  should  consider  a  sample  size  
of  at  least  ≥  2,000  samples. Afterwards, Mike Nalls’ talk followed at ~ 12:00PM. 
 
INSERT MIKE’S  SLIDES  HERE 
 
From Mike Nalls’   talk   it   seemed   clear   that   there   were   some   issues   due   to   low   overlap   among   chips  
(decreasing  the  number  of  SNPs  to  ≤  300K to be used for analysis) and to population stratification. Mike 
Nalls said  that  even  if  we  had  ≤  300K  other  SNPs  could  be  imputed  through  1000  Genomes  with  a high 
chance of calling SNPs correctly (at the same level or even better than if those SNPs would have actually 
been genotyped). Though, the issue representing major concern was the population stratification and 
substructure problem. Mike Nalls showed that in the study population there are 3 substructures northern 
Europeans,  southern  and  “other  Europeans. Mike Nalls suggested to find a way to better match controls: 
this would mean to collect control samples and genotype them on a similar platform. This could help 
regarding the stratification problem but would mean putting more time and funding into this project, fact 
that, as of now, is not affordable (without forgetting that we’d  probably  lose  further  ~  300  samples). Mike 
Nalls suggested that we could match and stratify by ancestry. Finally, Mike Nalls said that, prior primary 
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analysis, we should define the phenotypes we want to included in the analysis, delete all the samples that 
have different diagnosis/pathology and, ideally, we would need to precisely match cases with controls in a 
ratio 1:3. Nonetheless, we should decide for a pooling vs. meta-analysis strategy.  
 
12:40PM: lunch. After lunch discussion on FTD-GWAS followed. 
 
Main points that were discussed are the following: 
 
- Primary Analysis – samples inclusion criteria: primary analysis will depend on the precise 
definition of the phenotype of the samples. Samples with clinical diagnosis of bvFTD – SD – 
PNFA – FTD-MND will be included in the analysis (if there are path data that confirm the 
diagnosis this is even better). Of course, if path data reverse the diagnosis to some syndromes that 
differ from the aforementioned phenotypes those will be excluded. As a matter of fact, some 
normal controls seem to be present within the whole cohort, therefore, once identified, those will 
be excluded. As well, based on updated diagnosis or path info, cases designated as AD, PSP, 
CBS-CBD and logopenic aphasia will be excluded from the study and primary analysis. Raf 
Ferrari proposed to identify samples eligible for primary analysis in no longer than 2 weeks (by 
October 28th). Primary analysis could then start by October 31st and 3-4 weeks later results (hits), 
if any, should be identified. Importantly, Mike Nalls made clear that we will need to decide for a 
pooling vs. a meta-analysis type of approach. 
 
- Use of Van deerlin dataset: these data are freely available. It was discussed whether these data 
could be relevant during primary analysis or during replication analysis or at all. The debate 
didn’t  bring  to  any  conclusive  decision  as  this  dataset  contains, in vast majority, PGRN mutation 
carriers and it is not clear what the pros of including them in analysis would be. This is still an 
open question. Nevertheless here two points of view: John Hardy keen on using them during 
primary phase, whilst Andy Singleton leaned towards using them during replication. Nobody 
else expressed a clear position. 
 
- Replication arrays: for this purpose Andy Singleton proposed   the   use   of   Illumina’s   exome  
arrays convenient from, both, SNPs coverage and costs ($15/sample) points of view. Mike Nalls 
added that not only this platform is reliable and suitable for replication purposes but also that it 
could provide more genetic information to be evaluated and interpreted. Another option proposed 
by Andy Singleton was designing  an   “FTD-chip”   including also SNPs for other diseases (this 
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would make it cheaper for users and more reasonable for the providing company to invest on such 
a chip). This option, though, would have some critical issues, specifically, it would decrease the 
number of SNPs relevant to FTD and would have anyway a bigger cost ($70/sample); therefore, it 
seemed not a suitable option. Finally, Parastoo Momeni proposed the use of genotyping assays 
to be run on Illumina Veracode; this option was not convincing in part in terms of SNPs 
coverage, but mainly because of the costs ($18,000 for 384SNPs/well for 480 samples). 
  
- Replication costs: to cover for the replication phase, which was evaluated being ~$150,000, it 
was proposed that all participating groups (the whole FTD-Consortium) could allocate some 
funds   into   a   “common   account”   to   cover   for   replication   expenses.  This   possibility   needs   to be 
further discussed. John Hardy suggested that some funds for this could be available through the 
Alzheimer’s  Association.  Andy Singleton also said to keep in mind that costs could be discussed 
and negotiated with Illumina. 
 
- Chr9 screening: John Hardy said that knowing which samples hold repeats in intron 1 of 
C9ORF72 would, possibly,  be useful prior to and during analysis as it would help subdividing 
samples as well as having an idea about to what degree we should/could expect eventual hits on 
chr9 considering it as an internal positive control. Therefore, John Hardy suggested that 
everybody should start looking into their samples and that, in case specific sites would not be able 
to perform such experiments, those could be carried out at the following facilities: UCL, NIH, 
John  van  Swieten’s, Stuart Pickerin-Brown’s  or  van  Broeckhoven’s  labs. 
 
- Meeting ~December 16th in London: it was proposed by John Hardy that the whole consortium 
should participate in the analysis phase after results from primary analysis and that data after 
primary analysis should be free to circulate among collaborators. Moreover, John Hardy 
suggested that in this direction the FTD-Consortium should meet to discuss the next steps of the 
project, after the results from primary analysis, around December 16th in London. 
 
- Very next steps: Raf Ferrari will circulate an email to all collaborators to gather one more time 
the most updated and final info on the samples (specifically in relation to clinical, path and 
genetic data) to identify the samples that will go into primary analysis. This should happen in the 
next two weeks and be done by October 28th. In the following 3-4 weeks results for primary 
analysis will be generated by Mike Nalls at NIH. By nearly the end of November 2011we should 
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have results of primary analysis. Meanwhile, we should all keep in mind that sample collection 
for replication needs to be planned during the coming month starting from now. 
 
At 1:30PM the Chr 9 session started. 
 
Data were presented in the following order: Bryan Traynor, Rosa Rademakers, John van Swieten, 
Julie van der Zee, Ilse Gijselinck, Stuart Pickerin-Brown. Power points of the talks follow. 
 
INSERT ALL SLIDES 
 
During and after the presentations of chr9 repeats some issues were raised among participants: 
specifically, it is still not clear how reliable and indicative the methods that have been used are, especially 
the primed PCR. It seems that cases show a higher frequency of repeats than controls. But also controls 
have shown repeats (with lower overall frequency though). Furthermore, it is not clear how the repeats in 
an intronic region would affect the phenotype to the extent that they would explain the disease. No 
functional studies could give a hint of explanation. Does frequency alone explain the difference between 
cases and controls? None of the presenters was able to answer/address these questions. Parastoo 
Momeni, Raf Ferrari and John van Swieten were pointing out that the repeats were also found in some 
controls which were showing, graphically, the same repeats pattern as in the cases. Parastoo Momeni, 
Raf Ferrari and Rosa Rademakers highlighted that primed PCR method does not give an exact estimate 
of the repeats. Rosa Rademakers also pointed out that the southern blot experiments could be biased due 
to cloning of the cell lines. Andy Singleton remarked the possibility of cloning being responsible for 
seeing 700-1,500 bands as well as he suggested that it seems hard to associate the repeats with the 
diseased phenotype. Stuart Pickerin-Brown suggested that the differences in the frequencies between 
cases and controls are self explanatory. 
 
At 3:30PM Rita Guerreiro introduced the relevance and possible link between Nasu Hakola disease and 
FTD highlighting the possibility of evaluating homozygosity regions at the TREM2 (chr6) and TYROBP 
(chr19) loci in FTD cases. She asked for permission to look for this purpose into the FTD-GWAS 
samples. John van Swieten agreed. 
 
At almost 4:00PM the meeting ended with the understanding that John Hardy and Raf Ferrari would 
send minutes and presentations of the meeting to the whole FTD-Consortium in a week time. 
406
406
 Appendix 4-5. FTD-GWAS meeting December 2011: Minutes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
407
407
December 11, 2011 
 
 
FTD-GWAS primary association analysis – results meeting 
 
 
Attendees: 
 
John Hardy, Matthias Rimenschneider, Jon Rohrer, Rita Guerreiro, Jose Bras, Stuart Pickering Brown, 
Peter Hyslop, Raph Gibbs, Christine Van Broeckhoven, Andrew Singleton, Julie Van der Zee, Raf 
Ferrari, Dena Hernandez, Mike Nalls, Caroline Graff. 
 
 
Main points: 
 
- Data was presented from the ~2500 samples with FTD and ~7500 controls (for data cleaning see 
slides) 
 
- Highlights of analysis: 
 
• ApoE was highest. Could be interpreted as either a real effect or diagnostic bleed thru of 
~15% from AD 
• HLA was high: this could be population stratification or real. 
• Ch9 data had just sub significant score 
• TMEM data was unclear 
 
 
Resolved to do: 
 
- Site specific analyses to see if HLA disappeared 
- Diagnosis subtype specific analyses to try and understand ApoE signal 
- How to replicate and what samples to replicate in. 
 
Raf has emailed around and has ascertained that the sites who have contributed have in total about 1000 
new cases. Julie Van der Zee noted she had 500 additional samples from non-contributors which could 
contribute to these analyses with their permissions. 
 
There was a discussion of the need for replication in these 1000-2000 new samples. Two possibilities 
were discussed: 
 
1) The new exome chip + custom content, which would cost about $100 a samples, would take 
about 3 months to design and require the raising of about $300K (controls would be needed to be 
genotyped). We will send the content of the exome chip round when we have it, but essentially it 
has on it every coding SNP with a frequency >0.5% 
 
2) Christine Van Broeckhoven suggested the use of Sequenome platform for a few top SNPs with 
ancestry informative markers. This would allow the assessment of ~30 top SNPs with ancestry 
and gender markers if more than one population was assessed. 
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Further resolved: 
 
- Andy Singleton to try and get NIH money for exome plus chip 
- John Hardy and Stuart Pickering-Brown to try and get Alzheimer’s Research UK (ARUK) 
money for exome plus chip 
- Matthias Riemenschneider and John Hardy to try and get money for exome plus chip 
- Julie Van Der Zee and Christine Van Broeckhoven to see if they have budget or capability 
within Belgium for exome plus chip 
- $300K will be needed in total. 
 
Decision point for this will be in March while samples are gathered together. 
 
 
Conclusions: 
 
- The first analysis for publication will probably be a subtype analysis with a side by side with the 
Van Deerlin data as this will be very informative as to effects which are subtype and pathology 
specific. 
- As in other such consortia, there is a no-surprises policy and if any of these are written up we will 
circulate well before the final draft stage 
- It would be great if groups wished to do their own analyses (e.g. haplotype sharing).  It would be 
good to hear of these 
- Next meeting will be 8th September in Manchester (the day after the International FTD meeting). 
 
 
 
Following the slides presented at the meeting by Raf Ferrari and Mike Nalls. 
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FTD-GWAS – Manchester September 6, 2012 
 
Minutes 
 
 
Meeting started at 18:00 local time. Attendees were as follows: 
 
Attendees  Centers 
Caroline Graff; Huei-hsin Chiang  
 Karolinska Institute, Department of NVS, Stockholm, SWEDEN 
Matthias Riemenschneider Universität des Saarlandes, Klinikum für Psychiatrie & Psychotherapie, Homburg/Saar, GERMANY 
Javier Simon-Sanchez; Sasja Heetveld; Peter Heutink Department of Clinical Genetics, VU University Medical Centre, Amsterdam, Netherlands 
Innocenzo Rainero Department of Neuroscience, University of Torino, Italy 
Amalia C Bruni; Chiara Cupidi Regional Center of Neurogenetic, Lamezia Terme, Italy 
Agustin Ruiz; Isabel Hernandez ACE Foundation. Catalan Institute of Applied Neuroscience, Barcelona, Spain 
Agnes Camuzat; Isabelle Leber; Alexis Brice; Latouche GICM, Paris, France 
Marc Suarez-Calvet; Jordi Clarimon Genetics of Neurodegenerative Diseases Unit | IIB Hospital Sant Pau, Barcelona, Spain 
Giancarlo Logroscino University of Bari, Italy 
Markus Otto Uni Ulm, Germany 
Daniela Galimberti; Elio Scarpini; Giorgio Fumagalli; Andrea 
Arighi 
Department of Neurological Sciences, Dino Ferrari Institute, University of 
Milan, Italy 
Jorgen Nielsen; Lena Hjermino Section of Neurogenetics, University of Copenhagen, Denmark 
Peter Schofield; Carol Dobson-Stone Neuroscience Research Australia, Sidney, Australia 
Adrian Danek Department of Neurology, Ludwig-Maximilian University of Munich, Germany 
John van Swieten Department of Neurology, Erasmus Medical Center, Rotterdam, Netherlands 
Vivianna Van deerlin University of Pennsylvania Health System, Department of Pathology, Philadelphia, PA, USA 
Simon Mead; Jon Beck Institute of Neurology, Prion Unit, UCL, London, UK 
Giuliano Binetti; Roberta Ghidoni; Luisa Benussi NeuroBioGen Lab-Memory Clinic, Fatebenefratelli, Brescia, Italy 
Benedetta Nacmias Department of Neurological and Psychiatric Sciences, University of Florence, Italy 
Barbara Borroni; Alessandro Padovani Department of Medical Sciences, Neurological Clinic, University of Brescia, Italy 
Ekatrina Rogaeva Center for research in Neurodegenerative diseases, Toronto, Canada 
Elisabet Englund; Christen Nilsson; Maria Landqvist University of Lund, Sweden 
James Rowe University of Cambridge, Cambridge, UK 
Alfredo Ramirez University Bonn, Germany 
John Hardy; Jonathan Rohrer Institute of Neurology, UCL, London, UK 
Stuart Pickering-Brown (UK) University of Manchester, Clinical Neuroscience, Manchester, UK 
Bryan Traynor Laboratory of Neurogenetics, NIA, NIH, Bethesda, MD, USA 
Parastoo Momeni, Raffaele Ferrari Texas Tech University Health Sciences Center, Lubbock, Texas, USA 
 
 
Raf Ferrari introduces the main topics to be discussed in the meeting: 
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 1. FTD-GWAS: results – replication timeline – future directions  
2. FTD-GWAS: presentation & discussion of side projects 
3. FTD-ALS C9orf72: presentation of analysis spreadsheet and comments 
4. Conclusions 
 
 
1. FTD-GWAS: results – replication timeline – future directions 
 
Raf showed the slides that summarize Manhattan plots along with associated SNPs with p-values with 
genome wide significance (p<E-8) and close to genome wide significance (p<E-7) for each subtype and 
for the meta-analysis. Then he discusses the final summary of primary analysis results together with all 
attendees.   These slides are attached again. 
Main points are as follows: 
 
• We need to replicate our results (primary focus) 
• Association with chr 11, RAB38, in bvFTD subtype, especially if replicated, is going to be 
interesting and worthy of further investigations 
• Association with chr 9, C9orf72 locus, in FTD-MND subtype overlaps with previous ALS-
GWAS 
• Strong association with chr 6, HLA locus, in meta-analysis: 
-    might be true – overlaps with some previous PD-GWAS 
-     might be due to population stratification – redo analysis within a homogeneous    
cohort from the whole cohort 
• Association with chr 19, APOE locus, in bvFTD subtype and meta-analysis: 
-     might represent presence of samples other than FTLD in our cohort 
-     could it be true or does it represent minor (~10% contamination) with AD? 
-     no association with CLU, PICALM, CR1 loci 
• Lack of association with chr 17, MAPT & GRN loci, might be due to exclusion of mutation 
carriers 
• Lack of association with chr 9, C9orf72 locus, in all but FTD-MND subtype is worth 
consideration 
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• Lack of statistical association with chr 7, TMEM106B locus, in all subtypes and meta-analysis.  
See the attached file for this. Clearly, the OR cannot be close to the reported 1.6, but a weak 
association is possible (see data).  The replication chip will be important in this regard 
• All SNPs with p-values E-05/E-06/E-07 are included in replication chip 
• Raf has additionally hand checked all the files for MAPT and PGRN duplications and deletions 
and not found any 
 
At this point, John Hardy briefly introduced the NeuroX chip that will be used for replication. 
Characteristics of the chip, that will be available in October 2012, are as follows: 
 
Standard Human Exome v1.1 microarray: 
• 200K SNPs including: 
- SNPs from the exome sequencing project (ESP) dataset  
- ancestry informative makers  
- X/Y markers to verify gender  
- published GWAS hits 
• 30K SNPs for a number of neurological disorders: 
- known rare/coding variants 
- mendelian genes 
- follow-up for exome sequencing studies 
- candidate SNPs for current and future GWAS 
- GWAS replication SNPs  (~4K hits from phase I for FTD-GWAS replication) 
 
Following, Raf proceeds in explaining the plan and timeline for replication: replication phase (or phase 
II) has already started and several hundreds of samples and controls have been and are being collected at 
UCL. Raf emphasizes that, in fact, one of the aims of phase II is to collect both cases as well as controls 
to be run together using the same genotyping platform as well as the same type of chip to ease and 
empower analysis.  
Based on the timeline, the intention is, as of September 2012, to collect samples, to perform Quality 
Control (QC) on them, to genotype them, to strategize and perform analysis – all together – by ideally 
March-April 2013. A manuscript could be submitted by May 2013. It is, in fact, in the interest of the 
whole international FTD-consortium to proceed towards the end of this project to identify novel loci 
associated with FTD and publish them.  
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To help in this direction, Raf suggests to finalize samples collection asap: a strategy to ease this step 
could be promoting samples collection at UCL, NIH and also at the Texas Tech University Health 
Sciences Center (TTUHSC), where Raf works for most of the time. Sending samples to TTUHSC could 
be an idea to facilitate samples collection, QC and preparation for chips. Once Raf QCs samples and 
prepares them at the right dilution, he can send the plates directly either to UCL or NIH ready to be put on 
chip and to be run. Once the genotyping phase is concluded, the samples collected at TTUHSC will be 
sent back to the original source.  
Along, Raf explains the inclusion/exclusion criteria for phase II: 
 
• path confirmed FTD cases (if available) 
• bvFTD – SD – PNFA – FTD/MND diagnosed cases (Neary criteria – Neary et al., 1998) 
• firmly exclude any possible LPA 
• exclude mutation carriers in the candidate genes, but, if including, identify mutations  
• include results of screening of C9orf72 hexanucleotide repeats (if available) 
• amount of DNA (samples): 2 – 2.5 ug  
• include neurologically normal controls (to be genotyped as well): 2 – 2.5 ug (if available) 
 
It was gratifying that several other groups at the FTD meet were made known to Raf at the meeting and 
he will contact them for the GWAS analysis. 
Following, Raf mentioned that some side studies could already be started and performed during 
replication phase. Such studies are suggested and open for discussion as follows: 
 
• Redo analysis with and without C9orf72 positive cases 
• Tackle HLA association by looking just into a homogeneous cohort 
• Redo analysis with and without ApoE allele 4 
• Meta-analysis with FTD-TDP dataset (van Deerlin et al, 2010) using SD, PNFA and FTD-MND 
(TDP-43 path) 
• Meta-analysis with ALS-GWAS: our cohort with and without C9orf72 positive cases vs. Finnish 
cohort with and without C9orf72 positive cases (van Es et al, 2009; Laaksovirta et al, 2010) 
• Age of onset sub-analysis 
 
Then Raf mentions what could/should be done after conclusion of replication: 
 
• Targeted re-sequencing 
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• Pathways analysis 
• Functional studies 
 
 
2. FTD-GWAS: presentation & discussion of side projects 
 
At this point Raf opens the discussion for comments on results and on suggestions for side studies to be 
performed using the data generated during phase I. 
Dr. Riemenschneider mentions that it should be told that genomiphied samples are not suitable for 
genotyping unless, probably, samples are enriched and stabilized through certain kits. John and Raf 
replied that they will look into this possibility. Further, Dr. Riemenschneider mentions that his group 
would like to and could perform CNV analysis on the whole cohort.  
Dr. Mead mentions that it would be worth looking into our data and extract the exact p-values for the 
SNPs associated with TMEM106B providing as a reason that there are a lot of functional studies being 
performed on that gene and its interaction with PGRN. These data are now attached.   
Also, Dr. Mead mentioned that an interesting side study could be to look for relatedness within 
homogeneous cohorts to possibly identify founder effects. Dr. Hardy said this type of study was 
encouraged and we will follow up to offer help to anyone in this regard, but we would be delighted if 
people made individual contacts to do this as long as they kept the larger group informed. 
Drs. Mead and Pickering-Brown suggested that they could perform this type of analysis on the UK 
cohort.  
Dr. van Deerlin mentions that she would like to perform a new analysis on her ~500 samples TDP-43 
path confirmed cohort using a different set of normal controls and that she is looking for the availability 
of genotyping data of US neurologically normal controls. Dr. Singleton has such a data set. 
Dr. Ramirez mentions that the University of Bonn could participate in the study providing DNA of 
German neurologically normal controls.  
Dr. van Swieten asks if there is the possibility to further assess and refine the clinical data; on that point 
Dr. Rohrer answers that him and Raf have been spending hours to decide which samples to include or 
exclude into/from primary analysis. Moreover, Dr. Rohrer mentions that Raf has spent hours on the 
phone with each single participating colleague and has been in almost constant email contact with them to 
progressively discuss any update on the clinical information for each single sample prior primary 
analysis. John Hardy confirms and says that we really did all our best to thoroughly characterize all 
samples.  
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Finally, Dr. Dobson-Stone asks about the possibility to contribute with samples from Australia and if 
also Australian normal controls would be needed.  
After the discussion Raf introduces Dr. Bryan Traynor’s  presentation of the FTD-ALS C9orf72 project. 
 
 
3. FTD-ALS C9orf72: presentation of analysis spreadsheet and comments 
 
Dr. Traynor discusses the excellent progress that has been made. That FTD/ALS group is invited to 
circulate a progress report. 
 
 
4. Conclusion 
 
At this point John and Raf conclude the meeting.  
In summary, main points of the meeting are as follows: 
 
• Replication (phase II) is ongoing and samples collection is open 
• Contact Raffaele Ferrari (raffaele.ferrari@ttuhsc.edu) to organize samples shipment/collection 
• NeuroX replication chip will be available in October 2012 
• Minutes of the meeting will be sent out in ~ one week time 
• Several possible side projects will soon be listed and discussed to be approved by the whole 
consortium prior start. The approval will depend upon agreement of all sites that genotyping data 
can circulate among the consortium members (especially to those who will be directly responsible 
and in charge of a side-project) 
• Side projects will be performed by groups within the consortium under the understanding that 
generated results from side studies might be incorporated in the main manuscript or be published 
in satellite papers after the first comprehensive publication of the complete FTD-GWAS study 
• Next meeting for the members of the international FTD-consortium to discuss updates on the 
FTD-GWAS project will be at AD/PD (Florence) March 6th-10th or the AAN (San Diego) March 
16th-23rd 
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 Appendix 4-7. FTD-GWAS: Replication phase workflow 
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